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Abstract 
ABSTRACT 
One in three Australians die of cardiovascular disease and despite advances in treatment it 
remains the leading cause of death in Australia. MiRNAs play critical roles in the heart and 
specific miRNAs can promote or prevent cardiac hypertrophy, sparking interest to use 
rniRNAs as therapeutic targets. However, cells can produce both miRNAs and their 
mRNA targets in multiple processing variants increasing the complexity of miRNA-
mediated control. It is therefore critical to elucidate the role of these variants in cardiac 
disease. The aim of this thesis was to profile miRNA and mRNA 3' UTRs in cardiac 
hypertrophy and to interrogate this data for evidence of processing variation. 
We established a murine model of left ventricular hypertrophy using transverse aortic 
constriction as confirmed using haemodynamic, physiological and biochemical 
measurements. Cardiomyocyctes were isolated from pre-hypertrophic, hypertrophic and 
control hearts and RNA extracted for next-generation sequencing of miRNAs and mRNA 
3' ends. We identified 17 miRNAs and 776 mRNAs that changed in level during the 
hypertrophy, with the majority being upregulated. Overall, more mRNAs changed 
expression in the pre-hypertrophic cardiomyocytes, while the miRNAs were altered mostly 
in the hypertrophic samples. This is the first smdy to document the expression of miRNAs 
and mRNAs simultaneously in purified cardiomyocytes and their change in hypertrophy. 
Analysing the datasets for processing diversity revealed that nearly all miRNAs in 
cardiomyocytes showed some degree of processing diversity^ including expression from 
both hairpin arms, 5' and 3' isomiRs, or the presence of non-templated additions. There 
was little directional change in miRNA processing during hypertrophy but two examples 
were identified where the bias for particular variants changed sigmficandy. This is the first 
documentation of variable miRNA processing in purified cardiomyocytes. Such variants 
provide a mechanism to change the mRNA targeting properties of miRNAs from a given 
locus without changing the genomic sequence. In support of this, in vitro luciferase assays 
demonstrated that the different 5' isomiRs of the cardiac miR-133a-3p have distinct 
targeting preferences. 
Analysis of the 3' end sequencing data demonstrated that mRNAs expressed m 
cardiomyocytes had on average 2.35 distinct 3' UTRs with an average length of 3.7 kb. The 
proportion of short versus long 3' UTRs was altered for 424 mRNAs, with 272 3' UTRs 
getting shorter and 152 getting longer, in the pre-hypertrophic cardiomyocytes. This is the 
III 
Abstract 
first study to provide an in-depth mapping of mRNA 3' UTR diversity in purified 
cardiomyocytes and document changes to the proportion of these variants in cardiac 
hypertrophy. Aherations in the length of 3' UTRs can lead to inclusion of or exclusion of 
rruRNA target sites on mRNAs and thus change their sensitivit)' to regulation by miRNAs. 
Overall, the datasets reported here provide global mformation on expression changes to 
both miRNA sequence and mRNA 3' UTR lengths forming the basis for an improved 
systems level understanding of miRNA-regulation during cardiac hypertrophy. The 
realisation that cardiac miRNAs and their targets exist as currendy under-appreciated 
variants with potentially complex effects on target specificities has important implications 
for the role of miRNAs in cardiac disease. 
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Introduction 
1.1 CARDIAC HYPERTROPHY 
1 . 1 . 1 H E A R T DISEASE AND C A R D I A C H Y P E R T R O P H Y 
One in three Australians die of cardiovascular disease (CVD) and despite advances in 
treatment it remains the leading cause of death in Australia (/). CVD accounts for 18% of 
the overall burden of disease and injur)' within Australia, which is a measure of the years of 
healthy life an individual, or population, loses as a result of disease or injur)' (/). It has the 
greatest health expenditure compared to other diseases in Australia, costing the country' 
S5.9 billion in 2004 and 2005. CVD covers all pathologies that involve the heart or blood 
vessels. In Australia, the main t\pes of C\'D are coronary heart disease, stroke and heart 
failure. Heart failure is a loss in the abiHt)' of the heart to adequately pump blood in 
response to the body's needs. It can be induced by a number of pathological conditions, 
includmg aortic valve stenosis, dilated cardiomyopathies, ischemia associated with coronary' 
artery disease or myocardial infarction, and chronic h^-pertension {2). 
Prior to heart failure, the pathological conditions listed above first induce cardiac 
h\'pertrophy, defined as an increase in the size of the cardiomyocyte without cell division 
(3). This is initially a compensator^' mechamsm to maintain cardiac output, but prolonged 
hypertrophy often leads to heart failure, arrhythmia and/or sudden death. Hypertrophic 
signalling results in the rapid expression of the early response genes, c-fos, c-jun and c-myc, 
as well as heat shock protein genes (hsp70) (4). This is followed by re-expression of cardiac 
foetal genes, such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), P-
myosin heavy chain (P-MHC) and alpha skeletal actm (a-Ski\), which are now used as 
molecular markers of the hj-pertrophic phenot\'pe (5). 
1 . 1 . 2 C A R D I A C H Y P E R T R O P H Y SIGNALLING PATHWAYS 
Cardiac hj-pertrophy develops from the interaction of several signal transduction pathways, 
and as such dozens of ligands, receptors, transducers and transcriptional regulators 
modulat ing cardiac hypertrophy have been discovered (reviewed in (2)). The signalling 
pathways identified thus far include: calcineurin/nuclear factor of T cells (NFATc), cyclic 
guanosme monophosphate (cGMP)/protein kinase G-1 (PKG-1), phosphoinositide 3-
kinase (PI3K)/Akt, G protem-coupled receptor (GPCR), mitogen activated protein kinases 
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(MAPK), mterleukin-6 (IL-6) cytokine, JAK-STAT and the renin angiotensin system (RAS) 
(Reviewed in (2, <5)). The main signalling pathways involved in hypertrophy are summarized 
in Figure 1.1. There is significant cross talk and interaction between these signalling 
pathways, forming an integrated network that regulates heart homeostasis. These signalling 
pathways end in the nucleus, where they activate numerous transcription factors that then 
drive the expression of stress response and foetal cardiac genes. 
1 .1 .2 .A CALCINEURIN-NFAT SIGNALLING 
Calcineurin (CnA) is a calmodulin-dependent phosphatase that interacts with members of 
NFATc family, dephosphon lating their serine residues, which allows them to translocate 
to the nucleus and activate immune response genes (7). NFATc factors themselves bind 
weakly to DNA and so interact with other transcnption factors such as GATA-4, c-myc 
and myocyte enhancing factor 2 (MEF2) to modulate transcription {8}. 
CrL-\-NFAT signalling is activated in response to intracellular calcium concentrations. As 
calcium concentrations increase, the calcium samrates calmodulin, which leads to a 
stronger interaction between calmodulin and CrL\. This interaction generates a 
conformational shift and subsequent activation of CrL\ (9). Overexpression of Cni'i in the 
heart is sufficient to increase heart si2e and induce expression of the hypertrophic markers 
P-MHC, a-SkA and BNP (/O). This suggests a role for CrL\-NFAT signalling in the 
hypertrophic response. 
Calmodulin activates calmodulin-dependent protein kinase (CaMK), resulting in the 
phosphorylation of class II histone deacet)'lases (HDACs) (//, 12). Phosphorjlated 
HDACs are then exported from the nucleus to the cytoplasm, removing the inhibitor}' 
effects of HDACs from MEF2, which orchestrates the expression of stress-responsive 
genes {12). These genes include connective tissue growth factor (CTGF) and procollagens 
(Colla2 and Col3al), which promote cardiac fibrosis. 
Introduction 
1 . 1 . 2 . B G PROTEINS AND G P R O T E I N - C O U P L E D RECEPTORS 
Card iomyocytes sense changes in hormones and growth factors through a number of 
receptors including GPCRs . G P C R s are seven t ransmembrane domain receptors, which 
play an important role in heart homeostas is and disease. The majority of prescript ions for 
C V D are drug therapies that target a subclass of G P C R s either directly or indirecdy {13, 
14). B inding of a l igand induces a conformat iona l change in the GPCR, al lowing for 
coupl ing wi th the small or heterotr imeric guanine-nucleot ide regulatory proteins (G 
proteins) (Reviewed in {IS)). G proteins exist in two states, the inactive guanos ine 
d iphosphate (GDP) bound form and the active guanosine tr iphosphate (GTP) bound form 
{16). The heterotr imeric G proteins consist of a , P and y subunits and, after coupl ing with 
the GPCR, the G T P is converted to G D P on the a subunit , which dissociates the a f rom 
the Py subunits to activate intracellular signall ing pathways {17, 18). 
EndotheHn-l (ET-1), angiotensin II (Ang II) and catecholamines (such as phenylephrine 
(PE)), play important roles in cardiac growth and hypertrophy and bind to G P C R s that are 
coupled to the G a subclass of G proteins. These G proteins activate phosphol ipase C 
(PLC) result ing in the hydrolysis of phosphatidyHnositol 4 ,5-bisphosphate ( P I P J into 
inositol 1,4,5-tr isphosphate (IP,) and diacyl glycerol (DAG) {19). D A G activates protein 
kinase C (PKC), which promotes protein synthesis and activates protein kinase D (PIsD). 
P K D stimulates export of H D A C 5 from the nucleus via phosphon' lat ion, a l lowing the 
act ivat ion of hypertrophic genes {20, 21). Simultaneously, IP, accumulates and binds to the 
IP, receptors on the sarcoplasmic ret iculum (SR), releasing calcium into the cytoplasm. This 
susta ined calc ium release increases cytosolic calcium concentrat ion, feeding into the 
ca lc ineur in-NFAT signall ing pathway (see above). 
Introduction 
ET-1 
Ang II 
PE 
i 
= GPCR -
Protein 
synthesis 
p P L C - , 
DAG lns(1,4,5)P, 
1 1 
ANP 
BNP 
i 
= GC-A ; 
FGF 
: FGFR : 
IGF1 
Neuregulin 
EGF 
I 
; RTK = 
TGF3 
-TGFR-
Small G-proloins 
Ras RhoA Rac i 
- GPCR 
G., 
1 
: P I 3 K 
Raf Mekk1/2/3 
MLK Ask1 
MAPKK 
Uek1/2 MKK3/4/6/7 Protein svnth«sis 
MAPK 
JK ERK5 
18 ERK1/2 
- GSK3P 
Cell membrane 
TNFo 
I 
= TNFR = 
IKB 
NFKB 
Transcription Factors 
Hypertrophic gene expression 
• ANP BNP a-MHC a-SkA • 
Figure 1.1. S ignal l ing p a t h w a y s contro l l ing the hyper t rophic response. 
T h e extrace l lu lar s t imulus init iat ing s ignal l ing and their respect ive receptors are shown at the top, 
w i th the cell m e m b r a n e represented by the blue bar. The signal l ing downs t r e am of the m e m b r a n e 
reccptors have been s impl i f ied for ease of interpretat ion. The Nuc leus (brown bar represent ing the 
Nuc lea r membrane , Nuc l eus shown by b rown background) is shown at the bot tom. A N P , atrial 
natr iuret ic pept ide ; A n g II, ang iotens in II; A s k l , apoptos is s ignal-regulat ing k inase 1; a-Sk/\, a lpha 
skeletal act in; B N P , brain natr iuret ic pept ide ; P -MHC, beta myos in heav) ' chain; Ca2+, ca lc ium; 
C a M K , ca lmodu l in -dependent kinase; C D K , cyc l in-dependent kinase; c G M P , cyclic guanos ine 
m o n o p h o s p h a t e ; D A G , diacylgj ' lcerol ; E G F , ep iderma l g rowth factor; E R K , e.xtracellular signal-
regu la ted k inase ; ET-1 , endothe l in-1 ; FGF , f ibroblast g rowth factor; F G F R , F G F receptor ; G C - A , 
guany l cyc lase-A; G P C R , G prote in-coupled receptor ; GSK3|3; g lycogen synthase k inase-3p; 
H D A C , h is tone deacety lase ; I k B, inhibi tor of N F k B ; IGF-1, insul in-l ike g rowth factor-1; IKK, 
inh ib i tor of N F k B kinase; Ins( l ,4 ,5)P3, inos i to l - l , 4 ,5 - t r iphosphate ; J N K , c- jun N-termina l k inase; 
M A P K , mi togen-ac t iva ted prote in k inase ; M A P K K , M A P K kinase; MAPICKK, M A P K K kinase; 
M A P K I C K K , MAPICKK kinase ; M E F , myocy te enhanc ing factor; M E K , mi togen-act iva ted prote in 
k inase k inase ; M E K K , M E K kinase ; M L K , mixed- l ineage kinase; M K K , M A P K kinase ; m T O R , 
mammaUan target of r apamyc in ; N F A T , nuclear factor of act ivated T cells; N F k B , nuc lear factor 
k B ; N I K , NFKB- induc ing k inase ; P D K , phospho inos i t ide -dependent kinase; PI3K, 
phosphat idy l inos i to l 3 -k inase ; P K B , prote in k inase B; P K C , protein k inase C; PIsX), prote in k inase 
D; P K G , prote in k inase G; PLC , phospho l ipase C; Pol II, R N A polymerase II; R a c l , ras-re lated C3 
bo tu l i num to.xin substrate 1; Raf , rapidly acce lerated f ibrosarcoma; RhoA, Ras homo log gene family 
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member A; RTK, receptor tyrosine kinase; TAK, TGpp - activated kinase; TGFp, transforming 
growth factor (3; TGFR, TGF receptor; TNFa, tumour necrosis factor a ; TNFR, TNFa receptor. 
Figure modified from {2). 
In addition to the heterotrimeric G proteins that interact with GPCRs, small G proteins 
also play important roles m cardiac signaUing. The small G proteins are single polypeptides 
of low molecular weight, and are divided into 5 subfamilies: Ras (Ras, Rap and Ral), Rho 
(RhoA, Rac l and CDC42) , Rab, Arf and Ran {22). Members of both the Ras and Rho 
subfamilies have been described to participate in hypertrophic signalling (Reviewed in {23)). 
Ras, Rho and Rac can be activated by the Ga^/,, agonists ET-1, PE and Ang II (Reviewed 
in {24)). Admimstrat ion of ET-1 or PE to neonatal cardiomyocytes was sufficient to 
activate Ras, RhoA and Rac l within minutes {24). These small G proteins can also be 
activated by the gradual increase in Ca^^ induced by IP, {4), and by stretching of the 
cardiomyocyte {29). Furthermore, binding of growth factors, such as insulin growth factor 
1 (IGF-1) and fibroblast growth factor (FGF), with their respective tyrosine kinase 
receptors leads to Ras activation {26, 27). Once activated, downstream pathways regulate 
the cardiomyocyte cytoskeleton and ampliftf hypertrophic gene expression {4). The small G 
proteins stimulate the NL\PK pathways (see below); Ras activates extracellular-signal-
regulated kinases 1 and 2 (ERKl and 2), c-Jun N-terminal kinases (JNKs) and p38 
indirecdy through Rac/CDC42. Conversely, Rac l only stimulates the ERIC cascade by 
promoting c-Raf activity {2S). 
Both GPCRs and small G proteins lead to modulation of transcription factor activity, 
which in m m regulates hypertrophic gene expression. 
1 . 1 . 2 . C M A P K PATHWAY 
M A P K cascades are highly conser\'ed signalling pathways that lead to the activation of the 
M A P K s J N K , ERK and p38 {29). These pathways consist of three signalling levels; M A P 
kinase kmase kinases (MAPIsKXs) activate MAP kinase kinases (MAPI<K) by 
phosphorylat ing serine and threonine residues, which m turn aUows MAPKKs to activate 
M A P K s by phosphorylat ion of tj 'rosme and threonine residues {4). For example, the ERK 
M A P K s are activated by two MAPKKs , M E K l and MEK2, which are activated by the 
MAPKI-aCs Raf-1, A-Raf , B-Raf, and MEI-CKl-3 {29). 
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The ERK pathway is activated by binding of hormones (such as ET-1 and Ang II) to 
GPCRs, binding of growth factors to receptor tyrosine kinases (RTKs, for example IGF-
1)(2), and by mechanical stress (reviewed m (30)). The ERK family of MAPKs has been 
associated with cell growth and survival, while the p38 and JNK pathways are known to 
induce hypertrophic gene expression and increase protein synthesis {31, 32). Both JNK and 
p38 are also activated by myocyte strctch and activation of GPCRs {33-36). Once activated, 
the MAPKs phosphorylate and activate numerous transcription factors, including c-jun, 
Elk-1, activating transcription factor-2 (ATF-2), MEF2, NFAT, GATA4 and NF-KB {3S). 
Activation of these transcription factors collectively induces the reprogramming of 
cardiomyocyte gene expression during hj^pertrophy. MJVPKS also phosphorylate and 
activate other protein kinases, amplifying the hjfpertrophic signal. 
1 . 1 . 2 . D P R O T E I N K I N A S E C 
The PKC family consists of at least 12 serine/threonine kinases {37). Conventional PKCs 
are Ca^ ^ dependent and are activated by both phosphatidylserine and DAG (produced by 
PLC, described in GPCRs) (i7). PKC activates PKD by phosphor^'lating two serine 
residues in the activation loop of PKD {3g). PKD phosphorylates class II HDACs, which 
normally represses pathological cardiac gene expression by interacting with the 
transcription factor MEF2 and its partner transcription factors such as NFAT and GATA4 
{20). Once phosphorylated, HDACS binds to 14-3-3 proteins, which result in export of 
HDACS from the nucleus, allowing the expression of hypertrophic genes. It is possible 
that activated PKCs can also directiy phosphorylate HDACS, bypassing PI-CD and leading 
to the activation of hypertrophic genes {20). 
1 . 1 . 2 . E T H E P I 3 K - A K T P A T H W A Y 
The PI3K-Akt pathway occurs downstream of GPCRs and receptor tj'rosine kinases 
(Figure 1.1) (•/). Activated PI3K converts the plasma membrane lipid phosphatidylinositol-
4,S-bisphosphate [PI(4,5)PJ to phosphatidyHnositol-3,4,S-triphosphate |PI(3,4,S)P,] {39). 
Proteins with pleckstrin-homology (PH) domains can now accumulate at the ceU 
membrane by bindmg to PI(3,4,5)P,. Association at the membrane brings 
phosphoinositide-dependent kmase-1 (PDK-1) into close proximity to Akt/PKB, aUowing 
PDK-1 to phosphorylate and activate Akt/PKB {40). Now catalyticaUy active, Akt 
phosphorylates a number of proteins generaUy inhibiting their action. For example, Akt 
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phosphon-lates Bad (an apoptosis-inducer), which prevents Bad from binding to B-cel 
l ymphoma 2 (Bcl-2) family members and in turn, releases them to orchestrate a cell sun-ival 
response {41). Akt also phosphon' lates glycogen synthase kinase 3- (3 (GSK3P). GSK3P is 
normally active and inhibits transcription factors such as c-Myc, GATA4 and NFAT {39). 
GSK3P also negatively regulates the eukan'oric initiation factor 2B (eIF2B) {39, 42), and 
the structural protein P-catenin that interacts with transcription factors to induce gene 
expression {43). Phosphon lation of GSK3P by Akt represses its catalytic acti\-it)', allowing 
the activation of the downstream proteins normally repressed by GSK3p. 
The Akt/PKB pathway can also lead to increased protein s^-nthesis via activation of 
mammal ian target of rapamycin (mTOR) {39, 42). mTOR regulates multiple proteins 
involved in the regulation of m R N A translation, including the translational repressors 
eIF4E-bmding proteins (4E-BP1/2) and eukar\'otic elongation factor 2 (eEF2) kinase that 
inactivates eEF2 {44). The net result of mTOR activation is stimulation of protein 
synthesis and an increase in the components required for protein synthesis {44). 
1 . 1 . 2 . F SIGNALLING PATHWAY SUMMARY 
Hypertrophy pathways can be induced by various stimuli and involve numerous cell-
surface receptors, signaUing pathways and transcnption factors. However, the interactions 
that feed into and control these signalling pathways are still not completely understood. It 
is now evident that miRNAs are regulated during hj-pertrophy, and can interact with 
m R N A s that are mterl inked with hj-pertrophic signalling pathways {45). 
1 . 2 M I R N A S 
1 . 2 . 1 C A N O N I C A L B I O G E N E S I S O F M I R N A S 
The first step to produce a mature miRNA is transcription of the priman- miRNA (pri-
m iRNA) from die Genome (Figure 1.2). Akin to protem-codmg genes, pr i -miRNAs are 
transcribed primarily by RNA polymerase II and are capped and polyadenylated {46, 47). 
In the human genome - 5 0 % of miRNAs are intergemc with their own promoter elements, 
while the other 50% are co-transcribed from the mtrons of protein-coding genes (and thus 
under the same transcnptional regulation as the host gene). Pr i -miRNAs are larger 
transcnpts that can contain one or several miRNA sequences already folded mto hairpm 
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structures, for example the cardiac specific miRNAs, miR-133a-l and mLR-1-2, are co-
transcribed to produce one bicistronic primar)' transcript {4S). Maturation of miRNAs is 
mediated by the two RNase III endonucleases Drosha and Dicer {49). While still in the 
nucleus, the pri-miRNA is cropped by the "microprocessor" complex, consisting of 
Drosha and its cofactor DGCR8/Pasha (DiGeorge syndrome critical region gene 8), which 
assists Drosha to bind to its substrates {46, 50). Cleavage by Drosha ~11 nucleotides (nt) 
from the base of the hairpin yields a 60-70 nt long stem-loop with a 2 nt 3' overhang 
termed the precursor miRNA (pre-rrdRNA) (5/). The pre-miRNA is then transported to 
the cytoplasm via an exportin-5-dependent mechanism {52). Once in the cytoplasm, the 2 
nt 3' overhang is recognized and the pre-rrdRNA is then cleaved by Dicer ~22 nt from the 
Drosha cleavage site, with or without cofactors such as transactivation response element 
RNA-binding protein 2 CrRBP2) and Argonaute proteins (AGOs) {53, 54). The 
recognition of the harrpin and cleavage site choice appear to rely on certain structural 
features of the precursor {55). Similar obser\'ations were made in C.elegans, suggesting the 
structural preferences of Drosha and Dicer are consers'ed {56, 57). The cellular levels of 
pri-, pre- and mature miRNAs are often not well correlated and the processing steps are 
regulated through mechamsms that remain largely unknown. 
The sequential cleavage of Drosha and Dicer yields a miRNA duplex, from which usually 
one strand is selectively loaded into an AGO protein in the RNA Induced Silencing 
Complex (RISC). The mammalian AGOs have a strong preference for the first base of the 
loaded miRNA to begin with a uridine {56, 5K) and a 5' uridine bias is also obser\'ed in the 
cardiomyocyte miRNA population {55). Furthermore, there is a bias for the first base-
pairing to be thermodynamically unstable {59, 60), which may help in unwinding of the 
duplex by the wedge-shaped domain of AGO {61). However, as there are numerous 
examples that run counter to these preferences (see below), there are likely to be additional 
regulatory factors at play. Furthermore, unlike in Drosophila (and plants), very few 
mammalian miRNAs are preferentially associated with a particular AGO {67), leaving the 
specific roles of the four mammalian AGOs in miRNA-mediated repression a continuing 
area of debate (the function of AGOs is reviewed in {63)). 
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1 . 2 . 2 P R I N C I P L E S OF M I R N A : M R N A INTERACTIONS 
Once processed, one strand of the miRNA duplex (normally the strand with lower stability 
of base-pairing at the 5' end) is transferred onto an A G O protein to form an active RISC 
{53, 59). The A G O family proteins are the critical and best-characterised components of 
RlSCs . Mammals contain four A G O proteins, all of which function in miRNA repression, 
however only A G 0 2 shows sUcer activit\' and catalyses the miRNA-induced 
endonucleolytic cleavage of the target {64). This RNA interference (RNAi)-like cleavage is 
common in plants as miRNAs generally base pair to mRNAs with nearly perfect 
complementarit) ' in this system. However, in mammals this pathway is rarely used and in 
most cases miRNAs bind imperfectiy to their targets resulting in translational repression or 
exonucleolytic decay of the mRNA transcript (Figure 1.2)(reviewed in {65, 66)). 
Early experiments identified Watson-Crick base pairing of the seed region, which 
comprises nucleotides 2-7 of the miRNA, with the mRNA 3' UTR as an important 
determinant of miRNA-mediated repression of target mRNA {67). hi mtro reporter assays 
indicate perfect complementarit) ' to the miRNA seed alone is in some cases sufficient to 
induce repression {68). On the other hand, more recent work shows that seed pairing is 
neither necessary' nor sufficient for aU miRNA:mRNA interactions and relying on seed-
based pairing alone results in large false positive and negative rates {69). Additionally, it has 
also been suggested that the importance of seed matching for the binding of miRNAs to 
their targets may have been overestimated in miRNA overexpression studies (70). Our 
understanding of the miRNA:mRNA interaction has altered in response to a move from 
reporter-based experiments, to measurements of genome-wide endogenous 
miRNA:mRNA interactions using cross-linking techniques such as HITS-CLIP (high-
throughput sequencing of RNAs isolated by cross-linked immunoprecipitation (IP)) and 
PAR-CLIP (photoactivatable ribonucleoside-enhanced cross-linking and IP) on RISC 
complexes containing miRNA and mRNA {71, 72). Contemporary' bioinformatic 
predictions of targets therefore take into account the non-seed based binding of miRNAs 
to their targets as well as evidence from AGO-mRNA association studies in relevant cell 
t>'pes {73-75). 
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Translational Repression and exonucleolytic decay 
Figure 1.2. m i R N A biogenesis and targeting in mammalian cells. 
Primary m iRNAs (pri-rmRNAs) are transcribed from DNA in the nucleus by RNA pel II. They are 
then processed by the RNase III enzyme Drosha to form precursor miRNA (pre-miRNAs) that are 
exported to the cytoplasm with the assistance of Exportin-5. A second RNase III enzyme, Dicer, 
then cleaves the pre-miRNA to produce a miRNA duplex. The miRNA duplex is unwound and it 
was previously thought that only one miRNA strand, the mature miRNA, is incorporated into the 
RNA-mduced silencing complex (RISC) where it associates with a member of the Argonaute 
(AGO) family and gene silencing takes place. In animals, the miRNA binds with imperfect 
complementar i ty , predominantly by the seed regions (shown within the m iRNAimRNA binding 
interaction box) and this leads to translational repression and/or exonucleolytic decay. 
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Of importance for future cardiac miRNA research, a study performed A G 0 2 
immunoprecipitat ions and RNA-sequencmg on murine ventricular tissue to identify the 
subset of cardiac m R N A s enriched in the RISC complex (76). This approach defined the 
m R N A s being targeted by all the miRNAs in ventricular tissue and was used as the 
background signal for subsequent experiments. To discover miRNA-specif ic targets, the 
investigators then overexpressed specific miRNAs, for example iTLiR-133a or miR-499, to 
"reprogram" the RISC complex to favor the overexpressed miRNAs. Overexpression of 
specific m iRNAs and A G 0 2 immunoprecipitat ion was highly specific and several of the 
m R N A targets immunoprecipitated were not predicted using a seed-based algorithm 
(Targetscan), supporting the role of alternative miRNA:mRNA interactions in the heart. 
The m iRNA:mRNA interaction is nevertheless sequence-specific, thus any alteration to the 
miRNA sequence or the sequence within the 3' UTR could reduce or abrogate miRNA 
repression of a target. It is evident from these studies that our understanding of how 
miRNAs interact with their targets is evolving, as is our understanding of the complexity of 
the miRNA population, leading to more sophisticated and (hopefully) accurate target 
prediction methods. 
1 . 2 . 3 M I R N A P R O C E S S I N G V A R I A N T S 
It was originally thought that one pre-miRNA hairpin gives rise to a single dominant 
mature miRNA, however, it has recently become apparent that processing of one hairpin 
can result in several m iRNA variants, potentially with altered m R N A target specificity. This 
can arise from use of both strands of the miRNA:miRNA star (miRNA*) duplex with 
similar frequency, the occurrence of 5' and 3' isomiRs as well as RNA editing (Figure 
1.3A). It is postulated that these miRNA modifications could alter miRNA biogenesis and 
half-life, subcellular localization and/or targeting specificity. 
Initial m iRNA studies suggested that one strand of the pre-miRNA hairpin (known as the 
mature strand) was functional and incorporated into RISC while the other strand (known 
as the star or passenger strand) was non-functional and degraded. Strand selection is in part 
determined by the strength of the base pairing at the ends of the duplex (5/). It is now 
evident that both the mamre and star strands of the miRNA hairpin can be functional, with 
many m iRNA* variants detected in RISC complexes suggesting that they can repress 
m R N A s m vivo (62). Furthermore, their function in vivo has been highlighted by their role in 
human 
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F i g u r e 1.3. m i R N A proce s s ing and var iab i l i t y and c o n s e q u e n c e s for m R N A ta rge t ing . 
A) The canonical view on miRNA hairpin precursor processing, leading to accumulation of one 
mature miRNA. (B) Next generation sequencing reveals that variable processing, editing, and non-
templated additions can lead to the expression of miRNA sequence variants that (C) expand the 
mRNA targeting repertoire of a given miRNA locus. mRNA targets of canonical mature miRNA: 
small circle; collective mRNA target range of all expressed miRNA variants: large circle; miRNA 
seed regions: filled boxes. Image from (77). 
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disease (52, 78). For instance, miR-199a* (now called miR-199a-3p) is decreased in human 
hepatocellular carcinoma, where it normally funcdons to suppress the MEK/ERK pathway 
and cell growth (7S). 
Interestingly, the preferred strand can switch between tissue-tjpes and cellular contexts, 
gi\'ing rise to the term 'arm switching' [79, 80). This suggests that additional regulator)' 
mechanisms may determine which strand is functionally active in a certain cell t\ pe or state 
{81). In agreement with this notion, version 18 of miRBase (database of published miRNA 
sequences and annotation, www.mirbase.org) removed the mature miRNA/miRNA* 
nomenclature and reannotated all miRNAs based on the pre-miRNA arm they were 
derived from, with addition of the -5p or -3p suffix {82). The concept that miRNA* are 
functional greatly impacts the design and interpretation of cardiac miRNA studies, 
especially when the expression of the entire miRNA precursor is altered, potentially 
confounding the interpretation of phenot}'pe and mRNA targets. Furthermore, prior to the 
advent of next generation sequencing (NGS), the expression and importance of many 
miRNA* were under appreciated in cardiac-related studies, as they were not included on 
microarray platforms. Thus our understanding of the role of miRNAs in cardiac biology is 
lacking in regards to miRNA*. 
The availability of NGS has added further complexity- to our definition of a functional 
miRNA. NGS studies have identified length and sequence variants of known miRNAs 
giving rise to the term isomiRs (79, 83, 84). IsomiRs have been detected in Argonaute 
complexes and in translating ribosomes, implying that they are functional miRNAs {62, 85, 
86). IsomiRs with alternative 5' start sites (5' isomiRs) arc generated by differential Drosha 
and Dicer cleavage, which results in shifted seed sequences and, as the seed sequence is 
commonly a major determinant of miRNA targeting, it can be postulated that isomiRs 
target different sets of mRNAs. There are several recent studies that support this notion. 
Firstiy, microarray transcriptome analysis after deletion of miR-223 (which has two major 
5' isomiRs in neutrophils) revealed substantial re-expression of mRNAs matching the seed 
region of both the canonical miRNA and its co-expressed 5' isomiR {79). This was not due 
to an overlap in binding sites, suggesting that 5' isomiRs can direct the repression of 
distinct sets of targets. A study by Cloonan et al. used biotin labeled miRNAs or isomiRs to 
puU-down endogenous targets and found that 5' isomiRs bind both common and unique 
targets {85). These experiments demonstrate the potential for isomiRs to act individuaUy or 
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in concert to regulate gene expression, however there is much conjecture as to what is the 
biological role of isomiR expression. One hypothesis states that regulated changes to the 5' 
start site essentially generates a new miRNA with a different target spectrum, increasing the 
complexity of the miRNA pool {8S). Another hypothesis is that co-expression of isomiRs 
leads to reinforced repression of core mRNA targets, while diluting off-targeting events 
between several isomiR species {8S). Another possibility is that isomiRs are differentially 
located and regulated, and may associate with diverse effector proteins to create distinct 
outcomes (e.g. translational repression versus mRNA decay). The consequence of 5' 
isomiRs is more obvious in plants, where the first 5' nt of a miRNA is the major 
determinant for AGO protein association {87). For instance, addition of a U to the 5' end 
of Arabidopsis miR-156 leads to association with A G 0 5 instead of AGOl (which is the 
major AGO for miRNA post-transcriptional gene silencing in plants) {86). The analysis of 
isomiR expression and function will be an important aspect of future cardiac miRNA 
analysis. 
Even more enigmatic is the function of the extremely common 3' isomiRs. Sequencing 
data suggests that miRNA 3' ends are more heterogeneous compared to the 5' end (77, 88, 
89). The mechanisms of 3' end modification of miRNAs are not fuUy understood and 
appear to be varied, including 3' trimming, non-templated addition and alteration to 
Drosha and Dicer cleavage sites {62, 90, 91). However, it is Hkely that these modifications 
are biologicaUy important, as there is evidence that some modifications alter miRNA 
turnover {92), can alter preferential loading into one of 4 mammaHan Argonautes {62) and 
are developmentally regulated ( « ) . Although 3' isomiRs share a common seed sequence, 3' 
end changes can impact target selection or efficiency of repression in some cases. For 
example, terminal uridylation of miR-26 (which has high expression in the heart) in 
immune ceUs abrogates repression of interleukin {93). MiRNA 3' isomiRs need to be taken 
into account when designing primers for qPCR detection, as weU as mimics and inhibitors 
for experimental and therapeutic manipulations. 
MiRNA variation can additionaUy arise from RNA editing of internal nucleotides. Most 
RNA editing m human ceUs occurs by Adenosine Deaminases Acting on RNA (ADARs) 
that deaminate adenosine to create inosine (A-to-I), which then base pairs with cytosine 
{94). This editing can alter miRNA precursors and regulate miRNA biogenesis, as weU as 
change the sequence of the mature miRNA {99). The biological mipHcations of RNA 
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editing are highlighted by miR-376-a l -5p , 41% of which undergoes editing in the human 
medulla oblongata {96). The A-to-I edited site occurs within the seed sequence, changing 
the binding specificit\' of the miRNA. This alteration allows miR-376-a l -5p to target 
phosphoribosyl pyrophosphate synthetase 1 (PRPS l ) , an essential housekeeping enzyme in 
the uric acid synthesis cycle, to tightly regulate uric acid levels in select tissues such as the 
brain cortex {96). This form of RNA editing is most common in neuronal cells and there is 
Htde evidence for this modif icat ion in cardiomj'ocytes. However, as a splice variant of 
A D A R 2 is highly expressed in the heart (97), there may be cardiac environments where this 
modif icat ion is important to m iRNA action and regulation. 
Thus, the initial concept that miRNA processing leads to a single mature miRNA that 
targets a canonical set of m R N A s has to be modified. It is necessary to accommodate the 
potential for a broader collective targeting range of all the miRNA processing variants 
derived from a given miRNA locus (Figure 1 ..3). 
1.2.4 R i - g l ' i . a t i o n o I ' m i R N A b i o g e n i - : s i s 
Transcriptional regulation of miRNAs generally occurs via standard promoter element-
determined mechanisms, whether via their own promoter or the promoter of the gene they 
are embedded in {9S). Additionally, the epigenetic mechanisms that transcriptionally 
regulate m R N A s can also contribute to silencing of miRNA genes. For example, all three 
loci of the tumour suppressor miR-9 are hypermethylated in gastric cancer, which leads to 
repression of miR-9, and subsequently proliferation of gastric cancer cells {99). 
It is often observed that the levels of pr i-miRNA and mature miRNAs are poorly 
correlated (/OO), demonstrating the central importance of posttranscriptional regulation to 
the genesis of a specific miRNA population. And it appears that the regulation of Drosha 
cleavage is a central step. While DGR8/Drosha are the minimal components of the 
"microprocessor ' required for pr i -miRNA cleavage, in vivo Drosha resides in multiple 
protein complexes (which may commonly contain the p68 and p72 helicases) and 
associates with multiple regulator)- proteins. For example, l i R a and p53 interact with the 
microprocessor (probably through p68 and p72) to inhibit and stimulate miRNA 
biogenesis, respectively (/O/, 102). Interestingly, the biogenesis of miR-21 in smooth 
muscle is promoted by transforming growth factor beta (^rGF-P) and bone morphogenetic 
protem (BMP) signallmg, via interaction of S M A D l with p68 and direct mteraction of R-
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SMADs with the pri-miR-21 in a ligand and sequence-dependent manner {lOT). It remains 
to be seen if this regulation is also important for the central role of miR-21 in the heart 
{104). 
There is a plethora of other RNA binding proteins that directly bind to miRNA harrpins 
and regulate their processing. Of importance to cardiac function is the regulation of miR-1 
expression by LIN28 and musclebind-Hke splicing regulator 1 (MBNLl), which both 
compete for binding to the loop of pre-miR-1. Binding of LIN28 to pre-miR-1 stimulates 
Zinc finger CCHC domain containing 11 (ZCCHCl l)-mcdiated uridylation of the precursor 
and blocks Diccr processing, whereas binding of MBNLl is permissive to Dicer processing 
(/Oi). This regulation is permrbed in myotonic dystrophy, where overproduction of a 
CCUG repeats sequesters MBNLl and leads to downregulation of miR-1 expression and 
multiple cardiac phenotypes. Similar regulation of miRNA biogenesis is observed during 
the developmental fluctuations in let-7 expression, which result from competition between 
LIN28A (which again stimulates uridylation of the pre-miR) and KH-t)'pe splicing 
regulator protein (KSPR) for binding to the loop of pre-let-7 {WS). Interestingly LIN28B 
also represses let-7 processing, but this time in the nucleus through inhibition of 
microprocessor processing, highlighting the multiple levels of regulation microRNAs can 
be subjected to {107). 
Another example of hairpin binding provides insight into the differential expression of 
clustered miRNAs, which are co-transcribed but commonly differentially expressed. The 
highly abundant hnRNP A1 protein is essential for pri-miR-18a processing but not 
required for the expression of other members of the miR-17-92 cluster. In this case, 
hnRNP A1 binds to the loop of the hairpin to relax the stem region and facilitate Drosha 
cleavage {10S). Decreased expression of this cluster, including miR-18a, in cardiomyocytes 
has been linked to age-related heart failure {109). 
Importantly, the hairpm bindmg proteins described above have aU been demonstrated to 
regulate and/or bmd other miRNA precursors and there are Hkely to be further proteins 
discovered with similar functions. It is Hkely there are many more examples of signalling-
dependent miRNA processing. 
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1 . 2 . 5 C O R E C A R D I A C M I R N A S : T H E I R I - U N C T I O N A N D T H E I R 
V A R I A T I O N 
1 . 2 . 5 . A A B U N D A N T A N D SPECIFIC C A R D I A C M I R N A S 
In mos t , if not all, ce l l/t issue t) 'pes s tudied to date a smal l numbe r of m i R N A s are highly 
expressed , potent ia l ly enforc ing t issue ident i ty {110). In the adult m o u s e heart the top 18 
highly expressed m i R N A s account for > 9 0 % of the m i R N A populat ion (///) and inc lude 
m e m b e r s of the let-7, miR-22 , m iR-208 , m iR-133 and miR-30 famil ies. Th is abundance can 
result f r o m indiv idua l regulat ion or regulat ion of the "hos t " gene. For example , the two 
m i R - l / m i R - 1 3 3 a c lusters are highly expressed in both skeletal and cardiac musc le , wherea s 
the rmR-206/miR-133b cluster is only highly expressed in skeletal musc le {112, 113). Th is 
can be at t r ibuted to their independent regulat ion by key m y o g e m c transcr ipt ion factors, 
such as s e rum response factor (SRF) and M E F 2 {48, 112). Alternat ively , another heart-
spec i f ic m i R N A , miR-208a , is encoded wi th in an intron of a - m y o s i n heavy chain ( a - M H C ) 
gene M y h 6 {114). T h e (3-MHC gene (Myh7) encodes another m iR-208 family member , 
m i R - 2 0 8 b {IIS). Unl ike the m i R - l / m i R - 1 3 3 clusters that conta in their own promoters , the 
t issue specif ic i ty of m iR-208a and miR-208b is contro l led by the express ion of a - M H C and 
P - M H C , respect ive ly (//5), wi th a - M H C and miR-208a highly expressed in mur ine adult 
ca rd iomyocy tes . Interest ingly , mrR-133a exists as two i somiRs , wh i ch are p roduced f rom 
both of the m iR-133a clusters {79). T h e indiv idual roles of these miR-133a var iants in 
card iac funct ion and disease have yet to be addressed. 
1 . 2 . 5 . B E X P R E S S I O N P A T T E R N S OF M I R N A S IN CARDIAC DISEASE 
T h e express ion pat terns of m i R N A s in var ious cardiac hyper t rophy-assoc ia ted diseases in 
bo th h u m a n pat ients and mur ine mode l s have been extensively examined (rev iewed in 
{116-118)), for the mos t part us ing microarray analysis of canonica l , m iRbase -de f ined 
m i R N A species and s h o w that the major i ty of highly expressed cardiac m i R N A s are 
d i f ferent ia l ly regu la ted in cardiac disease (/19). 
T h e first prof i le of cardiac m i R N A s was descr ibed by V a n Rooi j et al. in 2006, w h o 
m e a s u r e d n d R N A express ion in two mode l s of cardiac hyper t rophy ; t ransverse aort ic 
constr ic t ion ( T A C ) and t ransgenic mice overexpress ing C n A {120). CoUectively, 60 
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tniRNAs were upregulated and 20 were downregulated, with 21 and 7 up or down in both 
models, respectively. Both, anti-apoptotic miRNAs, such as miR-21, and miRNAs critical 
for cell proliferation, such as miR-23, were upregulated during hypertrophy and it was 
hypothesised that they play an important role in hypertrophic cell enlargement. 
Furthermore, overexpression of miRNAs downregulated m hypertrophy, including miR-
133a, caused a reduction in cell size suggesting these miRNAs may function to suppress 
cell growth {120). The expression changes of miRNAs identified by subsequent murine 
studies are highlighted in Table 1.1. Importantly, different hypertrophic stimuK, such a 
phenylephrine (PE) and FGF, can activate distinct molecular pathways. In this case, PE 
triggers an increase in intracellular calcium, which stimulates hj'pertrophic gene 
transcription via NFATc, while FGF acts through MAPK signalling {4). Given that 
multiple pathways can initiate and transduce hypertrophy, it is not surprising that miRNA 
profiles are not always consistent between different models of hypertrophy. For example, 
miR-142-3p is upregulated in hearts after TAG but unaltered in cardiomyocytes treated 
with PE {121). 
The expression of many miRNAs alters significandy in other human heart diseases, 
including ischemic cardiomyopathy (ICM) and dilated cardiomyopathy (DCM), and it is 
thought these miRNA changes contribute to the progression of heart disease and 
subsequent heart failure {120, 122-124). Cardiomyopathies are heart muscle diseases that 
result in a deterioration of heart function, which usually leads to heart failure. DCM is 
characterized by dilatation of the cardiac chambers and impaired contractile function of 
one or both ventricles {125). It is a leading cause of hospitalization and death in Western 
countries and can result from several factors, such as pressure or volume overload, 
inherited mutations and ischemia {125). Alternatively, ICM, which accounts for >50% of 
heart failure cases, develops when coronary heart disease or heart attack leads to 
myocardial ischemia and/or infarction {126). It is hypothesised that, despite the underlying 
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Table 1.1. m i R N A s differentially expressed in murine models of hypertrophy. (A) TAG and 
constitutively activated ca lcmeunn (CnA) mice (120). (B) TAG at 24 hours, 7 days and 14 days 
(127). (G) Phenylephrine (PE) treated cardiomyocytes and 14 days post TAG {121). (D) TAG at 7 
days, 14 days and 21 days {128). (E) Early and end-stage hypertrophic cardiomyopathy (HGM) 
using a transgenic mouse (129). (F) TAG at 7 days (130). (G) TAG at 7 days (131). * conf irmed by 
Northern b lo t , " conf i rmed with RT-qPGR, ^ could not be confirmed. 
miRNA 
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T a b l e 1.1. cont . m i R N A s di f ferent ia l ly expressed in mur ine mode l s of hyper t rophy. (A) TAG 
and const i tut ive ly act ivated ca lc ineur in (CnA) micc (120). (B) TAG at 24 hours , 7 days and 14 days 
(127). (C) Pheny l ephr ine (PE) treated ca rd iomyocy tes and 14 days post TAG (121). (D) TAG at 7 
days, 14 days and 21 days (12S). (E) Early and end-s tage hyper t rophic ca rd iomyopathy (HGM) 
u smg a t ransgenic mouse (129). (F) TAG at 7 days (130). (G) TAG at 7 days (131). * conf i rmed by 
Nor the rn blot , " con f i rmed wi th RT-qPGR, ^ could not be conf i rmed . 
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etiology that initiates heart failure, there is a final common pathway in advanced or end-
stage heart failure {132, 133). These similarities arc reflected in the transcriptome and 
proteome, with littie detectable differences between ICM and DCM (132). It is of no 
surprise then, that numerous miRNAs are also consistently up or downregulated in the 
progression to heart failure, for example miR-195 increases and miR-222 decreases in end-
stage ICM and D C M (expression changes in human heart disease are shown in Table 1.2). 
MiR-195 is also uprcgulated early in murine hypertrophic hearts and cardiac specific 
overexpression of miR-195 induced adverse cardiac remodeling which led to heart failure 
{120). Whi le miR-195 regulates numerous cell cycle genes during development {134), it has 
been postulated that the role of miR-195 in heart failure is due to the downregulation of 
multiple pro-survival proteins {139). 
Nevertheless, while there are commonalit ies, there are distinct subsets of miRNAs 
expressed for each heart condition. For example, miR-19 is downregulated in DCM but 
unaltered in ICM patients, suggesting some miRNA changes do not simply reflect end-
stage heart disease but, instead, disease-specific gene expression changes {124). 
Distinguishing between ICM and D C M patients is currently difficult, with incorrect 
classification of ICM and D C M heart failure estimated to occur in 13% of heart failure 
patients (/i6) . Encouragingly, the miRNA profiles are sufficientiy dissimilar between 
disease classes that clinical diagnosis of DCM, ICM and aortic stenosis (AS) could be 
predicted in 69% of cases {124). Although promising, miRNA expression profiles are of 
l imited cKnical utility as biopsy of the heart is required. However, measurement of cardiac 
m iRNAs in the plasma may prove informative. For instance, miR-1 and miR-208a are both 
elevated in the blood of patients following myocardial infarction {137, 138) and circulating 
levels of miR-423-5p increase specifically in heart failure patients {139). One definite 
outcome of these profi l ing smdies is the identification of cardiac disease-related miRNAs 
that warrant functional interrogation in the heart. 
I n t r o d u c t i o n 
Table 1.2. miRNAs differentially expressed in human heart disease. (A) Dilated 
cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM) patients (123). (B) DCM, ICM and 
patients with aortic stenosis (AS) (124). (C) End stage heart failure (HF) patients (122). # confirmed 
by Northern blot," confirmed with RT-qPCR, ^ could not be confirmed. 
mIRNA ICM DCIvf icivf A S " 
End stage 
HF 
lel-7c-5p 
miR-10a-5p 
fniR-10b-5p 
miR-15b-5p 
miR-19a-3p 
miR-21 -Sp 
miR-22-3p 
mlR-23a-3p 
m.R-23b-3p 
miR-24-3p 
miR-27a-3p 
iiR-27b-3p 
miR-2e-5p 
miR-29a-3.. 
miR-30a-5p 
mtR-30c-5p 
miR-30e-5p 
miR-100-5p 
miR-101-3p 
miR-103-3p 
miR-106-5p 
miR-125a-5p 
miR-133a-3p 
miR-133b-3p 
miR-139-5p 
miR-181a-5p 
miR-181b-5p 
miR-214-3p 
mtR-221-3p 
miR-494-3p 
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1 .2 .5 .C M i R N A S ARE INVOLVED IN HYPERTROPHIC SIGNALLING 
PATHWAYS 
Profiling studies have been extended to experiments designed to understand the role of 
single miRNAs in the induction and progression of pathological cardiac hj^ertrophy to 
heart failure. Gain- and loss- of-function experiments have uncovered both pro- and anti-
hypertrophic miRNAs. A Hmited number of mRNA targets have also been identified, 
allowing us to begin to integrate miRNAs into the complexity' of hypertrophic signalling. 
miR-1 and miR-133a are anti-h)'pertrophic miRNAs and are downregulated during cardiac 
hypertrophy, which leads to stimulation of hypertrophic pathways via the de-repression of 
targets such as IGF-1, NFATc, calmodulin and calcineurin (//<?). Downregulation of miR-
1 results in increased levels of IGF-1, which leads to activation of the small GTP protein 
Ras and subsequent activation of the MAPK signalling pathway. As mentioned previously, 
the M A P K pathway results in the dual phosphorylation and activation of p38, J N K s and 
ERKs , which each phosphorylate multiple targets and transcription factors that induce 
hypertrophic gene expression. IGF-1 also results in activation of PI3K, which mrns on the 
serine/threonine kinase Akt, and leads to activation of mTOR and inhibition of GSK3p. 
Activated GSK3P normally negatively regulates hypertrophy transcription factors such as 
GATA4 and NFAT, while m T O R increases protein synthesis. Additionally, both miR-1 
and miR-133a have been implicated in the calcineunn-NFAT circuit. Activation of 
calcineurin dephosphorj'lates NFAT, which allows N F A T to translocate to the nucleus and 
activate the heart failure gene program. MiR-1 negatively regulates calmodulin, whilst miR-
133a represses both calcineurin and NFATc4. Thus, miR-1 and miR-133a are targeting 
ligands (IGF-1), effectors (calcineurin) and transcriptional regulators (NFATc4) of 
hypertrophy that ensures appropriate regulation of signalling pathways at all levels. In line 
with their anti-hypertrophic role, inhibition of miR-133a in vivo by an antagomiR (a small 
synthetic RNA that is perfectiy complementary' to the target miRNA, silencing its 
expression) is sufficient to induce the hypertrophic response {140). 
MiR-9 is another anti-hj'pertrophic miRNA whose expression decreases after hy-pertrophy 
stimulated by aldosterone and isoproterenol. Administration of a miR-9 mimic into the 
adult mouse heart was capable of inhibiting the hypertrophic response after stimulation 
with isoproterenol (a (3- adrenergic agonist that stimulates of (3- adrenergic receptor, a t>'pe 
of GPCRs) {141). MiR-9 overexpression prevented the increase in heart weight. 
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cardiomyocyte size and upregulation of hypertrophic markers as seen in the control 
animals {141). Furthermore, administration of miR-9 improved fractional shortening, the 
ratio between the diameter of the LV when it is relaxed and contracted and is a measure of 
the contractile function of the left ventricle (LV), consolidating its anti-hypertrophic role 
{141). MiR-9 inhibits hypertrophy by directly targeting myocardin, a transcriptional 
coactivator that mediates the signalling of NFATc3 by inducing expression of hypertrophic 
genes such as ANF, BNP, a-SkA and (B-MHC {141, 142). Isoproterenol leads to an 
increase in the dephosphorj'lated and active form of NFATc3, which transcriptionally 
upregulates myocardin to convey the hypertrophic signal. The decrease of miR-9 in 
isoproterenol and aldosterone stimulated hypertrophy removes the negative regulation of 
myocardin, and thus the calcineurin/NFAT-signaUing pathway is amplified. To date, 
changes in the expression levels of miR-9 in hypertrophy induced by pressure overload 
have not been documented. However, as myocardin levels also increase in the hearts of 
mice subjected to TAG, it is plausible that miR-9 regulation of myocardin is downstream of 
several hv-pertrophic stimuli {142). Interestingly, the length of both miR-9b and miR-9c are 
dynamically regulated at the 3' end during Drosophila development It is currently not 
known if miR-9 has variable 3' ends in mammalian cardiomyocytes and if they play a role 
in cardiac development and hypertrophy. 
Profiling studies have also revealed miRNAs whose expression increases during the 
hypertrophic response. Several of these miRNAs, such as miR-21, miR-208a and miR-195, 
are pro-h)pertrophic and stimulate cardiac remodeling and hypertrophy. Cardiac specific 
overexpression of miR-208a was sufficient to induce hypertrophy, and mice lacking miR-
208a are resistant to fibrosis and hj'pertrophy after cardiac stress {114, IIS). The pro-
hypertrophic properties of miR-208a are partially mediated by the repression of T3 
receptor coregulator 1 (THR.\P1) and myostatin, both negative regulators of muscle 
growtii and hypertrophy {IIS). Myostatin normally inhibits phosphor5'larion of p38, a 
downstream effector of the MAPK pathway, and Akt (see above)(/-^i). Repression of 
myostatin by miR-208a would thus increase hypertrophic signalling via the MAPK and 
PI3K/Akt pathways. It was recentiy shown that miR-27b is also pro-hypertrophic and can 
positively regulate hypertrophy in vivo. Wang et al. generated transgenic mice expressing 
miR-27b under the control of the a -MHC promoter {144). The miR-27b overexpressmg 
mice were born normal but developed severe cardiac hypertrophy at 3 months of age, 
characterized by increased heart weight, LV enlargement and expression of hypertrophy 
Introduction 
markers like A N F . Fract ional shortening was also decreased in miR-27b mice indicat ing 
impa i red cardiac funct ion. The levels of miR-27b normal ly increase in hearts subjected to 
pressure over load by TAG, whi le inhibit ion of miR-27b levels usmg antagomiRs in mice 
already subjected to TAG reversed the signs of hypertrophy and returned L V contracti le 
funct ion to normal . MiR-27b direcriy targets perox isome proliferator-acrivated receptor Y 
(PPARy) , a transcript ion factor that inhibits the deve lopment of cardiac h\'pertrophy likely 
through inhibit ion of N F - k B {144). 
It is evident f rom studies thus far that m i R N A s regulate signall ing pathways critical to 
cardiac hypertrophy. A n increased understanding of m iRNA function and their targets 
wi th in card iomyocytes will al low us to incorporate m i R N A s into the signall ing cascades 
that occur after cardiac insult. 
1 . 3 A L T E R N A T 1 \ ' E P O L Y A D E N L Y . V T I O N 
miRNA-med i a t ed regulat ion depends equally on the presence of the corresponding binding 
site(s) within the m R N A . This principle not only underl ies differential targeting of m R N A s 
orig inat ing f rom different genes but also applies to m R N A variants derived f rom the same 
gene. This is because ceUs, m addit ion to promoter choice and variable splicing, can also 
use mult ip le sites for alternative m R N A 3' end cleavage and polyadenylat ion (APA) to 
generate further transcript diversit}'. 
1 . 3 . 1 P O L Y A D E N Y L A T I O N 
The 3' U T R s of m R N A s contain var ious a.f-acting elements involved in post-
transcript ional gene regulat ion, including m iRNA and R N A binding protein binding sites, 
as wel l as one or more polyadenylat ion signals (PAS). Polyadenylat ion involves recognit ion 
of the P A S and subsequent c leavage at the downst ream polyadenylat ion (poly(A)) cleavage 
site, fo l lowed by polymer izat ion of the adenosine tail by poly(A) polymerase (PAP) to a 
species-specif ic length ( - 1 5 0 - 2 5 0 nucleot ides in mammal s ) {145. 146). 
The human 3' process ing complex consists of approximately 85 proteins, including 
c leavage and polyadenylat ion specificity- factor (CPSF), cleavage st imulat ion factor (CstF), 
c leavage factor I and II (CFIm and C F l I m ) and PAP, some of which interact with 
sequence e lements surrounding the poly (A) c leavage site (Figure 1.4) {U7). A conser\-ed 
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consensus hexamer A A U A A A , the PAS, is found 10-35 nt upstream of the poly(A) 
cleavage site and is recognized by the multi-subunit CPSF, which consists of at least five 
subumts (CPSF 160, CPSF 100, CPSF73, CPSF 30 and h F i p l ) {148). CPSF160 interacts 
with the PAS {149), CPSF73 is responsible for the cleavage of the mRNA {150), and hFipl 
{151) and CPSF30 {152) bind to the U-rich sequences that surround the cleavage site. The 
other predominant sequence element is a G/U or U-rich region located 30 nt downstream 
of the cleavage site (downstream sequence element, DSE). The DSE is recognised by 
CstF64, a component of the heterotrimeric CstF, which increases the efficiency of 3' end 
processing {155). In the absence of the canomcal PAS, cleavage of the 3' end depends on 
an upstream U G U A sequence, which is recogmsed by CFIm {154). Additional sequences 
located upstream (upstream sequence elements, USE) or downstream (auxiliar)-
downstream element, auxDSE) of the cleavage site act as accessor)' sequences for 3' 
processmg. USEs are U-rich and provide additional interaction sites for the canonical 3' 
end processing machinery or recruit auxilian,- processing factors {155). The auxDSEs are 
normally G-rich and regulate cleavage by providing a binding site for regulator)' factors 
enhancing 3' end processing efficicncy {156, 157). The sequence elements and associated 
proteins are critical for the regulation of poly(A) site usage. 
PAP 
< — - CFIIm 
CFIm CPSF CstF 
1 1 1 -1 1 1 1 1 1 1 1 1 
u-rich 
UGUA 
PAS 
AAUAAA 
GU-rich U-rlch G-rich 
cleavage site 
Figure 1.4. 3' end processing machinery and sequence elements. 
Components of the 3' end processing machinery and the sequence elements they interact with 
around the poly(A) cleavage site. CFIm; Cleavage factor I, CFIIm; Cleavage factor II, CPSF; 
Cleavage and polyadenylation specificity factor, CstF; Cleavage stimulation factor. Image modified 
from {158, 159). 
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1 . 3 . 2 A L T E R N A T I V E P O L Y A D E N Y L A T I O N 
More than half of the genes in the human genotne can be subject to alternative cleavage 
and polyadenylation, meaning that the terminal exon contains multiple poly(A) sites that 
can result in m R N A isoforms with different 3' UTR lengths (160) (Figure 1.5). Longer 3' 
UTRs generated from the distal poly(A) site are usually 2-fold longer than shorter 3' LITRs 
and thus place the m R N A under the regulation of more aV-acting factors For 
example, 52% of human miRNA target sites exist downstream of the first poly(A) site 
{162). 
Alternative polyadenyladon (APA) appears to be tightly regulated; it is controlled by both 
differentiation and proliferation states as 3' UTRs lengthen during embn'onic development 
and shorten in the generation of induced pluripotent stem (iPS) cells {161, 163). Cancer 
cells frequendy exhibit short 3' UTRs to escape regulation by miRNAs and other ds-Acxing 
elements, resulting m the over-expression of oncogenes {164). 
Studies using expressed sequence tag (EST) data have revealed that several tissue types are 
biased in their poly(A) site usage. For example, mRNAs in the brain have long 3' UTRs 
while testes have short 3' UTRs {165, 166). Despite the technological advances allowing 
measurement of 3' UTRs, the phenomenon of APA has not been extensively studied in 
cardiac biologj'. 
1 . 3 . 3 A P A IN C A R D I A C B I O L O G Y 
There is some evidence for alternative 3' UTR regulation of m R N A transcripts encoding 
important cardiac functions in existing EST databases, such as the poly(A) clcavage site and 
3' UTR database (PACdb)(/(f7). For example, ceU division cycle 42 (CDC42), a smaU GTP-
binding protein that amplifies hypertrophic gene expression {4), contains multiple poly(A) 
sites along the length of its 3' UTR (Figure 1.6). ESTs suggesting use of both the distal and 
proximal poly(A) cleavage sites for CDC42 have been derived from the heart. An 
important implication for its post-transcriptional regulation is the presence of binding sites 
for several cardiac miRNAs (including miR-133a and miR-1) after the proximal poly(A) 
cleavage site, which are not present in the shorter 3' UTR isoform (Figure 1.6). Therefore, 
use of different poly(A) sites along the CDC42 3' UTR substantiaUy changes the degree of 
expected miRNA-mediated repression. 
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Short 3'UTR CDS 
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targeting 
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Figure 1.5. Alternative m R N A 3' end formation and consequences for targeting by 
miRNAs. 
(A) Schematic of exon/intron organization of a gene. 5' and 3' UTR: grey areas; coding 
sequence: white area. m R N A 3' end cleavage and polyadenylation at alternative sites 
(poly(A) signal: A A U A A A ) can generate m R N A s of different 3' UTR lengths, thus (B) expanding 
the range of miRNAs that may target a gene. Core miRNA targeting sites included in all mRNA 
variants: small circle; targeting sites in extended m R N A variants: large circle; miRNA 
target sites: upright bars. Image taken from (77) with permission. 
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miR-29a/b/c 
• ^ p o l y l A ) site . used in the heart | Cardiac miRNA target sites 1 
Figure 1.6. CDC42 m R N A exists as multiple 3' UTR variants. 
Terminal exon of CDC42 indicating multiple functional poly(A) sites along its length. Lines 
represent EST data from PACdb (167) suppordng these sites. The EST data supporting the distal 
site (on the right) was extensive, for graphical reasons the number of ESTs below tliis site has been 
abbreviated (indicated by the dots). Poly(A) cleavage sites: triangles (striped if based on cardiac-
derived ESTs); target sites (confirmed/predicted) for miRNAs with cardiac function: coloured bars. 
Image taken f rom (77) with permission. 
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While initial global-based studies had insufficient depth (166), one recent study examined 
gene regulation in cardiac hypertrophy using genome-wide exon microarrays and analysed 
their data for altered 3' UTR usage (168). It was obsenxd that 315 mRNAs changed 3' 
UTR length, with 211 becoming shorter, including Cdkl3 and Tia l , suggesting there may 
be a tendency towards mRNAs losing miRNA-mediated regulation in hypertrophy. 
However, as this microarray analysis relied on poorly annotated murine 3' UTRs in public 
databases and lacks the sensitivity to unambiguously define expressed UTRs, further work 
is required to determine UTR usage in the heart and to understand UTR dynamics in 
h^'pertrophy. 
1 . 3 . 4 R E G U L A T I O N OI ' A P A 
While our appreciation that 3' UTR lengths are regulated is mamring, our knowledge of 
how this regulation occurs is still in its infancy. Genome-wide studies have indicated that 
there is a correlation between levels of proteins involved in polyadenylarion and the global 
3' UTR length. For instance, two of the core polyadenylation factors, CPSF and CstF, are 
strongly upregulated during the generation of iPS cells (16J). A higher concentration of 3' 
processing factors would allow the proximal poly(A) site, which often has a weaker PAS, to 
be chosen and, thus, shorter 3' UTRs generated. In agreement, mRNAs have shorter 3' 
UTRs in iPS cells (163). Interestingly, the mRNAs corresponding to CstF proteins are 
upregulated as early as three days post-transverse aortic constriction, indicating that 3' UTR 
isoform regulation may be a component of ver)' early stage hypertrophy {169). 
The functional outcomes of 3' UTR length variation have been best smdied in cancer, 
where it is recognized that oncogenes are often expressed with short/minimal 3' UTRs and 
become refractor)' to miRNA-mediated repression, greatly increasing their expression {164, 
170). Tissue-specific 3' UTRs have also been obser\'ed in Zebrafish, which presumably 
alter the abilit}' of specific miRNAs to repress the expression of the respective mRNAs in 
different cellular environments {171). Commonly, multiple 3' UTR isoforms arc co-
expressed and therefore different portions of the mRNA population fall under the 
regulation of miRNAs {170). Furthermore, short 3' UTRs often still encode miRNA-
bindmg sites, suggesting a shift to a different form of miRNA-mediated regulation in these 
cases. It is likely that the gene expression outcome of 3' UTR length variation will be 
specific for individual mRNAs and the miRNA environment they find themselves in. The 
obser\'arion that some mRNAs change theu- 3' UTR length m hj'pertrophy according to 
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microarray analysis suggests that complex changes to miRNA:mRNA networks are 
occurring in this response that warrant further analysis {16S). The possibility' of directing 3' 
UTR usage as a therapeutic inter\'cntion {172) further highlights this as an area of research 
interest for the heart and its disease states. 
There have been inconsistent findings in the literature examining the expression levels of 
polyadenylation factors in the mouse embryo. One study showed high levels of some 
polyadenylation factors but low levels of others in the embr)'onic heart {163), while another 
smdy showed low levels of all polyadenylation associated factors {t6ff). Furthermore, the 
global studies making use of ESTs have focused mainly on embrj'onic samples so litde is 
known about 3' UTRs in the adult and ver)' litde data is available on APA regulation in 
disease (with the exception of cancer). However, the fact that there is a correlation between 
the levels of the proteins involved in polyadenylation and global 3' UTR length suggests 
that 3' UTR length is dynamically regulated. 
1 . 4 A I M S 
MrRNAs play critical roles in the heart; they regulate the molecular pathways that are 
deregulated during the progression of heart disease. It is now known that cells can produce 
both miRNAs and their mRNA targets in multiple processing variants, which increases the 
complexity' of miRNA-mediated control. Thus, the hypothesis underpinning these smdies 
is that during the cardiac hypertrophic response there are changes to miRNA processing, as 
well as 3' UTR usage, which will alter miRNA;mRNA interactions. 
The overall aim of diis thesis is to examine variants of both miRNAs and mRNAs that can 
modify the miRNA:mRNA interactions in both normal and hypertrophic tissue. A mouse 
model of left ventricular hypertrophy will be cstabHshed and cardiomyocytes isolated to 
examine changes occurring specificaUy in this ceU type. Next generation sequencing will 
then be used to generate miRNA and mRNA 3' end datasets. The data will be interrogated 
for expression level changes during the development of hypertrophy, and for evidence of 
processing variants. 
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1 . 4 . 1 D E T A I L E D A I M S 
To achieve the overall aim of identifying miRNA and mRNA 3' UTR variant changes 
during cardiac hj'pertrophy, the project was divided into the following specific aims: 
Aim 1: To establish a murine model of left ventricular hj^pertrophy (Chapter 3). 
Aim 2: To identify changes in miRNA expression and processing in normal, pre-
hypertrophic and hypertrophic cardiomyocytes (Chapter 4). 
Aim 3: To determine mRNA 3' UTR usage and differential gene expression in normal, 
pre-hypertrophic and hypertrophic cardiomyocytes (Chapter 5). 
Aim 4: To investigate the functional and mechanistic implications of these processing 
variants on miRNA action (Chapter 6). 
CHAPTER TWO 
MATERIALS AND 
METHODS 
Methods 
2.1 MATERIALS 
2 . 1 . 1 C H E M I C A L S AND R E A G E N T S 
Amresco (Solon OH, USA) 
BD Biosciences 
(FrankUn Lakes, NJ, USA) 
Corning 
(Tewksbury, MA, USA) 
GE Healthcare 
(Little Chalfort, BICM, UK) 
Life Technologies 
(Carlsbad CA, USA) 
Merck 
(Darmstadt, Hesse, Germany) 
National Diagnostics 
(Adanta, GA, USA) 
New England Biolabs 
(Ipswich, MA, USA) 
PerkinElmer 
(Waltham, MA, USA) 
Ptomega 
(Madison, WI, USA) 
Roche Applied Science 
(IndianapoUs, IN, USA) 
Sigma 
RNA EZ-Vision® dye 
Bacto^"^ tryptone peptone digest, Bacto^" yeast extract, 
Bacto''''^ agar 
T-75 flasks, 6-well plates, 0.22 |xm Vaamm filter 
GE Hybond-N^ membrane 
Novex® TBE-Urca Sample Buffer, SYBR® Gold Nucleic 
Acid Gel Stain, DMSO, BigDye® Terminator v l . l Ready 
Reaction Mix, AmpiciUin, AmpliTaq Gold® 360 Master 
MLX, Glycogen, ATP, LipofcctamineT" 2000, Opt i -MEM® 
Reduced Serum Media, TRIzol® Reagent, Phenol, 
UltraPureTM DNase/RNase-Free Distilled Water, NaAc, 
DMEM, fetal bovme serum (FBS), Fast SYBR® Green 
Master Mix 
Ethanol, isopropanol, Na^HPO, Pellet Paint® Co-
precipitant 
SequaGel - UreaGel System 
Bovine serum albumin (BSA), Random primer mix, 10 x 
RNL2 buffer, NEB Next® Small RNA Library Prep Set for 
SOLiD^M, dNTPs, Streptavidin magnetic beads 
[y-"P]-ATP 
Passive Lysis Buffer, ammonium persulfate , X-gal 
LightCycler® 489 S^'BR Green I Master 
Agarose - Low gelling temperature, Claycomb media, 
Methods 
(St. Louis, MO, USA) 
\ 'WR International 
(Radnor, PA, USA) 
Penicil l in-streptomycin (Pen-Strep), noradrenaline, L-
glutamine, Tr^psin-EDTA, fibronectin, gelatin from bovine 
skin, T E M E D , acr)'lamiclc/bis-acr\'lamide 40% solution. 
Perfect Hyb Buffer, 24% Peg 8000, EtBr solution, Tns-HCl. 
KCl Bioultra, chloroform, trisodium citrate, HCl, KH^PO^, 
MgSO^-TH^O, NaHCO, , Na-Hepes, taurine, BDM, 
ascorbic acid, phosphate buffered saline (PBS), NaOH, 
NaOAc, EDTA, bromophenol blue, xylene cyanol, 
formamide 
NaCl, glucose, CaCl, , urea 
2 . 1 . 2 K I T S 
Agilent 
Life Technologies 
Promega 
Qiagen 
(Hilden, North Rhine-
Westphalia, Germany) 
RNA 6000 Nano LabChip kit, High Sensitivity DNA 
Analysis kit 
Poly(A) Tailing kit 
PureYield"'^" plasmid miniprep system, Dual-Luciferase® 
Reporter Assay System 
QIAquick gel extraction kit 
2 . 1 . 3 E N Z Y M E S 
Most enzymes were sourced from New England Biolabs. Other enzymes were supplied by: 
Affy'metrLx Optikinase 
(Santa Clara, CA, USA) 
Life Technologies Type II CoUagenase, Turbo DNase, RNaseOUTT" 
Recombinant Ribonuclease Inliibitor, TURBO'f'^ DNase, 
Superscript® III Reverse Transcriptase 
Promega Shrimp Alkaline Phosphatase (SAP) 
Roche AppHcd Science RNase T l , Fast Start Taq DNA polymerase 
Worthington Type 11 CoUagenase 
(Lakewood, NJ, USA) 
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2 . 1 , 4 B U F F E R S A N D S O L U T I O N S 
2 . 1 . 4 . A B U F F E R S A N D S O L U T I O N S FOR G E N E R A L M O L E C U L A R B I O L O G Y 
/ .V TAB: 
40 mM Tns-HCl (pH 8.2), 20 mM NaAc and 10 mM EDTA (pH 8.2). 
2 X RSA loading dye 
1 mM EDTA, 0.1% bromophenol blue, 0.1% xylene cyanol, 95% formamide. 
/ X TE: 
10 mM Tns-HCl (pH7.5) and 1 mM EDTA. 
1 X PAGE elution buffer: 
2.5 M NaAc in TE buffer. 
/ X Ijoiv TE: 
10 mM Tns-HCl (pH8) and 0.1 mM EDTA. 
OJx'lBE: 
45 mM Tns-borate (pH8), 1 mM EDTA. 
10 X diges! b i i f f h -
3 M NaCl, 10% Tris (pH7) in double distilled water (ddH^O). 
2 X ligation buffer: 
40 nl 24% Peg 8000 and 10 10 x RNL2 buffer 
2 . 1 . 4 . B B U F F E R S A N D S O L U T I O N S FOR N O R T H E R N B L O T T I N G 
20xSSC: 
3 M NaCl, 0.3 M trisodium citrate with the pH adjusted to 7 using HCl. 
2 . 1 . 4 . C B U F F E R S A N D S O L U T I O N S FOR C A R D I O M V O C Y T E I S O L A T I O N 
CM isolation perjiision buffer: 
120.4 mM NaCl, 14.7 mM KCl, 0.6 mM KH,PO„ 0.6 mM Na,HPO„ 1.2 mM MgS04-
7H2O, 4.6 mM NaHCOj, 10 mM Na-Hepes, 30 mM taurine, 10 mM 2,3-butanedione 
Methods 
m o n o x i m e (BDM), 5.5 m M Glucose. p H 7.3 and filtered through 0.22 |J,M filter. Prepared 
fresh each day. 
CoUagenase digestion buffer. 
C M isolation perfus ion buf fe r containing 2.4 m g / m l Type II CoUagenase. 
CoUagenase stop hnjfer: 
C M isolation perfus ion buf fe r containing 1 m g / m l BSA and 125 |xM CaClj. 
2 . 1 . 4 . D B U F F E R S A N D S O L U T I O N S FOR TISSUE CULTURE 
Koradretmline: 
10 m M Noradrenal ine made up in 30 m M ascorbic acid, filter-sterilized using 0.2 |Xm 
Acrodisc syringe filter. Noradrenal ine was made fresh monthly. 
Gelatin I Vihronectin: 
0.02% gelatin solution made u p in distiUed water then autoclaved. Fibronectin was then 
added to the gelatin solution to a final concentrat ion of 5 | ig /ml . 
Supplemented Oayamib media: 
Claycomb media containing 10% FBS, 100 Hg/ml Pen-Strep, 0.1 m M Norepinephr ine and 
2 m M L-Glutamine. Supplemented Claycomb media was stored in a luminum foil for a 
m a x i m u m of two weeks. 
hIL-l lree:(tng media: 
95% FBS, 5% D M S O 
Hl-^ / wash media: 
Claycomb media containing 5% FBS and 100 n g / m l Pen-Strep. 
2 . 1 . 5 P L A S M I D S 
I D T p I D T S M A R T 
Promega p s i C H E C K ™ - 2 , p G E M ® - T 
~ Methods 
2 . 1 . 6 O L I G O N U C L E O T I D E S 
Synthetic DNA primers for q-PCR and RNA oligonucleotides for small RNA Northern 
blots were synthesized by Integrated DNA Technologies (Coralville, lA, USA). Mission® 
miRNA mimics (Sigma) were used for miRNA functional studies. 
2 . 1 . 7 BACTi-RL-^L STRAINS 
Escherichia coli (E.coli) DH5a 
2 . 1 . 8 B A C T E R I A L GROWTH MEDIA 
]jtria Broth Agar: 
10 g/L Bacto® tryptone peptone digest, 5 g/L BactoC® yeast extract, 10 g/L Sodium 
chloride, 15 g/L Agar: agar was made up to a volume of 1 L with reverse osmosis (RO) 
HjO before autoclaving. One the media had cooled to approximately 55°C, ampicillin (100 
|Xg/ml) was added, the plates poured and then stored at 4°C. 
Vjiria broth: 
10 g/L Bacto® tryptone peptone digest, 5 g/L Bacto® yeast extract, 10 g/L Sodium 
chloride made up to a volume of IL with RO H2O before autoclaving. 
Transformation Buffer / fl't'B!): 
0.294 g Potassium Acetate, 0.989 g MnCl, 0.147 g CaCh. 15 ml 100% Glycerol were added 
to 75 ml H2O and the pH brought to 5.8 with HAc. L2g of RbCl was then added and the 
final volume brought to 100 ml with H2O. The buffer was then filter-sterilised using a 0.22 
fim Vacuum filter and stored at 4 °C 
Transjormaiion Buffer 2 fri'B2): 
0.294 g NaMOPs pH 7.0 was added to 1.1 g CaCl,. 0.12g RbCl and 15 ml 100% Glycerol. 
The final volume was brought to 100 ml with HjO. The buffer was then filter-sterilised 
using a 0.22 ^m Vacuum filter and stored at A°C. 
2 . 1 . 9 D N A MARKERS 
Aff)'metrix Low molecular weight marker 
Methods 
BioLme HyperladderTW-V 
(London, UK) 
Invitrogen lObp D N A ladder, Ikb plus DNA ladder 
2 . 1 . 1 0 C O L U M N S 
Bio-Rad Micro Bio-Spin^" Chromatography Columns 
Eppendorf Phase Lock GeF*^ Tubes 
GE Healthcare G-25 Microspin Column 
Sigma Corning® Costar® Spin-X® Plastic Centrifuge Tube Filters 
Qiagen MaXtract High Density Tubes 
2 .2 METHODS 
2 . 2 . 1 C L O N I N G 
2 . 2 . 1 . A CONSTRUCTION OF THREE SITE ISOMIR VECTORS 
Four miRNA bmding cassettes (CTGF, CTGF MUT, P G A M l and P G A M l M U T bmding 
sites) were ordered as one m imGENE within the p IDTSMART plasmid (Figure 2.1). Each 
cassette contained a specific restriction site at the 3' end (BsiWl, Spel , S a d and Nde l 
respectively), and a Not l restriction site separated each cassette. The plasmids CTGF, 
CTGF MUT, P G A M l and P G A M l M U T were created by digesting p IDTSMART with 
No/I and the fragments inserted into the No/l site (see Digestion of ps iCHECKfM-2 with 
No/l below) behind the Kenilla luciferase gene in the psiCHECK^'^-2 Vector (Figure 2.1). 
The specific constructs were selected using the restriction sites specific to each cassette and 
the final plasmid constructs were verified by sequencing at the Australian Cancer Research 
Foundation (ACRF) at the Garvan Institute, Sydney. The sequencing of all ps iCHFXK-2 
vectors are listed in Appendix 8.14 
2 . 2 . 1 . B D I G E S T I O N OF P S L C H E C K - 2 W I T H N O T I 
5 jxg of psiCHECK'^'^-2 was digested with 10 units (U) of No/I for 1 hour at i T O , 300ng 
was loaded onto a 2% agarose gel to check the digestion was successful. 
Dephosphorylat ion of the plasmid was necessary to ensure the plasmid did not recircularise 
Methods 
miR-133a binding sites 
M13(-20) Fonward 
pUC Origin 
M13(-27) Reverse 
Ampicillin 
B 
UAGCGGCCGCAUUAAAUUUGUUGAGAGUGUGACCAAAUGUCGACUAUUUGU 
UGAGAGUGUGACCAAAUAUAAUAUUUGUUGAGAGUGUGAGGAAAGGUACGU 
AGCGGCGGGAUUAAAUUUGUUGAGAGUGUGACGGAAAUGUCGACUAUUUGU 
UGAGAGUGUGAGCGAAAUAUAAUAUUUGUUGAGAGUGUGACCGAAAGACUA 
GUUAGCGGCGGGAUUAAGCUGCUGGCCCUAGAAGGUUGGGAUCAAUCUGUC 
GACUGCUGCUGGCCCUAGAAGGUUGGGAUCAAUCUAUAAUGCUGCUGGCCG 
U^AAGGUUGGGAUCAAUCGAGCUGUAGCGGCCGGAUUAAGCUGCUGGCCC 
UAGAAGGUUGGGAUCGAAUGUGUCGACUGGUGCUGGCCCUAGAAGGUUGGG 
AUCGAAUCUAUAAUGCUGCUGGCCCUAGAAGGUUGGGAUGGAAUGCAUAUGU 
AGGGGCCGGUUAUU 
— Not1 — BsiW1 — S a d 
- Sail - Spe1 Nde1 
CTGF binding site 
PGAM1 binding site 
eamHI 445 
SV40 Laie 
Figure 2.1. P lasmid m a p s of p I D T S M A R T and ps iCHECKT"-2 . 
(A) p I D T S M A R T - A M P conta in ing the miR-133a-3p binding sites for all four luciferase vectors . (B) 
T h e miR-133a -3p b inding site insert in p I D T S M A R T - A M P . T h e insert conta ined all three 
luc i ferase vectors wi th b inding sites for miR-133a-3p (CTF binding site) and the i somiR ( P G A M l 
site) as weU as muta ted b inding sites, separated by restr ict ion enzyme sites. (C) p s i C I l E C R T M . A M P 
luciferase vector . T h e miR-133a-3p binding sites were c loned behind the renil la luciferase gene 
us ing the No/I site. 
Methods 
without the insert sequence. Therefore, the cut psiCHECK'f'^-2 was treated with 1 U of 
Shrimp alkaline phosphatase (SAP) in 10% SAP buffer at 37°C for 30 minutes (min). 
The dephosphorylated psiCHECK''''^-2 was then purified using a phenol-chloroform 
extraction. An equal volume of phenol-chloroform was added to the sample, mixed briefly 
then centrifuged at 13 OOOg at room temperature (RT) for 5 min. The top layer was 
transferred to a fresh mbe and topped up to a final volume of 100 |xl with 1 x TE solution. 
An equal volume of chloroform was added and the sample centrifuged at 13 OOOg at RT 
for 5 min, again the top layer was transferred to a fresh tube and topped up to 100 |xl with 
with 1 X T E solution. The construct was then precipitated with 2.5x 100% ethanol (EtOH) 
containing 10% sodium acetate (NaOAc) and 1 ftl pellet paint and spun at 22 OOOg at 4°C 
for 5 min. The supernatant was discarded and the pellet resuspended in 400 |xl 70% EtOH, 
quickly spun and the supernatant discarded. The pellet was then dried under UV Hght, 
resuspended in 20 [xl H , 0 and stored at 4°C. 
2 . 2 . 1 . C REDUCING ISOMIR SITES IN PSICHECK-2 
2 sites: 
To keep 2 binding sites, Ifxg of each construct was digested with 10 U of SaH and 10 U of 
Xho\ for 1 hour at 37°C, followed by heat inactivation at 65°C for 20 min. U e n o w enzyme 
was then used to create blunt ends; 1 fxL Menow with 0.5 ^L dNTP were incubate at 37°C 
for 30 min, followed by heat inactivation at 75°C for 20 min. The fragments were separated 
by low melt agarose gel electrophoresis at 80 volts (V) for 20 min, the linearized plasmids 
excised and extracted with the QIAquick gel extraction kit. 250 ng of plasmid was then 
blunt ligated with 200 U of T4 DNA Ligase at RT for 2 hours. The vectors were then 
propogated in E.coli (see Transformation mto prokaryotic cells and propagation of vectors). 
Plasmids extracted from individual colonies were checked with No/I for insert size and 
redigested with Sali and Xhol (the sites should be removed from the Klenow and ligation 
reactions and therefore should not be digested). The final constructs were verified by 
conventional sequencing. The sequencing of aU psiCHECK-2 vectors are Hsted in 
Appendix 8.14 
/ site: 
To keep 1 binding site, 1 fxg of each construct was digested with Sa^ and the restriction 
site specific to each construct (Table 2.1). The DNA Polymerase 1, large (Menow) 
Methods 
Fragment was then used to create blunt ends; 1 U Klenow enzyme with 120 dNTPs 
was incubated at 37°C for 30 min, followed by heat inactivation at 75°C for 20 rmn. The 
fragments were separated by low melt agarose gel electrophoresis (80V, 1 hour 20 min), the 
linearized plasmids excised and extracted with the QIAquick gel extraction kit. 250 ng of 
each plasmid was then blunt ligated with 0.5 T4 DNA Ligase at RT for 2 hours. The 
vectors were then propogated in IL.coli (See Transformation into prokar)'otic cells and 
propagation of vectors). The constructs were checked by digestion with No/l for insert size, 
the final constructs were verified by conventional sequencing. The sequencing of all 
psiCHECK-2 vectors are listed in Appendix 8.14 
Table 2.1. Restriction site digestion conditions for miR-133a constructs. 
Construct Restriction 
Enzymes 
Buffet 
Conditions 
Reaction 
Conditions 
Deactivation 
CTGF' Sa^ + Bs^Wl NE buff. 3 37°C for 30min 
55°C for 30min 
80°C for 20mm 
CTGF Mut M + Spd NE buff 4. 
0.2 Hi BSA 
37°C for 1 hour 80°C for 20min 
PGAMl Sal\ + Sad N E b u f f 4 . 
0.2 [il BSA 
37°C for 1 hour 65°C for20 mm 
PGAMl Mut San + NM NE b u f f i . 37°C for 1 hour 65°C for 20min 
2 . 2 , 1 . D P R E P A R A T I O N OF D H F A L P H A E . C O L I 
A scraping of frozen DHFa ceUs were put into 1 ml LB media and grown for 3 hours at 
37°C with shaking at 220 rpm. The 1 ml was then transferred into 100 ml LB media and 
grown overnight at 37°C with shaking at 220 rpm. The optical density' at 600 nm (OD600) 
was monitored to ensure the E.coli was m the exponential growth rate. Once the ceUs had 
an OD600 between 0.4-0.5, the ceUs were coUected and alliquoted into 2 x 50 ml Falcon 
tubes, then chilled on ice for 10 mm. The ceUs were centi:ifuged at 2 000 g for 5 mm at 
4°C. The supernatant was removed and the cells resuspended gently in 30 ml ice cold 
TFBl and the two aliquots combined. The ceUs were chiUed on ice overnight and 
centirifuged again at 2 000 g for 5 mm at 4°C. The supernatant was removed and the ceUs 
Methods 
resuspended gendy in 4 ml of icc cold TFB2, aHquoted into 0.1 ml per eppendorf tubes 
and immersed immediately under dry ice. The cells were then stored at -80°C. 
2 . 2 . 1 . E TRANSFORXMATION I N T O P R O K A R Y O T I C C E L L S A N D P R O P A G A T I O N 
OF V E C T O R S . 
Competent H.coli bacteria were used to propagate standard expression vectors. For 
transformation, approximately 50 ng DNA was incubated for 5 min on ice with 75 |ll 
thawed H.coli cell suspension. The bacteria were exposed to heat-shock at 37°C for 1 min 
and then incubated for 5 min on ice. The bacteria were then plated on ampiciUin agar 
plates and incubated overnight at 37°C for growth of colonies. Single colonies were picked 
from the plate and inoculated into LB media containing 100 Hg/ml ampicillin, then 
incubated overnight at 37°C with shaking at 220 rpm. Overnight bacterial cultures were 
incubated in vessels with a volume of at least four times that of the culmre media to allow 
for sufficient aeration. Plasmid purification was performed using the PureYield''^" Plasmid 
Miniprep System kit according to the manufacturer 's instructions. Purified plasmid DNA 
was quantif ied using the Nanodrop spectrometer. 
2 . 2 . 1 . F C O N V E N T I O N A L S E Q U E N C I N G OF P L A S M I D S 
40ng of plasmid DNA and 3.2 pmoles of primer were submitted to the Australian Cancer 
Research Foundation (ACRF) at the Gar\-an Instimte, Sydney. 
2 . 2 . 1 . G A G A R O S E GEL E L E C T R O P H O R E S I S 
1-2% agarose gels were used in the analysis of PCR products and plasmid constructs. The 
agarose powder was added to 1 x TAE, heated until the agarose powder was dissolved and 
ethidium bromide (EtBr) added to a final concentration of 0.5 mg/ml. Gels were then 
poured into horizontal gel boxes to set. One-tenth the volume of Ez-Vision® Three DNA 
Dye was added to the samples and size markers before loading. 
D N A gels, once immersed in 1 x T A E buffer, were electrophoresed at 8()-100V for 40-60 
min. The EtBr was visuaUzed by medium wavelength UV Ught and photographed using the 
Typhoon^M pLA 9000 (GE Healthcare). 
Methods 
2 . 2 . 2 T I S S U E C U L T U R E 
2 . 2 . 2 . A M A I N T E N A N C E OF H L - 1 C E L L S 
Flasks or wells were pre-coated with geladn/fibroncctm and incubated at 37°C overnight, 
the excess gelatin/fibronectin solution was removed by aspiration just prior to adding cells 
to the flasks. HL-1 cells were maintained in supplemented Claycomb media, with fresh 
media added daily. The cells were passaged only after full confluence. Each flask was rinsed 
with PBS warmed to 37°C, and 3 ml of 0.05% trj-psin/EDTA per T-75 flask (flask with 75 
cm^ surface area) added and incubated at 37°C for 1 min. The tr}'psin/EDTA was 
removed, and fresh 0.05% tr\psin/EDTA added then incubated for an additional 2 min at 
37°C. If any cells remained adherent then the flask was tapped on the benchtop to dislodge 
remaining cells. 7 ml of HL-1 wash media was added and the cells collected in a 15 ml 
centrifuge tube. After centrifuging for 5 min at 500g, the supernatant was removed and the 
pellet genfly resuspended in 3 ml of supplemented Claycomb media. For HL-1 culture 
maintenance the cells were split 1:3. 
2 . 2 . 2 . B C R V O P R E S E R V A T I O N OF H L - 1 CELLS 
Mammal ian cell lines were preser\'ed by cryopreservation in liquid nitrogen. Cells were 
frozen to -80°C at a rate of ~ l °C/min using a Nalgene freezing container. One confluent 
T-75 flask cells) was frozen into one ctyovial. Cells were harvested as described above, and then 
resuspended in 1.5 ml of freeing media. HL-1 cells were thawed quickly (2 min) in a 37°C water bath 
and transferred into 10 ml of pre-warmed HL-1 wash media. The cells were then 
centrifugcd for 5 min at 500g, the wash media removed and the cells resuspended in 5 ml 
supplemented Claycomb media, and added to 10 ml of pre-warmed supplemented 
Claycomb media already in a T-75 flask. The media was replaced widi fresh supplemented 
Claycomb media 4 hours after plating. 
2 . 2 . 2 . C M A I N T E N A N C E OF H E L A CELLS 
HeLa ceUs were maintained in DMEM containing 5% FCS and 100 |lg/ml Pen-Strep. 
0 .05% tn 'psm/EDTA was used to detach the ceUs from the flask or dish. 
Methods 
2 . 2 . 2 . D LUCIFERASE ASSAYS 
HeLa cells were maintained in DMEM with 5% FCS. For 24-weU transfection, cells were 
plated at 5 x lO"* cells per well into DMEM without antibiotics 24 hours prior to 
transfection. psiCHECK''' '^-2 plasmids containing mlRNA binding sites were cotransfected 
with MISSION® microRNA mimics using Lipofectamine'"'" 2000 according to 
manufacturer 's instructions for transfection of plasmids. All transfections were performed 
in triplicate. l|xl Lipofectamine^" 2000/wcU was incubated in 50 |xl Opti-MEM 
transfection medium/weU for 5 min. This was then combined with 50 |xl Opt i -MEM 
containing 30 ng of plasmid and microRNA mimics at a final concentration of 10 nM and 
incubated at RT for 20 min to allow Mimic/Plasmid:Lipofectamine'f" 2000 complexes to 
form. Immediately prior to transfection, 100 |xl of media was removed from each well and 
replaced with 100 of transfection solution. The media was replaced after 6 hours and 24 
hour post-transfection the cells were harvested for luciferase assays. The growth medium 
was removed and the cells washed once in 1 x PBS solution. 100 1 x passive lysis buffer 
was added to each well and incubated at RT for 20 mm with gentie shaking. 10 |ll of cell 
lysate was used for luciferase assays; 50 |ll of Luciferase Assay Reagent (I.AR) and 50 |ll of 
Stop and Glo® reagent were used to determine the expression of Firefly luciferase and 
Renilla Luciferase respectively. Addition of the substrates and measurement of the 
luminescence signals were performed using the FLUOstar Optima plate reader (BMG 
Labtech), with a gain of 3500. R4uc measurements were normalised against the 
corresponding F-luc value to correct for transfection efficiency. 
2 . 2 . 3 R N A ISOI .ATION 
AU RNA work was done using UltraPure'^" DNase/RNase-Free Distilled Water. 
2 . 2 . 3 . A R N A EXTRACTION FROM HEART TISSUE 
RNA was extracted from left ventricular heart tissue using TRIzol®. Samples were 
completely homogemzed in TRIzol®; to ensure high quaHt)' RNA the samples were kept 
on dry ice before adding the TRIzol® and periodicaUy chilled during homogenization. 200 
|ll chloroform/1ml TRIzol® was added and the sample mixed vigorously for 15 seconds 
(sec) prior to incubation at RT for 3 min. The TRIzol® mix was then added to a pre-spun 
Maxtract high-density tube and spun at 12 OGOg for 4 mm at 4°C. The upper aqueous 
nhase which contains RNA, was transferred to a new 1.5 ml Eppendorf tube containing 5 
' ' 46 
Methods 
|ll glycogen (5 m g / m l ) and the R N A precipitated using 500 |ll i sopropanol . T h e 
precipi tated R N A was mixed, incubated at RT for 10 min, centr ifuged at 12 OOOg for 10 
min at 4°C and the resultant R N A pellet was washed with 75% E t O H . T h e R N A was then 
vor texed and centr i fuged at 7 500g at 4°C for 5 min. Following removal of the supernatant 
and briefly drj ' ing the pellet under a heat lamp, the R N A was redissolved using RNase- f ree 
water . 5 ^ L 3 M N a O A c was added and mixed, foUowed by 137.5 nl 100% E t O H and the 
R N A f rozen at -20°C overnight. T h e next day, the sample was centr i fuged at 20 OOOg for 
15 min at 4°C and the supernatant removed. The R N A was then washed again with 75% 
E t O H and centr i fuged at 7 OOOg for 5 nun at 4°C. Following removal of the ethanol, the 
pellet was dried under a heat lamp then redissolved in 30 water. Spec t rophotometr ic 
absorbance was measured by N a n o d r o p . The concentrat ion of R N A was determined by 
the absorbance at 260nm, with one Aj^, O D unit equivalent to 40 \ i g / m l of R N A . Af te r 
R N A isolation, the R N A qualit)- was assessed using an Agilent 2100 Bioanalyzer (Agilent) 
together with the reagents in the R N A 6000 N a n o LabChip kit. Samples with an R N A 
Integrit) ' N u m b e r (RIN) > 8 were considered suitable for downs t ream analysis. AU R N A 
was aliquoted and stored at -80°C. 
2 . 2 . 3 . B R N A E X T R A C T I O N FROM PRIMARY C A R D I O M Y O C Y T E S 
5 ml of T R I z o l ® was added per heart to the isolated cardiomyocytes, 1 ml aliquots were 
then t ransferred into E p p e n d o r f tubes. T h e R N A extraction was then pe r fo rmed as 
described in Section 2.2.3.A. It was necessary to fur ther purify the cardiomyocyte R N A 
samples due to low 2 6 0 / 2 3 0 ratios (indicative of protein, salt or solvent contamination). 
T h e R N A vo lume was b rough t up to 50 nl and passed through a Micro Bio-Spin™ 
Chromatography Columns according to manufacturers instructions. The R N A was then 
reprecipitated by adding 137.5 100% E t O H , 1 [ll glycogen (5 m g / m l ) and 5 3 M 
N a O A c and f rozen at -80°C overmght . The R N A was centr ifuged at 20 OOOg for 15 min at 
4°C and the supernatant removed. T h e R N A was then washed twice with 7 5 % E t O H and 
centr i fuged at 7 OOOg for 5 m m at 4°C. The E t O H was removed, the peUet dried under a 
heat lamp and redissolved in 30 |ll water. 
Methods 
2 . 2 . 3 . C D N A S E T R E A T M E N T OF R N A 
RNA that was used for real-time quantitative PGR (RT-qPCR) analysis of 3' UTR variants 
and mRNAs was first DNase treated to avoid genomic contamination (as the primers 
cannot be designed across an exon-exon junction). 2 U TL'RBO DNase was added to 1 [ig 
of total RNA, in 1 x TURBO DNase buffer at a final volume of 20 nl. The reaction was 
incubated at 37°C for 30 min. To inactivate the DNase, 3|il DNase inactivator was added 
and the sample vortexed and incubated at RT for 30 sec, this step was repeated 3 times. 
The RNA was then centrifuged in a mim-centrifuge for 1.5 min and the supernatant 
(approximately 20 )xl) transferred to a new 0.2 ml Eppendorf tube. 
2 . 2 . 4 R I : A L T I M E Q U A N T I T A T I V E P G R ( R ' 1 - Q P C R ) 
2 . 2 . 4 . A S T E M - L O O P R E V E R S E T R A N S C R I P T I O N ( M I C R O R N A ) 
RNA was extracted using TRIzol®, as described above. 300 ng of total RNA, 1 10 mM 
dNTPs and 1 nl of a microRNA specific stem-loop primer (Table 2.2) were incubated at 
65°C for 5 mm followed by 3 min on ice. 1 |il 0.1 M dithiothreitol (DTT), 40 U 
RNaseOUT^'^, 200 U Superscript® III, 1 x First-strand buffer and water to a total volume 
of 20 |ll were added. To perform reverse transcription, the reaction mixture was incubated 
at 16°C for 30 min, 42°C for 30 min, then 75°C for 15 min. cDNA was stored at -20°C 
and diluted 1:5 for individual expression analysis by RT-qPCR. 
2 . 2 . 4 . B R E V E R S E T R A N S C R I P T I O N ( M R N A ) 
RNA was extracted using TRIzol®, as described above. 10 |ll of DNase treated RNA 
( -500 ng), 2 nl random primer mix and 6 nl water were incubated at 65°C for 5 min then 
ice for 3 min. The random primer mix contains a mixture of hexamers and anchored-dT 
primers, providing greater coverage of the 3' ends of RNA templates in comparison to 
traditional random priming by hexamer (/7i). 1 nl 0.1 M DIT, 40 U RNaseOUT™, 200 U 
Superscript® III, 1 x First-strand buffer and nuclease free water to a total volume of 20 l^l 
were then added. To perform reverse transcription the reaction mixture was incubated at 
50°C for 2 hours, then 75°C for 15 mm. cDNA was stored at -20°C; and diluted 1:10 for 
individual expression by RT-qPCR. 
Methods 
2 . 2 . 4 . C R T - Q P C R F O R M I C R O R N A U S I N G STEXM-LOOP R T PRIMERS 
Forward specific and universal reverse primers (See Table 2.3) were used with the 
LightCycler® 480 SYBR Green I Master Mix or the Fast SYBR® Green Master MLX for rt-
RT-qPCR. Each reaction was performed in triplicate using 2 |xl of the diluted cDNA mixed 
with 8 |xl Master Mix (5 SYBR, 0.5 |ll of S^M each primer and 2 water). The Master 
Mix was dispensed using the epMorion robot (Eppcndorf). PGR amplification was 
performed in 384-weU plate format on the LightCycler® 480 system (Roche) or the 
QuantSmdio^" 12K Flex system (Tjfe Technologies), the annealing temperature for each 
primer set was optimized and the final reaction conditions were: heating at 95°C for 10 
min, 50 cycles of 95°C for 10 sec, annealing temp for 10 sec, 72°C for 4 sec, followed by 
melting cur\'e analysis. 
2 . 2 . 4 . D R T - Q P C R F O R M R N A 
Forward and reverse specific primers (See Table 2.4) were used with LightCycler® 480 
SYBR Green I Master Mix or the Fast S^'BR® Green Master Mix for RT-qPCR. Each 
reaction was performed in triplicate using 2 diluted cDNA mLxed with 8 |ll Master MLx 
(5 |xl SYBR, 0.5 |xl of 5 ^ M each primer and 2 |il water). The Master Mix was dispensed 
using the epMotion robot (Eppendorf). PCR amplification was performed in 384-wcll plate 
format on the LightCycler® 480 system (Roche) or the QuantStudio^" 12K Flex system 
(Life Technologies), the annealing temperature for each primer set was optimized and the 
final reaction conditions were: heating at 95°C for 10 min, 50 cycles of 95°C for 10 sec, 
anncalmg temp for 10 sec, 72°C for 6 sec, followed by melting cur\x analysis. 
Methods 
Table 2.2. Stem-loop reverse transcription primers for miRNAs. 
Name 
mSN( )1 IS.RT 
mSN( )234_RT 
mSN055_RT 
mSN0412_RT 
mSN02n2_RT 
miR-21_RT 
mmiR-451_RT 
mmiR-2l4-5p_RT 
miTOR-324-5p_RT 
iiirraR-9-5p_RT 
mmiR-199a-5p_RT 
mmiR-H)9a-3p_R'l' 
mmiR-31-5p_RT 
miR-214-3p_RT 
miR-199b-3p_RT 
miR-299-5p_RT 
miR-379-5p_RT 
miR-143-5p_RT 
lyp_miR-l(lla-3p_RT 
lyp_miR.l lh-5pJT 
llyp_miR-l5()-5p_RT 
r C A G K i C A C C C n X X X i A C X i T A T T C G C A C r G G A T A C G A C C n C A G 
GTCGTATCCAGTG(;AGGGT( ;CGAGGTARR( :G<;ACTC; ( ;ATACGACT( ,T<:A( ; 
c ;TCGTATGCAGTc ;< ;Ac ; tKr rcc { ;A ( ; cn -ATr< :G ( ;A (n ( i c ;ATACGAC 'n ( ; ( . TC 
c ;TCGTATc :cAGTcx ;AGGGT( ; c ( ;A (x ;TA 'n ' ( ; ( ; ( ;ACTc ;c ;A ' rACGA( :T ( ,TCA( ; 
r ,TCGTAT( ;CAGT(X ;AGGGK;CGAG<r i ;Vm;C;CACT( ;C ;ATACGACCAT( ;A ( ; 
;T(;crrAT(;cAGT(x;AcxxrrKC(;A(xrrArKx;(;ACK;GATA(x;Ac;T(;.ucA 
( n x x r r A T c x : A G T ( x ; A G G G T ( : < x ; A c x ; T A r r ( x ; ( ; A c r ( ; ( ; A T A c x ; A c ; AACTCA 
GTCGTATC( ;AC;TG( ;AGGGTCCC;ACX;TAIT(X; ( ;ACrt :GATA(X;ACC;CACA( ; 
( n ( x ; T A T c c ; A G T ( x : A c x ; G T c r x ; A ( ; G T A r r ( x ; ( ; A ( r r ( ; ( ; A T A C G A c ; AC;(;A(;<; 
c r r c c ; T A T C ( ; A G T G ( ; A G C x ; T < x x ; A c x n A r r ( x ; ( ; A ( n x x ; A T A ( x ; A c ; T t ; A T A C 
c r i x x n v \ T ( x ; A ( r r ( x ; A G ( x r r ( x x ; A ( x ; T A T T ( x x ; A C K x ; A T A C c ; A t ; c ; , \ , M ; A ( ; 
t i T C ( - , T A T c o K G T c x ; A G ( ; G T ( x x ; A c x r r A r r ( x x ; A ( , T ( x ; A T A c x ; A c ; T A A ( ; c A 
( R R ( x ; T A T c c A G T c x ; A c x x ; T ( x x ; A { x ; T A T r ( x x ; A c , T ( x ; A T A c ; G A c ; GAGCTA 
G T ( X i T A T < x ; A G T c x ; A ( x x ; T ( x x i A ( x ; T A T r ( x x ; A ( r r ( x ; A T A C ( ; A c ; A < r r G t x ; 
c n x x n ^ \ T c c A G T c x : A ( x x r n x x ; A ( x r n \ T r ( x x ; A ( , T ( x ; A T A ( x ; A C T A A c c A 
GT(Xn^VlXX:AGTCX;A (XXr iC (X ;AGGTArr (X- , t ;A ( ,TGGATAC( ;A ( ;ATGTAT 
GTCCrrAT(X;AGTC; ( ;AGGC;TC(X;AGGTAIT(XX:ACT(X;ATACGAC(X; ' rACC; 
( ; T < x r r A T ( x ; A G i x x ; A G ( x ; T ( x x ; A G G T A T r c c x ; A C T G c ; A T A C G A c a ; A G A c ; 
c r i ( x n A T ( x ; A G T c x ; A ( x x n G c c ; A c x n A n x x x ; A c n x x ; A T A C G A ( ; T c ; A ( ; T T 
( r i x x n \ \ T C ( : A G T ( x : A c x x n x x x ; A c x ; T A r i x x x ; A C T G c ; A T A ( x ; A ( ; A ( ;AAAT 
c r r ( x - / i A T < ; c A G T ( ; ( ; A c x x ; T ( x x ; A ( x r r A r r c x x ; A ( r r ( x ; A T A C G A C < : A C i G G 
sn„RNA-135 
sn<)RNA-234 
sn<)RNA-55 
sn<)RNA-412 
:>RNA-202 
R-2l-5p 
R-451 
R-214-5p 
R-324-3p 
m,R-9-5p 
.-199a-5p 
.-199a .3p 
.-31-5p 
.-214-3p 
.-199b-3p 
.-299-5p 
.-.379-5p 
.-143-5p 
.-l()la-.3p 
.-l(la-3p 
Table 2.3. Stem-loop RT-qPCR primers and experimental conditions for miRNAs. 
A n n c a l n i ^ 
Temp (°C) Name lucncc Gene Primer SSL. 
mlR_unlrcv 
m.SN()135J-()r 
mSN()234_Fc>r 
niSN<)55_F()r 
mSN()412_For 
inSN<)2()2_Fc)r 
miR-21_For 
mniiR-451_For 
mmiR-214-5p_Fi>r 
mmiR-324-.3p_F()r 
mmiR-9-5p_For 
mmiR-199a-5p_F<ir 
mmiR-199a-.3p_F<ir 
mmiR-31-5p_F<>r 
miR-214--3p_For 
miR-199b-.3p_For 
TT,iR-299-5p_F<ir 
miR-.379-5p_F<ir 
miR-143-5p_For 
Iyp_miR-l(lla-.3p_F<>r 
Iyp_miR-I(la-5pJ-i>r 
lvp_tmR-150-5p_Fcir 
c n x x ; A ( . x x : i ' ( X x ; A G G T 
T A G T C X ; T G A G ( X ; T C ; T G G T n T 
ITAA(;AA.\,\ARR<x;T<;ACTAC(;A 
GACTGACGACRCCATGTGTC 
( .TAA<x:Tc;ATix;AAGRRA(; ,\ .\AITA( ; 
, \ G T A ( ; m T G A A ( x x : T n T ( x ; A 
(XXX.TAtxnTATCAGACTCJA 
G(x;AAACCGrrA(x;ArrAC 
Gfxrrtxxn'GTcrACAinTG 
C;T(X:A(;TCXXXX:A(X;T 
(XXX:TCTITGC;-ITAT<;TA<X;T 
CXXXX;AGTGIT ( ;AGA( ;TA ( ; 
( x x ; A ( ; A G T A c n ( ; T c x ; A C A T 
N A C X X ; A A G A T G C I X X X : A 
CATA( ;ACX:A(XX;A( :AGA( ;A 
CXX;A( ;AGTAGT( ,T (X:ACAT 
c T A r r c x r n T A G f x r n x x A C 
( X X X r r t X i T A G A C r A T G G A A 
T A A C x n x x : A c n x i ( ; T c x ; A T 
ATXXXXN'ACACN'ACTGTGATA 
CGTA(XX;TGTAGAT(XX;A 
(iATCTCTCCCjmXXnTGTA 
UnivLTsal Reverse 
sn<iRNA-135 
sn<iRNA-2.34 
sn.iRNA-55 
snoRNA-412 
snciRNA-202 
miR-21-5p 
miR-451 
miR-214-5p 
miR-324--3p 
iniR-9-5p 
niiR-199a-5p 
miR-199a-.3p 
miR-31-5p 
rraR-214-.3p 
miR-199b-3p 
miR-299-5p 
miR-.379-5p 
miR-143-5p 
mlR-l(lla-.3p 
miR-10a-.3p 
miR-15()-5p 
Reverse 
)r\vard 
»r\vard 
invard 
Forward 
[)n\-ard 
Forward 
trvvard 
F(»r\vard 
Forward 
Forward 
For^vard 
For^vard 
For^vard 
For\\-ard 
Forward 
Forward 
I-'orward 
>r%vard 
irward 
)r^vard 
irward 
Methods 
2 . 2 . 5 3 ' R A C E V A L I D A T I O N OF 3 ' ENDS 
2 . 2 . 5 . A T V N REVERSE TRANSCRIPTION 
A superscript mix was made up with the following components: 6 |ll 5 x First-strand 
buffer , 1.5 III 0.1 M D I T , 60 U RNaseOUTTM, 300 U Superscript® III and 1.5 nl T V N 
(12x T, V=C,G,A, N=A,C,T,G) anchor. 0.5 \lg of RNA and 1 l^l 10 mM dNTPs were then 
added to H jO to give a final volume of 12 |xl. The reaction was incubated at 65°C for 5 
min, then 50°C for 5 min. 8 |ll of the superscript mix was added to the RNA mLx at 50°C, 
then the reaction was mixed at 50°C for 1 hour, followed by 75°C for 15 min. The cDNA 
was diluted 1:10 for PGR amplification. The sequences of primers and oligonucleotides 
used for 3' race validation are shown in Table 2.5. 
2 . 2 . 5 . B P G R AMPLIFICATION AND PURIFICATION OF P G R PRODUCT 
2 |xl of diluted cDNA was added to 0.4 (xl 10 mM dNTPs, 1 U Fast start Taq DNA 
polymerase, 2 |ll each of forward specific primer and reverse anchor primer (5 ^M) , 1 x 
buffer in a total volume of 20 |xl. The reaction was then amplified using the following 
conditions: heating at 94°C for 15 mm, 36-38 cycles of 94°C for 15 sec, 60°C for 30 sec, 
70°C for 30 sec, fol lowed by 70°C for 1 min. The PGR products were run with RNA EZ-
Vis ion® dye on a 1.5% agarose gel at lOOV for 45 min. The appropriate bands were 
excised and extracted using the QlAquick gel extraction kit according to manufacturer 's 
instructions. 
2 . 2 . 5 . C GLONING AND SEQUENCING OF P G R PRODUCTS 
4 Hi of the PGR product was Hgated into 50 mg of the pGEM®-T Vector with 400 U of 
T4 D N A Ligase in 1 x T4 D N A Ligase buffer at RT overnight. The Ugation mixture was 
then transformed mto competent E.co/i ceUs by adding 50 nl E.co/i suspension to each 
Ugation niLxture and incubating on ice for 30 min. The ceUs were then heat shocked at 
42°C for 45 sec and put back onto ice for 2 min. 200 LB media was added and the ceUs 
aUowed to recover by incubatmg them at 37°G for 1 hour with shaking at 220 rpm. 150 l^l 
was then spread onto ampicilHn plates coated with 25 pi ampiciUin (100 ^g/ml), 25 l^l X-gal 
(20 mg/ml) and 40 nl 0.1 M IPTG and incubated overmght at 37°C. Single white colomes 
were picked from the plate and inoculated mto 10 ml LB media containing 100 ^g/ml 
51 
M e t h o d s 
ampicillin, then incubated overnight at 37°C with shaking at 220 rpm. Overnight bacterial 
cultures were incubated in vessels with a volume of at least four times that of the culture 
media to allow for sufficient aeration. Plasmid purification was performed using the 
PureYield"'"'^ Plasmid Miniprep System kit according to the manufacturer's instructions as 
outlined. The insert size was confirmed by digesting pGEM®-T with 10 U EcoRl at 37°C 
for 2 hours and running the digestion products on an agarose gel. 4 |ll of pGEM®-T 
containing the PGR insert was combined with 1 |il BigDye® Terminator v l . l Ready 
Reaction MLx, 3.2 nl M13 reverse primer (1 pmole/|il) in 1 x buffer and HjO to a total 
volume of 20 |il. The sequencing PGR was run as follows: 94°G for 15 min, 30 cycles of 
96°G for 10 sec, 50°G for 5 sec, 60°G for 4 min. The PGR product was then precipitated 
by adding 1 |tl 3 M NaOAc, 5 |tl 125 mM EDTA and 50 100% EtOH, vortexing and 
centrifuging for 20 min. The supernatant was removed and the pellet washed twice with 
75% EtOH. Once dried, the samples were taken to the Biomolecular Resource Facility', 
Canberra, Australia for BigDye* Terminator Sequencing. 
2 . 2 . 6 N O R T H E R N BLOTS OF SMALL R N A S 
2 . 2 . 6 . A POLYACRYLAMIDE GEL ELECTROPHORESIS 
A 12% urea polyacnlamide gel (12% acr\-lamide:bisacr>-lamide 19:1, 7 M urea in 0.5 x 
TBE) was prepared m 16 x 20 cm gel plates (the large gel is necessary' to separate 
processmg variants of miRNAs). To prevent the gel from heating, aU electrophoresis was 
performed m a cold room at 4°G. The gel was prerun at 180V for 30 mm, and the weUs 
flushed carefuUy widi a syringe. 5-15 ng of total RNA was mixed with an equal volume of 2 
x RNA loading dye, denatured at 95°G for 5 min and cooled briefly on ice. Single-stranded 
RNA mimics of the miR-133a-3p were also loaded onto the gel for size comparison (miR-
133a-3p of 23 nt in length, 5 ' -UUUGGUCGCGUUCAACGAGGUGU-3' ; IsomiR of 22 nt 
m length, 5 ' -UUGGUCGGGUUCAACGAGCUGU-3' ) . The RNA was loaded onto the gel, 
and the gel run at 20 miUiamps (m.\) until the samples entered the gel. The gel was then 
run at 30-40m.A (maximum voltage at 600 until the dye was 2 cm from the bottom of 
the gel. Pnor to transfer, the gel was stained with EtBr (0.5 Hg/ml) for 5 min and visuaHzed 
by medium wavelength UV Ught and photographed usmg the Tj^^hoon™ FLA 9000 (GE 
Healthcare). 
Methods 
Table 2.4. RT-qPCR primers and experimental conditions 
AMUjd ingTe in i ) 
Gene m Prime r ^ p C 
mCiAPDl L^pcr^for CTTCiCKicrTACACTGAGGAt: CiAl'DH I-or\iard 
tnCiAl'DI I_qpcr_rcv CTGTrGtrrcnAGCCGTATTC GAI'DI I CA) Reverse 
mCANX^qpcr.for GClTTCiCCAGTGTTCaT CANXl l-onvard 
mCANX_c)pcr_rcv •n ' cATcccrcTTGTrcTnrrc CANXl 61) Reverse 
ml n'RT_ f<3r CCTAAGATGAGCGCAAGTIGAA I II>R1- F()r^ \'ard 
ml-IPRT.rcv CCACAGGACTAGAACACCTGCTAA I ll'RT 60 Reverse 
mARBP.for GGACCCGAGAAGACCTCCIT ARBl' l-bru-ard 
mARBP_rev Ci( :ACATCA(n"CAGAATnCAATGG ARBP 60 Reverse 
mDDR2_for Gt:ATrCTAAGC-,CrrGCTC,<,T DDR2 |-or\vard 
mDDR2_rcv GAAGACGGAGTrGGATCTGG 1)DR2 58 Reverse 
mCollal_for GTGTGATGGGATrCCCTGC;ACCTA COLlAl l-'onvard 
mC()llal_rcv CCTC:AG{ T ( :< ;AGcxicTCCATcrT CCJLIAI 58 Reverse 
mCol.^al.for ACCCCCTGGTCCACAAGGATTA COLJAl Forvx'ard 
mCol-'^ al.rev ACGTTCTCr.ACiG'lXiCACCAGAAT CGL!A1 58 Reverse 
ina-vim_f<)r GATn-CTCTGCCTCTC-.CCAACClT a VIM Forward 
ma-vifn_rcv CAITGATCACCIGTCCATCTCTGG a-VIM 58 Reverse 
mctiH_fur GATCTCTGCAG.ATGCCATGATGCA TNNT2 I-cmvard 
mctnt_rcv CAGTGCATCC.ATA-ITCTTGCC.CCA TNNT2 58 Reverse 
m-fT>lc2v_f()r TCTCCGTGGGTAATGATGTG MLC2V l-orward 
m-mlc3v_rcv ACTATGTCCGGCiAGATGCTG 1U.C2V 58 Reverse 
mnppa_f<)r ATTGACAGGATTGGAGCCCAGAGT NPI'A 1-orward 
mnppa_rcv TGACACACCACA^GGGCTTAC'.GAT NPPA 6f) Reverse 
maSka.for TGAGACXACCTACAACAGCA a-SKA Fonvard 
maSka_rfV CCAGAGCTGTGATCTCCTTC a-SKA 60 Reverse 
mNppb for GCCACnCi'CCAGAGCAAlTCA NPPB Forward 
mNppb.rcv 
mbMIIC_fut 
TG'lTG'nTiGTGAGGCCTTGG NPPB 60 Reverse 
CTACAGGCCTGGGCrTACCT P-MHC Forward 
mbMI IC_icv TCTCdTCTCAG.ACTTCCGC P-MIIC 60 Reverse 
mmuJIadh-FOR TGC TGG CCT CCA CIT TTT CA HADII Forward 
mmuj lajh REV CAC CAA GAG TCG GTT CAC GA IIADII 60 Reverse 
mmu_Cnnl l OR CGG CGT CAC (TC TAT GAT CC CNNl Forward 
mmu_Cnnl REV TCA AAG ATC TGC CGC TTG GT CNN] 60 Reverse 
miiiii_CLU-FOR AGC CGT GCG CiAA TGA GAT AG CLU l-DVX'ard 
mmu_CLU-REV r r c TTt: CCG AGA GCA GCA AG CLU 60 Reverse 
mmu_Klfl5-l-OR TGT ACA CCA AC;A GCA CiCC AC KJJT5 Forward 
mmu_Klfl5-REV ACA CTG G.TA CGG t m CAC AC KI.1-T5 6U Reverse 
mmu_lMk4-FOR CTGCCTGACCGCTTAGTGAA PDK4 Fonvard 
mmu Pdk4-REV TC;CCTTGAGCCATTGTAGGG PI:)K4 60 Reverse 
Methods 
T a b l e 2.4 con t . R T - q P C R pr imers and expe r imen ta l cond i t i ons 
A i m e a l m g ' i ' e m p 
N a m e Gene CC) 
SPARC-CDS-1-OR A' r rGCKx;A(;Tr ix ;Ac; / \AGc;TA SPARC -orvvard 
Sl'ARC-CDS-REV CACK'.GCiClCCiATGTAnTG SPARC 60 Icvcrsc 
mmu_Ndufal-l-OR lTATCiC;c;C;GTGTC;CTTC;GTC NDUFAl •orward 
mmu_Ndufal-REV ACGTCTATCCJCGrrCCATCA NDUFAl 60 Icvcrsc 
Acsll-CDS-F(m GCAGC.CC-llTCTCATAGCAG ACSI.l ^orward 
Acsll-CDS-REV AACKKXGTl-GTC AATAC; AAA AT ACSLl 6(1 <c\crsc 
mmu_(;alml-FOR GGCACCAITGACITCCCAGA CAl.Ml -brvvard 
mmu_Calml-Rl-.V TCTGf ;C( ;C AC'l'C i ATGTAACC (:AI.M\ 60 Reverse 
NfrUS 1 UTR_Start_l-OR C AC K i GCCACrrrTATCTTCiCJ A MTL'Sl short atid long 3'UTR Forward 
NH'US 1 _3 UTR_Start_REV GC-1-GGAAGAATGCTCAGA(^,G Nn-USI short and long 3'UTR 60 Reverse 
MTUS1 _.1UTR_Mid_l-OR " iTc;TGG(rrGAAAn"GG(rr ( :A MTUSl long .3'UTR Fot^vard 
MTUSl .SUTR.Mid .REV AAACACITAACIACCACAGCIGTTCC MTUSl long .rUTR 60 Reverse 
CCND2_3UTR_Start2_l-()R2 GACTTCJCCCTCACATTCCAT (X:ND2 short and Icmg .3'UTR l-onvard 
C( :N D2_3 UTR_Start2_Rl-: V2 CC:cnTCGCAAAAACACAAT ( ;(:ND2 short and long 3'UTR 60 Re\crsc 
(;CND2_.3UTR_Mid_l-OR CTG AGTCTG GTTCKJTGCTG A (X:ND2 long 3'UTR l-on^-ard 
C(:ND2_3UTR_Mid REV ACACCCGAC;A(:CACAGAAAC CCND2 long .3'UTR 60 Reverse 
CAM KK2_3 UTR_Start2_l-t)R2 CCCACICLTCCLAACIAACAAAG (:AMKK2 shorl and long .3'U"1"R Forward 
C:AMKK2_3UTR_Start2_Ri:V2 TTC.CACGCACrCTACCAAAC; CAMKK2 short and long .3'UTR 60 Reverse 
( ;AMKK23UTR_MID_I-()R TGGTTC^ A A G r n X ;c iC.TGTC 5 A CAMKK2 long 3'UTR Forward 
CAMKK2_3U'RR_M 11 )_REV c;c; ATAGCG C-.CTAC} ACC AC AG CAMKK2 long .3'UTR 60 Reverse 
Pl'MlK_3UTR_Start_l-()R AGTAGTGGTGCCCriTGGTC; I 'PMIK short and long .3'UTR Forward 
PPMl K_.-^U'rR_Surt_REV C A ATG AC AC ACGGGTAC AGO PPMIK short and long .3'UTR 60 Reverse 
PPMlK_.^UTR_MidJ-OR TC-CClTAGGAGGCiCiTCACrrr PPMIKUmg .3'UTR Forward 
PPMlK_3UTR_Mid_REV r(;(:(;A(Xxri'cJAAACA'iTCTC PPMIK long .3'UTR 60 Reverse 
GSK3b start_2_K)R rACrGCCACACCiCACAI'ACA GSK.3B short and long 3'UTR l-oiAvard 
(JSK.-ib start_2_REV AGTACACCACrCACCC JCACA GSK.3H short and long .3'UTR 60 Reverse 
(;SK3b middlc_2_l-C)R ATAATTGCCCiTGCGAAAGAC GSIC3B long 3'U'l'R 1-'orward 
CKSK3b middlc_2_REV CJACTCTAGCACGCACACCAA C;SK3B long 3'UTR 60 Reverse 
Etfl_Start_FOR AAAcrc. ; c c r ( x ; I GTCACJCTC Etfl short and long .3'UTR Forward 
Ktfl_Start_REV •nXJCTGCAriTCGCAGTGAC F.tfl short and long-3'UTR 60 Reverse 
litfl_Mid_l-()r AAACTGCCTCCrGTCAGCTC Etfl long 3'UTR Forward 
l-:tfl_Mid_Rcv iTc? C:TGC AITTCCtC AcrrG AC Etfl long 3'UTR 60 Reverse 
Utpf)_Start_FCJR GG AAAGCCCJTCCA'n 'nxX; G Utp6 short and long 3'UTR l-orward 
Utp6_Start_REV TGTCCCT(:AGTTCTCAGG'nT Utp6 short and long 3'UTR 60 Re\'erse 
Utpf._Mid_F()r 
Utpf)_Mid_RLv 
. \ATCGTITCCTCnGCCA(Xrr Utpf) long .3'UTR i-'orward 
RCACCC^/VAGTGACXXTGAAC Utpf. Icjng 3'UTR 60 Reverse 
1 Itatip3_Start_i-t)t CJGCCC^ATAAGTCCAGCAC.n- 1 Itatip2 short and long 3'UTR Forward 
I ltacip3_Start_Rcv 
I Itatip2_Mid_l-<)r 
Htatip2 Mid Rev 
CAAGAGTCTGGCAGAGAGCC I Itatip2 short and long 3'UTR 60 Reverse 
ICi ACtiGPG C ITl'AGACJCG ATG 1 Itatip long .3"UTR Forward 
CCrCf:AGCATGC;TCACAGTT Iltatip long .3'UTR 60 Reverse 
T a b l e 2.5. PGR pr imers and exper imen ta l cond i t ions for val idat ion of 3' ends . 
Name Sequence Gene 
Annealing 
Temp (°C) Reverse primer 
Number 
of 
Cycles 
Primer type 
CDC42_14(H)_4R<'''U"r 
(;nC42_5(LHR60-for 
Usf2_14(X)_qR6()_fot 
Usf2_63(L4R67_for 
SPAR(;_1100_qR6()_for 
.SPARC_100_QR60_for 
SRl-_2250_qR60_for 
SRF_y(HLqRC>0_f«r 
C;SK3b short .VUTR_4 
GSK3b long 3'UTR_4 
M13_ro\-
(XiAAccA/YiXK; r i T C r r c . T 
CTCC AG AACXXiAAC; AAC~I AC i 
CD(:42 3'UTR 
CDC42 r u m 
60 
60 
JC_anchor revl 
JC;_anchor revl 
36 
38 Forward 
CiACATCGACCC.TGTACTCAT U>f2 3' UTR 60 J(;_anchor revl 38 Forward 
cnATCiCGCcnGTGTGc :GT Usf2 3' UTR 60 JC.anchor rcv2 38 Forward 
f:TC:'l (; AC ACiC AATGTC^ AAG AG SPARC 3'UTR 60 )(^_anchor revl 38 l-onvard 
{ ;CTGCAGTCC:TGAA(:T(:TC SPARC 3'UTR 60 )C;_anch<)r revl 38 Forward 
CATGGTCACATCTTCTGTACAG 
CXX:AC,{ ri-GCTTTACTTAAGAG 
SRI- 3'UTR 
SRI- 3'UTR 
60 
60 
lC_anchor revl 
|(:_anchor revl 
38 
38 
I-'or\vard 
Forward 
ICrGrATCAC.CTTCCAACTC GSK.3B 3'U1"R 60 ]C;_anchc>r revl 38 l-orvvard 
TC;TC;GAAAGTATC;C;TC:AATGTIT 
C AGG AAAC:AGCTAI c; AC 
CC:A (TTC; C:AG GGT CCG AC;C} TAT 
GSK31i 3'UTR 
pGEM-T reverse pninor 
TVN anchor 
60 )C;_anchor revl 38 Forward 
Sequencing pniner 
'1"VN Anchor Reverse 
IC_lVNanchor r r r TTF T I T TTV N 
Transcription 
IC.anchurrevl 
|C anchor rev2 
GTG CAG GGT CCG AGG TA Anchor Re\'erse 1 
Reverse 
CCA CnXi CAG C,GT CCCi AGC, TA Anchor Reverse 2 
Re\erse 
Methods 
2 . 2 . 6 . B T R A N S F E R A N D C R O S S - L I N K I N G OF M E M B R A N E R N A 
After staining with EtBr, the gel was soaked in 0.5 x T B E for 15 min. Six sheets of 3MM 
Wha tman fdtet paper and a Hybond-N ' membrane were presoaked in 0.5 x TBE. Three 
filter papers were put onto a transfer cassette, followed by the gel, membrane and 
remaining fdter paper. The RNA was transferred using a wet electrotransfer system (Biorad 
Trans-Blot transfer cell) for 1 hour at 20V. The transfer was performed in 0.5 x TBE and 
in the cold room. The transfer was checked by restaining the gel with EtBr, and by 
visualizing the membrane using medium wavelength UV Hght. The RNA was immobil ized 
on the membrane by UV irradiation and baking: the membrane was UV cross-linked 
(120mJ/cm^) using the Stratalinker® 1800 UV Crosslinker (Stratagene) then baked at 80°C 
for 30 min. 
2 . 2 . 6 . C P R O B E L A B E L L I N G A N D H Y B R I D I S A T I O N 
A D N A probe complementary to miR-133a-3p ( 5 ' -ACAGCTGG'ITGAAGGGGA 
CCAA-3 ' ) was labeled with y-'^P. 15 pmoles of DNA oligonucleotide was added to 50 nCi 
of y -32P-ATP and 10 U OptiKinase in 1 x Opti ls inase buffer (total volume of 25 |ll), then 
incubated at 37°C for 1 hour. The reaction was terminated by heating at 65°C for 10 rmn. 
The probe was then purified using a Sephadex G-25 column. The resin in the column was 
resuspended by vortexing, the bottom closure opened and the column centrifuged for 1 
min at 735g to remove the liquid. The column was put into a fresh 1.5 ml Eppendorf mbe, 
the kinase reaction slowly added to the center of the resm and eluted by spinning at 735g 
for 2 mm. The membrane was pre-hybridised by rotating for 1 hour at 37°C in Perfect Hyb 
Buffer . The labeled probe was denatured at 95°C for 5 min, added to 5 ml Perfect Hyb 
Buffer and hybridized to the membrane by rotating overnight at 37°C. The membrane was 
then washed three times with 20 ml of 2 x SSC containing 0.1% SDS for 20 mm at 37°C, 
and the membrane exposed onto a Fu)ifilm phosphoimager cassette overnight. The 
Northern blot was visuaHzed using the Typhoon^" FLA 9000 (GE Healthcare). If the 
membrane needed to be reprobed, it was mcubated at 80°C with 0.2 x SSC and 0.1% SDS 
for 30 min. 
Methods 
2 . 2 . 7 M U R I N K M O D I : ] , O F ' R R A N S V I U I S I : A O R T I C C O N S T R I C T I O N 
This research was performed following the guidelines, and with the approval, of the 
Gar\-an Institute of Medical Research/St. Vincent's Animal Experimentation Ethics 
Committee (Project number 11/25). Male 11 week C57B1/6 mice were obtained from the 
Animal Resources Centre, Adelaide, Australia. The mice were housed in the Victor Chang 
Cardiac Research Institute, Sydney. 
2.2.1.A T I M E C O U R S E OF C A R D I A C H Y P E R T R O P H Y 
Transverse Aortic Constriction (TAC) or a sham procedure (identical surgen- except no 
constriction of the aorta) was performed on 12 week old male mice {17-f). Animals were 
anaesthetized with an itraperitoneal injection (IP) of xylazine (20 mg/kg), ketamine (75 
mg/kg) and atropine (1.2 mg/kg). Once unconscious, as determined by loss of toe pinch 
reflex, the mice were intubated and ventilated with oxygen and 1.5-2% isoflurane for 
maintenance. The aorta was constricted between the right and left carotid arteries using a 
27-gauge (27-G) needle and 7/0 silk suture. After surgen- and the following morning, 
analgesia was provided with Buprenorphine (0.07 mg/kg) subcutaneously. After 48 hours 
or 7 days the ventricular systohc and diastolic function was assessed by micromanometr)-. 
2.2.1.B M I C R O M A N O M E T R Y 
Micromanometry was used to assess cardiac function, including arterial blood pressure and 
heart rates as well as LV function (/7i) . Anaesthesia was induced by placing the mice in a 
sealed chamber, with 5% isoflurane flowing and from which gas was scavenged. Once 
unconscious, the mice were intubated and ventilated with oxygen and 1.5-2% isoflurane for 
maintenance. A l.OF micro-tip catheter (Millar Instruments) was inserted into the tight 
carotid arter)' for arterial pressure, and then progressed into the for pressure. The 
micromanometr\- data was analysed using Acqknowledge software (Biopac systems Inc.). 
2 . 2 . 7 . C I S O L A T I O N OF C A R D I O M Y O C Y T E S 
Cardiomyocytes were isolated from TAC and Sham mice according to a standard protocol 
(176). 500 ml of CM isolation perfusion buffer was prepared per heart; 50 ml of which was 
used to prepare the coUagenase digestion buffer. The mouse was first injected with 100 
L'/ml heparin to prevent coagulation of blood in the coronan- arteries. The mouse was 
Methods 
anaesthetized, the chest opened and the heart rapidly removed and mounted on a perfusion 
apparatus via a canula placed in the aorta just above the coronary. The heart was 
immediately perfused with the calcium-free perfusion buffer (4 ml/min at 37°C); blood 
rapidly clearing from the coronary arteries indicated correct cannulation and successful 
perfusion. After 4 mm, the heart was perfused with coUagenase digestion buffer (4 ml/min 
at 37°C), to digest the extracellular matrix, for 3 min. The coUagenase digestion buffer was 
collected and discarded. After 2-3 min, the heart was digested for a further 8 min at 
4ml/min (digestion times varied slightly from heart to heart) with coUagenase digestion 
buffer containing 40 |iM CaCl,. A weU-perfused heart became swoUcn, flaccid and slighdy 
pale. 
Once digestion was completed, the heart was cut just below the atria from the cannula 
(leaving the atria attached to the perfusion apparatus) and placed in a dish with 2.5 ml of 
coUagenase digestion buffer containing 40 nM CaCl,. The ventricles were teased into 10-12 
smaU pieces and 5 ml coUagenase stopping buffer containing 2 mM freshly added ATP at 
RT was added to the dish. The pieces were then pipetted gendy with a plastic transfer 
pipette for 60-90 sec to further disperse ceUs. The ceU suspension was transferred to a 15 
ml tube; the plate was rinsed with 2.5 ml coUagenase stopping buffer and the buffer also 
added to the tube (final volume of 10 ml containing 2mM freshly added ATP). The heart 
tissue was dissociated further until aU the large pieces were dispersed in ceU suspension (3-5 
min). UnUke the protocol for short and long-term culmre the calcium concentration was 
not increased at each wash step. At this point, 80 nl of ceU suspension was aHquoted to a 
microcentrifuge tube, and dupHcate 10 |xl aUquots were used to count rod-shaped and 
round cardiomyocytes m a hemocytometer. The total number of cardiomyocytes and the 
number of rod-shaped cardiomyocytes were calculated and recorded as the initial ccU 
numbers. If the total cardiomyocyte yield was low (<1 miUion) or the percent of rod-
shaped myocytes was low (<50%), which indicates a less than optimal isolation, the ceUs 
were excluded from deep sequencing analysis. 
WhUst counting, the remaining cardiomyocytes sedimented passively by gravity at RT. The 
ceUs were then centrifuged at 20g for 3 mm, the supernatant coUected as Wash 1, and the 
ceUs were resuspended m 10 ml coUagenase stopping buffer containmg 2 mM freshly 
added ATP (fmal calcmm concentration 12.5 ^iM). Wash 1 supernatant was spun at 168g 
for 3 mm and 1 ml TRlzol® was added to the peUet. The cardiomyocytes were washed a 
further 2 times (total of 3 washes) with 10 ml myocyte stoppmg buffer (fmal calcium 
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concentrat ion 12.5 [iM and 2 m M ATP). The rod-shaped and rounded cardiomyocytes 
were counted again using a hemacytometer (as above). The total number of 
cardiomyocytes, number of rod-shaped cardiomyocytes and percentage of rod-shaped 
cardiomyocytes were calculatcd and recorded as the fmal ccU numbers. If the total 
cardiomyocyte number was low (total cells < 8 x 10^) or cardiomyocyte purity poor (<60% 
rod-shaped myocytes) , then the cells were excluded from deep sequencing analysis. The 
fmal cells were washed once in PBS, to remove residual BSA contained in the wash buffer, 
and spun at 42g for 1 min. 5 ml of TRIzol® per heart was then added to the cell pellet, the 
pellet was dissolved in TRIzol® using a vortex and split into 1 ml aliquots for RNA 
extraction. 
2.2.1.a DISSECTION OF L V AND LUNGS FROM XMURINE HEARTS 
After micromanometry analysis, a cohort of mice were euthanized by cer\ncal dislocation. 
The chest area was dissected to expose the heart. The mouse was perfused by inserting a 
needle into the apex of the LV, and Hushing the blood out with 10 ml of PBS until clear 
fluid ran out. The major vessels were cut at the point they enter or exit the heart and the 
heart was excised from the chest. The heart was gendy squeezed onto a surgical gauze to 
remove all remaining liquid and the heart weight recorded. The atria were then removed, 
and the RV free wall cut from its attachment to the LV leaving only the LV and the 
septum. The LV weight was then recorded, the LV sectioned into 3 separate samples and 
transferred into a 1.5 ml Eppendorf tube and submerged in Hquid nitrogen for tissue 
preserv-ation. The samples were then stored at -80°C until used for RNA extraction. The 
lungs were also removed by gendy tugging on the trachea while snipping away the 
connective tissue and weighed to establish the lung wet weight. 
2 . 2 . 8 N E X T - G E N E R A T I O N S E Q U E N C I N G 
2 . 2 . 8 . A S M A L L R N A S E Q U E N C I N G 
Libraries were created usmg from RNA usmg the NEBNext® SmaU RNA Library Prep Set 
for SOLiD^M per manufacturer 's instructions. An overview of the library preparation 
method IS shown in Figure 2.2. In brief, 2 ng of total cardiomyocyte RNA was added to the 
imtial Ugation reaction together with the NEBNext® 5' and 3' SmaU RNA Adaptors. The 
PGR ampHfication was modif ied from the NEBNext® protocol to include the SOLiD® 5' 
PGR Primer and SOLiD® 3' Barcodes for each sample (Barcodes 2-9), and 13 cycles of 
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amplification were used. The PGR products were added to 5 Novex® TBE-Urea Sample 
Buffer and separated on a polyacrylamide gel (5% stacking gel, 8% resolving gel, SequaGel 
-UreaGel System) at 300 V for 45 min. Hyperiadder-V was run as a size marker. The gel 
was stained with 1 X SYBR® Gold staining solution for 5 min, then visualized by medium 
wavelength UV light and photographed using the Typhoon'^" FLA 9000 (GE Healthcare). 
PGR products approximately 110-120 nt in size were excised from the gel. The gel was 
dissolved by putting the gel sKce containing the PGR product into a 0.2 ml Eppendorf tube 
that had been pierced with a 19-G needle, then spun at 14 OOOg into a 1.5 ml Eppendorf 
mbe. 400 nL of PAGE elution buffer was added to the spun gel and rotated overnight at 
RT. The tube was briefly centrifuged and the supernatant transferred to a tube containing a 
Corning® Gostar® Spin-X® Plastic Gentrifuge Tube Filter, and centrifuged at 10 OOOg for 
30 sec. The product was precipitated by adding 2 |xl glycogen (5 mg/ml) and 1 ml 100% 
EtOH and storing at -80°G overnight. The samples were then spun at 20 OOOg at 4°G for 
30 min and the supernatant discarded. The products were washed with 500 |ll 70% EtOH 
and centrifuged at 7 OOOg for 5 min at 4°G. The supernatant was discarded, the pellet dried 
and then resuspended in 10 |ll Low TE Buffer. The size and concentration of the PGR 
products was confurmed by runmng 1 l^l of the PGR product on an Agilent High Sensitivity 
DNA Ghip. The products were diluted to similar concentrations (300 pM) and prepared 
for sequencing using Emulsion PGR (e-PGR) on the SOLiD® EZ Bead™ Emulsifier 
according to manufacturer's instructions. The libraries were then sequenced using the 
SOLiD^M 5500 platform. 
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1. Ligation of 3'Adaptor 
NEBNext 3' SR Adaptor 
2. Primer hybridisation 
3. Ligation of 5'Adaptor 
NEBNext 5 'SR Adaptor 3 
4. Reverse transcription 
cDNA 
5. PGR amplification 
SOLID 3' Barcode 
SOLID 5' PCR Primer 
6. Size selection and purification of miRNA PCR product 
Figure 2.2. Small R N A library preparation method. 
The N E B N e x t ® Small RNA Librar)' Prep Set for S O L i D f " was used for smaU RNA sequencing. 
Step 1: The N E B N e x t ® 3' adaptor is Ugated to the 3' end of the nuRNA. Step 2: The NEBNext® 
ST primer is annealed to the complementary sequence on the 3' adaptor. Step 3: The NEBNext® 
5' SR Adaptor 3 is ligated onto the 5' end of the miRNA. Step 4: The SR RT primer is used to 
reverse transcribe the miRNA and 5' adaptor. Step 5: The sequences within the 5' and 3' adaptors 
are used to prime the S O L i D ® 3' Barcode and 5' PCR Primer for PCR ampUfication. Picture 
modified from NEBNext® Multiplex Small RNA Library Prep Set for SOLIDT " manual. 
2 . 2 . 8 . B 3 ' END SEQUENCING 
Methods 
The cardiomyocyte RNA was sent to Dr Traudc Beilharz and the libraries were created 
using the PAT-Seq method developed by Dr Beilharz at Monash University {177). An 
outline of the Library preparation method is shown in Figure 2.3. 
1 ind lixtension: 
2 |Xg of RNA in 11 nL ddH,0 was added to 1 of 100 nM Biotm labeled oligo (Bio-EE 
oUgo; B i o t m - 5 ' - C T G C T G T A C G G C C A A G G C G T r r r n T m ^ r r - 3 ' ) , heated at 80°C 
for 5 min and briefly centrifuged. The heated RNA was then added to 1 0.1 M DTI', 40 
U RNaseOUT, 1 |xl lOmM dNTPs, 5 U Klenow polymerase Exo in IX SuperScnpt^M HI 
First-strand buffer at 37°C. The reaction was mixed, briefly ccntrifuged and transferred to a 
preheated PGR machine to incubate at 37°C for 1 hour, foUowed by 80°C for 5 min. While 
still at 80°C, 80 |xl digest solution (10 10 x digest buffer, 1 Hg carrier RNA and 70 [xl 
ddH,0) was added and then incubated at 80°C for a further 10 min. 
IJmiled RA'ase T, digestion: 
The end-extended RNA was cooled on ice for 5 min, then added to a pre-cooled Phase 
Lock Gel tube containing 100 |xl cold 10 x digest buffer and lOU RNase T1 and incubated 
on ice for 1 min. Then, the tube was vortexed briefly, returned to ice and the reacUon 
terminated by adding 200 |xl 50:50 phenolxhloroform. The reactions were shaken 
vigorously and ccntrifuged at top speed for 5 min, then extracted once with chloroform. 
The top layer was transferred to a new 1.5 ml tube containing 100 |xl 5mg/ml streptavidin 
magnetic beads prewashed m 1 x bmding buffer. The DNA:RNA duplexes were aUowed to 
bind the beads for 15 min at 37°C with shaking. The beads were concentrated using a 
magnetic rack (MagnaRack^M, invitrogen) and washed once with 300 l^l 1 x RT buffer at 
55°C. The beads were concentrated again and then washed once with 100 1 x T4 DNA 
Ugase buffer (containing ATP) at 37°C with shaking. The beads were concentrated a third 
time and resuspended in 20 |il 1 x T4 DNA Ugase buffer. 
Addition of 5'Phosphate to fragments: 
10 U Polynucleoude I<inase (PNK) was added to the 20 l^l RNase T1 fragments, and 
incubated at 37°C for 30 min, foUowed by heat inactivated at 70°C for 10 mm. Once 
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1. Anneal oligo d(T) anchor 
• AAAAAAAAAAAAAAAAAA. 
2. End extension with Klenow Polymerase 
M^^^^^H^^HT/^/^^HHAAAAAAAAAAAAAAAAAAAA 
3. Limited RNase T1 digestion 
Cuts after G residue, fragments RNA to 200nt. 
TOTCGTCf Biot in 
AAAAAAA«AAAAA.AAAAAAAMA««AA^ 
4. Pull down 3' end Fragments 
1 «AA>AAA«AAAAAAAAAAAAAAWAAAA«W^ (, BiOtitl StteptaVidin 
5. 5' phosphorylate fragments with PNK 
6. Ligate 5' SOLID linker 
WCGCCTTGGCCGTACAGCAG 
7. Reverse Transcription 
""^^'VagSIII 
8. Size selection of oDNA 
70-300nt selected lor mammalian 
Adaptor ~20nl 
ICTTGGCCGTACAGCAG 
RTGCGGAACCGGCATGTCGTC 
• AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACGCCTTGGCCGTACAGCAG 
• I I I I I I M I M I I N I I I I 11 N I I I I M I H I I I I I TTTGCGGAACCGGCATGTCGTC 
9. PCR amplif ication 
Primer 1 
B AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACGCCTTGGGCGTACAGCAG 
• 1 111 M 11 H 1 1 I I I N I I 1 1 I I I I I I 1 1 M 11 GCGGAACCGGCATGTCGTC 
Primer 2 
Methods 
Figure 2.3. 3' sequencing library preparation method. 
Steps 1-2: Polyadenylated RNA is extended by generating a 3' tag on polyadenylated RNA, ensuring 
that reverse transcription is only possible from true 3' ends. Step 3: The RNA is fragmented with 
RNase T l , which cuts after G residues. A limited digestion ensures all poly(A)-tails are left intact. 
Step 4; The 3' end fragments containing a poly(A) tail are puUed down using Streptavidin beads. 
Step 5: The RNase T l reaction generates a 5' hydroxyl group, which is not compatible with Hgating 
the 5' SOLiD linker. A 5' phosphate is added. Step 6: The 5' SOLiD linker is ligated onto the 3' end 
fragment, which is necessary for reverse transcription. Step 7: The 3' tag is used with SSIII to 
reverse transcribe the full poly(A) sequence and remaining 3' end fragment. Step 8: The cDNA is 
run on a 6% urea polyacrylamide gel and bands of 70-300nt purified. Step 9: The sequences within 
the 5' SOLiD linker and the 3' tag are used to amplify the cDNA product. 
Methods 
cooled to room temperature, 200 |ll of 1 x RT buffer was added to the beads and then all 
liquid removed. 
]Jgation of 5' SOIJD linker: 
The ligation of the 5' SOLiD adaptor is based on the SOLiD^^ Total RNA-Seq kit. The 
beads were then added to 2 |xl 5' Adaptor mix, 3 .^1 Hyb solution and 2 [il ddHjO on ice, 
then incubated at 65°C for 10 min and 16°C for 5 min. 10 |tl 2 x Kgase buffer and 2 |ll 
RNA ligase 2 were added, and the mix incubated at 16°C for 16 hours. 
Keverse Imnscription: 
To reverse transcribe the fragment contaimng the 5' linker, the ligation product was added 
to 2 10,1 O.IM D n \ 40 U RNaseOUT, 2 10 mM dNTPs, in IX SuperScriptT" III First-
strand buffer (total volume 39 [ll), then incubated at 70°C for 5 min, briefly centrifuged, 
incubated at 55°C for 1 min before adding 200 U Superscript 111. The reaction was mixed 
by rapid inversion, briefly centrifuged and incubated at 55°C for a further 60 min. 
J'z'^f selection ofcDNA: 
The cDNA products were size selected using PAGE. A 6% urea-polyacrj'lamide gel was 
pre-run at 180 V for 30 min, and the wells flushed carefully with a syringe. The products 
were added to 2 x RNA loading dye, heated at 80°C for 5 min and then loaded onto the 
gel, along with a 100 nt RNA ladder for size comparison. The gel was run at 180 V until 
the bromophenol blue was 2 cm from the bottom of the gel. The gel was stained with 1 x 
SYBR® Gold staining solution for 5 min, then visualised by medium wavelength UV light. 
The bands from 70-300 nt (50 nt sequence, up to 18 nt 3' end extension and poly(A)) were 
excised. The gel was dissolved by putting the gel containing PGR product into a 0.5 ml 
Eppendorf mbe that had been pierced with a 21-G needle, then spinning at 13 OOOg into a 
2 ml Eppendorf mbe. 300 jxl PAGE elution buffer was added to the shredded material, and 
incubated overnight with gentle agitation at 4°C. The buffer was transferred to a new tube, 
and another 300 [xl PAGE elution buffer added and incubated at 37°C for 1-2 hours with 
gende agitation. The elated material and remaining gel were put into an Eppendorf tube 
containing a Corning® Costar® Spin-X® Plastic Centrifuge Tube Filter, and centrifuged at 
10 OOOg for 30 sec. The product was precipitated by adding 2 |il glycogen (5 mg/ml) and 
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700 |il i sopropanol and centr i fuging at 13 OOOg for 20 tnin. T h e pellet was then washed 
once with 7 5 % E t O H , the supernatant removed and the pellet dried. 
PCR amplifiaition: 
T h e si2e-selected c D N A was then PCR amplified by adding 8 of the c D N A to 1 [xl 100 
(J,M S O L I D seq pr imer , 1 |xl barcoded reverse pr imer and 50 (tl 2 x AmpUtaq 360 master 
rrdx in a total vo lume of 100 |tl, and 15 cycles of amplification. The size and concent ra t ion 
of the P C R produc ts was conf i rmed by running 10 [xl of the PCR produc t on a Urea-
polyacrj ' lamide gel. Emuls ion PCR (e-PCR) was then pe r fo rmed on the S O L i D ® E Z 
Bead'"'"^ Emulsif ier according to manufacmrer ' s instructions. T h e libraries were then 
sequenced using the S O L i D ^ " 5500 plat form. 
2 . 2 . 8 . C SMALL R N A S E Q U E N C E ANALYSIS P I P E L I N E 
An individual deep sequence read is referred to as a tag and the n u m b e r of times it occurs 
as a count . 
Data filtering. 
Prior to mapp ing a cus tom Perl script was used to trim adaptors that are Hgated at the end 
of the m i R N A f r o m the sequence tags and remove all tags with an average qualit)' value of 
less than 18 across the tag (Appendix 8.1 - adaptortrim.pl). Each colour-call in S O L i D ^ " 
chemistrjf is associated with a qualitj ' value ranging f r o m -1 to 33; -1 being the lowest and 
33 being the highest qualit)?. These qualit)' values (<r/) reflect the probability of error ip) 
according to following equation. 
q = - l O l o g i o ( p ) 
All tags with a mean quality' value < 1 8 ( - 9 8 % accuracy) and tags containing an ambiguous 
color call, represented by ".", were removed to retain high qualit)' tags for fur ther analysis. 
Tags were retained only if the length was at least 20 nt after t r imming, cor responding to the 
length of a mature m i R N A 
Mapping to the reference ffnome: 
T h e remaining high quality tags were then mapped to the male mouse g e n o m e reference 
(assembly version m m 9 , 18S r R N A gi [ 374088232 and 28S r R N A gi 1120444900 rRNA) by 
using Bowrie sof tware (//(?), vers ion 0.12.8, that suppor ts colour-space data mapp ing 
(AppendLx 8.1 - miRNA.bowt ie .SGE.p l ) . Mapping parameters were chosen such that up to 
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2 colour-space mismatches were al lowed in the first 20 nt seed region, and the alignment 
was extended to the fuU-length of the tag if the sum of the quality values at mismatch 
posit ions did not exceed 70. 
Mapping protocol for total genome analysis: 
Mapping to the genome-. Tags were mapped such that one random mapping position was 
selected for tags mapping to more than 1 locations by invoking the - M 1 option in Bowtie 
command. This set of al ignments is referred to as genomic alignments from here on, and was 
used for counting tag distribution m various genomic features. 
Bowtie Command, Genomic alignments; 
bowtie -f -C -Q input.QV.qual —integer-quals -1 2 0 —nomaqround — 
maxbts 800 —tryhard —chunkmbs 2048 -M 1 -a —best —strata —snpfrac 
0.01 —col-cqual —col-keepends —sam —mapq 20 —offrate 2 —threads 
12 —shmem reference_bowtie_colorspace_index input.csfasta >output.sam 
Tag counting for distributions oj various genomicfeatures: 
The genomic al ignments were used to determine the proportion of tags mapping to various 
genomic feamres. Coordinates for genomic feamres such as protein coding loci, non-
coding RNA loci and genomic repeats (e.g. LINE, SINE, simple repeats) were obtained 
from Ensembl v67. In addition, miRBase v l 8 annotations were used for miRNA loci, 
p iRNA coordinates were obtained from the p iRNABank {179) and protract {ISO), and 
18/28S rRNA were obtained from the GenBank. A custom BAM file parser was designed 
( A p p e n d s 8.1 - countGff) by using the BamTools API {181) to identif)- the number of tags 
that overlap each genomic feamre. Tags were preferentially assigned to a miRNA loci, even 
if multiple, overlapping genomic features were present for that locus. If the mapped 
position of the tag overlapped a non-miRNA locus with multiple, overlapping genomic 
features, the tag was randomly assigned to one genomic feature. 
Mapping protocol for miRN.\-focused analysis: 
Mature miRNAs derived from multiple genomic loci can be identical in sequence. 
Therefore randomly assigning tags to all of the identical loci can effectively reduce the 
number of tags assigned to each individual locus. This random assignment can affect the 
downstream expression analysis. Therefore, we chose to assign tags to all of the identical 
loci to retain the true levels of tag counts observed for any mamre miRNA in our data. T o 
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assign the number of tags at each miRNA locus, tags were al lowed to map to up to 20 
locations. If a tag mapped equally to more than 20 locations, one location was randomly 
chosen. These set of a l ignments are referred to as miRNA alignments f rom here on. 
Bowtie Command , m'RNA alignments'. 
bowtie -f -C -Q input.QV.qual —integer-quals -1 20 —nomaqround — 
maxbts 800 —tryhard —chunkmbs 2048 -M 20 -a —best --strata — 
snpfrac 0.01 —col-cqual —col-keepends —sam —mapq 20 —offrate 2 — 
threads 12 —shmem reference_bowtie_colorspace_index input.csfasta 
>output.sam 
Tag counting for miRNA loci: 
Tags were assigned to a mature m iRNA if their mapped position was within +/-3nt of the 
miRBase annotated 5' start site and were between 20-26nt in length inclusive (S2). These 
mature m iRNA tags are referred to as miRNA tags and the count of these tags is referred to 
as the total tag countfor a miRNA f rom here on. 
Tag count information tables were generated by using miRNAcountsBAM.pl (Appendix 
8.1). These tables were then loaded into MySQL database. Using miRNAcounts.mysql .pl 
(Appendix 8.1), which used the mmu.feamres (Appendix 8.1) and MySQL database as 
input, final counts tables were generated. 
Many mature miRNAs are derived from multiple genomic locations but the mamre 
miRNA sequence is identical. These miRNAs have the same miRNA name followed by a 
suffix, for example miR-199a- l and miR-199a-2. Owing to the same nucleotide and seed 
sequence, it is assumed that they act similarly in m R N A regulation pathway in a given 
biological context. Therefore, we randomly chose one mamre miRNA in such instances for 
analysis of miRNA. 
Differential expression analysis: 
The total tag count for a m iRNA in each sample was obtained for differential expression 
analysis as described above. Effect ive Kbrar>' size for each sample was set to the sum of tag 
counts mapping to miRNAs in each sample. The edgeR package was used for the foUowing 
differential expression analysis (182). Tag counts were normaUsed for RNA output by the 
tr immed mean of M-value (TMM) scaling method described in {183) to obtain normaUsed 
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CPM (nCPM). All miRNA with mean nCPM across all samples below 10 were discarded 
from further analysis. Tests for the differential expression of miRNA between samples 
were carried out as described in the cdgeR user guide. The script used for all miRNA 
differential expression and associated analysis is listed in Appendix 8.2. The data was 
normalised separately using upper quartile normalization, the same script was used as listed 
above but the function calcNormFactors (x, method="upperquartile") was used. 
m/RA'A processing analysis: 
miRNAs can exist as 5' and 3' isomiRs, exhibit arm bias and undergo post-transcriptional 
modifications. In light of these properties, we analysed the sequencing data for such post-
transcriptional events to better understand these processes in our model. We focused on a) 
hairpm arm selection b) 5' isomiR c) 3' isomiR d) internal editing and e) non-templated 
additions. Distinct genomic regions can give rise to canonical mature miRNAs that ate 
identical in sequence. Nevertheless, difference in precursor sequence at 5' upstream or 3' 
downstream positions may lead to their differential processing for isomiR generation, arm 
bias, internal editing, and non-templated additions. Therefore, to systematically assay these 
processing events, each genomic position of a mamre miRNA was analyzed individually. 
Hairpin arm selection: 
The ratio between the total tag count for a miRNA (as described earlier) on the 5' arm of a 
given miRNA hairpin and the sum of the total tag counts for miRNAs on both 5' and 3' 
arms of the hairpin was calculated for this analysis. 
5' and 3' isomiR ratio: 
miRBase v l 8 annotated start and end positions for a mature miRNA were considered as 
the canonical start and canonical end positions, respectively. miRNA tags differing in their 
5' start positions compared to the canonical start position were considered as 5' isomiRs 
and those that differed at the 3' end positions compared to the canonical end position were 
considered as 3' isomiRs. The percentage of canonical miRNA tags for each mature 
miRNA in each sample was calculated with respect to total tags for that miRNA, 
Internal editing: 
miRNA tags with a nucleotide mismatch before the last two nucleotides of the tag and 
before the last two nucleotides of the canomcal end position were considered as tags 
containing possible editing events. For each mature miRNA the number of tags with 
possible editing event and the identity of the base substitution was determined. The mean 
percentage and tange of internally edited miRNAs was then calculated. 
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Non-templated addition (NTA): 
If miRNA tags (as described earlier) differed from the reference sequence in the last two 
nucleotides of the tag, then they were selected to contain non-templated nucleotide 
addition. For each mature miRNA the number of tags with NTA was recorded as well as 
the identity of the non-templated base. The percentage of NTA tags was then determined 
relative to the total miRNA tags for a given mature miRNA. The mean percentage of NTA 
was then calculated along with the range for aU miRNAs. 
Statistical model of miRNA processing variants: 
Differential processing of miRNA variants was determined using the proportion a tj'pe of 
processing variant contributes to each miRNA. The data was transformed to an 
approximate Guassian distribution by an arc sin of square root transformation. Count 
noise was then incorporated into the model by quadratic fit of variance versus total read 
counts for each miRNA, using the Voom method of Smyth et al. (1&4). A weighted linear 
model was then used for differential processing using Limma {i&4). The FDR was 
estimated using the Benjami-Hockberg method. 
CO-term enrichment for miR ! 33a-3p predicted targets: 
Target prediction was done using the can/23 nt and iso/22 nt seed sequences of miR-133a 
and Targetscan {67). Enrichment of gene function terms was determined with IPA 
software (Ingenuity® Systems), using the Benjamini-Hochberg multiple testing correction 
method and a threshold p-value <0.01. 
2 . 2 . 8 . D 3 ' E N D S E Q U E N C E A N A L Y S I S P I P E L I N E 
Data filtering: 
Prior to mapping to a reference, the tags were filtered to retain only high quality reads; any 
tags with a mean quality' value <18 were removed and tags with ambiguous colour calls 
were also removed usmg the perl script csqvfilter.pl (Appendix 8.3). 
Mapping to the reference genome: 
All clean sequenced tags were then mapped to the mouse genome reference (assembly 
version mm9, 18S rRNA gi| 374088232 and 28S rRNA gi| 120444900 rRNA) with Bowtie 
Software {VS), version 1.0.0 that supports colour-space mapping. Mapping parameters 
were chosen to aUow 3 mismatches m the 21 nt seed region, and the aHgnment was 
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extended to the full-length if the sum of the quaHtj' values at mismatch position was less 
than 150 (parameter --maqerr 150). Tags were allowed to map to up to 20 locations. 
Bowtie command. Genome alignments: 
bowtie -f -C —integer-quals —seedmms 3 —noraaqround —maxbts 800 — 
tryhard —chunkmbs 512 -M 20 —best —strata —maqerr 150 —col-cqual 
—col-keepends —sam —threads 12 — m m -Q filtered.QV.qual —un 
GNeg.csfasta mouse.e65chr.ncbirRNA.fa filtered.csfasta 
T o capmre exon junction-spanning reads, tags that failed to align to the genome were 
further mapped to the mouse cDNA and ncRNA sequences (Ensembl v67) using the same 
Bowtie parameters with the exception of allowing tags to match to up to 200 locations. 
Bowtie command, Transcriptome alignments: 
bowtie -f -C —integer-quals —seedmms 3 —nomaqround —maxbts 800 — 
tryhard —chunkmbs 512 -M 200 —best —strata —maqerr 150 —col-cqual 
—col-keepends —sam —threads 12 —mm -Q GNeg.csfasta.qual —un 
TNeg.csfasta Mus_musculus.NCBIM37.67.cdna.ncrna.fa GNeg.csfasta 
Read al ignments to RNA sequences were projected to genomic locations and merged with 
genomic al ignments using transcript2genome.pl (Appendix 8.3). All tags that did not map 
to cither genome or expressed RNA sequences were mapped to the genome by tr imming 
the last 54 nt (retaining the first 21 nt seed) using the Bowtie software, allowing up to 3 
mismatches in the first 21 nt. Up to 200 locations for each tag with mismatches ranging 
between 0 and 3 were identified and processed further to identify' non-templated poly(A) 
tail additions on reads. 
Bowtie command. Seed alignments: 
bowtie -f -C —integer-quals -v 3 —trim3 54 -M 200 —col-cqual —col-
keepends --sam —threads 12 — m m -Q TNeg.csfasta.qual —un 
SNeg.csfasta mouse.e65chr.ncbirRNA.fa TNeg.csfasta 
A custom Perl script (Appendix 8.3 - cspolyaextender.pl) was used to perform extension of 
aHgnments such that the mismatch proportion remained less than 10% m either the 
templated region of the read or non-templated region of the read. AU alignments were 
merged mto a single bam file for each sample and processed further to identify 3' 
sequencing peaks and poly(A) tail start positions. 
Methods 
Defining 3' sequencing peaks: 
Cont iguous stretches of nt along the length of the genome with at least 1 read coverage 
were bmned mto peaks representative of 3' end sequencing of RNA using the script 
coveragePeaks.pl . Tags linking two or more exons were identif ied using the following 
command; intersectBed -bed -wo -s -split -abam T2G. merged, bam -b 
ThreeUTRPeaks.6.gff >ThreeUTRPeaks . 6 . intersect. The script 
l inkCoveragePeaks.pl (Appendix 8.3) was run to mrn Hnks between 3' seq peaks into 
transcript umts. 
Information for each peak such as the length of the transcript, the exon IDs that make up 
the transcript, the number of reads that contribute to the peak, presence of poly(A) and 
poly(A) signal were dcfmed using the script getTranscripts.pl (Appendix 8.3). For a poly(A) 
cleavage site to be called, the start position for the cleavage site had to be supported by at 
least nvo reads with different start positions. The peaks were filtered by retaining only 
peaks longer than 75 nt and with tags present in at least two samples. Any downstream 
filtering was done in R. 
Counting peaks for distributions of x a i ious genomic feamres: 
Genomic feamres were identif ied using the canomcal transcript as defined in Ensembl v67 
using processTable.pl . The peaks were labeled as Annotated, Orphan, Exonic or Intronic 
based on the following critena: 
Annotated peaks: 
• If the peak overlaps with a known gene and it is within 20 kb downstream of the 
end/stop codon of a known gene then it is assigned as Annotated. 
• If die peak does not overlap with a known gene but it is within 20 kb downstream 
of an upstream end/stop codon of a known gene then it is assigned as Annotated. 
• If the peak overlaps with the intron of a known gene but m the antisense 
direction, and it is within 20 kb of an upstream end/stop codon of a known gene 
m the sense du'ection then it is assigned as Annotated to the gene in the sense 
direction. 
Orphan peaks: 
• If die peak does not overlap with a known gene and it is not within 20 kb of an 
upstream end/stop codon then it is assigned as an Orphan peak. 
Methods 
Exon peaks: 
• If the peak overlaps with the exon of a known gene then it is assigned as an Exon 
peak. 
Int ionic peaks: 
• If the peak overlaps with the sense strand of an intron of a known gene then it is 
assigned as an Intronic_sense peak. 
• If the peak overlaps with the antisense strand of an intron of a known gene and is 
not within 20kb of an upstream end/stop codon then it is assigned as an 
Intronic_antisense peak. 
Calculating distances to stop codon: 
These were calculated f rom the stop codon of the canonical transcript of a protein coding 
gene or from the 3' end of the canonical transcript of a non-coding gene (as defined in 
Enscmbl v67). 
Calculating novel or known 3' ends: 
All transcript isoforms defined in Ensembl v67 were used to determine if a peak was novel 
or known. If a peak overlapped a known 3' UTR and was within 100 nt from the end of 
the y UTR then it was considered as known. 
I'catures of die 3' sequencing peaks: 
• Searching for the canonical and non-canonical polyadenylation singals (PAS). 
o These were searched 50 nt upstream of the poly(A) start site with at least 2 
reads supporting the start site. Where the poly(A) tail was not present, the 
nearest PAS was identif ied to the 3' end of the peak (entire peak upstream 
and 50 nt downstream). Both the canonical and non-canonical PAS were 
recorded if present, then a preference was given to the canonical PAS. The 
distance from the start of the poly(A) tad or the end of the 3' seq peak was 
calculated. 
2 . 2 . 8 . E MERGING 3 ' SEQ PEAKS FOR GENE EXPRESSION 
The tag counts for 3' seq peaks assigned to the same gene were added together for 
differential expression analysis. The effective Hbrary size for each sample was set to the 
sum of tag counts assigned to genes. The edgeR package was used for the foUowing 
Methods 
differential expression analysis (182). Tag counts were normalised for RNA output by the 
t r immed mean of M-value (TMM) scaling method described m (/<?i) to obtain normalised 
C P M (nCPM). The 98''' percentile was retained for differential expression testing. Tests for 
the differential expression of m iRNA between samples were carried out as described in the 
edgeR user guide. The script used for all m R N A differential expression and associated 
analysis is listed in Appendix 8.4. 
GO-term enrichment of differentially expressed genes: 
Gene ontology enrichment was performed using the database for annotation, visualization, 
and integrated discovery (DAVID)(/,yi ) . The analysis was performed in R, using the script 
GOterm.pl . The enrichment was performed using differentially expressed mRNA 
transcripts (Appendix 8.5) with a FDR <10% and the top 98"' percentile as the 
background. Enriched G O _ F A T terms with FDR < 30% for biological process 
(GO_BP_FA'I ) , ceUular component (GO_CC_FA'I ) and molecular function 
(GO_MF_FAT) were recorded. 
2 . 2 . 8 . F DETECTION OF 3 ' U T R CHANGES: 
Using protein coding 3' UTR associated peaks with coverage >10 and tags in at least two 
samples. 
Noise reduction filter: 
A peak needed to contribute greater than 10% of total tags to a gene across all samples to 
be considered for analysis. An additional filter requiring > 4 reads across TAG and Sham at 
each time point. 
Differential polyfA') model : 
Used a model that eliminates changes that are confounded by overaU gene expression level 
changes. Alternative polyadenylation was detected as a proportion statistic between 
proximal and distal poly(A) sites. AU possible pairs of 3' seq peaks for a given transcript 
were used. The data was first transformed to an approximate Gaussian distribution by an 
arc sm of square root transformation. Count noise was then incorporated mto the model 
by quadratic fit of variance versus total read counts over each peak, using the Voom 
method of (184). A weighted moderate linear model was used for differential 3' end usage 
Methods 
est imation using Limma(/<?•/). The FDR was then estimated using the Benjamim-Hockberg 
method. 
GO- t cm i enrichment of 3 'UTRs with differential po!y(A): 
GO-term enrichment was performed as described in 2.2.7.E but using the mRNA 
transcripts with alterations in the proport ion of 3' UTRs (FDR <70%). 
2 . 2 . 8 . G M D S PLOTS AND HEATMAPS 
Mult idimensional scaling plots were drawn using the p lotMDS function in the edgeR 
package. The p lo tMDS function takes the top 500 genes with the largest biological 
variation between libraries (largest tagwise dispersion). Then the distance between each pair 
of libraries, termed the biological coefficient of variation is calculated. The spearman 
correlation was calculated using the function cor and the method "spearman", which refers 
to the Spearman's rho or rank statistic. 
Heatmaps were drawn using the hcatmap.2 function in the gplots package. Heatmap.2 
performs complete l inkage clustering, using a Euclidean distance measure. The dendrogram 
is then reordered using the row or column means. 
CHAPTER THREE 
HYPERTROPHY MODEL 
3 . 1 INTRODUCTION 
[ lypertrophy Model 
To examine the relevance of iniRNA and 3' UTR variants in cardiac disease, a model of 
cardiac hypertrophy was used in collaboration with Professor Robert Graham's laboratorj' 
at the Victor Chang Cardiac Research Institute. 
Transverse Aortic Constriction (TAG) is a commonly used and reproducible mouse model 
of pressure overload-induced left ventricular hypertrophy and heart failure {186). TAC 
closely mimics the clinical scenario in patients with aortic coarctation (a congenital 
condition resulting in narrowing of the aorta) and somewhat resembles aortic stenosis or 
hypertension {187). TAC is a microsurgical technique that involves tying off the aorta with 
a suture against a needle to yield a consistent constriction of the transverse aorta (Figure 
3.1). It has been previously shown that in 8-week-old G57BL/6 mice the diameter of the 
aorta at the site of constriction is 1.2 mm, and aortic constriction with a 7-0 nylon sumrc 
against a 27-G needle results in a 0.4 mm reduction in diameter once the needle is removed 
{186). This reduction in the diameter of the aorta increases the pressure that the heart has 
to push against. The increased pressure can be offset by an increase in LV wall thickness, 
an adaptive response that results from an increase in the size of the cardiomyocytes. 
TAC is initially a model of compensated hypertrophy, where the heart maintains cardiac 
output, but the response to chronic pressure overload can evenmaUy become maladaptive 
and result in heart failure. The progression to heart failure can be accelerated depending on 
the tightness of the aortic constriction, with severe TAC leading to impaired LV function 
as early as 7 days {18S). For this reason, we subjected 12-week-old C57BL/6 mice to mild 
TAG (using a 27-G needle) and analysed the hypertrophic response at 7 days where there is 
a reported change in cardiac structure but the cardiac function remains unaffected {188). 
To analyse pre-hypertrophic changes, animals were also analysed 48 hours post-TAG 
surgery. Increased load on the heart results in the parallel addition of sarcomeres in the 
cardiomyocyte, resulting in an increase in cardiomyocyte width and subsequent increase m 
LV wall thickness (J). It has been previously shown that there is no significant difference in 
LV waU thickness, and thus no hypertrophy, at 24 hours post-TAG but the LV waU 
thickness progressively increases until 10 days post-TAG surgerj' {189). Therefore, it was 
hypothesised that changes at 48 hours may be causative rather than a downstream result of 
hypertrophic signalling. 
Hypertrophy Model 
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Figure 3.1. Transverse Aortic Constriction. 
Schematic of TAG surgical procedure; the aorta is tied off with a nylon suture around a needle that 
IS placed parallel to the aorta, between the left carotid artery and the right brachiocephalic artery. 
Picture modified from {186). 
[lypertrophy Mode' 
Previous studies looking at miRNA and mRNA expression in the hypertrophic/failing 
heart have used whole LV samples {130, 190). The heart consists of multiple cell t}'pes 
including cardiomyocytes, cardiac fibroblasts and vascular cells such as the endothelium. 
Cardiac fibroblasts account for 60-70% of the total number of cardiac cells, and are 
essential in generating and maintaining the extracellular matrix of the myocardium [191). 
Although cardiomyocytes are fewer in number, they take up the bulk of the volume of the 
heart and are the contractile cells that provide mechanical force to the heart {192). Both 
cardiomyocytes and fibroblasts ate intrinsically involved in the progression to maladaptive 
hypertrophy and heart failure. Smdies looking at whole LV samples have therefore been 
looking at the gene expression changes in a number of cell types. We hypothesised that to 
correcdy establish miRNA interactions involved in hypertrophy it would be important to 
isolate cardiomyocytes. For this reason, once the animals had undergone haemodynamic 
studies using micromanometery thereby confirming successful pressure overload, the 
cardiomyocytes were enriched for subsequent RNA analysis. This would allow detection of 
miRNA changes and mRNA 3' UTR usage in cardiomyocytes independent of the other cell 
types. 
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3 .2 Rl'SULTS 
3 . 2 . 1 I ' : S T A B L I S H I N C ; A M O D l ' ; i . OL' H Y P I : R T R C ) P H Y 
Tight TAG (constriction of the aorta to the size of a 27-G needle) was performed on 12-
week C57BL/6 mice and the h\-pertrophic response analysed at 48 hours and 7 days post 
surger\'. 64 mice were used (32 Sham and 32 TAG), with 44 mice used for isolation of the 
whole LV and other tissues and 20 mice used for cardiomyocyte enrichment. An overview 
of the experimental procedure to obtain samples for SOLiD^"^ next-generation sequencing 
is shown in Figure 3.2. The animal surgeries and micromanometry were performed by Dr 
J ianxin Wu . Dr Nicola Smith and myself assisted in the pre- and post-operative care of the 
animals, performed the dissections after micromanomeOiy and data analysis. 
Micromanometr}' using a micromanometer catheter placed in the aorta and then the LV 
cavity was performed on all animals to conf i rm differential pressure across the aortic band 
and to assess the changes in cardiac function. As cardiac function is closely correlated with 
heart rate (193), the micromanometry measurements were taken when the heart rates for 
both Sham and TAG groups were comparable (Figure 3.3.A). Both aortic and LV systolic 
blood pressures (BP) were signif icandy increased in TAG banded animals at 48 hours and 7 
days (Figure 3.3.B). Aortic systolic pressure is the maximal pressure in the aorta following 
ejection of blood from the left ventricle. The aortic systolic BP was increased from 
116.8±2.9 m m H g in Sham animals to 155.9±3.3 m m H g (p<0.0001) in TAG animals at 48 
hours, with a further increase to 176.1±6.3 m m H g (p<0.0001) in TAG animals at 7 days 
(Figure 3.3.B). This indicates that the aortic constriction was indeed increasing the pressure 
that the LV must push against. Increased pressure at a point in a system causes a pressure 
backup to the preceding elements within the system. As the aortic pressure rises, the 
ventricular pressure will soon rise due to pressure backing up within the system. The 
increased pressure was reflected by an increase in LV systolic BP at 48 hours from 
113.9±1.8 mmFIg in the Sham animals to 149.2±4.3 m m H g (p<0.()()l) in the TAG banded 
animal. Sirmlarly, the LV systoUc BP also increased from 110.9±2.3 to 166.5±9.0 mmHg 
(p<0.00() l ) 7 days post-surgery. L\' systoHc BP is an indication of the total load on the 
heart, as it is a function of the pressure gradient from the TAG in addition to the systemic 
BP (194). The increased pressure occurs immediately after constricting the aorta, with 
increases in systolic pressure previously detected as early as one hour post-surger\- (195). 
Hypertrophy Model 
The increased pressure indicates the TAG banding successfully decreased the diameter of 
the aorta resulting in an increase in pressure that the heart must pump against. 
48 hours 7 days 
Pre-hypertrophic Compensated Hypertrophy 
•I 
Haemodynamic measurements 
Cardiomyocyte RNA / 
SoLiD Next-generation 
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Figure 3.2. TAG: a model of left ventricular (LV) hypertrophy. 
Overview of experimental approach: TAG was performed on 12 week C57BL/6 mice with a 27-G 
needle and hearts isolated 48 hours or 7 days post-surgery. Haemodynamics measurements were 
taken usmg micromanometery on all animals (n=64). Physiological and biochemical measurements 
were taken from tissues and whole LVs harx^ested from a subset of mice (n=44). The remaining 20 
mice were used for cardiomyocyte enrichment and subsequent SOLiD™ next-generation 
sequencing of small RNAs and 3' end whole transcriptome. 
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Figure 3.3. TAC leads to pressure overload. 
Haemodynarmc measurements were taken by micromanometr)'. (A) Heart rate (beats per minute, 
BPM) IS comparable between Sham and TAC animals. (B) TAC increases both aortic and LV 
systoUc blood pressure (BP). (C) TAC leads to a sUght decrease in Aortic DiastoUc BP at 48 hours, 
which normalised by 7 days. There was no significant difference in LV end diastolic pressure 
between Sham and TAC, {**** p <0.0001. p <0.001, * p <0.05, Two way-ANOVA with 
Bonferonni's post-hoc analysis). Data is shown as mean with SEM (n=ll-14) . 
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Diastolic pressure, which is the lowest pressure in the aorta just before the ventricle ejects 
blood, was also measured (Figure 3.3.C). There was a slight decrease in aortic diastolic BP 
from 83.3±2.1 to 72.9±3.6 mmHg (p<0.05) at 48 hours, which normalised at 7 days 
(78.8±2.1 mmHg in Sham animals versus 75.5±3.5 mmHg in TAG animals). There was no 
significant change in LV end diastolic pressure (EDP), which is the pressure at the end of 
diastole just prior to the heart's next contraction, at either time point; 6 .710.4 and 8.7±0.7 
mmHg for 48 hour Sham and TAG respectively, and 5.2+1.2 and 7.4+1.6 mmHg for 7 day 
Sham and TAG respectively. LVEDP is a measure of ventricular performance, with 
increasmg LVEDP associated with heart failure {196). Thus, as there is not a significant 
increase in LVEDP in the TAG banded animals there is no indication of cardiac 
dysfunction. 
To further determine if the TAG banding negatively impacted on heart function, the 
dP/dt„„and dP/dt„,„were calculated (Figure 3.4). The dP/dt„„ and dP/dt„,„ represent the 
maximum and minimum rate of pressure change in the LV, with dP/dt„,„ an indicator of 
systolic function and dP/dt„,„a measure of diastolic function. These values are commonly 
used as an index of LV function and contractility- {197). There was a significant decrease in 
dP/dt„„ from 11099.8±760.9 mmHg/sec in Sham animals to 8790.6±372.6 mmHg/sec 
(P<0.05) in TAG animals at 48 hours (Figure 3.4.A). There was no sigmficant difference in 
dP/dt„„ at 7 days; 9458.91320.0 and 9757.61710.4 mmHg/sec for 7 day Sham and TAG 
respectively. This suggests the L\' systolic function deteriorated soon after TAG but 
normalised by day 7. This is consistent with previous smdies that show LV systolic 
function decreases immediately after TAG, but recovers with the development of 
compensated hypertrophy {189). Reflecting the sUght decrease m Aortic diastoUc BP, there 
was a trend for higher dP/dt„,„ at 48 hours (-9765.61364.1 and -6871.21515.7 mmHg/sec 
for 48 hour Sham and TAG respectively) but this was not significant (Figure 3.4.B). There 
was no difference in dP/dt„,„ at 7 days; -8527.611611.6 and -8762.51728.9 mmHg/sec 
for 7 day Sham and TAG respectively. 
The micromanometr)' data shows that the aortic banding was successful, resulting in 
mcreased blood pressure and subsequent pressure overload of the heart. 
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Figure 3.4. Contractility in pre-hypertrophic and hypertrophic hearts. 
(A) T A C lead to a decrease in dP/dt max at 48 hours, with no detectable difference at 7 days. (B) 
T A C lead to a slight increase in dP/dt min at 48 hours (not significant) but was unchanged at 7 
days. (* p <0.05, Two w a y - A N O V A with Bonferonni 's post-hoc analysis). Data is shown as mean 
with SEM ( n = l l - 1 4 ) . 
8.3 
Ilypertroph; Model 
The increase in LV pressure resulted in LV h\fpertrophy at 7 days with an increase in the 
whole heart and LV weight, relative to tibia length or body weight (Figure 3.5). There was a 
significant mcrease in heart weight relative to body weight (5.1+0.1 to 5.9+0.1 rng/g, 
p<0.001) at 48 hours, but this increase in heart size did not reach significance when 
normalised to tibia length. Weight loss can occur as the health of the animal deteriorates. 
Loss of more than 20% body weight was considered an ethical endpoint in this study, 
however, none of the mice reached this endpoint indicating they were still m a healthy 
weight range. Normalising the changes in heart weight to tibia length is more accurate as it 
removes any bias due to loss in body weight. Heart weight was sigmficandy higher in TAC-
banded animals at 7 days, relative to both body weight and tibia length (32.6% and 34.8% 
increase respectively). As expected, this increase in heart weight was derived f rom the LV. 
The TAG animals had significandy heavier LV at 7 days (p<0.0001), compared to body 
weight and tibia length (44.8% and 46.8% increase respectively). Whilst the LV weight 
tended to be heavier at 48 hours, this slight increase was not significant. Importandy, there 
was no increase in right ventricular (RV) weight at 48 hours and 7 days compared to both 
body weight and tibia length (Table 3.1), reinforcing that the hypertrophy was derived only 
f rom the left ventricle. Furthermore, there was no increase in lung-wet weight (WW), 
indicating the model did not result in heart failure (which can be characterised by oedema 
of the lung and increased lung W W , Figure 3.6.A). The body weights of all Sham and TAG 
animals were comparable both pre-surgery and at the Endpoint of the smdy (Figure 3.6.B). 
At the molecular level, cardiac hj-pertrophy can be characterised by the re-expression of 
cardiac foetal genes; atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), beta-
myosin heavy cham ((i-MHG) and alpha-skeletal actin (a-Ska) {198). These foetal genes are 
commonly used as markers of hypertrophy. TAG lead to re-expression of these foetal 
genes in the whole LV samples; B N P was re-activated as early as 48 hours post-TAG 
(pO.OOOl), widi upregulation of the remaimng markers reaching sigmficance in the 7 day 
post-TAG animals (Figure 3.7). 
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Figure 3.5. TAC leads to LV hypertrophy. 
(A) TAC leads to a significant increase in heart weight normalised to body weight as early as 48 
hours (left). Significant increase is detectable only at 7 days when normaUsing heart weight to tibia 
length (right). (B) The increase in heart weight is derived from the LV; significant increase in LV 
weight compared to both body weight and tibia length at 7 days. (C) The increased heart weight is 
not derived from the RV; no difference between the RV weight of Sham and TAC animals. (•** p 
<0.001, **** p<0.0001, Two way -ANOVA with Bonferonni 's post-hoc analysis). Data is shown as 
mean with SEM (n=7 - l l ) . 
1 lypertrophy Model 
Sham 
TAG 
Sham 
TAG 
48 hours 7 days 
E 
I 
E 10 
S 5 
(n=7-9) 
7 days 
B 
Sham 
TAG 
7 days 
(n=15-16) 
B 30i 
Sham 
TAG 
7 days 
(n=12-15) 
Figure 3.6. T A G does not lead to H e a r t Fai lure . 
The lung wet weight (WW) did not increase in TAG animals compared to body weight (left) or tibia 
length (right). (B) The body weights of Sham and TAG animals were comparable at both pre-
surgery and the endpoint. Data is shown as mean with SEM (n=7-16). 
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Figure 3.7. T A C leads to re-activation of cardiac foetal genes. 
The hypertrophy markers atrial natriureUc peptide (ANP), beta-myosin heavy chain (p-MHC), brain 
natriuredc peptide (BNP) and alpha-skeletal actin (a-Ska) were upregulated 7 days post-TAC in the 
whole LV samples. BNP was upregulated pre-hypertrophy at 48 hours. (** p<0.01, p<0.0001, 
Two way-ANOVA with Bonferonni 's post-hoc analysis). Data is shown as mean with SEM (n=6-
9). 
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T a b l e 3.1 A s s e s s m e n t o f H y p e r t r o p h y . 
48 hours 7 days 
Sham TAG Sham TAG 
Physiological data 
HW/BW (mg/g) 5.1 ±0.1 5.9 ±0.1 4.8 ±0.1 6.4 ±0.2 
HWn-L (mg/mm) 7.7 ±0.4 8.7 ±0.4 6.9 ±0.2 9.3 ±0.3 
LV/BW (mg/g) 3.7 ±0.1 4.2 + 0.2 3.5 ±0.1 5.1 ±0.2 
LV/TL (mg/mm) 5.6 ±0.3 6.1 ±0.3 5.1 ±0.1 7.5 ±0.4 
RV/BW (mg/g) 0.7 ±0.1 0.7 ±0.0 0.6 ±0.0 0.7 ±0.1 
RV/TL (mg/mm) 1.0±0.1 0.9 ±0.1 0.9 ±0.1 1.0 ±0.08 
Lung WW/BW (mg/g) 5.8 ±0.2 6.5 ±0.5 5.9 ±0.3 6.8 + 0.8 
Lung WW/TL (mgAI) 8.7 ±0.3 9.4 ±0.7 8.5 ±0.3 9.8 ±0.9 
Initial BW (g) 28.5 ± 0.6 27.4 ± 0.5 26.6 + 0.6 26.6 ±0.5 
Endpoint BW (g) 26.5 ±0.6 25.4 ±0.5 25.7 ±0.5 25.8 ±0.5 
Haemodynamics 
Aortic SP (mmHg) 11 a s ± 2.9 155.9 ±3.3 9458.9 ± 320 176.1 ±6'3 
LV SP (mmHg) 113.9± 1.8 149.2 ±4.3 111.3±2.8 166.5 ±9.0 
Aortic DP (mmHg) 83.3 ±2.1 72.9 ±3.6 110.9±2.3 75.5 ± 3.5 
LV EDP (mmHg) 6.7 ±0.4 8.7 ±0.7 78.8 ± 2.1 7 .4+1 .6 
HR (BPM) 457.0 ± 6.7 487.0 ± 10.8 5.2 ± 1.2 477.2 ± 7.8 
dP/dT max (mmHg/sec) 11099.8 ±760.9 8790.9 ± 372.6 459.3 ± 11.3 9757.6 ±710.4 
dP/dT min (mmHg/sec) -9765.6 ±364.1 -6871.2 ±515.7 -8572.6+ 1611.6 -8762.5 ± 728.9 
T h e abbrev ia t ions used in this table are: B W , body we ight ; DP, diastol ic pressure ; EDP, end 
diastol ic pressure ; H R , heart rate; H W , heart we ight ; LV , left ventr ic le ; RV , r ight ventr ic le ; SP, 
systoEc pressure ; T L , tibia length ; W W , w e t we ight . (n=7-16) . 
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3 . 2 . 2 C A R D I O M Y O C Y T E E N R I C H M E N T 
T o select for transcripts expressed only by cardiomyocytes, these cells were enriched from 
the hearts of 5 Sham and 5 T A G anrmals at cach time point (20 animals in total) according 
to a standard protocol (176). In brief, the hearts were perfused with coUagenase to digest 
the extracellular matrix and release the cardiomyocytes, and the ventricles isolated for tissue 
dissociation to disperse the cardiomyocytes into a single-cell suspension. Differential 
centrifugation was then used to separate cardiomyocytes from other cell tj'pes, such as 
fibroblasts, based upon the density difference between cardiomyocytes and other cells 
(Figure 3.8). The wash fractions, which were presumed to contain fibroblasts and other 
cells, were retained to test for cell purity. Dr Ming Li performed the first stages of 
cardiomyocyte isolations up until the ventricles were isolated, subsequent steps were 
performed by Sara Holman with my assistance. I performed the R N A isolation and RT-
qPCR analysis, with assistance from Nadine Mourad. 
Table 3.2 shows a summary of the cardiomyocyte enrichment. The total number of cells 
and the proportion of rod-shaped cardiomyocytes were measured before and after 
differential centrifugation. On average, 2.2 million cells were isolated from each heart, of 
which 63% were rod-shaped cardiomyocytes. After washing and centrifugation, 1.3 million 
cells remamed, with 66% derived from rod-shaped cardiomyocytes. Samples with a low 
number of total cells or less than 60% rod-shaped cardiomyocytes were not considered for 
next generation sequencing. TRIzol® was added directly to the isolated cardiomyocytes for 
R N A extraction and the R N A quality assessed by an Agilent Bioanalyzer Chip. The 
extracted R N A was of high quaHt\^ indicated by a RIN higher than 7.2 (Table 3.2). 
T o test the enrichment of cardiomyocytes m the samples, expression of several marker 
genes of fibroblasts and cardiomyocytes were analysed by RT-qPCR. The fibroblast 
markers a-Vimentin, coUagen tjrpe 1 alpha 1 (Col la l ) , coUagen t)'pe III alpha 1 (Col3al) 
and discoidin domam receptor tyrosine kinase 2 (Ddr2), were enriched in the wash 
fractions compared to cardiomyocytes and whole L V tissue (Figure 3.9). Similarly, myosin 
Ught Cham 2v (Mlc2v) and cardiac muscle troponin T Crnnt2), markers of cardiomyocytes, 
were highly expressed only in the cardiomyocyte fraction (Figure 3.9). Importantly, these 
enriched cardiomyocytes still displayed reactivation of the hypertrophic markers a -SkA and 
A N P 7 days post-surgery (Figure 3.10). This confirmed there was an enrichment of 
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c a r d i o m y o c y t e s f r o m b o t h p r e - h y p e r t r o p h i c a n d h j ' p c r t r o p h i c hear t s , ind ica t ing that the 
s a m p l e s w e r e a p p r o p r i a t e l y p u r e f o r d e e p s e q u e n c i n g . 
Perfused 
Ventricles isolated 
Tissue dissociated 
Differential Centrifugation 
iWash 11 
Differential Centrifugation X 3 
|Cardiomyocytes| 
F i g u r e 3 .8 . M e t h o d o f C a r d i o m y o c y t e e n r i c h m e n t . 
Overview o f cardiomyocyte isolation f rom Sham and T A G hearts; hearts were excised rapidly and 
perfused with coUagenase to digest the extracellular matrix. The hearts were cut just below the atria 
to release the ventricles, and the ventricles dissociated into a single-ceU suspension. Repeated 
differential centrifugation was used to isolate the cardiomyocytes. The supernatant from the first 
wash, containing fibroblasts and cell debris, was retained to assess enrichment. 
Table 3.2. Assessment of cardiomyocyte enrichment. 
F ib rob las t ma rke rs CM m a r k e r s H y p e r t r o p h y 
u e i i c o u n t s (fold depletion) (fold enhchment) marl kers 
Mouse ID 
Cell no. Rods Cell no. Rods RIN a - v i m Ddr2 Col3a1 C o l l a l Mlc2v c T n T a - S k A Nppa 
pre wash (%) post wash (%) 
48 hour Shf m 
48 Sham 3 NG NC 1,30E+06 55 7.8 330 12.5 40 1 133 5.9 7.0 0.43 0 35 
48 Sham 1 2,90E+06 66 1.30E+06 69 7.2 398 10.3 58.0 10.3 5.9 7.3 0.46 0 2 8 
48 Sham 2 2.60E+06 75 1 70E+06 79 8.2 324 5 5 13.2 127.7 3.7 5.8 0.27 0.55 
48 Sham 4 2.45E+06 81 1 70E+06 73 7 4 19 1 9.4 119 5 5 10 7 11.0 0.46 0 4 5 
48 Sham 5 1,30E+06 41 3.00E+05 22 NA 11.3 3.3 12.1 3.8 3 3 3.0 0.15 0.17 
48 hour TA( 
48 TAG 3 2 40E+06 83 1,90E+06 76 7 6 48.3 8 4 101.4 590 2.3 3 0 0.50 0.37 
48 TAG 1 230E+06 81 1.60E+06 73 8 2 27 4 11 0 102 17.3 7 0 11 7 0.76 1.22 
48 TAG 2 2.50E+06 68 140E+06 73 8.3 245 111 9 1 17.0 7 3 6 9 0.89 1 45 
48 TAG 4 3 20E+06 57 1 10E+06 58 7 8 37.5 4.9 489 180 0.02 2.9 043 0 18 
48 TAG 5 1.40E+06 61 1 .OOE+06 63 8 5 187 5.6 3.7 18.0 9.2 16.9 0.66 0.95 
T j H t ^ h a i T ) 
7 Sham 3 2.50E+06 57 1.50E+06 67 7 8 26.1 8 8 120 130 7.5 6 3 0.21 0.15 
7 Sham 1 2,00E+06 70 1.70E+06 68 7.9 30 1 3.0 575 28.0 2 9 3.7 0.16 020 
7 Sham 4 1 80E+06 52 9.00E+05 58 7 8 23.3 5.5 400 145 3 5 3.5 0.31 0.16 
7 Sham 5 1.50E+06 46 3,00E+05 64 7.5 9.9 4 0 0.8 4.2 17 3 2 0.10 1.05 
7 Sham 2 2.80E+06 63 1 OOE+06 72 7.6 21.1 3.7 7.5 6.7 3.5 4 6 0.14 0.21 
7 day TAC 
7 TAG 3 276E+06 61 1,80E+06 69 8 3 182 127 6 0 8.5 51.5 34.0 2.46 058 
7 TAG 4 1 20E+06 47 1 20E+06 44 7.7 3 6 3 5 8.0 3 8 17.4 143 1 66 1 60 
7 TAC 1 240E+06 83 1 80E+06 75 8.1 20.1 9 7 5.1 100 3 8 6 8 265 3.59 
7 TAC 2 2.02E+06 63 900E+05 65 8 2 194 179 586 32 0 13.7 11 6 1.53 1.10 
7 TAC 5 2 10E+06 58 1 40E+06 59 7.9 NA NA NA NA NA NA 2.97 3.22 
The abbreviations used in this table are: Ddr2, discoidm domain receptor tj'rosine kinase 2; CoBa l , collagen tj-pe III alpha 1; Co l l a l , collagen t)'pe I alpha 1; 
cTnT, cardiac muscle troponin T; Mlc2v, myosin light chain 2v; a-SkA, alpha skeletal actin; Nppa, atrial natriuretic peptide; a-vim, alpha vimentin; RIN, 
RNA Integrit)' number; CM, cardiomyocyte; NA, not available - no fibroblast sample available; NC, not counted. 
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Figure 3.9. Enrichment of Cardiomyocytes for RNA extraction. 
Cardiomyocytes were purified from whole hearts; RT-qPCR was performed on RNA extracted 
from Wash 1, whole LV and the cardiomyocyte fractions (CM) and normalised to HPRT 
expression. (A) There was significantly higher expression of fibroblast markers a-vimcntm, CoL3al, 
Co l l a l and Ddr2 in wash 1 or whole LV compared to the CM fraction. (B) There was also 
significant enrichment of cardiomyocyte markers Mlc2v and Tnnt2 in the CM fraction compared to 
LV and wash L (** p <0.01, p<0.001, **** p<0.0001, One way-ANOVA with Bonferonni's 
post-hoc analysis). Data is shown as mean with SEM (n= 19-20). 
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Figure 3.10. Hypertrophy markers are upregulated in the enriched cardiomyocytes. 
Cardiomyocytes were purified from whole hearts; RT-qPCR was performed on RNA extracted 
from the cardiomyocyte fractions (CM) and normalised to HPRT expression. There was a 
significant upregulation of the cardiac foetal genes a - s K a and ANP at 7 days post-TAC. (** 
p<0.01, p<0.0001, Two way-ANOVA with Bonferonni 's post-hoc analysis). Data is shown as 
mean with SEM (n=5). 
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3 . 3 DISCUSSION 
In order to document the m R N A and miRNA changes that occur during cardiac 
hypertrophy, it was essential to set up a valid and consistent model of the disease. For this 
reason, transverse aortic constriction was used. The surgeries were performed on 12- week 
old male C57BL/6 mice of comparable weight (Figure 3.7.B). The LV hypertrophy was 
conf i rmed in the TAG banded animals by hacmodynamics , physiological and molccular 
measurements . The hearts were then enriched for cardiomyocytes using a standard 
method, for subsequent next-generation sequencing. 
3 . 3 . 1 P R l i - n V P E R T R O P I I I C AND C O M P E N S A T E D HYPERTROPHY 
The process of hypertrophy is a major undertaking for a cardiomyocyte and involves 
molecular, structural and physiological changes. The overall aim of this thesis was to 
examine the changes in m iRNA processing and 3' UTR lengths during the development of 
left ventricular hypertrophy, specifically within a cardiomyocyte. Thus, the aim of this 
chapter was to establish a robust and validated model of LV cardiac hypertrophy, and to 
isolate pre-hypertrophic hearts and compensated hypertrophic hearts prior to their 
progression to heart failure. But this begs the question, what is the definition of pre-
hypertrophic and compensated hypertrophy? Does hypertrophy begin when the 
appropriate molecular changes occur or when there is an increase m heart weight? The 
development of hypertrophy has previously been described in three stages: the initial 
myocardial damage and impairment of contractile function before there is an increase in 
heart mass , the second stage where normal function is restored due to an increase in 
cardiomyocyte mass, and the third stage that results in a gradual deterioration of cardiac 
funcuon and output leading to heart failure {199). W e have used the first stage of 
hypertrophy development to def ine pre-h\'pcrtrophic hearts; there is a sHght impairment of 
ventricular performance but no increase m the weight of the LV. However, it is evident 
from our molecular data that the hypertrophic signalling has already been initiated at this 
stage, as shown by the mcrease m B N P levels at 48 hours. This needs to be taken into 
account when considering the gene expression changes found in the next-generation 
sequencing data. 
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T h e 7-day time point was used to capture cotnpensated hypertrophic hearts. During this 
stage there is a temporary enhancement of cardiac contractility due to the thickening of the 
LV wall. Hypertrophy results in fibrosis, which is the deposition of extracellular matrix 
(ECM) proteins such as coUagen that stiffens the ventricle leading to decompensation and 
a decrease in the strength of the cardiac contraction. Importandy, the transition f rom 
compensated to decompensated hypertrophy is a gradual process, making it difficult to 
determine an exact point for compensated changes. It is known that L V E D increases with 
worsening fibrosis and cardiomyocyte damage, which is then followed by a decrease in 
cardiac output {200). As there was not a significant increase in L V E D in our experiments 
we can conclude that the hearts were compensated and stiQ maintaining cardiac output. 
Fur thermore, the absence of right ventricular hypertrophy or pulmonary oedema indicates 
that the mouse hearts were free of overt heart failure. 
3 . 3 . 2 H A t - M O D Y N A M l C M E A S U R E M E N T S USING M I C R O M A N O M E T R Y 
Micromanometrv' was used to measure the changes in pressure and cardiac function of the 
TAG banded animals. Micromanometr\ ' is an invasive technique that involves dissection of 
the right carotid arter)', and was therefore used only at the end-point of the study. 
Echocardiography is another method of evaluating cardiac function; it is a non-invasive 
ultrasound technique that can also be used to visualise cardiovascular structures. 
Echocardiography would have allowed the recording of dynamic changes to systolic and 
diastolic funct ion during the hj 'pertrophy time course. Furthermore, echocardiography 
allows the direct measurement of LV wall thickening {193) and thus a more accurate time-
point where the LV weight increases could have been determined. Despite the invasiveness 
of micromanometry, it still revealed the pressure overload in the TAG banded animals and 
the subsequent changes to cardiac function. 
3 . 3 . 3 T A G G E N E R A T E D L V H Y P E R T R O P H Y 
The physiological data indicated the TAG banded animals were undergoing LV 
hypertrophy but had not yet entered heart failure (Figure 3.5-3.6). The LV weight was 
significantly mcreased only at 7 days, with no change in the RV or the lung wet weight. As 
expected, the hypertrophy markers A N P and B N P were re-expressed in the TAG banded 
animals at 7 days post surgery. A N P and B N P have natriuretic, diuretic and vasorelexant 
activities, which alter blood pressure and volume. Both activate guanylyl cyclase-Unked 
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receptors leading to an increase in intracellular cGMP concentrations {201). The natriuretic 
peptides are antihypertrophic, with the increase in cGMP inhibiting hypertrophic signalling 
pathways such as calcmeunn-NFAT and MAPK/ERIv {202, 203). Increased levels of ANP 
and BNP also decrease the amount of sodium m the blood and thus blood volume, which 
in turn lowers blood pressure and increases cardiac output. Interestingly, BNP was the only 
marker to be upregulated with a significant increase already at 48 hours. Consistent with 
this, it has been previously shown that the concentration of BNP in plasma dramatically 
increases in patients with acute myocardial infarction, while the ANP concentrations 
increase only mildly {204). The transcription of BNP is more rapidly induced than ANP 
during cardiomyocyte hypertrophy in vitro {209), and it has been suggested that BNP is an 
emergency hormone in response to heart stress {206, 207). 
Pressure overload also resulted in the induction of the foetal isoforms of sarcomeric 
proteins a - S k A and P-MHC. These isoforms have different functional properties that are 
beneficial to the increase in hemodynamic load {208). The contractility and ATP 
consumption of the heart depends on the number and the composition of sarcomeres 
{209). |3-MHC is bioenergetically more efficient than the adult a - M H C isoform and it has 
been hypothesised that the shift from a - to (3-MHC is an adaptive response to conserve 
energy {210, 211). However, P-MHC has lower adenosine triphosphate activity and lower 
filament sliding velocity than a - M H C , ultimately decreasing contractile function {212, 213). 
Therefore, the increase in P-MHC in the compensated TAG hearts could later become 
maladaptive and contribute to heart failure. As mentioned above, the levels of a -SkA also 
increase in the hypertrophic heart. There is a linear relationship between the induction of 
a - SkA and the progression of LV hypertrophy {214). Like P-MHC, the increase in a -SkA 
IS an adaptive response to maintain normal cardiac contractiUt\^ and function, as the levels 
of a - S k A are positively correlated with myocardial contractility measurements {214). 
Consistent with these previous obsen'ations, the alterations in dP/dt,„.„ and dP/dt,„,„ 
observed at 48 hours are corrected by 7 days when the levels of a -SkA are upregulated 
(Figure 3.4. 37 ) . 
The haemodynamic measurements, physiological and molecular data indicate that TAC 
lead to pressure-overload induced LV hypertrophy. In agreement with previous studies 
using the TAC model, this hypertrophy was compensated and resulted in the re-expression 
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of natriuretic peptides and sarcomeric proteins, which impact on cardiac contractility and 
output. 
3 . 3 . 4 C A R D I O M Y O C Y T E E N R I C H M E N T 
Once the hypertrophy was confirmed, cardiomyocytes were purified from the hearts of the 
Sham and TAG animals. This was performed using a standard isolation protocol, which 
was modif ied for immediate isolation of the cells {176). In brief, the heart was perfused 
with coUagenase and differential centrifugation was used to isolate the cardiomyocytes. 
Normally the cells are then cultured for 24 hours by plating onto laminin-coated dishes for 
attachment. Once attached, the non-attached cells, which are mostly rounded 
cardiomyocytes are washed off The remaining cells in the flask are 90% cardiomyocytes, 
resuldng in a highly pure primary' cardiomyocyte sample. However, this protocol was 
modif ied to exclude the short-term culture and the cells were isolated immediately after 
washing. This resulted in 66% rod-shaped cardiomyocytes on average in our samples, 
compared to the 90% achieved with short-term culmre. It was hypothesised that culturing 
the cardiomyocytes for 24 hours could alter both the miRNA and mRNA expression and 
turnover, potentially confounding the next-generation sequencing analysis. The half-life of 
miRNAs in embrj 'omc fibroblasts is ~ 5 days, but the average half-life of miRNAs and 
mRNAs has not been measured in cardiomyocytes {215). The cardiomyocyte isolation 
procedure was completed within 3 hours to minimize the effects of RNA degradation. 
Furthermore, the rod-shaped cells mimic the cardiomyocytes in the intact heart while a 
majority of the round cells are hypercontracted cardiomyocytes (/7(5). This only becomes 
important when using the culture for signalling and mechanical assays. It is a lesser concern 
in the protocol used for this thesis, where the cells were immediately extracted for RNA. 
The percentage of cardiomyocytes was therefore also potentially underestimated, as the 
hypercontracted cardiomyocytes were not counted. A more accurate measurement of 
cardiomyocyte enrichment may have been to sort the ceUs using flow cytometr)' based on 
cardiomycoyte and fibroblast ceU surface markers. This was not performed as incubation of 
the ceUs with antibodies and subsequent flow cytometry' analysis would have been lengthy 
and potentiaUy damaging to the cardiomyocytes, again potentiaUy impacting on the miRNA 
and m R N A expression profiles. 
The cardiomyocyte enrichment was confirmed using RT-qPCR against multiple 
cardiomyocyte and fibroblast markets. The majority of markers (a-vimentin, c o l l a l , coBa l 
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and tnnt2) were identified from a study that used laser microdissection to isolate pure 
cardiomyocytes and fibroblasts at a single-cell level {2J6). Alike to the results presented in 
Figure 3.9, a-vimentin, co l l a l and coBa l are highly abundant in fibroblasts and tnnt2 is 
expressed in isolated cardiomyocytes. Mlc2v (one of the major myosin Light chain isoforms 
in the heart), is specific to ventricular cardiomyocytcs and was highly enriched in the 
cardiomyocyte samples {217). Furthermore, an additional fibroblast marker, Ddr2, was 
significantly depleted m the purified cardiomyocytes compared to the fibroblasts. Ddr2 is a 
collagen specific receptor t)'rosine kinase that is expressed on cardiac fibroblasts, but not 
on cardiomyocytes or endothelial cells {191). All of the cardiomyocyte preparations were 
enriched for the expression of cardiomyocyte markers and depleted in fibroblast markers. 
There was however variability in the expression of markers between samples, with some 
samples having high fold enrichment of one marker but not another (Table 3.2). This could 
reflect differences in enrichment or variation in the expression of a marker within a sample. 
The eight samples used for next-generation sequencing had 65-79% rod shaped 
cardiomyocytes and are highlighted in Table 3.2. The identical samples were used for next-
generation sequencing of miRNAs (Chapter Four) and mRNA 3' ends (Chapter Five). 
CHAPTER FOUR 
MIRNA SEQUENCING 
4 .1 INTRODUCTION 
— miRNA sequencing 
miRNAs have in the past been measured using microarrays, PGR or northern blotting. All 
of these approaches require a priori knowledge of miRNAs and their sequences. The 
original studies on global miRNA expression in the normal and hypertrophic murine heart 
were performed using microarray platforms that rely on hybridisation to an oligonucleotide 
probe {120, 12!, 127, 128) or RT-qPCR arrays {129). The use of such platforms does not 
allow for discrimination of processing variants and often does not include probes against 
what was referred to as the miRNA*. More recently, two studies published in 2012 used 
NGS to profile the miRNA expression in whole LV samples 7 days after TAG banding 
{130, 131). In both of these studies, aU of the sequences that matched a known strand of a 
miRNA locus were clustered and counted towards that miRNA strand. They did not 
investigate the sequencing variants of the expressed miRNAs. Furthermore, there are no 
published studies of miRNAs in purified cardiomyocytes during hypertrophy. Therefore, 
information regarding miRNA processing and variants in cardiac hypertrophy is currently 
lacking, which could impact the way we think about miRNA interactions and their targets. 
NGS allows the discover}' of miRNA variants in a population as it has single-nucleotide 
resolution. 
The aim of this chapter was to sequence the cardiomyocyte miRNA population of normal 
(Sham), pre-hypertrophic (48 hour TAG) and hypertrophic (7 day TAG) samples. Firsdy, to 
identify those miRNAs differentiaUy regulated in pre- and hj'pertrophic cardiomyocytes. 
Secondly, to generate a reference for all the miRNA processing variants in murine 
cardiomyocytes, and then to estabhsh if any of these processing variants change in 
frequency during the induction of hj'pertrophy. To do this we used SOLID^M sequencing 
and a bioinformatics analysis pipeUne modified from a previous study in which we 
documented the miRNA population in the HL-1 cardiomyocyte cell line (55). 
miRNA sequencing 
4.2 RliSULTS 
This chapter describes the small RNA sequencing of normal, pre- and hypertrophic 
cardiomyocytes, focusing on differential expression of miRNAs and miRNA processing 
variants. 
4 . 2 . 1 C O N V E R S I O N OF M I R N . A S INTO LIBRARIES FOR SEQUENCING 
The RNA extracted from purif ied cardiomyocytes (Chapter Three) was used for NGS of 
small RNAs. The library preparation was performed under the guidance of Dr David 
Humphreys at the Victor Chang Cardiac Research Instimte, while Dr David Humphreys 
completed the e-PCR and subsequent steps. Eight samples in total, two Sham and two 
TAG from each time point, were subjected to sequencing. The libraries were prepared 
using the NEBNext® Small RNA Library' Prep Set for SOLiD^^", an oudine of the method 
is shown in Chapter Two, Mgure 2.2. In brief, adaptor sequences are ligated to the 3' and 5' 
end of the miRNA, which are then used to reverse transcribe the miRNA into cDNA. The 
samples were mult iplexed for sequencing so that all samples could be sequenced 
simultaneously. This was achieved by including unique barcode sequences into the PCR 
primers for each sample. After PCR amplification, the miRNA products were size selected 
using polyacrylamide gel electrophoresis. The expected size of a 21 nt miRNA after 
addition of the adaptor sequences is ~ 114 nt. Therefore, PCR products corresponding to 
~ 110-125 nt were excised from the gel to allow for variations in the length of a miRNA 
(Figure 4.1). The larger bands represent other RNA species such as tRNAs and rRNAs that 
would have been cloned using the library preparation method. The miRNA-derived 
products were purif ied and the sizes conf irmed with a second polyacr>'lamide gel (Figure 
4.2). Note that less of the 7 Sham 2 sample was loaded onto the gel, however this was 
accounted for when diluting for subsequent steps. 
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Figure 4.1. Size selection of miRNA PCR products for next-generation sequencing. 
Representative polyacrylamide gels for two sham samples (48 Sham 1, 48 Sham 2) before (A) and 
after (B) excision of bands corresponding to 110-125 nt in length. The expected locauons of the 
miRNA are indicated by the red arrow, and expected size of adaptor dimers and non-miRNA 
species are indicated in blue. HypV; hyperiadder V. 
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Figure 4.2. Confirmation of miRNA library size. 
(A) Polyacrj'lamide gel for eight of the samples subjected to sequencing after size selection. The 
isolated PGR products are between 100-125 nt. (B) The sizes and concentrations of the sequencing 
Ubraries were then checked on an Agilent Bioanalyzer Chip. The results are shown for the size 
ladder and three of the samples. The grey arrows refer to the lower and upper markers, and the 
black arrow in each sample refers to the average size of the mam peak. The sizes of the ladder 
corresponding to the same elution time as the samples are also indicated. HypV; hyperladder V. 
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After purif ication, the PGR products were brought to the same concentration and analysed 
using an Agilent Bioanalyzer Chip. Figure 4.2.B shows the Agilent Chip results for three of 
the sequencing Kbraries, the apparent size of the libraries was 122-123 nt. This is consistent 
with the instructions for the NEBNex t® Small RNA Library Prep Set for SOLiD'^'^, where 
the expected peak size on the Agilent Bioanalyzer is described as between 114 and 123 nt. 
It was determined that aU the samples were within a comparable concentration range and 
were used for emulsion PCR (e-P( 'R). In the e-PCR reaction, the PCR products arc mixed 
into a water-in-oU emulsion, such that cach water droplet contains a single PCR product as 
the template attached to a single bead coated in primers to form a clonal colony. The beads 
were then deposited onto three chambers or lanes of a glass flow cell and sequenced on the 
SOLiD 5500TM. 
4 . 2 . 2 G E N E R A L F E A T U R E S O F THI' . I . I B R A R I E S 
The following section documents the features of the small RNA libraries as well as details 
for mapping the data. Dr Hardip Patel from A N U performed the mapping of the mlRNA 
libraries, and 1 completed the secondary' analysis, including graphical representations and 
differential expression, using the R programming language. The libraries were sequenced 
on average to a depth of 3.97 x lO' tags (up to 35 nt in length), yielding a total of 3.18 x 10" 
tags. The shortest known products of Dicer cleavage are 19 nt and anything shorter than 
this is unHkely to be a miRNA {21S). Therefore, the tags were restricted to a length greater 
than or equal to 19 nt. Approximately 72% of the tags met this criterion as shown in Figure 
4.3.A. As the samples were diluted to equivalent concentrations prior to sequencing, the 
yield of sequenced tags was relatively even across libraries, although the 48 Sham 2 had 
approximately twice the number of tags seen with the other libraries. This suggests that 
more of the 48 Sham 2 Hbrary was added, resulting m more tags. This difference in tags is 
accounted for when normalising the libraries. 
During SOLiD'TM sequencing, each nucleotide or ligation cycle is associated with a colour 
caU and associated quaHt>' value. The quaHty value is related to the strength of the signal 
and IS a measure of confidence that the colour caUed for that Hgation cycle is correct. The 
data was filtered to retain only tags with high average quaHty values (representing more 
than 98% accuracy). Importantiy, aU of the Ubraries were of high quaUty, as 99.2% of tags 
were retained after applying this quality value filter (Figure 4.3.A). 
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T o ident i fy known m i R N A s and their process ing variants , tags were mapped to the mouse 
g e n o m e (mm9 assembly inc luding rRNA) . miRBase vers ion 18 annotadons were used to 
determine m i R N A coordinates and tags that started within ± 3 nt of a miRBase annotated 
5' start site were ass igned to that m i R N A . 
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Figure 4.3. General features of the small RNA library. 
(A) Number of tags m sequential order of filtering steps; number of raw tags, number of tags with 
length > 19 nt, number of tags with quaUty value (QV) > 18 and miRBase vl8-mapped tags. S, 
Sham; T, TAG (B-D) Combined feamres of all eight smaU RNA Ubraries. (B) Distribution of 
2.36xl0« mappable tags across the mm9 mouse genome assembly after length and QV filter. (C) 
Distnbution of tag lengths for aU miRNA-mapped tags. (D) Distnbution of tag counts across the 
one hundred most abundant miRNAs. Contribution of individual miRNAs to total tag count 
(green), or cumulative tag contribuUon (blue) is plotted against ranked miRNA abundance. 
miRN/V sequencing 
On average, 32% of raw tags mapped to a miRNA locus after restricting the length to > 19 
nt and the QV > 18, detecting 806 miRNAs (Figure 4.3.B). Figure 4.3.B-D illustrates the 
mapping statistics and general features of all small RNA libraries combined. A large 
proportion of tags mapped to other RNA species, including rRNA and tRNA. Again, this 
could also be due to the size range taken during the library' preparation. The modal tag 
length of miRNA-mapped tags was 22 nt (Figure 4.3.C), which is consistent with miRBase 
where the majority of miRNA sequences are 21-22 nt {82). To remove tags representing 
very lowly expressed miRNAs and spurious tags, the miRNAs were filtered for those that 
have average expression at levels of at least 10 counts per million (CPM) across the eight 
Kbraries, resulting in 260 confidently detectable miRNAs. The 20 most abundant miRNAs 
contributed 87.3% of all miRNA-mapped tags in the combined libraries (Figure 4.3.D), 
with the most abundant miRNA, cardiac specific miR-133a, contributing 30.2% of the tags. 
4 . 2 . 3 N O R M A L I S A T I O N OF M I R N A TAG C O U N T S 
In order to use NGS data for differential expression analysis, tag counts must be 
normalised for each library to remove technical bias while maintaining true biological 
signal. As each librar>' had a different total miRNA tag count, the libraries were initially 
normalised to the size of the librarj' (based on miRNA mapped tags) by converting the tags 
to CPM. However, highly expressed miRNAs can sometimes take up a lot of "sequencing 
real estate" in a sample {21S). The composition of the RNA population m each librar)' is 
not the same, which can influence the detection of true differentially expressed transcripts 
{219). For this reason, we utilised the normalisation method 'trimmed mean of M-values' 
(TMM) that takes into account the composition of each library'. This method assumes that 
most transcripts are not differentiaUy expressed and their true levels remain constant, 
except for the data points that He within the extreme M-value (log expression ratio) and A-
value ranges (log-intensit)' averages). It then uses a simple linear scaUng factor after 
trimming the data points that are located in these extreme ranges {219). AU of the miRNA 
tags were used for normaUsation and then the data was filtered for an average expression of 
at least 10 CPM. 
To measure the effect of normaHsing the miRNA Ubraries, multi-dimensional scaUng plots 
(MDS) for the eight miRNA NGS Kbraries using CPM and die TMM normaHsed samples 
were generated (Figure 4.4.A). The distances in the MDS correspond to leading log2-fold 
changes between each pair of RNA samples 
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Figure 4.4. Normalisat ion of the m i R N A sequencing libraries. 
(A) MDS plots of miRNA CPM to miRNA mapped tags (i) and TMM normaUsed miRNA Ubraries 
(ii). The miRNA Ubraries were normalised by TMM normaUsation factors (lii). (B) MDS plots of 
individual lanes both before, represented as CPM (i), and after (ii) TMM normaUsation. Each 
sample is represented by a different colour and was sequenced on three lanes. 
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and can be interpreted as a type of unsupervised clustering. The leading log2-fold change is 
defined as the average of the largest absolute log2-fold changes between each pair of 
samples for the genes that distinguish those samples {182). In essence, MDS plots show the 
relative similarities between samples. Dimension 1 separates the Sham from the TAG 
samples after the data has been normalised using TMM (Figure 4.4.A.ri). There is not a 
complete separation of the Sham from the TAG after normalisation. However, the 
normalisation factors calculated using the TMM method are close to one, indicating that all 
of the libraries are fairly similar in composition (Figure 4.5.A.iii). As mentioned previously, 
the libraries were multiplexed and sequenced on three lanes of a SoLiD^" flow cell, with 
each lane being a techmcal replicate of each library. This data was exploited to determme 
the efficiency of the normalisation method. The samples on each lane were treated as 
individual samples and TMM normaUsation applied. It is expected that after normalisation 
the individual lanes for each sample will cluster together as the biological signal is 
equivalent. The MDS plots based on individual lane data are shown in Figure 4.4.B, where 
each sample is a different colour and represented three times (lanes 1-3). It is clear that 
after normalisation the technical replicates are brought together and the three lanes for 
each sample overlap (Figure 4.4.B.ii). To conclude, the miRNA libraries are similar in 
composition but the use of TMM normalisation still brings the biological replicates closer 
together. 
The data was also normalised independently using upper quartile (UQ) normalisation. 
Here, the normalisation factors are calculated from the 75% quantile of the tags for each 
library, after removing transcripts that are zero in all libraries {220}. All of the miRNAs 
with a FDR <10% are equivalent between normalisation methods, and 13 of the 17 
miRNAs with a FDR <30% are consistent between TMM and UQ normalisation. This 
suggests that the normaUsation methods triaUed give fairly consistent normaUsed tag counts 
for differential expression. The miRNAs identified as differentiaUy expressed using UQ 
normalisation are listed in Appendix 8.7. 
The miRNA populations m aU the cardiomyocyte samples are very similar, regardless of 
their treatment. This is mdicated by the Spearman rank correlation, which is a measure of 
the strength of the relationship between two samples (Figure 4.5). The lowest Spearman 
correlation is 0.92, which occurs when comparing the 48 TAG 2 and the 7 TAG 1 samples. 
Hierarchical clustermg based on the Spearman correlation clusters the Sham and the TAG 
separately, suggesting the TAG samples are more closely related to each other than to the 
108 
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Sham samples and vice versa. This provides further support for the use of TMM 
normalisation, which assumes that the samples are highly similar and majority of miRNAs 
do not change {219). 
Spearman correlation 
0.92 0.96 1 
Figure 4.5. The cardiomyocyte samples have similar miRNA populations. 
The heatmap shows the clustering of samples according to their Spearman rank correlation. The 
lowest Spearman correlation is 0.92. 
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4.2.4 MIRNA D I F F E R E N T I A ] , E X P R E S S I O N 
One of the main interests of this project was to look at miRNA processing variants. 
However , the data presented an opportunity to look at differential expression of miRNAs 
in purif ied cardiomyocytes during cardiac hypertrophy, which has not previously been 
done. To detect m iRNAs that are differentially expressed between the TAG banded 
animals and the controls, pairwise comparisons were made between biological replicates 
using the empirical analysis of digital gene expression in R (edgeR) package {182). The 
edgeR package requires biological replicates and detects differential expression using an 
overdispcrsed Poisson model that accounts for increased variability' and an empirical Bayes 
procedure to moderate the degree of overdispersion {182). A parameter then estimates the 
spread between replicates and separates the true biological variation from the technical 
variation. This package has previously been used in other smdies to analyse the expression 
of miRNAs (221-223). Several pairwise comparisons were made (Figure 4.6, listed in Table 
4.1) to maximise the chances of finding differentially expressed miRNAs. Using this 
method, 44 miRNAs with a p value <0.05 were detected. However, when making multiple 
comparisons a p value of 0.05 can result in a large number of false positives. For this 
reason, the p values need to be adjusted to take into account multiple testing. The edgeR 
package uses the Benjamini-Hochberg method to adjust p values and gives a false 
discovery rate (FDR) (224). The FDR is a measure of false positive, where a I'DR of 10% 
means that 10% of significant tests will result f rom false positives. A FDR less than 30% 
was chosen to detect differentially expressed miRNAs as we could test the expression 
changes in the extended cardiomyocyte sample set. The fold change and expression levels 
of these m iRNAs are illustrated in Figure 4.6. After adjusting the p values, 17 miRNAs had 
a false discovery rate (FDR) less than 30% (Figure 4.6-4.7). 
The miRNAs with an FDR less than 30% are shown m Table 4.1, with many of the 
miRNAs being sigmficant in multiple pairwise comparisons such as nuR-21-5p. The 48 
hour TAG vs remaining samples identif ied miR-324-3p as a candidate, however the levels 
of this m iRNA increase 3-fold in both the 7 day Sham and TAG samples compared to the 
48 hour sample. Thus, this m iRNA was excluded from subsequent analysis. Importandy, 
when a comparison was made between the 48 hour and 7 day Sham samples, there were 
only two miRNAs with a p value <0.05. Furthermore, these miRNAs had a FDR close to 
100% indicating no differences could be found bet%veen the 48 hour and 7 day Sham 
no 
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samples and therefore they were suitable controls (details for all pairwise comparisons are 
shown in Appendix 8.6). 
Table 4.1. Differentially expressed miRNAs with a FDR <30%. 
Pairwise comparisons were made using the cdgeR package. Each pairwise comparison is 
indicated by the bold text. 
TAG vs Sham 
miRNA 
miR-21-5p 
miR-223-3p 
rmR-34c-5p 
miR-451 
miR-143-5p 
miR-10a-5p 
logFC 
2.48 
1.73 
2.02 
2.07 
-1.63 
- 1 . 0 1 
logCPM 
13.83 
5.70 
3.57 
7.54 
5.48 
8.41 
p value 
1.21E-09 
1.74E-05 
0.001 
0.002 
0.004 
0.006 
FDR (%) 
3.14E-05 
0.23 
8.78 
11.77 
23.02 
24.60 
48hr TAG vs Sham 
miRNA 
miR-451 
miR-21-5p 
logFC 
2.74 
1.94 
logCPM 
7.36 
13.61 
p value 
2.91E-04 
0.001 
FDR (%) 
7.24 
11.24 
7 day TAG vs Sham 
miRNA 
miR-21-5p 
miR-34c-5p 
miR-150-5p 
logFC 
3.24 
3.11 
-1.61 
logCPM 
14.12 
4.27 
10.31 
p value 
1.9402E-08 
1.04E-04 
0.003 
7 day TAG vs remaining samples 
miRNA logFC 
miR-34c-5p 2.52 
miR-214-3p 2.03 
miR-199a-5p 1.53 
miR-199b-3p 1.46 
miR-199a-3p 1.46 
miR-299-5p 1.30 
miR-379-5p 1.18 
miR-101a-3p -1.45 
miR-150-5p -1.26 
miR-31-5p 1.38 
miR-410-3p 1.09 
miR-224-5p 1.00 
miR-21-5p 1-55 
logCPM 
3.57 
6.77 
9.25 
10.61 
10.60 
3.94 
3.74 
10.29 
10.27 
8.98 
3,56 
3.87 
13.83 
p value 
1.25623E-07 
2.03236E-06 
2.23636E-05 
6.79032E-05 
7.03649E-05 
8.36E-04 
0.002 
0.003 
0.005 
0.007 
0.007 
0.011 
0.012 
48 ht TAG vs remaining samples 
miRNA logFC 
miR-324-3p -4.06 
logCPM 
3.89 
p value 
9.29671E-05 
FDR (%) 
5.06E-04 
1.36 
26.3 
FDR (%) 
3.27E-03 
0.03 
0.19 
0.37 
0.37 
3.62 
8.25 
8.25 
13.46 
17.59 
17.59 
23.41 
23.41 
FDR (%) 
2.42 
Log is log2; EC, fold change; CPM, normaUsed counts per milUon; FDR; false discovery rate. 
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Figure 4.6. Identification of differentially expressed miRNAs. 
Log2-fold change (FC) is plotted against the Log2- average counts per milUon (CPM) for the 
pairwise comparisons used to identify differentially expressed miRNAs. The Unes indicate a log2-
FC of 1 and the miRNAs identified as differentially expressed with a FDR <30% are shown in red. 
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F igu r e 4.7. Dif ferent ia l l y exp r e s s ed m i R N A s w i th a FDR <30%. 
Pairwise comparisons were made with edgeR package and miRNAs with a FDR <30% were 
considered differentiaUy expressed. miRNAs with a black star have been previously reported to be 
regulated in the same direction in a model of hypertrophy. miRNAs with a red star are pro-
hypertrophic (functional studies have shown they promote the hypertrophic response). miRNAs 
with a green star indicate that the other strand of the miRNA hairpin has been previously reported 
to be regulated in the same direction in a model of hypertrophy. Data is shown as TAC/Sham log2 
fold change (average of duplicate samples) at each time point. 
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Intriguingly, 13 of the miRNAs were upregulated and only 4 were downregukted. As 
shown in Table 4.1. more miRNAs were differentially regulated at 7 days compared to 48 
hours. In fact, only miR-21-5p and niiR-451'' had sigmficant changes at 48 hours. This 
suggests that the induction and processing of most miRNAs may take longer than 48 hours 
to reach a significant level of change. 
Reassuringly, 13 of the 17 differentially expressed miRNAs have been previously reported 
to change levels m the same direction. These changes were reported in similar TAG 
experiments [120, 121, 127, 128, 130, 131), PE-treated neonatal cardiomyocytes {121), 
transgenic mice with early and end-stage hj 'pertrophic cardiomyopathy (129), as well as 
human paUents with D C M or ICM (123, 124) and patients with end-stage heart failure 
{122). For instance, miR-214-3p, which is highly upregulated 7 days post-TAC, is well 
documented to be upregulated at this point in several other smdies {127, 128, 130, 131). Its 
expression also increases in transgenic mice with hypertrophic cardiomyopathy {129), as 
well as in patients with DCM, ICM and AS {124). Detection of miRNAs previously found 
to alter expression levels in hypertrophy provides further evidence that the approach to 
find differentially expressed miRNAs was valid. 
For four miRNAs, the other strand on the miRNA hairpin has been previously reported to 
be regulated in hypertrophy. For mstance, miR-299-3p is upregulated 7 days after TAC 
{130), but in our data 99% of miR-299 is derived f rom the 5p arm and miR-299-3p docs 
not make our threshold for expression. Similarly, both strands of miR-199a are significandy 
upregulated 7 days post-TAC, suggesting the hairpin is upregulated at the transcriptional 
level. The detection of a different strand than previously reported, such as miR-299-3p, 
could indicate a difference in the processing of the miRNA hairpin. 
Interestingly, three pro-hypertrophic miRNAs (miR-21-5p, miR-34c-5p and miR-199b-3p) 
are strongly upregulated at 7 days, with both miR-34c-5p and miR-21-5p being upregulated 
as early as 48 hours {225-227). This is consistent with the physiological data that suggests 
that at 7 days the hearts are hjrpertrophic. The upregulation of miR-34c-5p and miR-21-5p 
at 48 hours may form part of the initial response to pressure overioad that results m cardiac 
hypertrophy. 
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4 . 2 . 4 . A M I R N A V A L I D A T I O N U S I N G R T - Q P C R 
The expression of the miRNAs in Figure 4.7 was tested using RT-qPCR. As mentioned in 
Chapter Three, a total of 20 cardiomyocyte samples were originally isolated for RNA 
extraction (2 Sham and 2 TAG for each time-point). Only eight samples were subjected to 
next-generation sequencing but aU samples were used for RT-qPCR validation. miRNA 
expression was detected using stem-loop reverse transcription (see section 2.2.4 for a 
description). The stem-loop primers are more efficient and provide better specificity for 
miRNAs than conventional reverse transcription {22S). Furthermore, as the reverse 
transcription is a different method than the preparation of the next-generation sequencing 
Hbrarj' it should not validate changes based on sequencing bias alone. The miRNA 
expression was normalised to the expression of five small nucleolar RNAs (snoRNAs); 
snoRNA-135, snoRNA-202, snoRNA-55, snoRNA-412 and snoRNA-234. snoRNAs are 
better for miRNA normalisation than control genes such as GAPDH, as they arc closer in 
length (60-300 nt) to miRNAs than mRNA transcripts and they are constitutively 
expressed across multiple tissues. Furthermore, the levels of snoRNAs are detected using 
the same stem-loop reverse transcription and RT-qPCR reactions as miRNAs. In addition, 
it has been previously shown that snoRNA-202 and snoRNA-234 show the least variability 
across tissues and cell lines {229). The expression of the snoRNAs was consistent across all 
20 cardiomyocyte samples (Figure 8.1) and as a result, the average of the five snoRNAs was 
used for normalisation. Rina Soetanto from the ANU performed the RT-qPCRs for four 
of the miRNAs. 
Of the eight miRNAs considered for testing the expression changes of six followed the 
same trend m the samples subjected to NGS (Figure 4.8.A-B). The levels of four of these 
could be validated by RT-qPCR in the extended cardiomyocyte dataset (Figure 4.8.A). 
miRNA expression changes were considered as validated if a two-way ANOVA with 
Bonferoni's post-hoc analysis on the RT-qPCR data resulted m an adjusted p value of less 
than 0.05. The levels of miR-31-5p, miR-199a-3p, miR-21-5p and miR-223-3p were 
significantly upregulated m the extended cardiomyocyte sample set for 7 days. miR-223-3p 
was also significandy upregulated at 48 hours. On the contrary, the change in levels of miR-
451 could be seen in the samples used for sequencing, but this increase in expression level 
was not seen when looking at the larger pool of cardiomyocyte samples. Similarly, miR-
143-5p was decreased by more than 2-fold at both time points according to the sequencing 
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Figure 4.8. Validation of differentially expressed miRNAs by RT-qPCR. 
Fold change (TAC/Sham) values for the next-generation sequencing data (NGS), RT-qPCR on the 
eight samples subjected to next generation sequencing (RT-qPCR sequencing samples) and RT-
qPCR on the extended cardiomyocyte sample set (RT-qPCR extended dataset). (A) miRNA 
expression changes could be validated by RT-qPCR in both the samples used for sequencing and 
the extended dataset. (B) miRNA expression changes could be validated in the samples used for 
sequencing but not the extended dataset. (C) The decrease in miR-150-5p could be observed in the 
extended dataset but did not reach significance. (D) The decrease in miR-101a-3p could not be 
observed in the sequencing samples or the extended dataset. The dashed grey line indicates a fold 
change of 1. Data shown as mean fold change with SEM. (n=4-5 for RT-qPCR sequencing sample 
and RT-qPCR extended dataset, n=2 for NGS * p <0.05, Two way -ANOVA with Bonferonni 's 
post-hoc analysis). The log2FC, log counts per million (CPM) and false discover}' rate (FDR) for 
the N G S data are shown below each graph. 
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data. RT-qPCR on the samples used for sequencing also showed the dramatic decrease at 
48 hours but only a 20% decrease at 7 days. Furthermore, the extended dataset indicated a 
minor 10% drop in the levels of miR-143-5p at both 48 hours and 7 days that did not reach 
significance. A slight decrease in the levels of miR-150-5p was seen in the extended dataset 
at 7 days but this too was not significant (Figure 4.8.C). Lasdy, the levels of miR-101a-3p 
showed no difference at 7 days in the RT-qPCR data in comparison to the decrease seen in 
the N G S data (Figure 4.8.D). RT-qPCR primers were also designed against the major 
isoforms of miR-34c-5p, mrR-299-5p, miR-379-5p, miR-214-3p and miR-10a-5p for 
validation (primers provided in Methods). Unfortunately, the RT-qPCR assays for the 
above miRNAs could not be optimised to detect a specific product and these miRNAs did 
not go forward for validation. In summary, the same directional trend could be observed 
for seven of the eight m iRNAs tested, with four reaching statistical significance in the 
extended cardiomyocyte sample set. 
4 . 2 . 4 . B P R E V I O U S L Y D O C U M E N T E D M I R N A S 
Numerous miRNAs have already been documented to be deregulated in the hypertrophic 
response, with some miRNAs consistently reported among studies. Therefore, we 
examined the expression levels of a 53 miRNAs that have been reported to change in more 
than two studies (listed below) across the time course regardless of their I-DR (Figure 4.9). 
These miRNAs were derived from similar studies that looked at the expression of miRNAs 
across various experimental models and patients with heart disease. These studies include 
LV isolated after T A C experiments (120, 121, 127, 128, 130, 131), PE-treated neonatal 
cardiomyocytes {121), LV from transgenic mice with early and end-stage hypertrophic 
cardiomyopathy {129), and human patients with DCM or ICM {123, 124) and patients with 
end-stage heart failure {122). For majorit>' of the miRNAs, the trend remains the same but 
the miRNAs have not made the cut-off for statistical significance. Importantly, pro-
hypertrophic m iRNAs are mosdy upregulated at 7 days, while anti-hypertxophic miRNAs 
are downregulated. There arc 12 miRNAs that arc documented to be upregulated whose 
levels increase by more than 1.5 fold at either 48 hours or 7 days, five of which have a I'DR 
less tiian 30% and are present in Figure 4.8. The remaining seven miRNAs increase in 
expression but have a li igh FDR. For example, both strands of miR-208b, miR-208b-5p 
and miR-208b-3p, appear to have increased levels at 7 days. On closer inspection, miR-
208b-3p has very low levels in one of the 7 day Sham samples that is driving the 
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Figure 4.9. miRNAs previously reported to be regulated in hypertrophy show similar 
expression patterns. 
Data IS shown as TAC/Sham log-2 fold change at each time point, for miRNAs previously 
reported to be up- or down-regulated in hypertrophy. These studies include TAG experiments {120, 
121, 127, 128, 130, / i / ) , P E - t r e a t e d n e o n a t a l c a r d i o m y o c y t e s ( / 2 / ) , t r a n s g e n i c m i c e with early and 
end-stage hypertrophic cardiomyopathy {129), and human patients with DCM or ICM {123, 124) 
and patients with end-stage heart failure {122). The red star indicates miRNAs that promote or 
induce hypertrophy, while the green star indicates miRNAs that can prevent or suppress the 
hypertrophic response. 
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upregulation in the 7 day TAG samples. Furthermore, miR-208b-5p is barely detectable in 
the dataset and does not make our threshold of 10 CPM. There are no tags representing 
miR-208b-5p in 5 of the samples, and only 5 tags in one of the 7 day TAG samples making 
it appear that there is a strong upregulation at 7 days. There are also a large number of 
miRNAs that have been reported to be upregulated, but for which we see no change (iniR-
27b-3p to miR-191-5p in Figure 4.9). For instance, miR-23a-3p is reported to be 
upregulated in TAG banded animals {120, 127), PE-treated neonatal GM (/2/) as well as in 
patients with DGM, IGM and AS {123, 124). Yet miR-23a-3p has ver\' small fold change 
values in our experiment. This could be due to differences in experimental design, such as 
the dme point investigated after hypertrophy, as well as the platform on which the 
measurements were made. In line with this, a recent paper that used next-generation 
sequencing to examine miRNAs 7 days post-TAG acmally used ten miRNAs that remained 
unchanged in their data as normaliscrs {131). This included miR-23a-3p, miR-24-3p and 
miR-23b-3p which also remain unchanged in our dataset. 
All of the miRNAs pre\'iously reported to be downregulated, with the exception of miR-
133a-3p and miR-133b-3p, have lower expression levels either at 48 hours or at 7 days. 
miR-22-3p, miR-486-5p and miR-98-5p look to be strongly downregulated at 48 hours. 
However, variation between biological repHcates confounds the fold change values and 
results in a high FDR. For instance, the levels of miR-486-5p appears to decrease 3-fold at 
48 hours but the FDR is 64% because the 48 hour TAG 1 sample has considerably lower 
levels. miR-133a-3p and miR-133b-3p show littie to no regulation at 7 days, but these 
miRNAs were also used as normalisers in the smdy mentioned above as their expression 
levels did not change between the control and the TAG banded mice 7 days after surgery 
{131). In agreement with the previously upregulated miRNAs, the downregulated miRNAs 
did not reach significance due to variation between biological replicates or die levels 
remained the same between the Sham and TAG samples. To summarise this comparison, 
23 miRNAs previously reported to be up- or down-regulated in other studies showed the 
same trend in our data with an absolute fold-change greater than 1.5, four miRNAs did not 
make our 10 GPM threshold for expression level, three were regulated m the opposite 
direction and 21 did not change expression in response to pressure overload. 
In conclusion, we have detected a smaU number of differentially expressed miRNAs that 
change levels between the Sham and TAG samples. Only 50% of those tested for 
expression could be vaHdated in the extended sample set of cardiomyocytes, mostly due to 
120 
miRN'A sequencing 
variation in the levels between biological replicates. Despite this, several of the iniRNAs we 
detected have been previously reported to change in the same drrecrion, suggesting we arc 
detecting changes consistent with other studies. 
4 . 2 . 5 M I R N A P R O C E S S I N G V A R I A N T S 
O n e of the main aims of this thesis was to look for miRNA processing variants. The 
processing variants of m iRNAs in purified cardiomyocytes, let alone cardiomyocytes f rom 
pre and hj 'pertrophic hearts, have not been documented thus far. As mentioned earlier, one 
m i R N A hairpin can result in several miRNA variants, potentially with altered m R N A target 
specificity. This can arise f rom use of both strands of the miRNA:miRNA star duplex with 
similar frequency, the occurrence of 5' and 3' isomiRs as well as RNA editing. It is 
postulated that these miRNA modifications could alter miRNA biogenesis and half-life, 
subcellular localisation a n d / o r targeting specificity. For this reason, we interrogated all of 
the mature miRNAs that had expression levels greater than 10 CPM for the presence of 
processing variants. Once a static picmre had been generated, D r Brian Parker f rom the 
A N U applied a weighted linear model to each type of processing variant looking at the 
proport ion of variants for each miRNA. 
4 . 2 . 5 . A A R M BIAS 
We first looked at the arm bias of miRNAs, which is the preference of the miRNA to be 
derived f rom one or bo th strands of the miRNA hairpin (Figure 4.10.A). Appendix 8.8 
documents the proport ion of 5' arm bias for all miRNAs with greater than 10 CPM. There 
were 37 miRNAs that had greater than 20% of their tags derived f rom each strand of the 
miRNA hairpin, meaning bo th strands could function to target m R N A s (T'able 4.2). For 
example, let-7d has 52.2% 5' arm hairpin bias, meaning that 52% of let-7d is derived f rom 
the 5p arm and 48% is derived f rom the 3p arm. CriticaUy, this Hst includes 15 miRNAs 
with known expression a n d / o r function in the heart. This data becomes important when 
interpreting the functional smdies associated with a miRNA locus. 
Changes in arm bias in hypertrophy 
It IS known that miRNAs can switch strands in a tissue specific manner (79, 80) so we 
hypothesised that the strands may also change under conditions of ceUular stress like 
hypertrophy. Once we had estabHshed that numerous miRNAs express both strands of the 
hairpm, the data was interrogated to look for examples where this proportion changed 
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across the hypertrophy time course. In doing so, 35 miRNAs were identified where the 
proportion of arm bias changed in range by more than 20% across the eight cardiomyocyte 
samples (blue datapoints in Figure 4.10.B, Table 4.3). This included 19 miRNAs that had 
previously been reported to change expression in h)'pertrophy and/or have a known role in 
the heart (Figure 4.11). 14 of which also have more than 20% derived from both strands at 
any one time (Table 4.1). However, on closer inspection of some individual examples, it 
appears that there is no directionalit)' to the changes m arm bias proportions and the large 
range is due to variation in the biological replicates (Figure 4.11). To confirm that there 
was no change, a weighted Imear model looking at the proportion statistic for each miRNA 
hairpin was applied to the data (the results for all processing variants are shown in 
Appendix 8.13). This did not result in detection of any miRNA hairpin bias change with a 
FDR <80%. It can thus be concluded that we did not detect any change in arm bias 
between the Sham and TAG samples. 
The majorit}' of miRNAs give rise to one predominant strand, with only 12.5% of the 
miRNA hairpins detected giving rise to both strands simultaneously. In addition, it is 
evident from this data that while there is fluctuation in the arm bias for 35 miRNA hairpins 
it does not correlate with the hypertrophic response. 
rtiiRNA sequencing 
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Figure 4.10. M i R N A s exhibit arm bias in cardiomyocytes. 
(A) MiRNA arm bias; the miRNA can be derived from both strands of the miRNA hairpin in 
varj'ing proportions. (B) The mean and range of 5p strand bias of each miRNA. MiRNAs with 
average tag count greater than 10 CPM were used for analysis. MiRNAs with a range less than 20% 
are shown in red, those with a range greater than 20% are indicated by blue. Diagrams to the side 
of the graph indicate the strand bias for that portion of the graph. 
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Table 4.2. m i R N A hairpin precursors with >20% of tags derived from both the 5p and 3p 
Arm bias (5p tag counts /hairpin tag counts) 
m i R N A 48 hour 48 hour 7 day 7 day 
Mean Range Sham TAC Sham TAC 
let-7d 52.2 70.75 45.02 39.50 73.20 51.09 
let-7i 38.93 34.13 32.24 36.11 42.11 45.24 
miR-126# 24.66 15.35 29.23 23.50 24.10 21.82 
miR-140# 38.14 23.78 36.01 42.40 41.48 32.66 
miR-151# 67.22 72.22 77.10 79.75 67.13 44.91 
miR-154# 71.99 71.42 54.00 76.54 91.91 65.51 
miR-1839 62.15 12.62 66.19 56.90 63.50 62.02 
nuR-1843 75.14 35.27 77.16 65.67 79.68 78.06 
miR-199a# 28.45 23.12 34.49 24.67 27.05 27,57 
miR-208a#* 55.56 69.84 35.66 72.93 55.50 58,14 
miR-322# 60.75 12,05 62.01 59.85 61.32 59,79 
miR-330# 30.19 64.31 32.53 44.25 36.94 7.05 
miR-335# 68.13 21.48 74.54 60.64 75.64 61.69 
miR-337# 29.97 26.46 28.79 34.83 24.08 32.18 
miR-338 32.18 11.71 28.72 31.06 34.61 34.33 
miR-362 65.47 31.05 72.85 64.80 56.77 67.46 
iTiiR-378# 25.34 34.32 29.62 14.32 28.50 28.92 
miR-423# 38.73 37.86 45.12 43.57 43.16 23.08 
miR-434# 28.76 16.57 29.15 32.91 24.46 28.53 
miR-490 34.67 59.10 45.35 62.43 17.14 13.75 
miR-501 71.49 36.40 83.96 65.23 69.16 67.63 
miR-503 25.54 27.08 24.76 16.05 27.91 33.45 
miR-5117 25.35 38.52 22.16 35.36 27.14 16.72 
miR-532# 59.97 42.60 66.08 59.07 66.84 47.89 
miR-542 21.98 20.54 19.24 30.11 21,47 17.09 
miR-582 50.43 16,35 55.42 46.97 52,19 47.12 
miR-652 29.63 96.77 9.91 9.71 47,77 51.12 
miR-674# 52.61 64.81 42.59 35.18 68.54 64.16 
miR-676 20.85 54.77 16.71 21.64 34.15 10.87 
miR-700 73.15 18.02 69.03 71.58 71.84 80.17 
miR-744 67.52 52.22 72.06 51.80 69.83 76.37 
miR-7a-l 20.7 16.37 23.90 26.15 14.95 17.79 
miR-872 74.07 20.10 71.71 73,79 77.31 73.45 
nuR-874 40.54 78.25 24.05 30.70 55.55 51.85 
nuR-9* 32.51 48.85 27.11 29.13 43.20 30.60 
niiR-98* 79.71 56.53 87.92 61.10 85.82 84,01 
heart. miR-199a includes miR-199a-l and miR-199a-2. miR-9 includes miR-9-1, miR-9-2 and miR-
9-3. 
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Table 4.3. miRNA hairpins with a range of arm bias proportion greater than 20% across the 
cardiomyocyte samples. 
Arm bias (5p tag counts/hairpin tag counts) 
miRNA 48 hour 48 hour 7 day 7 day 
Mean Range Sham TAG Sham TAG 
let-7d 52.2 70.8 45.0 39.5 73.2 51.1 
let-7i 38.9 34.1 32.2 36.1 42.1 45.2 
miR-140# 38.1 23.8 36.0 42.4 41.5 32.7 
miR-151# 67.2 72.2 77.1 79.7 67.1 44.9 
miR-154# 72.0 71.4 54.0 76.5 91.9 65.5 
miR-1843 75.1 35.3 77.2 65.7 79.7 78.1 
miR-1843b 84.6 25.3 86.6 78.7 85.5 87.4 
nuR-lSa 90.0 23.0 95.3 84.9 88.3 91.5 
miR-193# 11.5 21.9 9.5 10.4 10.3 15.5 
miR-199a# 28.5 23.1 34.5 24.7 27.1 27.6 
miR-208a#* 55.6 69.8 35.7 72.9 55.5 58.1 
miR-210# 12.0 77.4 1.3 39.1 4.8 2.7 
miR-31# 83.4 58.1 87.8 63.5 89.2 93.0 
miR-324# 87.1 27.0 92.5 98.6 76.0 81.4 
miR-330# 30.2 64.3 32.5 44.2 36.9 7.0 
miR-335# 68.1 21.5 74.5 60.6 75.6 61.7 
miR-337# 30.0 26.5 28.8 34.8 24.1 32.2 
miR-362 65.5 31.1 72.9 64.8 56.8 67.5 
miR-378# 25.3 34.3 29.6 14.3 28.5 28.9 
miR-423# 38.7 37.9 45.1 43.6 43.2 23.1 
miR-486# 81.2 43.6 87.0 67.2 84.8 86.0 
miR-490 34.7 59.1 45.4 62.4 17.1 13.7 
miR-501 71.5 36.4 84.0 65.2 69.2 67.6 
miR-503 25.5 27.1 24.8 16.1 27.9 33.4 
miR-5117 25.4 38.5 22.2 35.4 27.1 16.7 
miR-532# 60.0 42.6 66.1 59.1 66.8 47.9 
miR-542 22.0 20.5 19.2 30.1 21.5 17.1 
miR-652 29.6 96.8 9.9 9.7 47.8 51.1 
miR-674# 52.6 64.8 42.6 35.2 68.5 64.2 
miR-676 20.9 54.8 16.7 21.6 34.2 10.9 
miR-744 67.5 52.2 72.1 51.8 69.8 76.4 
miR-872 74.1 20.1 71.7 73.8 77.3 73.5 
miR-874 40.5 78.3 24.1 30.7 55.5 51.8 
miR-9* 32.5 48.8 27.1 29.1 43.2 30.6 
miR-98* 79.7 56.5 87.9 61.1 85.8 84.0 
heart. miR-199a includes miR-199a-l and miR-199a-2. miR-9 includes miR-9-U miR-9-2 and miR-
9-3. 
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Figure 4.11. Card iac m i R N A s wi th a rm bias across the hyper t rophic samples . 
T h e 5 ' a rm bias is shown for several cardiac m i R N A with more than 2 0 % range across the e ight 
samples . T h e a rm bias represents the amount the 5' or 5p a rm contr ibutes to the m i R N A hairpin, 
w i th 0 % indicat ing all of the m i R N A is der ived f rom the 3p a rm and 100% indicat ing all of the 
m i R N A IS der ived f r o m the 5p arm. Data is presented as the mean and S E M of 5' a rm bias (%) 
der ived f r o m the smal l R N A sequenc ing data (n=2). 
4 . 2 . 5 . B 5 ' AND 3 ' ISOMIRS 
miRNA sequcncmg 
Next-generat ion sequencing also allows the examination of a miRNA strand for variation 
at the start or end position, termed 5' and 3' isomiRs respectively. Unlike arm bias, the 
presence of isomiRs represents a subder variation. IsomiRs will bind to the same 
microarray probe and will often be detected with the same RT-qPCR primers as the 
canomcal miRNA because the majority of the sequence remains the same. Next-
generat ion sequencing can detect these subtle differences, as the sequence of the adaptors 
originally Hgated onto the miRNA is known. Thus, the exact start and end position of the 
miRNA can be established. W e have mined the data for miRNAs with evidence of 5' and 
y isomiRs. W e have defined isomiRs as a miRNA tag that starts/ends within 3nt upstream 
or downstream of the miRBase canonical def ined start/end site (Figure 4.12.A). 
5' isomiRs 
As shown in Figure 4.12.B, the majority of miRNAs start where expected, with close to 0% 
being derived from a 5' isomiR (the proportion of 5' isomiRs for all miRNAs with CPM 
greater than 10 are listed in Appendix 8.8). However, 55 miRNAs have more than 20% of 
their tags derived from a 5' isomiR (Table 4.4). Importantly, these miRNAs have a large 
range of tag counts indicating that the presence of 5' isomiRs is not confined to only lowly 
expressed and potentially spurious miRNAs. This list includes several cardiac miRNAs, 
such as miR-133a, miR-9 and miR-98, which act as anti-hypertrophic miRNAs by 
supressing the expression of transcripts that play into the hypertrophic signalling pathway 
{140, 141, 230). 
Variation in 5' isomiRs during hypertrophy 
After determming that 5' isomiRs were detectable in 55 miRNAs, we wanted to know if the 
proport ion of 5' isomiRs for each miRNA changed between the Sham and TAG 
cardiomyocytes. Only eight m iRNAs have a range greater than 20%, suggesting that while 
several m iRNAs have a large proportion of isomiRs, the processing remains static between 
the control and the hypertrophic hearts (Table 4.5). The contribution of 5' isomiRs at each 
time pomt for these eight miRNAs is shown m Figure 4.13. In support of this obser^-ation, 
analysis usmg the weighted linear model did not yield any miRNAs with a FDR < 60% 
(Appendix 8.13). As seen with the variation in arm bias, we could not detect any directional 
change in 5' isomiRs with hypertrophy induction across the time course. 
miRNA scquencm 
3' isomiRs 
In contrast to 5' isomiRs, 248 out of the 260 miRNAs with coverage greater than 10 CPM 
have more than 20% 3' isomiRs (Figure 4.12.C). Further information about the 3' isomiR 
percentage for each of these miRNAs can be found in Appendix 8.8. As majority of the 
miRNAs have 3' isomiRs we did not interrogate the miRNAs for their individual 
involvement with cardiac hjfpertrophy. 
Changes in 3' isomiRs during hypertrophy 
The 3' isomiR proportions were then analysed for any change between the Sham and TAG 
samples. The percentage of 3' isomiRs changes more than 20% in 50 miRNAs across the 
time course (Table 4.6). This includes 16 miRNAs whose expression has been documented 
to change in hypertrophy or with known functional roles in the heart. After applying the 
weighted linear model to look for changes in the proportion of 3' isomiRs, one miRNA 
with a FDR of 31% was identified with a difference between the Sham and TAG samples 
at 48 hours (Appendix 8.13). miR-125a-5p exists as three predominant 3' isomiRs, the 
canonical miR-125a-5p (Can miR-125a-5p), a 3' isomiR that finished one nucleotide 
upstream (Isol miR-125a-5p) and another 3' isomiR that finished two nucleotides 
upstream (Iso2 miR-125a-5p) as illustrated m Figure 4.14.A. The proportion of Can miR-
125a-5p increases in the 48 hour TAG samples relative to the other 3' isomiRs (Figure 
4.14.B.ii). This change in proportion was also visible in the 7 day samples. The expression 
levels of miR-125a-5p decrease sHghtly at both time points (Figure 4.14.B.1), however the 
change in expression is small with the largest absolute log2-FC of 0.3. To sum up, 19% of 
miRNAs have a difference in the proportion of 3' isomiRs across samples, with one 
miRNA having a directional change with hj'pertrophy. 
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Figure 4.12. 5' and 3' i somiRs are detected in cardiac m i R N A s . 
(A) I somiRs we re de f ined as m i R N A s that started or ended with in ± 3nt f rom the annotated start 
pos i t ion of a m i R N A . (B) 5' i somiRs in the hyper t rophic heart ; the proport ion of tags represent ing 
5' i somiRs for each m i R N A . (E) 3 ' i somiRs in the hypertrophic heart ; the proport ion of tags 
represent ing 3 ' i somiRs for each m i R N A . M i R N A s with a range less than 2 0 % are shown in red, 
those wi th a range greater than 2 0 % are indicated by blue. 
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Table 4.4. miRNAs with >20% 5' IsomiRs. 
Mean 
CPM 
5' IsomiRs (%> 
miRNA 48 hour 48 hour 7 day 7 day 
Mean Range Sham TAG Sham TAG 
miR-133a-3p#* 292300 57.1 7.2 57.15 59.95 54.64 56.77 
miR-126-3p# 15030 37.2 10.1 33.78 36.38 39.17 39.59 
niiR-345-5p 1721 88.4 7.3 90.65 86.93 88.25 87.61 
miR-101a-3p# 1256 35.0 21.6 27.76 30.01 37.00 45.06 
miR-29b-3p# 861.1 38.3 11.2 35.82 40.75 34.52 42.26 
miR-378b 610 85.5 9.8 83.00 88.35 84.32 86.23 
miR-145-3p 490.3 37.3 8.8 37.08 37.21 39.41 35.48 
miR-133a-5p* 418.8 93.4 6.2 94.15 91.17 95.37 92.87 
miR-30a-3p# 418.6 26.4 5.8 26.76 26.94 24.74 27.27 
miR-101b-3p# 322.5 49.7 28.9 43.96 45.31 48.81 60.70 
nuR-140-3p# 250.1 36.5 3.0 36.50 37.05 36.78 35.67 
miR-322-3p 157.1 38.9 3.8 37.40 38.52 39.97 39.73 
miR-7a-l-3p 146.6 25.3 6.7 25.81 26.95 23.43 24.81 
miR-5105-3p-novel 115.4 67.8 10.1 71.39 70.68 63.69 65.46 
miR-582-5p 102.3 52.5 7.3 51.27 55.90 52.83 50.00 
let-7g-3p 100.0 98.7 3.5 99.29 98.62 98.72 98.26 
miR-582-3p 96.9 50.7 12.6 47.58 50.88 52.76 51.64 
miR-5109 86.9 97.6 3.6 96.77 99.03 96.67 97.86 
miR-28c 84.6 99.8 0.7 99.75 99.78 99.66 99.84 
miR-5097 57.7 23.3 .30.8 18.57 27.08 16.17 31.39 
miR-lOlc 57.2 99.8 0.8 99.62 99.64 100.00 99.89 
niiR-24-l-5p 55.6 48.4 9.0 48.73 45.27 47.33 52.29 
miR-101a-5p 50.0 22.1 9.9 19.04 22.12 22.97 24.08 
miR-455-3p# 45.6 29.3 10.2 27.50 32.26 30.54 27.05 
miR-1843-5p 41.6 33.8 8.5 31.44 31.71 34.39 37.64 
miR-504-5p 32.6 49.0 19.3 54.49 43.96 42.81 54.72 
miR-3107-3p 31.4 39.6 19.7 35.92 42.18 38.24 41.84 
miR-30c-l-3p 30.5 36.4 32.0 38.59 29.59 32.81 44.70 
rmR-330-3p 30.2 64.4 15.2 66.44 63.28 65.31 62.68 
# miRNAs with known expression changes i 
heart. mjR-9 includes miR-9-1, nuR-9-2 and miR-9-3. 
•. * miRNAs with known function in the 
tniRNA sequencing 
Table 4.4 cont. miRNAs with >20% 5' IsomiRs. 
miRNA 
Average 
CPM 
5' IsomiRs (%) 
Average Range 
48 hour 
Sham 
48 hour 
TAG 
7 day 
Sham 
7 day 
TAG 
miR-345-3p 29.9 67.9 22.5 74.41 65.08 65.60 66.34 
miR-361-3p 29.6 44.0 19.0 44.04 39.31 45.71 46.97 
miR-467b-5p 27.6 96.7 2.8 97.41 96.93 96.78 95.76 
miR-503-3p 25.5 70.4 12.3 65.73 72.25 69.55 73.95 
i-niR-3963 23.5 39.2 10.7 43.41 38.78 33.55 41.06 
miR-5117-3p 20.2 92.9 14.5 93.28 87.23 96.44 94.82 
miR-1843b-5p 19.9 55.0 19.8 57.16 61.67 49.67 51.58 
miR-9-3p#* 18.9 77.0 8.5 77.11 74.72 80.71 75.40 
miR-208b-3p#* 18.9 22.6 31.7 22.76 29.88 9.62 28.08 
miR-5099 18.3 98.0 3.8 97.72 98.71 97.78 97.72 
miR-425-3p 17.3 30.7 17.3 35.56 26.35 34.98 25.72 
miR-466b-3p 16.8 42.1 14.7 39.93 46.89 42.06 39.38 
miR-466c-3p 16.7 41.9 14.2 39.10 46.50 42.43 39.47 
miR-466e-3p 16.6 61.1 17.1 62.90 55.84 62.07 63.43 
miR-466p-3p 16.6 41.5 14.1 38.88 45.85 41.99 39.22 
miR-1949 16.4 92.4 8.5 93.70 92.01 92.50 91.19 
miR-29a-5p 16.3 31.9 15.1 35.57 26.35 34.82 30.65 
miR-466a-3p 16.2 60.1 18.5 61.85 53.61 61.93 62.80 
miR-203-3p 15.5 53.8 15.4 53.58 57.98 49.80 53.88 
miR-324-3p# 14.6 70.7 42.9 68.29 83.33 67.06 64.04 
miR-1306-5p 11.9 100.0 0.0 100.00 100.00 100.00 100.00 
miR-98-3p* 11.5 56.1 29.9 56.35 63.02 47.80 57.35 
miR-30d-3p 11.0 20.1 13.3 20.20 19.30 21.94 19.12 
miR-337-3p 10.4 75.1 18.8 76.12 78.12 76.46 69.77 
miR-107-5p 10.3 25.8 8.5 26.10 27.78 23.36 26.05 
miR-505-3p 10.2 59.7 14.1 63.60 58.64 58.69 57.68 
# miRNAs with known expression 
heart. miR-9 includes miR-9-1, miR 
changes i 
9-2 and miR-9-3. 
Table 4.5. miRNAs with a range >20% 5' isomiRs across the timecourse. 
miRNA 
miR-101a-3p# 
miR-101b-3p 
miR-5097 
miR-30c-l-3p 
miR-345-3p 
miR-208b-3p'' ' 
miR-324-3p# 
miR-98-3p' 
Average 
CPM 
1256.0 
322.5 
57.7 
30.5 
29.9 
18.9 
14.6 
11.5 
Average 
35.0 
49.7 
23.3 
36.4 
67.9 
22.6 
70.7 
56.1 
Range 
21.6 
28.9 
30.8 
32.0 
22.5 
31.7 
42.9 
29.9 
5' IsomiR (%) 
48 hour 
Sham 
27.76 
43.96 
18.57 
38.59 
74.41 
22.76 
68.29 
56.35 
48 hour 
TAG 
30.01 
45.31 
27.08 
29.59 
65.08 
29.88 
83.33 
63.02 
7 day 
Sham 
37.00 
48.81 
16.17 
32.81 
65.60 
9.62 
67.06 
47.80 
7 day 
TAG 
45.06 
60.70 
31.39 
44.70 
66.34 
28.08 
64.04 
57.35 
# miRNAs with known expression changes in hypertrophy. * miRNAs with known function in 
heart 
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Figure 4.13. miRNAs with variation in the proportion of S' isomiRs across the 
cardiomyocyte samples. 
The contribution of 5' isomiRs for each miRNA with more than 20% difference in 5' isomiRs 
across the eight samples. Data is presented as mean and SEM of 5' isomiR (%) derived from the 
small RNA sequencing data (n=2). 
millNA scquencii;_ 
Table 4.6. miRNAs with >20% difference in the proportion of 3' isomiRs across the 
cardiomyocyte samples. 
m i R N A 
Average 
CPM 
3' IsomiR (%) 
Average Range 
48 hour 
Sham 
48 hour 
TAG 
7 day 
Sham 
7 day 
TAG 
14550.0 61.6 32.3 58.52 78.33 50.08 59.48 
5161.0 30.8 61.4 22.57 53.52 23.22 24.01 
4179.0 26.7 22.7 26.29 20.85 36.02 23.58 
1429.0 65.4 36.3 77.47 59.98 76.02 48.14 
504.6 70.6 28.4 67.42 82.77 67.99 64.28 
436.2 74.6 22.9 79.42 73.45 77.65 67.75 
418.4 73.9 40.5 70.46 81.07 81.05 62.88 
407.1 77.6 22.0 77.24 82.57 71.32 79.35 
357.5 75.0 36.7 69.42 80.55 68.71 81.23 
281.5 54.6 22.6 58.00 58.73 57.55 43.97 
244.9 46.3 30.7 42.94 50.92 51.98 39.50 
173.0 25.6 21.3 26.57 33.04 21.37 21.48 
167.9 52.4 43.9 52.37 53.61 56.88 46.67 
84.9 34.2 37.0 26.85 35.59 46.18 28.18 
80.4 75.2 21.2 74.19 80.35 66.46 79.92 
61.1 65.7 20.8 67.40 61.67 63.09 70.55 
57.2 43.3 47.8 61.58 53.28 34.59 23.70 
55.6 68.8 25.8 72.77 64.60 75.85 61.84 
51.7 69.5 37.2 74.66 70.22 74.69 58.47 
50.0 41.4 20.6 36.55 46.34 41.12 41.69 
45.7 53.9 31.8 59.70 42.46 58.16 55.20 
41.6 77.3 22.8 73.42 83.66 77.79 74.43 
39.1 28.2 24.9 27.41 19.57 34.83 30.95 
36.5 67.7 23.0 67.99 70.72 69.42 62.79 
35.3 74.9 21.8 70.66 68.70 72.20 87.87 
34.1 87.0 75.0 61.13 92.75 97.79 96.28 
32.6 44.1 30.4 52.17 41.26 40.93 42.13 
30.5 43.2 22.6 39.28 50.61 40.61 42.19 
30.2 58.3 27.1 54.27 70.86 53.09 55.08 
30.1 40.6 26.4 46.07 32.63 42.84 40.82 
26.2 83.1 21.3 76.23 85.59 86.31 84.31 
20.2 73.3 26.6 75.75 72.16 80.28 64.92 
20.2 32.7 25.6 33.38 46.30 24.46 26.50 
miR-21-5p#* 
miR-378-5p 
miR-27b-3p#* 
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miR-31-5p# 
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Table 4.6. cont. miRNAs with >20% difference in the proportion of 3' isomiRs across the 
cardiomyocyte samples 
Average 
CPM 
3' IsomiR (%) 
miRNA 48 hour 48 hour 7 day 7 day 
Average Range Sham TAG Sham TAG 
miR-208b-3p#* 18.9 59.2 50.1 65.46 64.88 60.53 45.75 
miR-1839-5p 17.5 58.1 20.9 64.83 59.17 60.88 47.41 
miR-466a-3p 16.2 42.4 21.8 34.80 43.86 47.59 43.18 
miR-17-3p 16.2 53.9 34.2 66.24 53.41 42.50 53.40 
miR-490-3p 15.2 89.1 23.5 79.91 92.09 92.48 91.91 
miR-874-5p 13.6 84.3 25.8 82.36 90.96 79.03 84.88 
miR-379-5p# 12.9 40.7 32.8 51.30 34.36 44.85 32.37 
miR-154-5p# 12.6 38.4 32.4 36.76 37.99 32.89 46.11 
miR-676-3p 12.5 76.2 26.0 77.57 76.02 83.56 67.66 
miR-139-3p 12.4 88.0 20.5 84.04 92.81 88.53 86.64 
miR-1843-3p 12.2 43.8 21.3 42.96 39.35 50.05 43.00 
miR-1306-5p 11.9 70.2 20.2 63.02 73.21 74.23 70.14 
miR-301a-3p 11.6 42.2 26.3 40.31 43.25 31.82 53.38 
miR-30d-3p 11.0 35.7 33.7 37.68 29.39 43.44 32.19 
miR-9-5p* 10.6 35.1 30.1 32.13 47.25 35.69 25.18 
miR-1839-3p 10.5 70.7 21.8 75.95 71.94 67.46 67.36 
miR-107-5p 10.3 50.1 20.2 53.08 48.40 48.21 50.67 
# miRNAs with known expression 
heart. miR-9 includes miR-9-1, miR 
changes i 
-9-2 and miR-9-3. 
known function in the 
miRNA sequencing 
miR-125a-5p 
TGGGTCCCTGAGACCCTTTAACCTGTGAGGAC 0_ 
Can miR-125a-5p TCCCTGAGACCCTTTAACCTGTGA 
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Figure 4.14. The 3' isomiRs of miR-125a-5p alter in cardiac hypertrophy. 
(A) The canonical rmR-125a-5p is defined as the sequence corresponding to miR-125a-5p in 
miRBase (shown in blue). The major forms of miR-125a-5p found in the cardiomyocyte NGS are 
listed below with the corresponding tag counts on the right. (B) (i) miR-125a-5p decreases slightly 
in the both the 48 hour and 7 day TAC samples. Data is shown as average Log2 FC (n=2). (u) 
Contribution of each miR-125a-5p 3' isomiR to the miR-125a-5p locus. 
miRN A sequencmg 
miR-133a-3p exists as 5' and 3' i somiRs: 
A predominant example of 5' and 3' i somiRs is the cardiac specif ic miR-133a , which is the 
mos t abundant m i R N A in the sequencing libraries. m i R 4 3 3 a exists as multiple 5' and 3' 
i somiRs derived f rom both the 5p and 3p arms, which could gready increase its target 
m R N A spectrum. The predominant species of miR-133a-3p is actually a 5' i somiR that 
starts one nucleot ide downs t ream of the annotated start site (Figure 4.15.A). The 5' 
i somiRs are also associated with mult iple 3' ends. The same miR-133a isomiRs were 
ident i f ied by our group in an earlier study that documented the m iRNA populat ion of the 
HL-1 card iomyocyte cell line ( 5 i ) . In further support of miR-133a-3p isomiRs, the top 
sequencing tags for miR-133a-3p listed in miRBase also include the 5' i somiR that begins 
one nucleot ide downst ream of the canonical start site (Figure 4.15.B). 
MiR-133a-3p is anti-h) 'pertrophic and its downregulat ion is suff icient to induce 
hypertrophy in mice {120). As the i somiRs differ by only one or two nucleotides and the 
remainder of the m i R N A sequence remains the same, it is not possible to validate the 
existence of 5' or 3' i somiRs by convent ional PGR methods. For this reason, a northern 
blot protocol was deve loped to probe against the miR-133a-3p sequence. A large amount 
of R N A is required for northern blotting, which was not available f rom the cardiomyocyte 
samples used for sequencing. Therefore , the northern blot was run using HL-1 
card iomyocyte R N A which contains the same proport ion of miR-133a-3p i somiRs(5 i ) , and 
R N A f rom a mur ine whole L V sample (Figure 4.15.C). The size of the endogenous miR-
133a was compared to artificial single stranded RNA molecules that mimic the sequences 
of the canonica l and the i somiR (labelled can/23 nt and iso/22 nt respectively). The 23 nt 
and 22 nt mimics are clearly visible on the blot, and when mixed at 50:50 proport ions the 
bands can be dist inguished. Whi le faint, the two bands corresponding to 22 nt and 23 nt 
are visible for the HL-1 card iomyocyte R N A . The signal for miR-133a-3p is stronger m the 
whole L V sample , with the predominant species being 22 and 23 nt in length. This 
conf i rmed that miR-133a-3p is present as mult iple lengths in both a cardiomyocyte ccU line 
and pr imary L V tissue. 
m i R N A sequenc ing 
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UUGGUCCCCUUCAACCAGCUGUAG 
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Figure 4.15. m i R - 1 3 3 a - 3 p exists as both 5' and 3' i somiRs . 
(A) Ma jor mature m iR-133a -3p spec ies and their abundance in card iomyocytes . Sequence tags are 
g rouped into those wi th canonica l (black, 'can ' ) and +1 (red, ' iso') start sites. T h e immics used for 
northern blots are indicates by the brackets (B) Nor the rn blot of miR-133a-3p in the HL-1 
ca rd iomyocy te cell Une compa red to the i so/22nt m i R N A mimic . (C) Northern blot of m i R 4 3 3 a -
3p in the HL-1 ca rd iomyocy te cell Une and R N A f rom who le mur ine LV, compared to can/23nt 
and i so/22nt m i R N A mimics . 
miRNA sequencin. 
After examination of the isomiRs present in cardiomyocytes purified from murine hearts, it 
is evident that several miRNAs exist as 5' isomiRs and majority of miRNAs have variation 
at the 3' end. The proportion of both 5' and 3' isomiRs remains relatively unchanged 
between normal, pre-hypertrophic and hypertrophic cardiomyocytes suggesting that 
regulation of isomiRs is not a primary mechanism to alter miRNA regulation in the heart. 
4 . 2 . 5 . C N O N - T E M P L A T E D A D D I T I O N S 
miRNA sequences can also differ from the canonical sequence by addition of non-
templated nucleotides (NTA) to the ends of the miRNA {231). Numerous studies using 
next-generation sequencing have now obser\'ed NTA that differ from the genomic 
sequence at the 3' end of a miRNA (79, 23I-23J). The miRNA data was examined for 
evidence of NTA, defined as nucleotides that did not match the genomic sequence within 
the last 2 nt of the sequencing tag. Using this criterion, we identified 131 miRNAs that had 
evidence of NTA (more than 20% of the tags had NTA, Appendix 8.8). This is consistent 
with a prior study where 50% of the miRNAs expressed in normal human prostate tissue 
had NTA to some extent {233). Previous publications have obser\xd that the most 
frequently added nucleotides to mammalian miRNAs are U and A {79, 232). Indeed, we 
also found that U and A were the predominant nucleotide added to individual tags (Figure 
4.16.B). When comparing a single nucleotide position across multiple tags, U was the most 
frequently added nucleotide (Figure 4.16.C). It has been posmlated that NTA has a strong 
preference for some miRNAs over others, with certain miRNAs consistently being 
modified in multiple tissue and cell t)'pcs {233). For instance, miR-143-3p is frequendy 
extended with b^-lTU NTA reported in the murine brain {233) and 63% NTA reported in 
another study looking at murine brain, ovarj' and testes {79). Notably, miR-143-3p has 64% 
NTA in our data which is in agreement with these previous studies. In fact, of the ten 
miRNAs with the highest proportion of NTA according to Wyman et al., nine had NTA in 
our data while one miRNA was not expressed at all {233). Furthermore, the average NTA 
for eight of these miRNAs was within 10% of the proportion documented in Wyman et al. 
{233). In short, 50% of the miRNAs m purified cardiomyocytes have evidence of NTA 
with the U the most frequendy added nucleotide. 
NTA events are altered in hypertrophy 
The addition of nucleotides, in particular A and U, can change both the stabilit)' of the 
miRNA and its function {234, 23S). Therefore, we investigated if the proportion of NTA 
i tuRNA s equenc ing 
Canonical miR-101a-3p sequence 
5'-AAAGGUACAGUACUGUGAUAACUGAAGGAUGGCA-3' Genomic sequence 
GUACAGUACUGUGAUAACUGAAU 
ACAGUACUGUGAU AACUGAAAU miRNA sequencing 
UAGAGUACUGUGAUAACUGAAGUA 
Non-templated additions 
B NTA per nt 
Most frequent NTA 
Proportion of NTA in cardiac miRNAs 
2 3 4 5 
Log 10 miRNA abundance (CPM) 
Figure 4.16. Cardiac m i R N A s undergo non- templa ted addit ions. 
(A) N T A were de f ined as m i sma tches to the genomic sequence in the last two nucleot ides of the 
sequenc ing tag. (B) T h e contr ibut ion of each nucleot ide to N T A posi t ion in individual tags. (C) The 
mos t c o m m o n nuc leot ide for each N T A pos i t ion in indiv idual tags. (D) T h e proport ion of tags 
represent ing non- t empla t ed addi t ions per m i R N A . M i R N A s with average tag count greater than 10 
C P M were used for analys is . M i R N A s w i th a range less than 2 0 % are shown in red, those with a 
range greater than 2 0 % are indicated by blue. 
miRNA SI .equencmg 
Table 4.7. miRNAs where the proportion of NTA changes by more than 20% across the 
cardiomyocytes. 
miRNA Average CPM 
NTA (%) 
Average Range 48 hour Sham 
48 hour 
TAG 
7 day 
Sham 
7 day 
TAG 
miR-92a-2-3p# 1595 77.4 28.5 81.9 74.5 84.0 69.1 
miR-145-3p 490.3 31.8 27.2 24.0 33.1 30.4 39.9 
miR-101b-3p# 322.5 27.7 20.8 31.3 22.4 30.5 26.4 
miR-146a-5p# 281.5 30.4 20.5 33.4 32.9 33.5 21.8 
let-7g-3p 100.0 42.3 28.0 43.4 41.5 34.4 50.0 
miR-28c 84.6 32.0 30.6 31,3 28.1 29.5 39.2 
miR-674-5p# 61.4 27.3 26.3 29.0 21.2 34.9 24.0 
miR-143-5p 44.5 20.6 41.8 7.8 30.2 13.9 30.4 
miR-532-5p 39.1 15.3 20.3 16.3 8.1 19.6 17.0 
miR-874-3p 35.3 19.6 25.5 20.2 24.7 11.3 22.3 
miR-652-3p 34.1 69.4 100.0 42.6 74.6 93.6 66.7 
miR-330-3p 30.2 26.1 23.4 20.9 33.9 27.6 22.1 
miR-345-3p 29.9 30.8 56.1 15.6 33.0 35.1 39.6 
nuR-671-5p 26.2 42.0 47.6 28.6 46.6 46.1 46.7 
miR-425-3p 17.2 37.1 24.8 36.1 33.8 45.3 33.1 
miR-5100 17.2 89.7 29.4 91.8 80.7 92.7 93.5 
miR-17-3p 16.2 26.8 22.7 28.4 21.0 29.2 28.6 
miR-203-3p 15.5 31.0 20.9 28.5 35.9 31.9 27.8 
miR-490-3p 15.2 19.3 21.4 15.9 18.9 17.3 25.0 
miR-324-3p# 14.6 20.5 32.8 27.8 10.0 20.9 23.1 
miR-224-5p# 14.2 10.5 20.8 8.3 7.8 16.9 9.0 
miR-125b-2-3p# 13.1 34.1 25.6 35.2 30.7 42.9 27.5 
miR-379-5p# 12.9 27.4 24.0 25.4 23.8 36.0 24.2 
miR-154-5p# 12.6 20.5 36.5 24.6 14.1 13.3 30.2 
miR-676-3p 12.5 37.1 25.3 38.9 33.5 44.1 32.1 
miR-139-3p 12.4 18.7 24.8 21.1 9.1 24.4 20.4 
miR-1306-5p 11.9 20.0 20.7 18.5 20.7 26.8 14.2 
let-7e-3p 11.4 25.0 25.6 22.5 32.0 24.0 21.7 
miR-34c-5p#* 11.1 11.0 21.9 17.4 6.4 10.6 9.5 
miR-9-5p* 10.6 29.7 52.7 17.0 29.4 35.0 37.5 
miR-337-3p 10.4 43.6 29.1 41.6 35.0 54.4 43.4 
miR-547-3p 10.4 70.8 21.1 72.8 73.0 72.0 65.5 
miR-505-3p 10.2 27.5 22.2 30.3 24.4 31.4 
23.9 
heart. miR-9-5p consists of miR-9-l-5p, miR-9-2-5p and miR-9-3-5p. 
miRNA scquencr 
changed for any miRNA between Sham and TAG. We found 35 miRNAs where the 
proportion of NTA changes more than 20% across the eight cardiomyocyte samples (Table 
4.7). The weighted linear model comparing the proportion of NTA for each miRNA was 
applied, and this identified one miRNA with a FDR of 21% that had a different proportion 
of NTA between the Sham and TAG samples at 48 hours (Appendix 8.13). miR-143-5p 
has an increase in the proportion of NTA that correlates with a decrease in the overall 
expression of the miRNA (Figure 4.17). On average, 20.6% of miR-143-5p tags have NTA 
in the last two nucleotides of the tag, the most prominent addition being a non-templated 
A (Figure 4.17.A). miR-143-5p is significantly downregulated at both 48 hours and 7 days 
in the TAG samples (Figure 4.17.B). The downregulation of miR-143-5p correlates with an 
increase in the NTA of Adenosine to the 3' end of miR-143-5p. 
A large portion of miRNAs have evidence of NTA. However, only one example could be 
found where this NTA is correlated to changes in expression levels. This suggests that in 
general, the NTA may be a part of normal miRNA regulation and mrnover and is not 
influenced by the stress induced on the cell during hypertrophy. 
miRN,\ sequencing 
Canonical mlR-143-5p sequence 
Genomic sequence 5'-GAGGUGCAGUGCUGCAUCUCGGUCAG-3' 
GGUGCAGUGCUGCAUCUCGG Canonical miR-143-5p 
GGUGCAGUGCUGCAUCUCGA •<- NTA miR-143-5p 
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Figure 4.17. miR-143-5p is modified at the 3' end with NTA. 
(A) The major forms of miR-143-5p found in the cardiomyocyte next-generation sequencing. The 
canonical miR-143-5p is defined as the sequence corresponding to miR-143-5p in miRBase. The 
NTA miR-143-5p is defined as a variant of miR-143-5p that contains an non-templated A at the 3' 
end. (B) The NTA miR-143-5p negatively correlates with the expression level of miR-143-5p. (i) 
miR-143-5p expression decreases in both the 48 hour and 7 day TAG samples. Data is shown as 
Log2 FC (n=2). (ii) Contribution of the canonical miR-143-5p, NTA miR-143-5p and all other 
miR-143-5p variants to the miR-143-5p locus. 
4 . 2 . 5 . D I N T E R N A L E D I T I N G 
miRNA acquenciiig 
The other form of post-transcriptional modification reported for miRNAs is internal 
editing, most commonly the deamination of adenosine (95, 232). Deamination of 
adenosine to inosine (A-to-I editing) is detected as an A-to-G change in nuRNA 
sequencing products (99). Internal editing was defined as a nucleotide mismatch before the 
last two nucleotides of the canonical end posiuon and before the last two nucleotides of 
the tag. There is notably verj ' litde internal editing compared to N T A s (proportion of tags 
with internal editing for all miRNAs with CPM greater than 10 arc listed in Appendix 8.8). 
Only five miRNAs were detected with internal editing in more than 20% of their tags 
(Figure 4.18.A). The miRNAs with more than 20% internal editing or greater than 20% 
difference across the timecourse are listed in Table 4.8. 
Each miRNA in Table 4.8 was checked manually for the location of the nucleotide change, 
a potential match to another genomic location and if the same editing was found in 
miRBase. In 50% of the tags for miR-lOlc, there is a U at the 5' end instead of the 
genomically encoded C. While the same editing is found in miRBase, the edited sequence 
actually matches 100% to miR-101a-3p, which is identical to miR-lOlc except for the 
additional U at the 5' end. Thus, it cannot be concluded that miR-lOlc is edited as the tags 
may be derived f rom the miR-101a-3p locus. Both miR-652-3p and miR-210-3p have more 
than 20% difference in internal editing events across the samples. However, both miRNAs 
have extremely low tag counts in at least two samples that is confounding the proportion 
of editing events. For instance, miR-652-3p has only two tag counts in the 370S sample, 
one of which is not an identical match to the genomic sequence resulting in an apparent 
editing of 50%. 
miR-3963, miR-490-3p and miR-5097 are more convincing candidates for internal editing 
events. The mam variant of miR-3963 contains a non-templated C instead of a U at the 5' 
end of the miRNA. This change is also detected at very low levels in the miRBase 
sequencing data, and importandy the edited sequence does not match any other miRNA in 
miRBase. miR-5097 has a high level of internal editing, with 85% of tags containing an A 
to G mismatch in the 3' end of the miRNA. While this was an ideal candidate for A-toT 
editing, miR-5097 has now been removed f rom the last release of miRBase as it is derived 
f rom a fragment of a tRNA and is not loaded into Ago2 (2i6)- miR-490-3p is edited in 
32% of Its tags, accounted for by an A to U or G transition towards the 3' end of the 
iTiillN.V sccjuen( 
m iRNA (Figure 4.18.B). The edited sequence does not match another miRNA deposited in 
miRBase . Whi le there is large difference in the proportion of miR-490-3p edited between 
the different samples, there is no correladon between expression level of miR-490-3p and 
the editing events. 
Internal editing does not change durmg cardiac hypertrophy 
W e next investigated if the proport ion of internal editing is altered for a miRNA during 
cardiac hypertrophy. The proportion of internal editing changed more than 20% in 5 
miRNA (listed in Table 4.8). However, only one miRNA, miR-221-3p, was identified with 
a FDR of 6 .2% when applying the weighted linear model comparing the proportion of 
mternal editing (Details in Appendix 8.9). On closer inspection, miR-221-3p is edited on 
average in 3.1% of miR-221-3p tags, and the change in the proportion of miR-221-3p was 
only 2.8%. Due to the low levels of editing, miR-221-3p was not investigated further. 
Table 4.8. miRNAs with >20% internal editing and/or with a range >20% internal editing 
miRNA 
Average 
CPM 
Internal editing (%) 
Average Range 
48 hour 
Sham 
48 hour 
TAG 
7 day 
Sham 
7 day 
TAG 
miR-lOlc 57.2 48.82 26.11 60.11 50.12 45.93 39.12 
miR-3963 23.54 58.93 9.51 54.88 58.80 63.49 58.56 
niiR-490-3p 15.21 32.04 44.07 20.26 26.47 53.63 27.82 
miR-5097 57.63 86.16 22.36 90.30 86.42 90.16 77.77 
miR-652-3p 34.07 21.43 100 3.02 4.96 51.18 26.55 
miR-210-3p# 245.03 6.988 23.356 2.83 13.62 6.57 4.93 
miR-324-3p# 14.56 14.42 40 12.06 20.00 11.96 13.67 
# miRNAs with known expression changes in hypertrophy 
To summarise, there is vet) ' litde editing detected in the miRNAs expressed in murine 
cardiomyocytes. miR-490-3p is the most convincing candidate for internal editing, which 
contains an A-to-G transition that reflects A-to-1 editing. This alteration to the miRNA 
sequence occurs in the 3' end of the miRNA making it difficult to posmlate what the 
biological function of such a change could be. 
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Figure 4.18. A smal l n u m b e r of m i R N A s have ev idence of internal editing. 
(A) Internal edi t ing in the hyper t roph ic heart ; the propor t ion of tags represent ing internal edit ing 
events per m i R N A . M i R N A s wi th average tag count greater than lOCPM were used for analysis. 
M i R N A s w i th a range less than 2 0 % are shown in red, those wi th a range greater than 20% are 
indicated by blue. (B) m iR-490 -3p conta ins ev idence of internal edit ing; the miRBase def ined 
sequence is shown in blue, w i th the ma jor i so fo rms in the ca rd iomyocyte data shown below. The 
red nuc leot ides indicate m i sma tches to the genomic sequence . 
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4 . 3 D I S C U S S I O N 
In this chapter, I performed genome-wide profil ing of miRNyVs in control, pre-
hypertrophic and hypertrophic cardiomyocytes. The data was analysed for differential 
expression of miRNAs, the presence of miRNA processing variants and indications of 
variant changes between Sham and TAG samples. 
4 . 3 . 1 F E A T U R E S OE THE SMALL R N / \ I . IBRARY 
The library construction is based on size selection of PGR products corresponding to 110-
125 nt to avoid contamination by other small RNAs such as tRNA and primer dimers. 
However, there was still a large proportion of reads that mapped to tRNA and rRNA. Due 
to the namre of the library preparation, tRNA-derived RNA fragments, which can give rise 
to functionally active miRNAs (237), are also incorporated into small RNA libraries. 
Another study using 454 sequencing, made small RNA libraries from fragments 
corresponding to 17-26 nt in length and found miRNAs contribute to only 40% of the 
total tags (238). A large proportion of the library was derived from tRNA, rRNA, protein 
coding loci and transposable elements (238). The ligation of adaptors requires a 5' 
phosphate and 3' OH group, so while non-phosphor)'lated degradation products would not 
be incorporated, any other RNA species of the correct size could be sequenced {23?}. 
These other RNA populations have sizes ranging from 19-26 nt and therefore would be 
present in our sequencing libraries along with miRNAs (239). 
In addition to other RNA species, 17% of our reads did not overlap with any features in 
the mouse genome. Another study using SOLiD sequencing for smaU RNAs found that 
37-43% of the mapped reads that did not overlap with annotated features were non-
annotated small RNAs {240). It is therefore possible that the tags that do not overlap with 
known features are novel small RNAs, which remain to be explored. 
The contribudon of each miRNA to the Hbrar>' was highly heterogeneous, with the top 20 
miRNAs contributing 87.3% of the tags and the highly abundant miR-133a alone 
accounting for 30.2% of tags. This distribution of tags has been found in other smdies. For 
example, the top miRNA in the Zaragosi et al. smdy also accounted for 30% of tags {240). 
On the other hand, a previous study m the lab indicated that miR-145 was the most 
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abundantly expressed miRNA contributing only 13% of tags in the HL-1 cardiomyocyte 
cell line {55). It could be postulated that these differences are due to different miRNA 
profiles in the cell line compared to cardiomyocytes derived from the mouse heart. 
However, the apparent abundance of miRNAs in next-generation sequencing depends 
heavily on the library preparation method and the sequencing platform used {241). While 
both of these studies were conducted using the SOLiD^'^ platform, our earlier work used 
the SOLiD'"''^ Small RNA Expression Kit and the libraries discussed here were prepared 
with the NEBNext® SmaU RNA Library Prep Set for SOLiDTm. The biases introduced by 
the sequencing platform and preparation method arc highly reproducible, meaning that 
next-generation sequencing is suitable to make comparisons of relative expression changes 
between samples, whereas the absolute expression or rank of a miRNA between different 
smdies is not as accurate {242, 243). 
4.3.2. SAMPLE HiiTHROGENFiixY 
There is no defined or best practice for normalisation of miRNA sequencing data, and only 
a handful of studies have made comparisons of the available normalisation methods {244, 
245). Some of the earlier studies have normalised only to the total number of miRNA 
mapped reads {242, 246). But as mentioned previously, this doesn't take into account 
differences in the RNA composition that may occur between samples. Other normalisation 
strategies used for miRNA sequencing include normalisation to miRNAs that do not 
change or to the levels of synthetic miRNAs. Normalisation to other miRNAs involves 
choosing a subset of miRNAs that remain stable between samples according to RT-qPCR 
data {13t). Alternatively, a synthetic oligonucleotide can be added to the first step of libran' 
preparation and can then be used to normalise the levels of small RNAs between samples 
{247). Both of these methods would account for the input of RNA in each sample but 
would not account for RNA composition differences in the initial samples. For this reason, 
we used TMM normahsation, which takes into account the RNA population of each 
sample {2!9). 
Our samples are closely related as reflected by the high Spearman correlations. The top 
expressing miRNAs m our Hbraries, such as miR-133a-3p, miR-133b-3p and miR-22-3p, 
remain unchanged between the Sham and the TAG, which would contribute to the large 
Spearman correlations. In Une with this, another study looking at miRNA expression 7 days 
post-TAC found that more moderately expressed miRNAs change compared to the most 
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abundant miRNAs {131). Despite the large similatit}' between samples, the Spearman 
correlation does cluster the Sham and the TAG samples separately, indicating that there arc 
distinct expression differences between the two groups. 
4 . 3 . 3 D I F F E R E N T I A L E X P R E S S I O N o i - M I R N A S 
This was the first study to document the differential expression of miRNAs in purified 
cardiomyocytes during the hypertrophic response. A small number of miRNAs were 
identified with a significant expression difference between the Sham and TAG samples. 
More miRNAs were upregulated than those downregulated. This is consistent with another 
study that used lUumina sequencing to document the miRNA changes in the whole LV 7 
days post-TAG [131). This study also found more miRNAs upregulated and hypothesised 
that there may be a lag period for miRNA elimination resulting in less detectable 
downregulated miRNAs {131). 
There arc multiple mechanisms by which a miRNA can be regulated, including processing 
and turnover. Several of the upregulated miRNAs are under the control of transcription 
factors known to be involved in cardiac hypertrophy. For example, miR-199b is 
upregulated in the 7 day TAG samples (Figure 4.7) and is a target of the calcineurin/NFAT 
pathway that is upregulated in response to pressure overload {10, 227). Other miRNAs are 
under the control of their host gene. For instance, miR-208b is encoded within an intron of 
the P-MHG gene and miR-208a is located within a-MHC {24S). The ratio of P-MHG to a-
MHG increases during the hypertrophic response (refer to Chapter 3.3.3) to conser\re 
energy and change cardiac output {210, 211). We observed a slight increase in P-MHG at 48 
hours and a significant overexpression at 7 days (Figure 3.7). We also obser^x-d an increase 
in the levels of miR-208b-5p at both 48 hours and 7 days albeit not significant. Similarly, 
the levels of both strands of miR-208a decreased at 7 days, possibly reflecting the decrease 
in a-MHG. 
It was originally anticipated that miRNAs would be a component of the initial response to 
cardiac stress and thus we would see expression changes on or before the 48 hour time 
point. In fact, only three miRNAs had sufficient dysregulation at 48 hours to make 
statistical significance (miR-451, miR-223-3p and miR-21-5p). miR-451 is m a cluster with 
miR-144 and is direcdy regulated by the transcription factor GATA-4 {249). GATA-4 lies 
downstream of multiple hypertrophic signalling pathways, such as the calcineurm/NFAT 
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and the PI3K-Akt pathways (reviewed in (•/)). It is known that in response to TAG or 
pressure overload, the D N A binding activity of GATA-4 increases, which leads to the 
activation of genes such as a - M H C , A N P and B N P (250, 251). Since B N P is strongly 
induced at 48 hours (Figure 3.7), it is possible that the upregulation of niiR-451 is also due 
to stimulation by GATA-4. 
In addition to transcriptional control, regulation of miRNA biogenesis and turnover can 
influence the levels of a miRNA. In line with this, certain miRNAs are expressed in a tissue 
or developmental stage specific manner without variation in the levels of the pre-miRNA, 
suggesting regulatory mechanisms that act on the mature miRNA (252). A study looking at 
miRNA decay disrupted transcription and found that 95% of human miRNAs remained 
stable for at least 8 hours (25J). This could account for the small number of downregulated 
miRNAs in our smdy. If the locus was transcriptionally silenced, it could take a 
considerable amount of time before the existing miRNAs are cleared. While miRNAs are 
generally considered to be very stable, it is also known that the turnover rate can be 
miRNA specific. For instance, miR-208a has a half-life greater than 12 days in rat hearts, so 
even after repression of the miR-208a locus it would take several days before any 
downregulation would be visible (114). While other miRNAs are unstable and can be 
rapidly degraded by enzymes such as Xrn l and Eri l (253, 254). It is not yet known if there 
are specific enzymes, such as exonucleases, that regulate miRNA turnover in the 
mammalian heart. But it is possible that the miRNAs downregulated in this study have high 
turnover rates in cardiomyocytes. 
It is also interesting that we only see strong upregulation of pro-hypertrophic miRNAs, 
while miRNAs found to be anti-hypertrophic are notably absent f rom Figure 4.7. It could 
be hypothesised that anti-hypertrophic miRNAs are upregulated early in the timecourse to 
try and combat the hj 'pertrophic signalling, and the levels of these miRNAs then decrease 
once the hypertrophic response is estabHshed. It is possible that we did not sample the 
cardiomyocytes early enough; if the anti-hypertrophic miRNAs are upregulated before the 
48 hour time point. O n the other hand, while these miRNAs are known to be 
antihypertrophic, the heart is trying to compensate for the increase m pressure and thus the 
hypertrophy is an adaptive mechamsm. Thus, the levels of anti-hypertrophic miRNAs may 
be high in normal cardiomyocytes to prevent unnecessary' hypertrophy f rom occurring. It 
has been shown that anti-hypertrophic miRNAs are more important during regression of 
hypertrophy once the stimulus has been removed and thus we would not obser\ 'e their 
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upregulation in our study (259). This data provides more insight into the regulation of 
hypertrophy prior to the onset of symptoms. The miRNAs upregukted early could provide 
a clue as to which miRNAs to target for therapeutic inter\'ention against heart disease. 
4 . 3 . 3 . A V A L I D A T I O N OF M I R N A E X P R E S S I O N 
The expression of the differentially expressed miRNAs were tested using RT-qPCR. 
Importantly, the PGR primers were designed against the major variant of the miRNA 
present in the sequencing data. This is particularly important for the 3' end of the miRNA, 
as the ligation of the stem-loop reverse transcription primer relies only on the last six 
nucleotides. The RT-qPCR was performed on the identical eight samples subjected to 
small RNA sequencing, plus the additional cardiomyocyte samples as documented in 
Chapter 3. The expression levels of sLx miRNAs followed the same trend in the RT-qPCR 
on the same samples used for sequencing, with four of these having a statistically 
significant difference in the extended dataset. There was often a large variation in the levels 
between biological replicates. The most prominent example is miR-451, which has a large 
increase at 48 hours in the sequencing data. The RT-qPCR for the samples subjected to 
sequencing follows exactiy the same trend as the next-generation sequencing itself 
However, large variations in the expression levels across the extended dataset actually result 
in a decrease in expression between Sham and TAC. 
Discrepancies between the expression levels could be attributed to variation in the 
cardiomyocyte enrichment, as there was a difference in the number of cardiomyocytes and 
expression of cardiomyocyte markers between samples. The question was then asked if any 
of the miRNAs tested for validation were cell type specific. However, the only known 
miRNA that is purely cardiomyocyte specific is miR-208a (//•/), the remaining miRNAs 
just have enhanced expression is certain ceUs. Three of the miRNAs that could be vaHdated 
in the extended dataset are abundant in cardiomyocytes; miR-199 is predominandy 
expressed in cardiomyocytes {256), miR-223-3p is locaHzed to cardiomyocytes in 
cryosections in the heart (257), and while miR-21 is highly expressed in fibroblasts it is still 
abundant in cardiomyocytes (25S). On the other hand, miR-31-5p was also vaHdated but is 
mainly expressed m vascular smooth muscle ceUs (259). Of those that could not be 
vaUdated, miR-143-5p and miR-101a-3p have the highest expression in the waUs of the 
aorta and cardiac fibroblasts respectively (260, 261). The specificity' of miR-451 and miR-
150-5p are less defined, both arc known to have a functional role in cardiomyocytes and 
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miR-451 is regulated by G A T A - 4 so it is possible they are cardiomyocyte specific {249, 
262, 263). It is plausible then that if the m i R N A s tested for validation have cell specificity 
then the levels could be variable between samples. The expression of these m i R N A s could 
also be tested in the Wash samples obtained during cardiomyocyte enrichment. This would 
help ascertain if these m i R N A s are altering expression due to enrichment or due to the 
hypertrophic response. The downstream analysis, such as correlation with m R N A levels, 
should concentrate on the m i R N A s that could be validated in the extended cardiomyocyte 
sample set. 
4 . 3 . 3 . B N O V E L M I R N A C H A N G E S IN H Y P E R T R O P H Y 
O f the m i R N A s we found to change expression levels, only three are novel to cardiac 
hypertrophy (miR-143-3p, miR-224-5p and miR-299-5p). This begs the question as to why 
they have not been documented previously? miR-143-3p was previously called miR-143* , 
as it has low expression levels in comparison to miR-143-5p. In our dataset, miR-143-3p 
contributes only 0 .3% o f the tags that m a p to the miR-143 hairpin. miR-143-5p also has 
lower levels in the 7 day T A G samples, but variable expression in the 7 day Sham samples 
resulted m a high F D R . It is known that miR-143-5p has the highest expression levels in 
the heart, and is mos t abundant in the walls o f the aorta and coronarj' vessels {260). miR-
143 is encoded within a cluster along with miR-145, and is regulated by the transcription 
factors S R F and Nkx2-5 {264). Therefore, miR-143-3p would also be under the control o f 
the same transcription factors, and if regulated transcriptionally, would have the same 
localisation as miR-143-5p. Studies thus far have concentrated on the role o f miR-143 in 
vascular smooth muscle ccUs (VSMCs) , where a downregulation of miR-143-5p and miR-
145 results in the de-differentiation, migration and proliferation of V S M C s {260). In a 
previous smdy, the expression of miR-143-5p did not change in the myocardium after T A G 
but did decrease in the aorta immediately upstream and downstream of the T A G site {260). 
The levels o f miR-143-3p were conf irmed by R T - q P C R in the sequencing samples at 48 
hours but could not be validated in the extended dataset. A s mentioned above, this could 
be attributed to the expression being limited to V S G M s . The differences in miR-143-3p 
expression could therefore be due to subtie differences in the purification of the 
cardiomyocyte samples. 
miR-224-5p increases at 7 days, but it is moderately to lowly expressed. It has been 
previously shown to decrease expression in patients with IGM but its role m cardiac disease 
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remains u n k n o w n {12J). It is k n o w n that miR-224-5p is upregulated in several cancer 
types, and it is postulated to play a role in the regulation of apoptosis and proliferation 
{265-267). T h e levels of rmR-224-5p increase after stimulation with T G F - P l in follicular 
cells (266). T G F - P l is upregulated in the heart in response to pressure overload (268) and 
feeds into the M A P K pathway (see section 1.1.2.C). T h e increase in miR-224-5p 7 days 
pos t -TAC could therefore be at tr ibuted to activation of the M A P K pathway. 
miR-299-5p increases at 7 days, bu t it is also moderately to lowly expressed. It was 
previously annota ted as miR-299*, and the other strand miR-299-3p has previously been 
repor ted to increase 7 days pos t -TAC (/iO). However , miR-299-3p has next to no 
expression in our dataset. It is highly Likely that because miR-299-5p and miR-143-3p were 
previously annota ted as the star f o rm of a m i R N A hairpin they were not present on the 
earlier microarrays and thus they have no t been repor ted to date. T h e only hint on the 
funct ion of miR-299-5p is that it controls haematopoiet ic progenitor fate and is 
upregulated in megakan 'oblas ts (the precursor to megakarj 'ocytes that produce platelets) 
{269). 
T h e three novel m i R N A s to be regulated in our study have been missed previously due to 
cell specificit)' and the low expression that may have been confounded in whole LV 
samples. Nevertheless , two of them are linked to signalling pathways that are activated 
during the hyper t rophic response suggesting they are upregulated in response to pressure 
overload. 
4 . 3 . 3 . C C O M P A R I S O N W I T H O T H E R STUDIES 
W e also examined the fold changes for several m i R N A s that have been shown to change in 
one or m o r e previous studies of h}'pertrophy. There were 21 miRNAs that appeared 
unchanged in our dataset or only had slight changes in their expression. There are a 
n u m b e r of reasons why this could be the case. Firstly, the miRNAs may be enriched or 
specific to cell types o ther than cardiomyocytes. For example, members of the miR-
2 3 - 2 7 - 2 4 cluster ate repor ted to be upregulated 7 days pos t -TAC in multiple studies, yet 
the fold changes found in our data are minimal {127, 128, 130). The m i R - 2 3 ~ 2 7 - 2 4 cluster 
IS highly expressed in endotheUal cells and thus the levels of these miRNAs would have 
been reduced during cardiomyocyte enr ichment {270). T h e same appUes for miR-126-5p, 
the miR-30 family and the m i R - 1 7 - 9 2 cluster (that includes miR-20a and miR-92a), which 
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are enriched in endothelial cells or cardiac fibroblasts (271, 272). Therefore, although yet 
undef ined, it is possible that some of the other miRNAs that did not make our cut off for 
statistical significance are derived from other ccU tj'pes in the heart. 
Secondly, there is a difference in the detection of miRNAs depending on the platform and 
the Ubrary preparation used {242). Each library-preparation method preferentially capmres 
a distinct set of miRNAs, therefore some of the miRNAs previously detected may not 
make our thresholds for expression. Finally, the criteria used to defme "differentially 
expressed" miRNAs are not consistent between studies. Some of the earlier studies did not 
apply a statistical threshold but instead used only the fold change as an indication of 
differential regulation {120). Furthermore, another next-generation sequencing study had 
five biological replicates per group and could therefore confidendy detect changes as small 
as 25% {131). It is known that when the number of transcripts, in this case miRNAs, is 
small or the fold changes are small then you need a larger number of replicates to control 
for the FDR {271). It is possible that if we changed the criteria used to dctect differential 
expression, or included more biological replicates for sequencing then we would increase 
the overlap of our data with miRNAs others have previously found to be regulated in 
hypertrophy. 
4 . 3 . 4 M I R N A P R O C E S S I N G V A R I A N T S IN T M E H Y P E R T R O P H I C H E A R T 
This was the first study to document the miRNA processing variants in the hypertrophic 
heart. W e have documented that 97% of miRNAs in cardiomyocytes have some form of 
variation in their processing. Individual examples were identiBed where this processing 
changes during cardiac hypertrophy but broadly speaking there was no wholesale change in 
processing variants. 
4 . 3 . 4 . A A R M B I A S 
Our analysis of m iRNA arm bias identif ied that 82.3% of miRNA hairpins produce mature 
miRNAs predominantiy f rom one strand. Our previous study looking into the miRNA 
population in HL-1 cardiomyocytes found smular results, with 87.5% of miRNA hairpins 
producing one predominant strand {59). W e reported 36 miRNA hairpins with more than 
20% of the tags derived from both strands. Of these, 35 were expressed in HL-1 
cardiomyocytes, of which 26 had more than 20% derived from each strand (55). WhUe 
majority of miRNA hairpms give rise to one strand, the predominant strand in our data is 
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not necessarUy the miRNA strand that has been studied to date. This is because the 
previous view on miRNA processing was that only one miRNA strand from the miRNA 
hairpin was functional and the other strand was degraded. It is now acknowledged that 
both strands of the hairpin are functional and the predominant miRNA strand can change 
{79, 80). This change in view is reflected by miRBase, which dispensed with the 
mamre/miRNA* nomenclature and renamed all miRNAs based on the strand they were 
derived from {82). It is important to determine the predominant strand expressed in the 
biological system of mterest, particularly when looking at the functional or therapeutic 
potential of a miRNA. For instance, miR-9-5p was previously defined as the mature mir-9 
and functional smdies have been performed to elucidate its role and targets in systems 
including the heart. Yet in our data, 67.5% of miR-9 is actually derived from the miR-9-3p 
strand (Figure 4.19). It is known that miR-9-5p directly targets myocardin in the heart to 
suppress the hypertrophic signalling that is stimulated by NFATc3 {141). Additionally, 
several other cardiac related mRNAs were identified as miR-9 targets by a study that 
determined miRNA:mRNA interactions m AGO proteins in the mouse brain {71). Albeit 
m the brain, mRNAs that regulate fibrosis and cardiac contractility were found cross-linked 
with miR-9-5p {71). The targets of miR-9-,3p on the other hand, remain unknown. Strand 
expression is important when knocking out or overexpressing a whole pre-miRNA hairpin 
as you cannot assume that only one strand will be expressed. 
WhUe several miRNA hairpins had miRNAs derived from both strands, we could not find 
evidence that strand preference changed between Sham and TAG. It has been posmlated 
that certain sequence and thermodynamic properties of the pre-miRNA and miRNA 
duplex can mOuence strand selection into RISC {59, 274). For instance, the strand whose 
5'-end is less tightly paired is incorporated into RISC and the highly expressed strand tends 
to have a U-bias at the 5' end {274, 275). These rules however, do not account for the 
strand preference that occurs in certam tissues, miplying that there are additional regulator)' 
mechanisms determining which miRNA strands are predominant m the heart. This lead us 
to speculate if there would be an advantage to switching strands m response to stress or 
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Figure 4.19. T h e role of miR-9 in the heart . 
The sequencing coverage is shown for miR-9-5p ancj niiR-9-3p, with niiR-9-3p being the 
prerJominant strand. The target interactions of both strands are shown below the sequencing 
coverage. Several targets of miR-9-5p have been documented, these targets and the pathways they 
regulate are listed. The solid red line indicates a direct target of miR-9-5p in the heart {141), while 
the dashed lines indicate targets identified from an A G O IP in the murine brain {71). 
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disease. While the targets between the strands is different, it may be more efficient to 
upregulate a m i R N A f r o m a different locus via transcription. Although the strand 
regulation is consistent between Sham and TAG, knowledge about the strands expressed is 
critical for unders tanding the functional role of a m i R N A hairpin. 
4 . 3 . 4 . B 5 ' A N D 3 ' ISOxMIRS 
Approximately 20% of the miRNAs we detected had greater than 20% of their tags derived 
f rom 5' isomiRs, including 13 miRNAs that have previously been studied in hypertrophy. 
O f the 55 miRNAs with greater than 20%) 5' isomiRs, 41 were also expressed in HL-1 
cardiomyocytes, of which 31 were also found to have more than 20% 5' isomiRs (55). It 
has been postulated that Drosha and Dicer cleavage with relaxed specificity is the reason 
behind m i R N A start and end heterogeneity (88, 276, 277). As the miRNA relies on the 5' 
end for targeting specificity, there is an evolutionary pressure to maintain constant 5' ends 
of the m i R N A {57). Consistent with other studies, 95% of miRNAs had variation at the 3' 
end {88, 232, 276)., suggesting that 3' isomiRs may also derive f rom post-processing 
addition a n d / o r t r imming events. In agreement, Drosophila miR-34 has multiple 3' ends that 
result f rom the 3' to 5' exoribonuclease Nibbler tr imming the 3' end while miR-34c is 
within the RISC complex {27S). 
Multiple cardiac miRNAs existed as 5' isomiRs with varv'ing 3' ends. This included miR-
133a-3p, which has been extensively studied in the heart {UQ, 279, 280). The impact of 
these isomiRs on the targeting specificity of iTuR-133a-3p is documented in Chapter Six. 
The length heterogeneit) ' of miR-133a-3p found in the sequencing data was confirmed 
using high resolution Nor the rn blotting. Length variation such as this has been detected 
using Nor the rn blotting for several miRNAs across different cell lines (57). It is important 
to note that the results of the Nor the rn blot conf i rm two major lengths of miR-133a-3p, 
which correspond to the major 5' isomiRs, but the exact sequence of these two lengths 
could not be established with this method . 
Notably, there was n o obvious difference in processing of 5' isomiRs between the Sham 
and the T A C samples. O n e miRNA, miR-125a-5p, had variation in 3' isomiRs between 
samples, with more of the canonical miR-125a-5p 3' end in the TAC samples. As 
ment ioned in the Introduct ion, alteration of the 3' end of a miRNA can alter its loading 
mto specific A G O complexes or its mrnover {62, 92). There is a sUght decrease in the 
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levels of miR-125a-5p in the TAG samples so it is possible the 3' end is altering the stability 
of the miRNA but this remains to be confirmed. In summary, there is evidence for 5' and 
3' isomiRs in several miRNAs but the isomiRs produced remain consistent during the 
cellular stress induced by cardiac hypertrophy. 
4 . 3 . 4 . C N O N - T E M P L A T E D A D D I T I O N S 
Approximately half of the miRNAs in our smdy have low levels of non-templated 
nucleotides in the last two positions of the sequencing tag. This was not confined to just 
lowly expressed miRNAs, which is consistent with a previous study that showed the 
amount of NTAs is not correlated with expression levels {281). As mentioned previously, a 
subset of miRNAs are frequendy modified by A and U addirions, irrespective of their 
expression {28!). In agreement, several of the miRNAs we detected with NTA such as 
miR-143-5p, have similar proportions in other studies (79, 2 i i ) . 
It is important to note that the level of NTA we have detected may be an underestimate. 
There is a 25% chance that the NTA will coincidentaUy match the genomic sequence 
masking any true NTA events. This was explored in a study by Westholm et al., where they 
used mirtrons (miRNAs spliced out of introns independently of Drosha) to examine NTA 
as the exact cleavage position is defined {282). They found that miRNAs with NTA are 
quite abundant once the nucleotides that fortuitously match the genomic sequence are 
accounted for. 
The nucleotide most frequently added in the NCiS data was a U. Llrdiylation is catalysed by 
ZCCHCl 1 and commonly occurs on the pre-miRNA to block the uptake into Dicer, while 
adenylation is catalysed by PAD4 and occurs after cleavage by Dicer {281). You would 
therefore expect a larger proportion of miRNAs to be derived from the 3p arm to have a 
larger proportion of U addition, as this is the 3' end available for uridylaUon in the pre-
miRNA hairpin. We found a sHght preference for uridylation on the 3p arm (9% more than 
the 5p arm), which is consistent with this notion. It has been shown before that an increase 
m U addition on the 3' end of a miRNA results in a decrease in miRNA abundance. 
However, we could only find one example where the proportion of NTA consistently 
changed in the same direction between Sham and TAG {28?). The levels of miR-143-5p 
decrease as the amount of A addition to the 3' end mcreases, implying that an increase in A 
destabilises the miRNA or marks it for degradation. The addition of an A to the mamre 
— inil^^A aecpencing 
miRNA can reduce its ability to interact with AG02 and AG03 (281). In agreement, there 
is a bias towards mono uridylation and away from mono adenylation among miRNAs 
found in AGO complexes {23 i). The binding of a miRNA to the AGO protein stabilizes 
the miRNA, with increasing levels of AGO proteins correlating with increased levels of 
mature miRNAs {284). Therefore, the addition of an A to miR-143-5p may reduce its levels 
m the TAG samples by preventing its incorporation into the RISC complex. 
To conclude, at least 50% of the miRNAs in cardiomyocytes have NTA but in general the 
levels of NTA do not change in the pre- and hj-pertrophic cardiomyocytes. 
4 . 3 . 4 . D I N T E R N A L E D I T I N G 
The other form of posttranscriptional modification we searched for was internal editing of 
the miRNA. RNA editing is common in the murine brain, but our data would suggest that 
A-toT editing in mature miRNAs is incredibly rare in the heart. The editing of pri-miRNAs 
is more common then mamre miRNAs, and can alter their processing by supressing either 
Drosha or Dicer cleavage {P6, 28S). It is possible then that A-to-I editing does occur more 
frequendy in the heart on pri-miRNA segments that do not get cleaved into the mature 
miRNA strand, and thus are not detected in out data. There was one plausible example of 
editing in miR-490-3p. It is conceivable that miR-490-3p is modified at the pri-miRNA 
level, which could hinder the expression of the miRNA. In support of this hj'pothesis, 
niiR-490-3p is lowly expressed in the sequencing library. However, the impact of such a 
modification on the mature miR-490-3p is not clear. There is no correlation between the 
extent of internal editing and the expression levels of miR-490-3p, implying the 
modification is not altering the degradation or stability' of the miRNA. It is possible that 
this base change could alter the targeting potential of miR-490-3p. The editing does not 
occur within the seed region, which is conventionally thought of as the main determinant 
of miRNA binding. However, binding witiun the 3' region of the miRNA can enhance 
target interactions and supplement mismatches within the seed region {28/ .^ Thus, there 
may be subtie differences in the mRNA target spectrum of the internaUy edited miR-490-
3p. 
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4 . 3 . 5 C O N C L U S I O N S 
This a im of this chapter was to analyse N G S data for differential ly expressed miRNAs , to 
detect m i R N A process ing var iants and their regulat ion in cardiomyocytes derived f rom 
control , pre-h^fpertrophic and hypertrophic hearts. This was the first study to examine 
m i R N A different ia l express ion during hypertrophy in purif ied cardiomyocytes , and analysis 
revealed a small number of m i R N A s that are deregulated during the hypertrophic response. 
Importandy , the major i ty of these m iRNAs have been previously reported to change in the 
same direction, suggest ing w e have captured the correct m iRNA changes with our 
approach to differential express ion analysis. 
The most novel aspect of this work is the analysis of m iRNA processing variants. W e 
found ample ev idence of a rm bias, 5' and 3' i somiRs and N T A for cardiac miRNAs . AU of 
these variants provide a mechan i sm to change the sequence and potentially the function of 
a g iven m i R N A locus wi thout changing the genomic sequence. There is a high correlation 
be tween the total trdRNA populat ion and the m iRNAs found within the RISC complex, 
suggest ing that the m i R N A s w e have detected are a lmost entirely a bioactive populat ion 
{131). I detected individual examples that have variable processing in h^'pertrophy but 
overal l there was no wholesa le change in processing. Despite this, the existence of m iRNA 
variants is still vital when determining the m R N A network that one rrdRNA can regulate. 
This ne twork is further compHcated by the processing variants of m R N A s that the miRNA 
interacts with. Chapter Five investigates the differential expression of m R N A transcripts, as 
wel l as 3 'UTR variants that wil l determine the m R N A pool available for m iRNA regulation. 
CHAPTER FIVE 
3' UTRs IN THE MURINE 
HEART 
3' end sequencing 
5 .1 INTRODUCTION 
The number of investigations into 3' UTR usage on a global scale has increased in the past 
five years. The initial studies used microarrays that had a select number of probes against 
alternative 3' UTRs {161, 287). This included one study on cardiac hypertrophy, which 
documented that for the mRNAs observed, there was a tendency towards mRNAs 
becoming shorter in hypertrophy {t6S). However, the microarray reHes on a pnon 
knowledge of the 3' UTRs present in the sample and thus the fuU spectrum of 3' UTRs 
expressed in the heart remain unknown. 
The first study to use next-generation sequencing (NGS) technology to investigate 3' UTRs 
was published in 2010 and used a modified RNA-seq protocol {28S). Since then, a number 
of methods to interrogate the 3' ends of mRNA transcripts with NGS have been 
developed {2S9-292). All of these methods rely on capturing the poly(A) tail at the 3' end of 
the mRNA. Hovi^ever, these methods can also result in internal priming of poly(A) 
stretches encoded within an mRNA transcript which would be detected as a false 3' end. 
To overcome this caveat, another method was published that relies on the ligation of a 
double stranded primer to the 3' end of the poly(A) tail and thus cannot capture internal 
poly(A) stretches {29J). These methods have been used to document the 3' UTRs in 
several cell lines, as well as in mouse and human tissues {289-29J). However, 3' UTRs have 
not been examined using NGS in the heart or during the progression of cardiac 
hypertrophy. 
The aim of this chapter was to sequence the 3' ends of mRNA transcripts from normal, 
pre-hypertrophic and hypertrophic cardiomyocytes. Firstiy, to document the number of 3' 
UTRs for each mRNA transcript, and secondly to establish if the 3' UTRs of these 
mRNAs change during the induction of hypertrophy. To do this we used a 3' sequencing 
protocol with the SOLID^M sequencing platform and developed a biomformatics analysis 
pipeline to annotate 3' ends. 
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5.2 RESULTS 
The RNA extracted from purif ied cardiomyocytes (Chapter Three) was used for NGS of 
m R N A 3' ends. The cardiomyocyte RNA was sent to Dr Traude Beilharz and the libraries 
were created using the PAT-seq method developed by Dr Beilharz at Monash University 
{177). Similar to the method published by Jan et al. (293), this method relies on the 
presence of a single-stranded poly(A) tail and thus wUl only capture the 3' end of the 
poly(A) tail and not internal poly(A) stretches (see Figure 2.3 for details). For full details of 
the method, refer to section 2.2.7. 
5 . 2 . 1 G E N E R A L F E A T U R E S OF I IIE LIBRARY 
The libraries were sequenced on the SOLiD 5500'^" to an average depth of 4.54 x lO' tags 
(up to 75 nt m length), yielding a total of 3.63 x 10" tags (Figure 5 .LA). Dr Hardip Patel 
f rom A N U performed the mapping of the 3' seq libraries, and I completed the secondarj' 
analysis, including filtering, graphical representations and differential expression, using the 
R programming language. The data was then filtered for tags with an average quality value 
greater than or equal to 18 (98% accuracy), which retained 82% of the 3' sequencing tags. 
The filtered tags were mapped directly to the mouse genome assembly mm9 including 
rRNA. Those tags that did not map to the genome were then mapped to mouse 
transcriptome sequences to account for tags that may span exon-exon junctions. All tags 
that did not directiy map to cither genome or transcriptome may contain the beginning of 
the poly(A) tail in the tag. For this reason, the remaining tags were tr immed and the first 21 
nt of the tag mapped to the genome and then extended until the start of a poly(A) stretch. 
The majority of the tags (68%) mapped to the mouse genome, with only a smaU proportion 
that mapped to the transcriptome or contained poly(A) sequences, 2 .7% and 5% 
respectively (Figure 5 .LA) . 
The mapped tags were then merged to form functional units, defined as 3' sequencing 
peaks (3' seq peaks) (Figure 5 .LB) . Overlapping or contiguous stretches of tags along the 
genome with at least one read coverage were merged into 3' seq peaks, resulting in 412 332 
peaks. Each sequencing tag was 75 nt, therefore to remove clonal peaks, the peaks were 
filtered for those that had a length greater than 75 nt which resulted in 169 700 3' seq 
peaks. A min imum threshold was then appUed, considering only peaks with an average 
3' end sequencing 
coverage greater than 10 and the presence in two or more samples, which resulted in 106 
869 3' seq peaks. This min imum threshold was used for all subsequent analyses. 
• R a w tags » Genome mapped lags • Transcript mapped tags 
• QV 2 18 » Poly(A) extended mapped tags 
B 
Genome 
75nt 
3' seq tags aligning 
to genome 
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Continuous stretch of 75nt 3' seq tags 
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Genome 
Figure 5.1. Alignment of 3' seq tags. 
(A) Number of raw tags, number of tags with quaUty value > 18, genome mapped tags, transcript 
mapped tags and poly(A) extended mapped tags. S, Sham; T, TAG; QV, quaUty value (B) Defining 
3' seq tags; a continuous stretch of 75 nt 3' seq tags with at least one tag coverage were merged into 
3' seq peaks representative of 3' UTR ends. 
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The 3' seq peaks were then assigned to genomic features using the canonical transcripts 
defined in Ensembl v67 (Figure 5.2). Peaks that did not overlap a known gene and were 
further than 20 kb downstream from the closest gene were annotated as Orphan peaks 
(Figure 5.2.B). The peaks that overlapped a known gene were annotated based on their 
location relative to the annotated stop codon or canonical transcript end. Peaks located 
upstream of the stop codon were termed Exon or Intron peaks respectively (Figure 5.2.C-
D). Peaks located within 20 kb downstream of a stop codon or transcript end were defined 
as downstream peaks (Figure 5.2.A). The breakdown of peak annotations is shown in 
Figure 5.3. 35% of 3' seq peaks are annotated as downstream peaks (Figure 5.3.A). Non-
coding RNAs known to undergo polyadenylation, such as lincRNAs and miRNAs, 
represent a small portion of peaks {294, 295). 90.6% of downstream peaks are associated 
with the y UTR of protein coding mRNAs, referred to from now on as 3' UTR peaks 
(Figure 5.3.B). 
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Figure 5.2. Strategy to annotate 3 ' sequencing peaks. 
Peaks were annotated as a Downstream peak if (i) the peak overlapped a known gene and was 
downstream of the stop codon or the peak was within 20 kb downstream of a stop codon for 
protein coding transcripts or the transcript end for non-coding RNAs. (ii) the peak overlapped an 
intron on the opposite DNA strand and was within 20 kb downstream of a stop codon or 
transcript end. (B) Orphan peaks were defined as those that did not overlap with a known genomic 
feature and were more than 20 kb downstream of a stop codon or transcript end. (C) Exon peaks 
were defined as those peaks that overlapped with an exon of a known gene but upstream of the 
stop codon or transcript end. (D) Intron peaks were defined as those that are (i) withrn an intron 
on the same strand of the DNA or (ii) within an intron on the opposite strand of the DNA and 
greater than 20 kb downstream of a stop codon or transcript end on the same strand. The red 
arrows indicate the direction of the DNA strand. CDS, Coding region; 3' UTR, 3' untranslated 
region. 
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Figure S.3. Annotation of 3 ' sequencing peaks. 
(A) Proportion of 3' sequencing tags that were assigned as Orphan peaks, Intron peaks, Exon peaks 
and Downstream peaks. (B) Distribution of 36 994 Downstream peaks across genomic features. 
Data IS shown as the sum of all eight sequencing Libraries. 
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5 . 2 . 2 F E A TURES OF P O L Y A D E N Y L A T I O N 
Once the 3' peaks had been categorised, we looked for features of polyadenylation. Due to 
the nature of polyadenylation and the library preparation, it was expected that some of the 
peaks would contain the beginning of the poly(A) tail (Figure 5.4.A). For instance, as 
RNAse T1 was used to digest the RNA, the cleavage site from the start of the poly(A) tail 
is variable as shown in Figure 5.4.A. Figure 5.4.B-C shows the proportion of peaks that 
contain a stretch of A's at the 3' end of the peak, for all peaks (5.4.B) or those peaks 
associated with protein coding 3' UTRs (5.4.C). A higher proportion of 3' UTR peaks 
contain evidence of a poly(A) tail compared to all of the 3' seq peaks. 
We also looked for the presence of the polyadenylation signal (PAS) in the 3' seq peaks. 
The conser\'ed canonical PAS (AAUAAA) or single-nucleotide variants, defined as a non-
canomcal PAS, are the main signals used to determine the site of cleavage and 
polyadenylation {160). The canonical PAS was searched for within 50 nt upstream of the 
poly(A) for peaks containing the poly(A), or within the 3' seq peak and 50 nt downstream 
of the 3' end of the peak for peaks without poly(A). Peaks without the canonical PAS in 
this region were interrogated for the presence of a non-canonical PAS. 69% of 3' seq peaks 
contain either the canonical PAS or one of the twelve non-canonical PAS variants. This 
proportion increases to 76% when considering only the peaks associated with protein 
coding 3' UTRs. 
The peaks were then split further into those containing poly(A) stretches and those without 
poly(A) stretches. The breakdown for poly(A) contaimng peaks and polyadenylation signals 
is shown m Table 5.1. The peaks contaimng evidence of a poly(A) tail had a higher 
proportion of tags with either the canonical or a non-canomcal PAS. The most likely 
reason for this is that the region to search for the PAS m those peaks contaimng a poly(A) 
stretch is weU defined, whereas the PAS for those peaks without a poly(A) stretch may be 
further downstream of the peak and thus the PAS was not detected. Despite this, between 
65% and 80% of peaks contained either a poly(A) stretch and/or a PAS. 
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Figure 5.4 Polyadenylation features are enriched in peaks associated with protein 3' UTRs. 
A) Variation in the RNAse T1 digestion site can change the distance of the tag start site to the 
poly(A) taU. (B-C) The proportion of peaks that contain evidence of a poly(A) tail at the 3' end of 
the peak in total peaks (B) or protein 3' UTR peaks (C). (E-F) The proportion of peaks that contain 
the canonical PAS or non-canonical PAS in total peaks (E) or protein 3' UTR peaks (F). 
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Table 5.1. Proportion of peaks containing evidence of a poly(A) tail, canonical and non-
canonical PAS. 
Canonical 
PAS (%) 
Non-
canonical 
PAS (%) 
No PAS (%) 
Peaks with 
a poIy(A) 
feature (%) 
Total peaks 106869 36,05 33.10 32.00 
Poly(A) peaks (%) 19.75 57.29 35.56 12.91 70.55 
No polv(A) (%) 80.25 30.82 32.49 36.69 
Biotype associated peaks 36994 42.71 32.19 25.10 
Poly(A) peaks (%) 40.27 59.57 30,06 10.37 79.07 
No poly(A) (%) 59.73 31.34 33,62 35.04 
Orphan peaks 28487 35.30 29.21 35.49 
Poly(A) peaks (%) 9.85 53.26 29.32 17.42 66.22 
No polv(A) (%) 90.15 33.34 29.19 37.47 
Intron peaks 37470 31,49 32.67 35.84 
Poly(A) peaks (%) 6.91 52.14 28.33 19.53 65.51 
No poly(A) (%) 93.09 29.96 32.99 37.05 
Exon peaks 3918 22.05 43.06 34.89 
Poly(A) peaks (%) 20.83 45.83 31.37 22.79 69.86 
No poly(A) (%) 79.17 15.80 46.13 38.07 
Protein 3' UTR peaks 33507 43.07 32.59 24.35 
Poly(A) peaks (%) 42.87 59.79 30.13 10.08 79.97 
No poly(A) (%) 57.13 30.52 34.43 35.05 
peaks with or without evidence of poly(A) tall are listed below. The proportion of tags that contain 
a canonical PAS, non-canonical PAS or no PAS are Usted in the rows, with breakdowns for the 
total peaks, poly(A) peaks and no poly(A) containing peaks. The right hand row documents the 
proportion of tags that contain a poly(A) signature and/or a PAS. 
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5.2.3 P E A K S 7\.SSOCIATED WITH 3' UTRs 
One of the main aims of this thesis was to look at the 3' UTRs of m R N A transcripts and 
alternative polyadcnylation. Therefore, the remainder of the analysis on 3' scq peaks was 
restricted to those peaks associated with the 3' UTRs of protein coding genes (termed 3' 
UTR peaks). As ment ioned above, 43% of 3' UTR peaks contain evidence of the canonical 
PAS. The location of the PAS relative to the 3' UTR peak was then determined. As 
discussed in section 1.1.3, a number of sequence elements determine cleavage and 
polyadenylat ion (Figure 5.5.A). This includes the PAS which is located 10-35 nt upstream 
of the poly(A) cleavage site {148), U-rich elements upstream and around the cleavage site 
and a GU-rich DSE (reviewed in {160)). While all of these elements contribute to and 
enhance cleavage and polyadenylation, the PAS is the dominant signal {160). Therefore, we 
determined the location of the PAS relative to the start of the poly(A) stretch or the end of 
the peak for those 3' peaks without evidence of a poly(A) stretch. The canonical PAS was 
found predominantly 17.5 nt upstream of the end of the 3' seq peak, which is within the 
expected region of the PAS(Figure 5.5.B.i). The signal is also found at low levels beyond 
the peak, which can be attributed to those peaks without a poly(A) stretch where the 
poly(A) cleavage site may be further downstream. In agreement, a higher proportion of 
peaks arc located 16 nt upstream of the start of the poly(A) stretch (Figure 5.5.B.ii). 
W e next looked at the peaks that did not contain the canonical PAS, but one of the 12 
non-canonical PAS (Figure 5.6.A) {160). For aU protein 3' UTR peaks, the second most 
abundant PAS was A U U A A A , which is consistent with a previous study that documented 
mouse PAS {160). When we considered the peaks with and without a poly(A) stretch 
separately, A U U A A A was the more predommant PAS in peaks with a poly(A) (Figure 
5.6.C), while A A G A A A was the most frequent PAS in peaks without a poly(A) stretch 
(Figure 5.6.B). As for the canonical PAS, the distance of the non-canonical PAS from the 
peak end or poly(A) stretch was then determined. When considering aU protein coding 
peaks, A U U A A A has a predominant peak between 10-25 nt upstream of the peak end, 
whae A A G A A A has a peak that centres around 0. Agam, the location of the PAS is more 
obvious m the peaks that contain a poly(A) stretch, where most PAS variants have a peak 
m the expected location, with the exception of UUUAAA that centres around the start of 
the poly(A) tail. 
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Figure S.S. Canonical PAS is found at the expected position from the cleavage site. 
(A) Schematic of sequence elements that surround the poly(A) cleavage site. Modified from ( / i9) . 
(B) The location of the canonical PAS (AAUAAA) in peaks that contain the canonical PAS. (i) The 
density of the canonical PAS from the end of the 3' seq peak, (ii) The densitj' of the canonical PAS 
from the start of the poly(A) in peaks that contain evidence of poly(A) taU. The density is a 
proportion, with the area under the curve equal to 1. 
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Figure 5.6. Non-canonica l PAS in protein coding associated peaks. 
(A) The proportion of non-canonical PAS in protein coding associated peaks that do not contain 
the canonical PAS. (B-C) Breakdown of non-canonical PAS in protein coding peaks with (C) and 
without (B) evidence of a poly(A) tail. (D) The location of non-canonical PAS in all protein coding 
associated peaks. (E) The location of non-canonical PAS in protein coding associated peaks that 
contain a poly(A) tail. The density is a proportion, with the area under the cur\'e ecjual to 1. 
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W e next analysed the 3' UTR peaks for their association with mRNAs. On average, one 
m R N A transcript was associated with 2.35 3' seq peaks representing individual 3' UTRs 
(Figure 5.7.A). Despite al lowing a distance of 20 kb downstream of a stop codon, more 3' 
seq peaks occurred closer to the stop codon, with a mean distance of 3.7 kb, median 
distance of 1.6 kb and the max imum peak density at approximately 350 nt downstream of 
the stop codon (Figure 5.7.B). 
To determine how many novel 3' ends were in our dataset, the 3' seq peaks were compared 
to the transcript coordinates in Ensembl v67. A 3' seq peak was considered a known 3' end 
if the peak overlapped the last exon of a transcript and the 3' end of the peak was within 
100 nt of the end of the transcript (Figure 5.7.C). 34% of 3' seq peaks aligned with a 
known 3' end and were annotated as known 3' UTRs. 37% did not overlap with a known 
3' UTR, and the remaining 29% overlapped the last exon of a transcript but were further 
than 100 nt away from the known 3' end, representing shorter 3' UTRs. These 3' UTRs 
represent novel 3' ends. The 34% of tags that aligned with a known 3' end accounted for 
69% of the tags, suggesting a tendency of highly expressed 3' UTRs to already be 
annotated. 
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Figure 5.7. Major i ty of protein cod ing transcripts have mult iple 3' ends. 
(A) T h e n u m b e r of transcr ipts wi th 1-8 3 ' U T R s is plotted. (B) The locat ion of peaks f rom the stop 
codon in prote in cod ing transcr ipts . T h e Peak densit) ' is a proport ion , wi th the area under the cun ' e 
equal to 1. (C) Ass ign ing peaks to k n o w n 3' ends ; peaks over lapping a known 3' U T R and with in 
100 nt f r o m a k n o w n transcr ipt end were annota ted as K n o w n 3' UTRs . Peaks that over lap the 3 ' 
U T R but we re fur ther than 100 nt f r o m the transcript end are Shorter 3 ' UTRs , and peaks that do 
not over lap the 3 ' U T R were annota ted as Longe r 3 ' UTRs . 
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5 . 2 . 4 C A R D I A C M R N A S W I T H M U L T I P L E 3 ' E N D S 
Firstly w e wan ted to establish the static picture of m R N A 3' UTRs. In particular, the 3' 
U T R status of m R N A s impl icated in cardiac hypertrophy. 803 genes related to cardiac 
hyper t rophy were col lected f rom the GeneCards database {29(i). Of these, 652 could be 
detected in our sequencing data. The number of 3' seq peaks associated with each gene ID 
was then calculated. Similar to the overall dataset, on average each gene had 2.65 3' ends 
(Figure 5.8). Flowever, this list was fdtered further by looking only at 3' seq peaks that 
contr ibuted at least 10% of the tags towards the m R N A transcript. In doing so, the average 
number of 3' ends per gene was reduced to 1.44, indicat ing that a large number of 3' seq 
peaks contr ibuted only a small proport ion to the whole m R N A transcript (Figure 5.8). 
Table 5.2 summar ises the number of 3' U T R s for the detectable genes associated with 
cardiac hypertrophy. Cardiac hypertrophy genes that contain one or more novel 3' ends are 
highl ighted in blue in Tab le 5.2. Notably , for some of the genes with only one 3' end this 3' 
U T R is novel . It is important to note that if the peak did not overlap with a known 3' UTR 
it wa s considered novel regardless of its distance to the closest upstream transcript end 
(Figure 5.7.C). Examples of cardiac hypertrophy related m R N A s with two, three or four 3' 
ends are i l lustrated in Figure 5.9. For the m R N A s visually inspected, the novel 3' UTRs 
tend to be shorter than the annotated 3' UTR. 
11 Coverage >10 
H 3'peak contributing >10% 
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Number of 3 'UTRs 
Figure 5.8. Number of 3' UTRs for cardiac hypertrophy associated genes. 
The number of cardiac hypertrophy genes with 1-10 3' seq peaks, which represent individual 3' 
UTRs. Data is shown for aU 3' seq peaks associated with cardiac hypertrophy genes (blue) or only 3' 
seq peaks that contribute more than 10% to the mRNA. 
3' end sequenciiij. 
Table 5.2. The number of 3' UTRs for mRNAs associated with cardiac hypertrophy. 
The number of 3' UTRs is based on peaks with a coverage >10, presence in more than 2 samples 
and contribution of greater than 10% to the mRNA transcript. Genes highlighted in blue indicate 
that the gene has one or more novel 3' ends. 
One 3' UTR 
Abcg2, Abra, Acadm, Acadvl, Acta l , Acta2, Actb, Actc l , Actg2, Actn2, Ada, Adcy3, Adcy6, 
Adipoq, Adk, Adm, Adra lb , Adra2a, Adra2c, Adrb3, Agk, Agt, Agtrla, Ai fml , Akapl , Akapl3, 
Akt l , Aldh2, Ankrdl , Ankrd2, Anxa5, Apoal , Atf2, Atf3, Atf4, Atp2al , Atp2a2, Atp2a3, Bakl , 
Bcar l , Bdkrb2, Bglap, Bmpl , BmplO, Bmp4, C3, Cabinl , Cacnala, Cacnalb, Cacnalg, Cacnalh, 
Cacnals , Cacna2dl , Cacna2d2, Cacnb3, Cacngl , Cacng2, Cacng4, CacngS, Cacng7, Calcrl, 
Calm2, Calr3, Camkl , Camk2g, Camk4, Camta2, Casp9, Cat, Cavl , Cav3, Cck, Cdk7, Cdknlb, 
Cflar, Chkb, Chrm2, Ckm, Ckmtlb , Cmal , Cntf, Co l l a l , Col3al, Conn, Cox6c, Cpe, Creb3, 
Creb314, Cr>'ab, Cs, Csk, Csrp3, Cst3, Ctgf, Ctnnbl , Ctsl l , Cxcr2, Cyba, Cybb, Cycs, Cyp l9a l , 
C y p l b l , Cyp2el , Ddah2, Des, Duspl , Ecel , Edf l , Ednl , Ednra, Egf, Egfr, Egrl , Eif2bl, 
Eif2b2, Eif2b4, Eif2b5, Eno2, Ep300, Epor, Eprs, Erbb2, Esrrg, F2rll , Fabp3, Fgf9, Fgfr2, 
Fgfr3, Fhl l , Fkbp4, Flnb, Fn l , Fos, G6PD, Gaa, Gadd45b, Galr2, Gas6, Gast, Gata4, Gata6, 
Gca, Gdf l , Ghl , Ghr, Gja l , Glrx3, Gnal2, Gnal3, Gnai l , Gnai3, Gnb2, Gnb3, Gng3, Gng4, 
Gpbar l , G p r l l 9 , Gprc6a, Gpsm2, Gsk3a, Gstpl , H2afz, Mandl, Iland2, Ilbegf, Hcn2, Hcn4, 
Hdacl , HdaclO, Hdac l l , Hdac2, l ldacS, Hdac6, Hdac7, Hdac8, Hdac9, I l ey l , Hey2, Hgf, 
Hmgal , Hmoxl , Hnf la , Hopx, Hp, Hsf l , Hspa4,1 IspaS, Hspbl, Hspb8, Iltr2a, Htr2b, Igfl , 
Igf2, lgfbp3, Ikbkb, 1111, 1115,114R, 116st, InppSf, Ins, Insr, Irsl , Itgal, ltga2, ltga2b, ltga3, ltga4, 
ItgaS, ltga6, ItgaS, Itgav, Itgax, Itgbl, l tgblbp2, ltgb2, ItgbS, ltgb6, ItgbT, ItgbS, Itpr2,jak3, 
Jph2, Kat2b, Kcnh2, Kdm4a, l<lfl5, Ivritl, Lama2, Lect l , Lepr, Lmcdl , Lmna, Lpl, Map2kl, 
Map2k5, Map3k l l , Map3kl2, Map3kl3, Map3kl4, Map3k4, Map3k5, Map3k6, Mapk l l , 
Mapkl2, Mapkl3, Mapkl4, Mapk3, Mapk4, Mapk6, Mapkapk3, Met, Mgp, Mkks, Mkl l , Mkl2, 
Mme, Mmp2, Mmp3, Mterf, Mtor, Mybpcl , Mybpc2, Mybpc3, Myef2, Myh6, Myh7, Myl3, Myl4, 
Mylk2, Myocd, Myog, Myot, Myoz2, Nedd4, Nes, Nexn, Nfatcl , Ngf, Nisch, Nppa, Nppb, 
Nppc, Npr l , Nr lh2 , Nr3c2, Nras, Nrg l , Nripl , Ntrk3, Nuprl , P2rx4, Pcna, Pdela, Pdelc, 
PdeSa, Pdgfrb, Pdhal , Pik3r2, Pik3r3, Pik3r4, Pitx2, Plat, Plcd4, Plcel, Plcgl, Plcg2, Plcll, Pld2, 
Pnkd, Polrlc, Pome, Ppara, Ppard, Pparg, Ppbp, Ppig, Ppp2r4, Ppp3cb, Ppp3cc, Ppp3rl, Prkabl, 
Prkaca, Prkarlb, Prkar2b, Prkcb, Prkcd, Prkch, Prkcz, Prkgl , Psmc4, Ptgsl, Pthlh, Ptk2b, 
P tpn l l , Rac2, Rac3, Ramp2, Ramp3, Rapgef3, Rcanl, Retn, Rgs2, Rgs4, Rhod, Rnls, Rockl , 
Rps27a, Rrad, Rras, Ryr2, SlOOal, Scarbl , Sdhb, Selp, Serpinel, Setd2, Sfn, Sfrp2, Shbg, Shcl , 
Sirt l , Slc29a2, Slc2al, Slc2a4, Slc9al, Sin, Smad3, Smnl , Socs3, Sodl , Sosl , Sos2, Sox4, Spon2, 
Sppl', St3gal4', Stat3, Stkl 1, T a d , Tbpl2, Tcap, Tfb lm, Tgfa, Tgfb3, Tgfbrl , Tgfbr3, Thbsl , 
Timpl , Tkt, Tnc, Tnf, Tnfaip3, Tnf r s f l l b , Tnfrsf la , Tnncl , Tnni3, Tnni3k, Tnnt2, Tpml , 
Tpm4, Trapl , Trim63, Trpc3, Trpc6, Ttn, Ttr, Tubb, Txn, Txnip, Ubtf, Vcaml , Vcl, Vegfa, 
Vegfb, Vim, Vip, WntSa, Xdh. Xirpl , Ywhag, Zfpm2 
Two 3' UTRs 
Abcc9, Ablim3, Acadl, Ace, Actg l , Actnl , Adaml7 , Adrala , Alir, Ak l , AkapS, Akt2, Apln, 
Aplnr, Asph, At f l , Atp2b4, Bmp6, Braf, Cacnalc, Cacnbl , Cacnb2, Cacnb4, Calml, Calm3, 
Camk2b, Camk2d, Camp, Casq2, Cast, Ccl2, CD36, CDC42, Cdh2, Cdk9, Cdkn3, Chka, Cntfr, 
Crebl , Crebbp, Cregl , Ctf l , Dmd, Duspl9, Ednrb, Eif2b3, Eif4e, Eif4ebpl, Elkl , Eln, Enppl , 
Erbb3, FbUml, Fbxo32, Fgf l , Fgf23, Fgfr l , Fgfr4, Fkrp, Foxol , Gal, GdflS , G n a l l , Gnai2, 
Gnaq, Gnb l , Gnb5, Gng2, Grb2, Grk5, Hdac3, Hdac4, Hdc, l i fe , Hmgcr, Hras, Idua, 111b, 116, 
ItgalO, ltgb4, Jak2, Junb, KcnjS, Lgals3, Lifr, Lparl , Lrp6, Map2k2, Map2k3, Map2k4, Map2k6, 
Map3kl , Map3kl0, Map3k3, Map3k7, Map3k8, Mapkl , MapklO, Mapk8, Mapk9, Mapkapk2, 
Mef2a, Mef2c, Mef2d, Mras, Mstn, Mthfr, Mtpn, Myc, Mylk, Mylk3, Nfatc4, Nfkbl , Nkx2-5, 
Nos2, Npr2, Npr3, O d d , OsbpB, Osm, Parpl , Pdgfa, Pdgfra, Pdkl , PdlimS, Pdpl , Pdpkl, 
Pik3ca, Pik3cb, Pik3rl , Plcb2, Plcb4, Pldl , Pin, Pol2rl, Ppargcla, Prkaal, Prkacb, Prkag2, 
Prkarla, Prkar2a, Prkce, Prkci, Prkcq, Pten, Ptgs2, Ptp4a3, Pxn, Racl , Raf l , Rgs5, Rhoa, 
Rps6kal , Rps6ka5, Rras2, SlcSal , Smad2, Smad4, Sp3, Srf, Stat6, Tagln, Teadl , Tfam, Tfe2m, 
3' end sequencing 
Table 5.2 cont. The number of 3' UTRs for mRNAs associated with cardiac hypertrophy. 
The number of 3' UTRs is based on peaks with a coverage >10, presence m more than 2 samples 
and contribution of greater than 10% to the mRNA transcript. Genes highlighted in blue indicate 
that the gene has one or more novel 3' ends. 
Two 3' UTRs 
Tgfb l , Tgfbr2, Thbs2, Thra, Timp2, Trdn, Twf l , Ubc, Uts2r, Vdr, Wt l , Yes l , Ywhaq, Yy l 
Three 3' UTRs 
Ace2, Acp l , Adra ld , Ape, Atf6, Camk2a, Ccnd2, Cptla , Csnk l a l , Erbb4, F2, F2r, Fgf2, Foxpl, 
Fzd4, Gla, Glial, Gnb4, Heximl, ld2, IftSl, ltga9, Itprl, J ak l , Jun, Map3k2, Myl2, Nahl , Pde4a, 
Plcb3, Plxna2, Prkca, Prkdl , Rock2, Rps6kbl , Scn4a, Soatl , Sp l , Tead4, Zbtbl6 
Four 3' UTRs 
Gsk3b, Igflr, Itgal 1, Ppp3ca, Prkaa2, Ptk2, SmcS, Tgfb2, Vcaii 
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Figure 5.9 Cardiac m R N A s with multiple 3' ends. 
Schemaucs of the annotated 3' U T R and 3' seq peaks are sliown for some cardiac mRNAs with 
two, three or four 3' seq pealcs. The darli blue boxes represent the annotated 3' UTRs, with the 
location of the 3' seq peaks indicated above by the red Unes. Peaks that contained a poly(A) tall are 
indicated by the green Une, Each 3' UTR represented by the 3' seq peak is drawn below, with their 
corresponding tag count on the right. The coloured bars represent the canonical or non-canomcal 
PAS. 
3' end sequencing — 
5 . 2 . 5 V A L I D A T I O N OF M R N A S WI TH MUI/I IPLF. 3 ' ENDS 
The 3' ends of several cardiac mRNAs were mapped by an independent 3' RACE method. 
cDNA was made using a TvN anchor, which captures the end of the mRNA at the point 
where the poly(A) tail begins. This is achieved by twelve T's, followed by a G,A or C and 
then any nucleotide. After reverse transcription, PGR is performed using a reverse primer 
that detects the anchor sequence and a forward primer specific to the 3' UTR of interest. 
The PGR products were size selected and then subjected to conventional sequencing. Rina 
Soetanto from the A N U performed the validation of 3' ends. 
Six genes with multiple 3' UTRs were tested. Of these, all of the 3' ends detected with 3' 
sequencing could be validated using conventional sequencing (Figure 5.10). The fuU 
sequences are listed in Appendix 8.10. The transition point into a poly (A) tail found in the 
conventional sequencing data were within the locality of the poly(A) tail as determined by 
NGS. In some cases, if multiple poly(A) start positions were present in the 3' seq peak then 
not all cleavage sites were confirmed with conventional sequencing. This is most Hkcly 
because only a small number of clones were used for analysis. One peak, GDC42 Peak 1, 
did not contain evidence of a poly(A) tail in the 3' sequencing data (Figure 5.10.D). As a 
result, the conventional sequencing maps the beginning of the poly(A) tail slighdy 
downstream of the 3' seq. To summarise, the location of the 3' seq peak could be validated 
for all mRNAs investigated. Furthermore, the cleavage sites present in the 3' sequencing 
data were often visible using conventional sequencing. 
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Figure 5.10. Validation of 3' ends detected with 3' sequencing. 
Schematics of the annotated 3' UTR and 3' seq peaks for validated niRNAs are shown (A) SPARC, 
secreted protein, acidic, cysteine-rich (B) SRF, serum response factor (C) USF2, upstream 
transcription factor 2 (D) CDC42, cell division cycle 42 (E) GSK3B, glycogen synthase kinase 3 
beta (F) MTUSl , microtubule associated tumor suppressor 1. The dark blue boxes represent the 
annotated 3' UTRs, with the location of the 3'seq peaks indicated above by the red lines. Peaks 
containing a poly(A) tail are shown by the overlapping green line. Each 3' UTR represented by the 
3' seq peak is drawn below, with their corresponding tag count on the right. The coloured verucal 
bars represent the canonical (green) or non-canonical (purple) PAS. The Yellow lines indicate the 
area that was validated by conventional sequencing and contained a poly(A) stretch. The region 
validated by conventional sequencing is zoomed, showing the genomic sequence (blue) and the 
sequence found by conventional sequencing (yellow). The number of clones supporting each 
transition is shown to the left. The red triangle indicates the predominant cleavage site found in the 
NGS, and the grey triangles represent minor cleavage sites. Con seq clone; conventional sequencing 
clone. 
3' end sequencing 
5 . 2 . 6 3 ' S E Q D A T A AS P R O X Y F O R G E N E E X P R E S S I O N 
Prior to looking at changes in 3' U T R usage, the 3' seq data was used as a measurement for 
overall differential gene expression. In order to get the overall expression for each m R N A 
transcript, the protein coding 3 ' U T R peaks associated with the same gene I D were added 
together (Figure 5.11.A). T h e 33 507 peaks associated with protein coding genes were 
merged to give 14 2 3 2 expressed genes. T h e contribution o f individual genes is shown in 
Figure 5.1 l . B . Noticeably, there is a larger range in the expression values o f the m R N A s 
compared to the m i R N A data (see Figure 4 .3 .D) . T h e top expressing m R N A , Cox2, 
contributed 6 . 9 % o f aU the protein coding tags (Figure 5 .10 .B) and the top 20 m R N A s 
contribute 3 2 . 7 % o f tags. In fact, the top 1000 m R N A s contribute to 8 7 % o f the tags. 
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Figure S . l l Merging 3 ' seq peaks for gene expression analysis. 
(A) The tag counts for 3' seq peaks associated with the same gene ID were added together to 
generate total coverage for a gene. (B) Distribution of tag counts across the one thousand most 
abundant mRNA transcripts. ContribuUon of individual mRNAs to total tag count (green), or 
cumulative tag contribution (blue) is plotted against the ranked mRNA abundance. 
i nd sequencing 
5 . 2 . 6 . A N O R M A L I S A T I O N OF M R N A S 
The same 'trimmed mean of M-values' (TMM) normalisation method used for the miRNA 
sequencing was applied to the merged 3' seq data (See section 4.2.3 for further details). 
TMM normalisation and downstream use of the edgeR package has been applied to RNA 
sequencing data in a number of studies [296-299). Figure 5.12 shows multi-dimensional 
scaling plots (MDS) for the 8 cardiomyocyte samples showing CPM and the TMM 
normalised samples. As mentioned in Section 4.2.3, the distances in the MDS plots are a 
reflection of the similarities between samples. After normalisation, the Sham and TAG 
samples are separated more by Dimension 1 (Figure 5.1 l .A). The normalisation factors for 
the 3' seq peaks range between 0.9-1.1, indicating that the libraries are fairly similar in 
composition (Figure 4.5.A.iii). This is reflected by the Spearman correlation, with the 
lowest correlation value of 0.73 occurring between '7 Sham 2' and '48 TAG 1'. Hierarchical 
clustering groups three of the TAG samples together, while 7 TAG 1 is clustered with three 
of the Sham samples. Interestingly, the 7 Sham 2 sample is a separate cluster from the rest 
of the samples, indicating that the expression profile from this sample is dissimilar 
compared to the rest. The percentage of rod shaped cardiomyocytes, as well as the 
expression of the fibroblast and cardiomyocyte markers in the 7 Sham 2 sample were 
equivalent to the remaining samples used for sequencing, suggesting that the 
cardiomyocyte enrichment is not the reason for a difference in mRNA expression (Table 
3.2). 
5 . 2 . 6 . B D I F F E R E N T I A L E X P R E S S I O N 
To detect genes that are differentially expressed between the TAG banded animals and the 
controls, pairvvise comparisons were made between biological replicates using the edgeR 
package {1&2). The data was filtered to retain the top 98'"' percentile of mRNAs, leaving 
approximately 6000 transcripts for analysis. Pairwise comparisons between 48 hour Sham 
vs TAG and 7 day Sham vs TAG were performed to determine differentiaUy expressed 
mRNAs. In total, 776 mRNAs were differentiaUy expressed with a FDR of less than 10% 
(Figure 5.13). The detaUs for the normaHsation and differential expression analysis are 
avaUable m Appendix 8.11. The data was then divided into subsets based on direction of 
regulation and the time point, as shown in Figure 5.14. There were 469 mRNAs 
upregulated, with the majorit)' (333 mRNAs) bemg regulated only at the 48 hour time 
point. 81 mRNAs were upregulated only at 7 days and a smaU proportion (56 mRNAs) 
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F i g u r e 5 .12 N o r m a l i s a t i o n o f m e r g e d 3 ' s e q p e a k s . 
(A) M D S plot for merged 3 ' seq peaks expressed as C P M and (B) after normalisation using T M M . 
(C) T h e size o f each Ubrary and T M M normaUsation factor. (D) Heatmap o f each sample based on 
the Spearman correlation. 
3' end seqi 
were upregulated at both 48 hours and 7 days. In comparison, 303 m R N A s were 
downregula ted , wi th 233 be ing regulated only at the 48 hour t ime point. A small number of 
m R N A s were downregu la ted at 7 days (37 m R N A s ) or at both time points (37 mRNAs) . 
T o summar ise , the majority of m R N A transcripts were regulated at 48 hours, with a larger 
proport ion increas ing in express ion. 
T o start to discern the biological pathways that these m R N A s regulate, gene ontology 
(GO) enr ichment was pe r fo rmed using the database for annotation, visualisation, and 
integrated discovery (DAVID)(/ ,y i ) . GO-te rms are grouped into three ontologies: 
biological process , cel lular component and molecular function {300). A molecular function 
descr ibes the activity of the gene at the molecular level, for example transporter activity. 
The biological process is a series of molecular functions. For instance, signal transduction 
is a broad biological process . The data was interrogated for enr ichment of biological 
processes , molecular funct ion, cellular component and K E G G pathways using the top 
9 8 % of m R N A s as the background. GO-terms with a FDR less than 30% were considered 
signif icant and are listed in Append ix 8.12. The enr ichment within each GO-term category 
was related to the same pathway or function, so for ease of interpretation the Biological 
processes are presented. The m R N A s were first split into those upregulated or 
downregulated regardless of the t imepoint (Table 5.3). The main GO-terms enriched in the 
upregulated transcripts are those involved in actin f i lament processes, translation and 
adhesion. Converse ly , the majority of the GO-terms enriched in the downregulated 
transcripts arc l inked to fatt>' acid and lipid metabol i sm and oxidation reduction. SLx genes 
related to the regulat ion of heart contract ion are also downregulated. 
The hea tmap was then broken down into the subgroups il lustrated in Figure 5.14 to 
estabUsh the biological processes that may be specif ic to certain time points fTable 5.4). 
The m R N A s upregulated at 48 hours are involved in translation and the actin f i lament 
processes. The upregulated m R N A s at 48 hours are drivmg the enr ichment of these 
processes when consider ing aU of the upregulated transcripts. The 7 day upregulated 
transcripts are involved in ceU adhes ion but also introduce another term, proteolysis, which 
is the breakdown of proteins. Interestingly, when considering the m R N A s that are 
upregulated at both time pomts , numerous terms involved in angiogenesis and blood vessel 
deve lopment become signif icant. 
3' end sequencuig 
The m R N A s downregulated at 48 hours are enriched for the same GO-terms when 
considering all of the downregulated transcripts, just with a slighdy smaller number of 
genes contributing to each GO-term. For instance, fatty acid metabolic process and lipid 
catabolic process remain the GO-terms with the lowest FDR. In contrast, no biological 
processes had a FDR less than 30% for the 7 day downregulated transcripts. There were 
only 37 transcripts that were downregulated at both time points, and a small number of 
these were involved in the positive regulation of transcription. For both the up and 
downregulated transcripts, the 48 hour time point is driving the enriched GO-terms. 
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Figure 5.13. Identification of differentially expressed niRNA transcripts. 
Log-2 fold change (FC) is plotted against the Log-2 average counts per milUon (CPM) at 48 hours 
and 7 days. The Unes indicate a Log2 FC of 1 and the mRNAs identified as differentially expressed 
with a FDR <10% are shown in red. 
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Figure 5.14. Differentially expressed mRNA transcripts with a FDR <10%. 
Pairwise comparisons were made with the edgeR package, data is shown as log2-fold change for 
each cardiomyocyte sample. 
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Table 5.3. GO-TERM enrichment of up- and down-regulated genes. 
Biological processed with FDR <30%, comparing all upregulated and downregulated transcripts. 
TermID | TermDescription | Count 1 FDR 
Upregulated 
G0:0007015 actin filament organisation 11 0.018 
G 0 : 0 0 0 6 4 1 2 translation 36 0.039 
G0 ;0030036 actin cytoskeleton organisation 18 0.057 
0 0 : 0 0 3 0 0 2 9 actin filament-based process 19 0.060 
0 0 : 0 0 0 7 0 1 0 cytoskeleton organisation 21 2.881 
0 0 : 0 0 3 0 1 9 8 extracellular matrix organisation 8 11.426 
0 0 : 0 0 4 2 2 5 4 ribosome biogenesis 12 21.919 
0 0 : 0 0 2 2 6 1 0 biological adhesion 20 22.848 
0 0 : 0 0 0 7 1 5 5 cell adhesion 20 22.848 
0 0 : 0 0 5 1 0 1 7 actin filament bundle formation 4 24.164 
0 0 : 0 0 1 0 3 2 4 membrane invagination 10 27.719 
0 0 : 0 0 0 6 8 9 7 endocytosis 10 27.719 
0 0 : 0 0 5 1 2 5 8 protein polymerisadon 5 28.788 
Downregulated 
0 0 : 0 0 0 6 6 3 1 fatty acid metaboHc process 26 4.01E-10 
0 0 : 0 0 1 6 0 4 2 lipid cataboUc process 13 0.001 
0 0 : 0 0 4 4 2 4 2 cellular Upid catabolic process 9 0.017 
0 0 : 0 0 5 5 1 1 4 oxidadon reducuon 34 0.044 
0 0 : 0 0 0 9 0 6 2 fatty acid catabolic process 6 0.407 
0 0 : 0 0 3 4 4 4 0 Upid oxidation 6 0.407 
0 0 : 0 0 1 9 3 9 5 fatty acid oxidation 6 0.407 
0 0 : 0 0 0 6 6 3 5 fatty acid beta-oxidation 5 0.782 
0 0 : 0 0 4 2 4 9 3 response to drug 8 0.863 
0 0 : 0 0 0 6 0 8 4 acetyl-CoA metabolic process 7 2.170 
0 0 : 0 0 0 6 0 7 1 glycerol metabolic process 5 3.203 
0 0 : 0 0 3 0 2 5 8 lipid modification 6 4.300 
0 0 : 0 0 0 6 6 3 7 acyl-CoA metabolic process 4 4.352 
0 0 : 0 0 0 6 7 3 2 coenzyme metabolic process 13 4.550 
0 0 : 0 0 1 9 4 0 0 alditol metabolic process 5 4.574 
0 0 : 0 0 1 6 0 5 4 organic acid catabolic process 8 4.866 
0 0 : 0 0 4 6 3 9 5 carboxylic acid catabolic process 8 4.866 
0 0 : 0 0 1 5 6 7 2 monovalent inorgamc cadon transport 11 9.788 
0 0 : 0 0 0 6 8 1 3 potassium ion transport 7 9.811 
0 0 : 0 0 5 1 1 8 6 cofactor metabolic process 14 12.478 
0 0 : 0 0 0 8 0 1 6 reguladon of heart contraction 6 19.423 
0 0 : 0 0 4 8 8 7 8 chemical homeostasis 13 22.059 
0 0 : 0 0 0 6 0 8 5 acetyl-CoA biosynthedc process 3 23.268 
0 0 : 0 0 0 9 7 1 9 response to endogenous stimulus 9 28.310 
0 0 : 0 0 0 6 8 6 9 lipid transport 7 29.205 
3' cud scquencir; 
Table 5.4. GO-Term enrichment for up- and down-regulated transcripts at 48 hours or 7 
days. FDR <30%. 
Biological processes with a FDR <30%, comparing the subgroups illustrated in Figure 5.14. 
TermID TetmDescription Count 1 FDR 
48 hour upregulated 
G0 ;0006412 translation 35 2.42E-05 
G0 :0007015 actin filament organisation 9 0.069 
G0 :0030029 actin filament-based process 14 0.646 
0 0 : 0 0 3 0 0 3 6 actin cytoskeleton organisation 13 0.914 
G0 :0006897 endocytosis 10 3.227 
G0 :0010324 membrane invagination 10 3.227 
0 0 : 0 0 3 4 4 7 0 ncRNA processing 12 7.442 
0 0 : 0 0 4 2 2 5 4 ribosome biogenesis 10 16.524 
0 0 : 0 0 0 6 3 6 4 rRNA processing 8 17.786 
0 0 : 0 0 1 6 0 7 2 rRNA metabolic process 8 19.599 
0 0 : 0 0 2 2 6 1 3 ribonucleoprotein complex biogenesis 11 21.079 
0 0 : 0 0 0 7 0 1 0 cytoskeleton organisation 14 29.386 
7 day upregulated 
0 0 : 0 0 0 6 5 0 8 proteolysis 12 9.125 
0 0 : 0 0 2 2 6 1 0 biological adhesion 7 14.514 
0 0 : 0 0 0 7 1 5 5 cell adhesion 7 14.514 
48 hour and 7 day upregulated 
0 0 : 0 0 6 0 2 8 4 regulation of cell development 5 0.506 
0 0 : 0 0 0 1 5 2 5 angiogenesis 5 3.620 
0 0 : 0 0 5 0 7 6 7 regulation of neurogenesis 
regulation of nervous system 
4 4.496 
0 0 : 0 0 5 1 9 6 0 development 4 4.891 
0 0 : 0 0 4 8 5 1 4 blood vessel morphogenesis 5 10.951 
0 0 : 0 0 4 5 5 9 6 negative regulation of cell differentiation 4 17.604 
0 0 : 0 0 0 1 5 6 8 blood vessel development 5 19.790 
0 0 : 0 0 0 1 9 4 4 vasculature development 5 20.360 
0 0 : 0 0 3 1 5 8 9 cell-substrate adhesion 3 25.013 
48 hour downregulated 
0 0 : 0 0 0 6 6 3 1 fatty acid metabolic process •^ 2 5.15E-09 
0 0 : 0 0 1 6 0 4 2 lipid catabolic process 12 5.80E-04 
0 0 : 0 0 4 4 2 4 2 cellular lipid catabolic process 8 0.025 
0 0 : 0 0 0 6 6 3 5 fatty acid beta-oxidation 5 0.253 
0 0 : 0 0 5 5 1 1 4 oxidation reduction 26 0.358 
0 0 : 0 0 0 6 0 8 4 acetyl-CoA metaboHc process 7 0.462 
0 0 : 0 0 1 9 3 9 5 fatty acid oxidation 5 1.563 
0 0 : 0 0 3 4 4 4 0 lipid oxidation 5 1.563 
0 0 : 0 0 0 9 0 6 2 fatty acid catabolic process 5 1,563 
0 0 : 0 0 0 6 7 3 2 coenzyme metabolic process 11 4.756 
0 0 : 0 0 4 6 3 9 5 carboxylic acid catabolic process 7 5.055 
y end scciucncmg 
Table 5.4 cont. GO-Term enrichment for up- and down-regulated transcripts at 48 hours or 
7 days. FDR <30%. 
TermID TermDescription | Count 1 [FDR 
48 hour downre gulated cont. 
G0:0016054 organic acid catabolic process 7 5.055 
G0:0006869 lipid transport 7 8.418 
G0:0051186 cofactor metaboUc process 12 9.385 
0 0 : 0 0 3 0 2 5 8 lipid modification 5 9.440 
00 : 0006071 glycerol metabolic process 4 12.651 
0 0 : 0 0 0 6 0 8 5 acetyl-CoA biosynthetic process 3 13.831 
0 0 : 0 0 1 0 8 7 6 lipid localisation 
branched chain family amino acid 
7 15.855 
0 0 : 0 0 0 9 0 8 1 metabolic process 4 16.078 
0 0 : 0 0 1 9 4 0 0 alditol metabolic process 4 16.078 
0 0 : 0 0 0 9 7 1 9 response to endogenous stimulus 8 19.842 
0 0 : 0 0 4 3 6 4 8 dicarboxylic acid metabolic process 4 19.872 
0 0 : 0 0 0 6 6 3 3 fatty acid biosynthetic process 5 26.607 
0 0 : 0 0 1 9 2 1 6 regulation of lipid metabolic process 5 29.707 
0 0 : 0 0 0 6 6 3 7 acyl-CoA metaboUc process 3 29.889 
0 0 : 0 0 0 6 5 7 3 valine metabolic process 3 29.889 
0 0 : 0 0 0 1 6 7 6 long-chain fatt)' acid metabolic process 3 29.889 
48 hour and 7 day downregulated 
positive regulation of transcription. 
0 0 : 0 0 4 5 8 9 3 DNA-dependent 
positive regulation of RNA metabolic 
5 15.380 
0 0 : 0 0 5 1 2 5 4 process 5 16.503 
0 0 : 0 0 5 5 1 1 4 oxidation reduction 7 17.039 
0 0 : 0 0 4 2 4 9 3 response to drug 3 19.144 
0 0 : 0 0 0 6 6 3 1 fatt)' acid metabolic process 4 22.188 
0 0 : 0 0 4 5 9 4 1 positive regulation of transcnption 5 22.269 
0 0 : 0 0 1 0 6 2 8 positive regulation of gene expression 
positive regulation of nucleobase, 
nucleoside, nucleotide and nucleic acid 
5 22.712 
0 0 : 0 0 4 5 9 3 5 metabolic process 
positive regulation of macromolecule 
5 28.306 
0 0 : 0 0 1 0 5 5 7 biosynthetic process 5 28.793 
3' end secjuenciiig 
5 . 2 . 6 . C COMPARISON TO PUBLISHED DATA 
T o identify novel expression changes, the differentially expressed mRNAs were compared 
to other studies that have documented gene expression changes during hypertrophy. The 
first study performed TAG with a 28-G needle, resulting in a tighter constriction, and took 
whole LV samples at 1, 3 and 12 weeks post-surgery {16S). Another performed TAG with a 
27-G needle and isolated whole LV samples after 48 hours, 1, 2, 3 and 8 weeks {301). 
Similarly, a study by Zhao et al. performed TAG with a 27-G needle but isolated whole 
hearts after 48 hours, 10 days and 3 weeks {187). The final study induced hypertrophy with 
Isoprotenol or Angiotensin II via a mini-pump and isolated whole LV after 7 or 14 days 
respectively {302). All o f these studies used microarrays for expression analysis. 215 of the 
differentially expressed mRNAs identified here were also reported in one or more of these 
studies (Figure 5.15.A). 189 have been shown to change expression in the same direction, 
while 28 were regulated in the opposite direction when compared to the published data 
(Figure 5.15.B). One of these smdies also analysed microarray data for heart development 
and intriguingly, we found that 136 of the mRNAs regulated in our data were altered in the 
opposite direction during development (Figure 5.15.B), providing further evidence that the 
heart is returning to a foetal like gene program {I6S). 
The mRNAs that had been previously identified to change expression "were then removed 
from the heatmap and the GO-term enrichment was repeated to see if the depth of our 
sequencing uncovered any novel biological processes (Table 5.5). The full list of enriched 
GO-terms for the novel mRNAs is Hsted in Appendix 8.12. For both the upregulated and 
downregulated lists, the CiO-terms remain essentially the same but the number of genes 
contributing to the biological process changes, which then alters the FDR. For example, 36 
mRNAs are involved in translation when considering all upregulated mRNAs but this 
number is reduced to 31 when looking at only the novel mRNAs. The mam processes are 
still enriched; with actin cytoskeletal processes enriched in the upregulated genes and fatt)' 
acid or Hpid metaboHsm enriched in the downregulated transcripts. Similarly, the majority 
o f the terms associated with either the 48 hour upregulated or downregulated mRNA 
transcripts remain the same but with a smaUer number o f genes contributing to each term 
(Table 5.6). After removing the previously identified transcripts, there was no enrichment 
of biological processes m the mRNAs upregulated at 7 days or those upregulated at 48 
hours and 7 days. This suggests that the processes of proteolysis, ceU adhesion and 
angiogenesis have been documented in the previous smdies. On the other hand, the 
3' ciid sequencing 
number of genes associated with transcription remains unchanged when comparing all 
m R N A s downregulated at 48 hours and 7 days and those that have not been reported 
before, indicating that regulation of transcription is specific to the novel mRNAs. 
Published 
data LVH 215 560 
VJ 
Differentially 
expressed mRNAs 
B 
Same direction Same direction 
LVH Dev 
Opposite direction Opposite direction 
Dev LVH 
Figure 5.15. Comparison between differentially expressed mRNAs and published data. 
(A) Overlap between differentially expressed mRNAs with a FDR <10% and mRNAs previously 
reported to be differentiaUy e.xpressed during LVH {US, 187, 301, 302). (B) Overiap between 
mRNAs reported to be differentiaUy regulated m LVH and development (Dev) {US). Majority of 
mRNAs are regulated in the same direction during LVH or in the opposite direcuon during 
development. 
3' end sequencing 
Table 5.5. GO-TERM enrichment for novel mRNAs. 
Biological processes with FDR <30%, comparing all upregulated and downregulated transcripts. 
TetmID TermDesctiption | Count 1 FDR 
Upregulated 
G0 :0006412 translation 31 0.002 
G0 :0030036 actin cytoskeleton organisation 13 0.700 
G0 :0042254 ribosome biogenesis 12 1.282 
G0 ;0030029 actin filament-based process 13 1.716 
G0 :0022613 ribonucleoprotein complex biogenesis 13 2.105 
G0 :0034470 ncRNA processing 12 5.978 
G0 ;0007015 actin filament organisation 6 14.773 
G0 :0006364 rRNA processing 8 15.391 
G0 :0016072 rRNA metaboUc process 8 17.003 
Downregulated 
G0 :0006631 fatty acid metabolic process 19 5.06E-06 
G0 :0016042 lipid catabolic process 12 7.79E-04 
G0 :0044242 cellular lipid catabolic process 9 0.002 
G0 :0009062 fatty acid catabolic process 6 0.116 
G0 :0019395 fatty acid oxidation 6 0.116 
G0 :0034440 lipid oxidation 6 0.116 
G0 :0006635 fatty acid beta-oxidation 5 0.282 
G0 :0016054 organic acid catabolic process 8 1.070 
G0 :0046395 carboxylic acid catabolic process 8 1.070 
G0 :0042493 response to drug 7 1.310 
G0 :0030258 lipid modification 6 1.338 
G0 :0055114 oxidation reduction 23 6.632 
G0 ;0009791 post-embryonic development 6 14.057 
G0 :0043648 dicarboxylic acid metabolic process 4 21.245 
regulation of transcription, DNA-
26.289 G0 :0006355 dcpendent 23 
.V cud s equencing 
Table 5.6. GO-Term enrichment for up- and down-regulated novel transcripts at 48 hours 
or 7 days. 
Biological processes with a FDR <30%, comparing the novel mRNAs witliin the subgroups 
illustrated in Figure 5.14. 
TermID fTermDescription | 1 Count FDR 
48 hour upregi alated 
G0:0006412 translation 30 5.41 E-05 
G0:0034470 ncRNA processing 12 1.140 
G0:0042254 ribosome biogenesis 10 3.705 
0 0 : 0 0 2 2 6 1 3 ribonucleoprotein complex biogenesis 11 4.414 
0 0 : 0 0 0 6 3 6 4 rRNA processing 8 5.212 
0 0 : 0 0 1 6 0 7 2 rRNA metaboUc process 8 5.837 
0 0 : 0 0 3 0 0 3 6 actin cytoskeleton organisation 10 6.348 
0 0 : 0 0 0 7 0 1 5 actin filament organisation 6 6.367 
0 0 : 0 0 3 0 0 2 9 actin filament-based process 10 11.773 
0 0 : 0 0 3 4 6 6 0 ncRNA metabolic process 11 24.026 
48 hour downregulated 
00 : 0006631 fatt)' acid metabolic process 16 4.05E-05 
0 0 : 0 0 1 6 0 4 2 lipid catabolic process 11 5.82E-04 
0 0 : 0 0 4 4 2 4 2 cellular lipid catabolic process 8 0.005 
0 0 : 0 0 0 6 6 3 5 fatt)' acid beta-oxidation 5 0.099 
0 0 : 0 0 0 9 0 6 2 fatty acid catabolic process 5 0.630 
0 0 : 0 0 1 9 3 9 5 fatty acid oxidation 5 0.630 
0 0 : 0 0 3 4 4 4 0 lipid oxidation 5 0.630 
0 0 : 0 0 4 6 3 9 5 carboxyUc acid catabolic process 7 1.509 
00 : 0016054 organic acid catabolic process 7 1.509 
0 0 : 0 0 3 0 2 5 8 lipid modification 5 4.079 
0 0 : 0 0 4 3 6 4 8 dicarboxylic acid metabolic process 4 10.743 
0 0 : 0 0 5 5 1 1 4 oxidation reduction 18 15.699 
00 : 0009791 post-embr\'onic development 5 24.651 
48 hour and 7 day downregulated 
00 : 0045893 positive regulation of transcription, DNA-
dependent 5 3.914 
0 0 : 0 0 5 1 2 5 4 positive regulation of RNA metabolic process 5 4.240 
00 : 0045941 positive regulation of transcription 5 5.997 
0 0 : 0 0 1 0 6 2 8 positive regulation of gene expression 5 6.138 
0 0 : 0 0 4 5 9 3 5 positive regulation of nucleobase, nucleoside, 
nucleotide and nucleic acid metabolic process 5 7.995 
0 0 : 0 0 1 0 5 5 7 positive regulation of macromolecule 
8.164 biosynthetic process 5 
00 : 0009891 positive regulation of biosynthetic process 5 9.041 
0 0 : 0 0 5 1 1 7 3 positive regulation of mtrogen compound 
9.041 metabolic process 5 
0 0 : 0 0 3 1 3 2 8 positive regulation of cellular biosynthetic 
9.041 process 5 
3' end sequencin 
T a b l e 5.6 cont. G O - T e t m enrichment for up- and down-regulated novel transcripts at 48 
hours or 7 days. 
T e r n i l D TermDescr ip t ion Count F D R 
48 hour and 7 day downregulated cont. 
G0 :0006357 regulation of transcription from RNA 
polymerase II promoter 5 11.789 
G0 ;0045944 positive regulation of transcription 
from RNA polymerase II promoter 4 15.948 
G0 :0010604 positive regulation of macromolecule 
metabolic process 5 17.228 
0 0 : 0 0 0 6 3 5 5 regulation of transcription, DNA-
dependent 6 20.838 
0 0 : 0 0 5 1 2 5 2 regulation of RNA metabolic process 6 23.126 
3' end sequencing 
5 . 2 . 6 . D E X P R E S S I O N O F H Y P E R T R O P H I C M A R K E R S 
The hypertrophic markers ANP, BNP, a -Ska and P-MHC were all upregulated and 
detected in the m R N A s with a FDR less than 10% (Figure 5.14, Figure 5.16). The 
expression of these four markers was ascertained prior to sequencing using RT-qPCR on 
another lot of LV samples (Figure 3.7). Furthermore, the expression of a -Ska and ANP 
was conf i rmed to be upregulated in the purif ied cardiomyocyte samples, including those 
subjected to sequencing (Figure 3.10). This provided further validation that merging the 
peaks associated with the same gene could be used as a proxy of gene expression. 
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Figure 5.16. Cardiac hypertrophy markers are upregulated according to the 3' seq data. 
The normaUsed CPM for the hypertrophy markers ANP, BNP, a-Ska and p-MHC. Data is 
presented as mean with SEM (n=2). 
5 . 2 . 6 . E V A L I D A T I O N OF M E R G E D 3 ' E N D S W I T H R T - Q P C R 
The expression of nine m R N A s with vanning CPM, fold change and FDR values from 
Figure 5.12 were tested using RT-qPCR. The expression was tested in the samples 
subjected to next-generation sequencing as well as in the additional cardiomyocyte samples. 
Of the nine mRNAs considered for testing, the expression changes of six could be 
validated in both the samples used for sequencing and the extended dataset (Figure 5.14). 
The m R N A expression changes were considered validated if a two-way A N O V A with 
Bonferonni 's post-hoc analvsis on the RT-qPCR data of the extended dataset resulted in an 
adjusted p value of less than 0.05. 
The downregulation of N d u f l and Acs l l could be obser\'cd in the RT-qPCR data for the 
sequencmg samples and the extended dataset, but this did not reach significance (Figure 
5.17.B). In fact, the fold change for Acs l l using the sequencing samples at 48 hours had a 
fold change greater than or equal to the NGS data. But as there are only two replicates for 
this analysis, the result was not significant. The extended dataset had a greater variability m 
the expression of Acs l l , leading to a higher standard error and adjusted p value greater 
than 0.05. Ndufa l had a lower absolute fold change value in comparison to the other genes 
that could be validated. On the other hand, Ca lml did not show any upregulation in the 
sequencing samples or the extended dataset compared to the NGS data (Figure 5.17.C). 
Alike to N d u f a l , the log2-FC for Ca lml according to NGS was less than 1. The absolute 
log2-FC of the s k mRNAs that could be validated was greater than 1, suggestmg diat this 
could be the factor that determines if the expression changes can be validated. 
In summan-, the expression levels of eight mRNAs followed the same trend as the NGS 
data when analysed using RT-qPCR. Furthermore, the expression of sLx mRNAs was 
statistically significant in the extended cardiomyocyte sample set. 
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Figure 5.17. Validation of differential gene expression by RT-qPCR. 
Fold change (TAC/Sham) values for the next-generation sequencing data (NGS), RT-qPCR on the 
eight samples subjected to next-generation sequencing (RT-qPCR sequencing samples) and RT-
qPCR on the extended cardiomyocyte sample set (RT-qPCR extended dataset). (A) mRNA 
expression changes that could be validated in both the samples used for sequencing and the 
extended dataset. (B) The same trend could be observed in the q-PCR for both the sequencing 
samples and the extended dataset but it was not significant. (C) The trend could not be obser\'ed in 
either the sequencing samples or the extended dataset. The dashed grey line indicates a fold change 
of 1. Data shown as mean log FC with SEM (n=4-5 for RT-qPCR sequencing sample and RT-
qPCR extended dataset, n=2 for NGS * p <0.05, Two way -ANOVA with Bonferonni 's post-hoc 
analysis). The log2FC, log counts per million (CPM) and false discovery rate (FDR) for the NGS 
data are shown below each graph. 
3' end sequencing 
5 . 2 . 7 D E T E C T I O N o i - A L T E R N A T I V E 3 ' U T R U S A G E 
The next step was to determine if there was any evidence for changes in 3' U T R usage 
within the data. D r Brian Parker from A N U conducted the analysis into the m R N A length 
changes and the weighted linear model for alternative polyadenylation. T o detect changes 
in m R N A length overall, the mean 3' U T R length was calculated for the Sham and TAG 
samples. The distances were weighted according to the number of counts, with highly 
expressed m R N A s being more heavily weighted. The mean 3' UTR length was shorter in 
the T A G samples at both time pomts, with a greater difference at 48 hours. The weighted 
mean was reduced from 450 to 430 nt in the TAG samples at 48 hours, and from 482 to 
448 nt at 7 days. However, while a trend could be obser\'ed, both of these analyses had a p 
value greater than 0.05 (0.13 at 48 hours and 0.22 at 7 days). 
Alternative polyadenylation was then detected at the gene level by looking for a change in 
the proportion of 3' seq peaks for those genes with multiple 3' ends. The peaks associated 
with protein coding genes were used, and only peaks that contributed more than 10% to 
the tags associated with a gene were considered. Alternative polyadenylation was detected 
as a proportion statistic between proximal and distal sites using a weighted Linear model 
(Refer to section 2.2.7.E for more details). Similar to the gene expression data, more 
candidates of alternative polyadenylation were detected at 48 hours compared to 7 days. 
However, the F D R for both time points was verj' high, therefore we ranked the mRNAs 
according to F D R and looked at m R N A s with an F D R less than 70%. There were no 
examples at 7 days with an F D R less than 70%, so we looked only at the changes occurring 
at 48 hours. We filtered this further by looking only at m R N A s that had an average tag 
count greater than 100, and had a change in proximakdistal ratio greater than 15% between 
the Sham and TAG samples (Figure 5.18). This resulted in 424 m R N A s with a change in 3' 
UTRs at 48 hours; 152 where the 3' U T R was longer in the TAG samples, and 272 mRNAs 
where the 3' U T R was shortened in the TAG samples. Therefore, more genes had a 
shortening of the 3' UTR, which is consistent with the analysis of genome wide averages. 
3' end sequenc ing 
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Figure 5.18. mRNAs with FDR <70% at 48 hour. 
T h e m e a n and range of Proximal/dis ta l rat io for m R N A s with a F D R less than 7 0 % at 48 hours. 
m R N A s with a range less than 15% are shown in red, those with a range greater than 15% are 
indicated in blue. T h e m R N A s with a loglO average tag count greater than 2 (to the right of the red 
dashed l ine) and wi th a range greater than 15% were used for downs t r eam analysis. 
5 . 2 . 7 . A V A L I D A T I O N O F 3 ' U T R C H A N G E S 
10 mRNAs were chosen for validation of 3' UTR changes, five linked to cardiac 
hypertrophy (Mtus l , Ccnd2, Camkk2, GSK3b and P p m l k ) and five chosen with varj'ing 
FDRs and proportion changes (Atg3, Usf2, E t f l , Utp6 and Htatip2) {303-307). Rina 
Soetanto from the A N U performed the RT-qPCRs for 3' UTR changes. RT-qPCR was 
performed using primers downstream or upstream of the proximal 3' seq peak in the 3' 
UTR (Figure 5.19.A). The primers for Atg3 and Usf2 could not be optimised and were 
excluded from downstream analysis. If both 3' UTRs were regulated to the same extent, 
then the fold change values for both primer pairs would be equivalent. If the 3' UTR was 
getting shorter, then the fold changc for the primers amplifying the Long 3' UTR would be 
lower. If a greater proportion of 3' UTRs was longer, then the fold change for the primers 
amplify ing the Long 3' UTR would be higher. The decrease in the use of the long or distal 
3' UTR could be conf irmed with the extended samples at 48 hours for the five mRNAs 
tested for shortening 3' UTRs (Figure 5.19.B). In some cases (Ccnd2, Gsk3b and Ppmlk ) , 
this decrease in the long 3' UTR could also be seen at 7 days. 
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Figure 5.19. The change in 3' UTRs could be validated with conventional RT-qPCR. 
(A) Schematic of a 3' UTR showing the position of two 3' sequencing peaks (red) and the primers 
used for val idadon (green). Primer 1 was designed before the proximal 3' seq peak and amplifies 
both variants of the 3' UTR (Short and Long 3' UTR) while Primer 2 is designed before the distal 
peak and ampHfies only the long 3' UTR (Long 3' UTR). (B) mRNAs with shorter 3' UTRs in the 
48 hour TAG samples. (C) m R N A s conf i rmed to have longer 3' UTRs in the 48 hour TAG 
samples. (D) Lltatpip2 had more of the long 3' UTR m the TAG samples according to NGS, this 
could not be conf i rmed with RT-qPGR. RT-qPCR with the extended cardiomyocyte sam pie set, 
data is shown as mean fold change with SEM (n=2-5). 
— 3' end sequencing 
The increase in the use of the long or distal 3' UTR was validated in the extended samples 
at 48 hours for tvvo of the three mRNAs tested (Figure 5.19.C). For the third mRNA, 
Htatip2, the increase in the long 3' UTR could not be confirmed using RT-qPCR on the 
extended dataset. 
5 . 2 . 7 . B CORRELATION WITH GENE EXPRESSION 
T o begin to untangle the possible outcome of alternative polyadenylation, the mRNAs 
detected to have alterations in the proportions of 3' UTRs were compared to the mRNAs 
differentially expressed in Figure 5.14. It could be hypothesised that a decrease in the 
length of the 3' UTR would increase the amount of the transcript overall, as there would be 
less regulatory elements present in the 3' UTR sequence. Only 29 mRNAs overiapped with 
the m R N A s differentially expressed with an FDR <10% (Figure 5.20). Of these, there was 
no obvious correlation between the direction of change in the 3' UTR and the expression 
overall. For instance, for mRNAs with a shortened 3' UTR, there are candidates where the 
overall gene expression increased or decreased. This analysis was extended to the 424 genes 
that change 3' UTRs, but again no correlation could be obsers'ed between the 3' UTR 
change and gene expression levels (data not shown). 
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F i g u r e 5.20. 3 ' U T R c h a n g e s do not cor re l a t e w i t h g e n e exp r e s s i on c h a n g e s . 
(A) Log2-fold change (FC) for m R N A s that shorten their 3' UTRs m the TAG sample. (B) Log2-
fold change for m R N A s that lengthen their 3' UTRs in the TAG samples. 
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5 . 2 . 7 . C C A R D I A C H Y P E R T R O P H Y A S S O C I A T E D G E N E S W I T H A P A 
W e next asked if any of the genes associated with cardiac hypertrophy altered their 3' 
UTRs in response to the TAG banding. 31 of the 652 genes from the "cardiac 
hypertrophy" genecard list had a change in their 3' UTR with a FDR less than 70% (Table 
5.6). This list included genes involved in ceU cycle regulation, transcription, energy and 
metabol ism, as well as factors direcdy involved in the hypertrophic signalling pathways 
{308-312). In summary, the functions of the cardiac h^jpertrophy related genes with 
changing 3' UTRs are diverse. 
These m R N A s were also investigated for their correlation with overall gene expression. 
Three genes, Ppargc l a , Ppp3ca and Cacna l c , had more of the distal 3' UTR and a decrease 
in their absolute expression levels (log2-FC less than -1). While only one gene, Rras2, had 
an increase in the proximal 3' UTR and a log2-FC greater than 1. This is consistent with 
the previous section, where there was no correlation overall between the 3' UTR changes 
and the log2 FC for the gene in entiret}' (Table 5.7). 
Some of the mRNAs with three or four 3' UTRs were documented as having a change in 
ratio between the proximal and distal 3' seq peaks. In this case, one of the pairwise 
comparisons between two of the 3' seq peaks was significant. For example. Peak 1 and 
Peak 4 of GSK3b showed a change, with less of Peak 4 present in the TAG samples 
(Figure 5.10.E). For such examples, the change is still biologically meaningful as one of the 
3' seq peaks is changing in comparison to the others. 
The data provided in Table 5.7 is particularly important when considering the miRNA 
interactions with these hypertrophy related mRNAs. For instance, miR-495-3p is predicted 
to target GSK3b but this miRNA binding site is not present m the TAG samples once the 
proximal poly(A) site is used. Information such as this is critical when considering miRNAs 
or s iRNAs against specific genes for therapeutic inter\'entions. 
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Table 5.7. 3' UTR changes for cardiac hypertrophy associated genes. 
Number of 3' UTR Overall Log2-
Name 3' UTRs change FC 
Cd36 2 Lengthen -0.79 
Polr21 2 Lengthen 0.72 
Ppargc 1 a 2 Lengthen -1.85 
Tfam 2 Lengthen -0.05 
Pten 2 Lengthen -0.61 
Gnb5 2 Lengthen 0.41 
J ak l 3 Lengthen 0.35 
Ppp3ca 4 Lengthen -1.21 
Cacnalc 2 Lengthen -1.72 
Prkaa2 2 Lengthen -0.73 
Pin 2 Shorten -0.22 
Acadl 2 Shorten -0.99 
Ak l 2 Shorten 0.05 
Prkarla 2 Shorten 0.07 
Ubc 2 Shorten -0.55 
Ccnd2 3 Shorten 0.11 
Akt2 2 Shorten 0.21 
Csnk la l 3 Shorten -0.17 
Jun 3 Shorten -1.30 
SlcSal 2 Shorten 0.33 
Racl 2 Shorten -0.16 
Rras2 2 Shorten 1.24 
Hfe 2 Shorten -0.58 
KcnjS 2 Shorten -1.02 
Cpt la 3 Shorten -0.68 
Atf6 3 Shorten -0.46 
Pdgfa 2 Shorten -0.62 
Mef2a 2 Shorten -0.87 
Smad4 2 Shorten -0.44 
AbUm3 2 Shorten 0.46 
Gsk3b 4 Shorten 0.68 
Overall Log2-FC refers to the fold change (TAC/Sham) for the mRNA transcript. 
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5 . 2 . 7 . D G O - T E R M ENRICHMENT OF M R N A S WITH 3 ' U T R CHANGES 
T o more systematically examine the genes undergoing 3' UTR changes, GO-term 
enrichment was performed to functionally annotate the genes with shortened or 
lengthened 3' UTRs in the 48 hour TAG samples. However, the mRNAs with a longer 3' 
UTR in the 48 hour TAG samples did not show any enrichment for a biological process 
with an FDR less than 30%. The shortened mRNAs were enriched for some biological 
processes, but the enriched GO-terms were very broad (data not shown). For example, 
cellular protein cataboHc process was the most highly enriched GO-term. This result is 
consistent with a publication that examined UTR changes in TAG banded mice using 
microarray probes. N o GO-terms were significandy associated with the mRNAs with 
shortened 3' UTRs {168). This suggests that the 3' UTR changes are a broad phenomenon 
in h^'pertrophic cardiomyocytes and are not confined to a functional subclass of mRNAs. 
5 .3 DISCUSSION 
In this chapter, we performed genome-wide profil ing of mRNA 3' UTRs in control, pre-
hypertrophic and hypertrophic cardiomyocytes. The data was annotated for 3' UTRs and 
interrogated for features of polyadenylation, then used to generate a static picmre of all 3' 
UTRs, with a focus on mRNAs involved in cardiac hypertrophy. The 3' sequencing data 
was successfully used as a measure of overall gene expression, and then analysed for the 
presence of alternative polyadenylation during hj'pertrophy. 
5 . 3 . 1 F E A T U R E S OF TIU-: 3 ' SEQUENCING LIBRARY 
5 . 3 . 1 . A G E N E R A L FEATURES OF THE LIBRARY 
As expected, the majority of the tags mapped direcdy to the mouse genome, with only a 
smaU number mapping to the transcriptome. The smaU proportion of tags that map to the 
transcriptome span exoniexon boundaries and Ukely represent short 3' UTRs where the 3' 
seq peak begins prior to the the stop codon. 20% of peaks contained evidence of a poly(A) 
tail towards the 3' end of the tag. This variation was expected, due to variable poly(A) tail 
length, the Ubrary preparation and size selection of the cDNA which ranged from 70-300 
nt. As the sequencing tag was 75 nt in length, the sequencing will not always read far 
enough into the cloned product to detect the poly(A) tall. While this does not matter for 
def imng the 3' UTRs of a given m R N A transcript, it does mean that the exact poly(A) 
cleavage site cannot always be determined. As next-generation sequencing improves and 
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the length of sequencing reads become longer, we will be able to read into the poly(A) tail 
and define the exact cleavage sites for more 3' ends. 
5 . 3 . 1 . B A S S I G N I N G T O G E N O M I C F E A T U R E S 
Peaks were assigned to a genomic feature if they overlapped the 3' UTR region for mRNAs 
or they were less than 20kb downstream of a stop codon or transcript end. Other studies 
have used similar criteria to defme 3' ends but using 5 or 8 kb to assign 3' seq peaks to 
upstream genes {171, 313). While we allowed 20 kb, the mean distance from the stop 
codon of mRNA transcripts was 3.7 kb. In further support of the 20 kb range, a recent 
study discovered that putative HncRNAs were acmaUy extended 3' UTRs of upstream 
genes and they validated 3' UTRs up to 19 kb m length using Northern blotting {31-f). In 
fact, the length of the 3' UTRs for six genes (PpplrV, DnajclS, T lmml7a , Hmboxl , Pdk3 
and Ppargclb) found in our dataset were also found in Miura et al.s data and were validated 
using Northern blotting {31-f). Therefore 20 kb is a suitable cut off to define 3' UTRs while 
retaining the long, potentially novel 3' UTRs. 
Just over 25% of the peaks were annotated as Orphan peaks, meaning they did not overlap 
with any known genomic feature and were more than 20kb away from the closest upstream 
gene. This proportion is consistent with another study that found 22.5% of detected 3' end 
sites discovered using NGS in Zebrafish were unannotated {171). Despite accounting for 
one quarter of the peaks, the Orphan peaks contribute only a small proportion of tags 
(7.6% of total mapped tags), suggesting that they are expressed at low levels. The RNA 
sequencing by the Encyclopedia of DNA Elements (ENCODE) project revealed that 
83.7% of the human genome undergoes per\'asive transcription {3 IS). It has been 
demonstrated that transcription of unannotated regions such as where the Orphan peaks 
map, results in the production of a large number of lincRNAs {316). The low but 
widespread coverage of our Orphan peaks is consistent with per\'asive transcription and it 
is plausible that these Orphan peaks are derived from as yet unannotated lincRNAs. 
Peaks that were derived from Exons upstream of the stop codon or Intron regions 
accounted for 22.4% and 10.9% of the tags respectively. For simpHcit)', we used the 
canomcal transcript defined in Ensembl for annotation. Therefore, it is possible that these 
Exon and Intron peaks are still bona fide 3' ends and represent Intromc APA or alternative 
spHcing. Alternative spKcing can generate an mRNA transcript variant with a different last 
V end sequencing 
exon, thus altering the location of the 3' UTR on the genome. Intronic APA results from 
cleavage at a PAS within the intron, extending the previous exon and making it the 
terminal one (317). While we did not investigate such peaks in this study, they can be 
interrogated in the future for changes in expression levels that may relate to APA of 
shorter m R N A transcript variants. 
Of the peaks that were downstream of a stop codon or transcript end, the majority were 
derived f rom protem coding genes as expected. However, other RNA species such as 
l incRNAs, snoRNAs and miRNAs were also detected at low levels. l incRNAs are 
processed in a similar manner to mRNAs, including the addition of a poly(A) tail {2PS). 
Similarly, the pr iman' miRNA precursor is capped and polyadenylated (294). In further 
support of our data, polyadenylation sites for miRNAs, l incRNAs and snoRNAs are 
documented in the expression and polyadenylation database (xPAD), which provides a 
map of polyadenylation sites in human cancer tissues and cell Lines {318). In addition, 
another PolyA-seq study capmred polyadenylated non-coding miRNAs in their data, 
including primary miRNA precursors and anrisense RNAs {289). The polyadenylation of 
non-coding RNA species was not the focus of this smdy, but nonetheless our data will also 
provide a resource for the expression and polyadenylation of non-coding RNAs. 
5 . 3 . 1 . C FEATURES OF POLYADENYLATION 
After the peaks were assigned to genomic features, we searched for features of 
polyadenylation. As mentioned above, a proportion of tags and therefore a proportion of 
peaks contained evidence of a poly(A) tall at the 3' end. This proportion mcreased when 
considering only protein coding associated peaks. All transcripts containing a poly(A) tail 
should have been cloned mto the sequencing Hbrary but the poly(A) tail may have been 
further downstream of the sequencmg region. It's plausible that as the protein coding 
transcripts are the most abundant, contributing the most tags in the sequencing Hbrar)', 
then there is a higher chance of detecting a poly(A) stretch within the 3' seq peak. 
W e also searched for the presence of the canomcal PAS or one of its variants. The 
canomcal PAS was found m 43% of protein coding associated peaks, with this number 
mcreasing to 60% when considering protein coding associated peaks that contain a poly(A) 
tail. This IS consistent with previous studies that found bet^veen 53-58% of PAS hexamers 
in human are the canomcal A.\UAAA {319). The proportion of peaks where no PAS was 
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detected increases f rom 10% in protein coding peaks with a poly (A) stretch to 35% when 
considering protein coding peaks without any indication of a poly(A) tail. As mentioned 
previously, this could be attributed to the region in which the search for the PAS is 
conducted. For those peaks without the poly(A) tail, the cleavage site and thus the PAS 
may be much further downstream making it hard to determine the exact PAS. 
Approximately 20% of human poly(A) cleavage sites do not have an upstream PAS {317). 
These sites rely on strong binding of the CFIm 3' processing factor to the upstream 
U G U A element {154), or on Cstf to the DSE with other auxiliary elements {320). 
Therefore, the 3' seq peaks that do not contain a PAS could rely on other sequence 
elements for processing. 
This analysis was then extended by looking at the location of the PAS. In agreement with 
the known literature, the canonical PAS was found 17.5 nt upstream of the cleavage site. 
The second most abundant PAS was AUUAAA, which has been reported previously in the 
mouse as the second most abundant PAS {160). Curiously, the most abundant non-
canonical PAS is not consistent between peaks that do or do not contain a poly(A) stretch. 
A U U A A A remains the most abundant non-canonical PAS in poly(A) containing peaks and 
is present at 10 to 25 nt upstream of the cleavage site. However, AAGJ\AA is more 
abundant in the peaks without poly(A). This PAS variant has been reported to contribute 
to only a small proportion of PAS sites in the mouse {160), and it is centred around the 
cleavage site in our data. The algorithm to detect the PAS searches for the canonical PAS 
frrst, fol lowed by the non-canonical PAS variants and reports the distance from the end of 
the 3' sequencing peak. As the actual cleavage site may be much further downstream, it is 
possible that the canonical PAS or a more common PAS variant exists further downstream. 
The third most abundant PAS was UUUAAA, which contains two peaks, one at the 
expected location between -10 and -25, and another centred around the 3' seq peak end. It 
is known that the region around the cleavage site and PAS is U-rich {160), therefore we 
may be detecting a U-rich region rather than an actual PAS. Conclusions about the use of 
PAS are more accurate for the peaks that contain the start of the poly(A) tail, and of these 
we observe the most common PAS. 
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5 . 3 . 2 A P A IN P R O T E I N C O D I N G G E N E S 
5.3.2.A N U M B E R OF 3 ' UTRs FOR P R O T E I N C O D I N G G E N E S 
W e found that on average each protein coding gene had 2.35 3' UTRs. Similar studies in 
Humans and Zebrafish have identif ied that on average an mRNA has 2.5 and 2.8 3' UTRs 
respectively {171, 315). 34% of our 3' seq peaks associated with protein coding genes 
overlapped with a known 3' end and accounted for 69% of the tags, which is consistent 
with other studies that suggest that most 3' ends are novel but the majority of the tags are 
derived from known 3' ends (171, 315). Due to the depth of NGS, we are detecting the 
novel 3' ends that are expressed at lower levels. In some cases, the main 3' UTR detected 
was not at the exact cleavage site as defined in Ensembl. Changing the length of the 3' 
UTR can increase or decrease the area available for regulation by RNA binding proteins 
(RBPs) and miRNAs. 
5 . 3 . 2 . B C A R D I A C M R N A S W I T H M U L T I P L E 3 ' ENDS 
W e detected several mRNAs implicated in cardiac hypertrophy that have multiple 3' UTRs. 
Having a static picture about the 3' UTRs available, regardless if they change between the 
Sham and TAG samples is important for understanding the regulation of the mRNA 
transcript. In some cases the mRNA had only one 3' UTR, but this 3' UTR was not the 
annotated 3' end in Ensembl. A detailed map of the 3' UTRs available in the heart can help 
more accurately predict miRNA binding sites. 
5.3.2.C I M P L I C A T I O N S OF M U L T I P L E 3' UTRs 
The 3' UTR can determine the stabiKty, ceUular locaKsation and translation efficiency of the 
transcript. The length of a 3' UTR has been linked to nonsense mediated decay (NMD) in 
a sequence-independent manner {321). The protein U p f l regulator of nonsense transcripts 
homolog ( U p f l ) binds along the length of a 3' UTR, and as more U p f l molecules can bind 
a longer 3' UTR the probabiUty of U p f l binding factors that regulate N M D increases {321). 
Regulatory sequence elements, such as miRNA and RBP bmding sites, are also present 
within a longer 3' UTR. For instance, the Au-binding factor 1 ( A U F l ) protein binds to 
AU-r ich regions m the 3' UTR and promotes the degradation of mRNA targets by 
recruitmg the exosome {322). The interaction between miRNAs and the 3' UTR variants is 
discussed in Chapter Seven. 
3' end sequenci; 
The localisation of mRNAs is mostly determined by aj-regulatory sequences within the 3' 
UTR. For example, the long 3' UTR of brain-derived neurotrophic factor (BDNF) targets 
the mRNA to the dendrites in neuronal cells, resulting in site-specific translation (323). 
Similarly, the calmoduHn-dependent protein kinase 11 (CaMKl la ) is targeted to dendrites 
by a sequence just after the proximal poly(A) site (32-f). The 3' UTR variants of the cardiac 
mRNAs may therefore result in different subcellular localisations, which could have 
downstream implications for translation. 
The 3' UTR choice can also influence the translation or protein output. Accurate 
conclusions about the translational efficiency of mRNA 3' UTRs can be made by analysing 
the levels of protein {32S). It is known that shorter mRNAs can produce up to 40 times 
more protein than a longer variant, as they escape regulation by miRNAs and other RBPs 
{164). For example, the Rat ATPase, Na-H/K-I- transporting, beta 1 polypeptide (ATPIBI) 
mRNA uses three predominant PAS (326). Use of the proximal PAS results in a short 3' 
UTR that is translationally more efficient than the longer 3' UTR, as the longest 3' UTR 
contains a unique translational repressor sequence (327). There are also examples of long 3' 
UTRs producing more protein than the short 3' UTR variant or both producing 
comparable amounts (323, 328, 329). The long 3' UTR variant of the amyloid precursor 
protein (APP) has higher translation efficiency and produces more protein than the short 3' 
UTR {323). There are proteins that specifically bind to the short but not the long .\PP 3' 
UTR, reducing its translational efficiency {323). Similarly, the longer 3' UTR of the brain-
derived neurotrophic factor (BDNF) produces more protein in neuronal cells {329). On the 
other hand, the first 24 nt of the lipoprotein lipase (LPL) 3' UTR contains a motif for 
translational inhibition and upstream or downstream elements do not affect translation 
{330). So while it is generally thought that a shorter 3' UTR produces more protein, it is 
clear that there are individual examples where the opposite is true. The 3' UTRs 
documented in this thesis can provide valuable mformation about sequence regulator^' 
elements controlling a mRNA transcript and their potential impact on translational 
efficiency, localisation and stability. 
5 . 3 . 3 3 ' S E Q U E N C I N G AS A PROXY FOR GENE EXPRESSION 
5 . 3 . 3 . A DIFFERENTIAL EXPRESSION 
While the mam aim of this chapter was to document the 3' UTRs of cardiac mRNAs, we 
took advantage of the available data to look at gene expression. The 3' seq peaks associated 
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with a protein coding gene (downstream of the stop codon) were merged together to 
generate tag counts for differential expression. Other studies have shown that NGS of 3' 
ends can accurately be used as a proxy of gene expression, with the method highly 
correlated with normal RNA sequencing, microarrays and RT-qPCR {289, 33!, 332). In 
fact, 3' sequencing removes any length bias that standard RNA sequencing encounters as it 
does not span the entire transcript {332). It also has the advantage of identifj ' ing low to 
moderately expressed genes {332). This is reflected in the dynamic range of the data, with 
the top 1000 genes contributing 87% of the tags. 
Out of the 6000 m R N A s that were used for assessing differential expression, 
approximately 13% were differentially expressed at an FDR of less than 10%. The majority 
of the m R N A s were upregulated and more mRNAs were differentially regulated at 48 
hours. There is a uniform increase in total RNA synthesis that accounts for the 30-50% 
increase in cell volume during hypertrophy {333). This is achieved by an increase in the 
activit}' of RNA pol I {334), pol II and pol III {335). In addition, there is a more dramatic 
increase in the expression of specific genes such as the cardiac hypertrophy markers 
This could account in part for the larger number of upregulated m R N A transcripts 
compared to downregulated transcripts in the TAG samples. 
5.3.3.B GO -TERM E N R I C H M E N T 
GO-term enrichment of the differentially expressed mRNAs reveals processes that are well 
documented to change or regulate cardiac hypertrophy. The GO-terms for all of the 
upregulated transcripts are mainly involved in actin or cytoskeletal organisation, translation 
and cell adhesion. Compensated hypertrophy results in the accumulation of cytoskeletal 
proteins that counteract the pressure on the heart {337). The cytoskeleton in 
cardiomyocytes consists of the sarcomeric skeleton, the true cytoskeletal proteins, 
membrane-associated proteins and the proteins of the intercalated disc {337). It is the thin 
and thick fi laments of the sarcomere that form the contractile units of a cardiomyocyte 
{338). The upregulated genes included alpha actm cardiac muscle 1 (Actc l ) , an alpha actin 
that forms part of the sarcomere {339). Other genes include alpha-Actinm and Filamin, 
which Hnk the sarcomere and cytoskeleton to the extraceUular matrix (ECM). Alpha-actinin 
is an intermediary^ molecule that transmits signals from Integnn receptors on the cell-
surface to the actin fi laments {340). Similarly, Filamin acts as a scaffold between the 
cytoskeleton and transmembrane receptors {341). Filamins help maintain the membrane 
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integrity, which is particularly important during increased mechanical stress that would 
occur during pressure overload. The enrichment of biological and cellular adhesion is also 
related to the E C M and cytoskeleton of the cardiomyocyte. Cellular adhesion is defined as 
the attachment of a cell to another cell or to a substrate such as the ECM via adhesion 
molecules. The focal adhesion complex is a cluster of Integrin transmembrane receptors 
that connect the E C M to the cell via actin bmdmg proteins {34Z). These actin-binding 
proteins include TaHn, alpha-Actrnin and FUamin. In our data, the expression of both 
TaHnl and Integrin-alpha 5 increase after TAC. There is also an increase in proteins that 
are involved in the ECM, such as connective tissue growth factor (CTGF) that stimulates 
ECM synthesis {343). 
The biological process translation is also enriched in the upregulated genes. It is known 
that there is an increase in protein synthesis in response to h\'pertrophy. Initially, this is due 
to an increase in the efficiency of translation within hours of the hypertrophic stimulus 
{344). However , this is not sufficient to account for the drastic increase in protein that 
accompanies cardiac hypertrophy and as a result, the amount of ribosomal protein also 
increases after 12-24 hours {34^). In agreement, we saw a number of transcripts encoding 
ribosomal proteins as well as eukaryote initiation and elongation factors increase expression 
at the 48 hour time point. This increases the capacity for protein synthesis. 
The downregulated transcripts were enriched for terms associated with fatty acid 
metabol ism and oxidation-reduction. Energy is generated in the normal heart by the 
oxidation of fatty' acids {346). In agreement with the re-expression of the foetal isoforms of 
M H C and skeletal actin, the metabol ism of the heart reverts back to a foetal metabolic 
profi le with an increase m carbohydrate utilisation during cardiac hypertrophy {347). 
Conf irming our GO-term enrichment, it is well documented that Fatty acid metabolism is 
drastically decreased in the hypertrophic heart {348-351). Furthermore, it is known that this 
decrease is achieved in part by the downregulation of genes that encode fatty acid oxidation 
enzymes {352, 353). While we obser\'ed this decrease in genes involved with fatty acid 
metaboKsm, we did not sec an upregulation of genes involved in glycolysis. However, an 
mcrease in the expression or capacity of glycolytic enzymes does not always correlate with 
mcreased glycolysis {354). Consistent with our data, other studies have found no significant 
change in the expression of glucose transporters or enzymes involved in the glycolytic 
pathway {354-356). Subsequendy, it is thought that an increase in glucose uptake is the 
reason for an increase in glycolysis {357). 
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To better understand the molecular mechanisms of hypertrophy occurring at the different 
stages of disease, the GO-term enrichment was performed on subsets of the data. The 
most significant GO-terms enriched for the mRNAs upregulated at 48 hours remain 
translation and actin filament organisation, suggesting that this is an early response to the 
pressure overload. Another two terms, endocytosis and ncRNA processing are also 
enriched. The endocytosis machinery is activated in response to stimulation of (3-
adrenergic receptors (P-AR), a type of GPCR {35K). The internalisation of Pi-AR is 
required for the activation of Akt, which then results in the expression of transcription 
factors that regulate the hypertrophic response (see Section 1.1.2.E for more details on the 
Akt pathway). It is possible then that the upregulation of genes involved in endocytosis 
mediate the internalisation of P-ARs for downstream signalling. As mentioned above, the 
other process enriched at 48 hours is ncRNA processing. The majorit)' of the genes 
contributing to this enrichment are involved in rRNA or tRNA processing, which is 
consistent with the upregulation of translation. Interestingly, Dicerl was also upregulated 
at 48 hours. The majority of miRNAs we obsenx-d to change expression levels occurred at 
7 days. The miRNA processing pathway also involves several steps so the questions 
remains if upregulating one of the miRNA processing enzymes would drastically increase 
the levels of functional miRNAs if the remaining proteins do not change. In summar)', 
changes in gene expression relating to translation and actin filament orgamsation occur 
before the heart has increased in size. 
The hypertrophic cardiomyocytes at 7 days upregulated genes implicated in proteolysis and 
biological adhesion. As mentioned earHer, cardiac hypertrophy results in an increase in 
protein synthesis or translation, which was detected at the mRNA level at 48 hours. In the 
normal ceU, up to 50% of proteins are degraded by the proteasome even prior to peptide 
elongation (359). Due to the stress on the cardiomyocyte, the increase in translation that 
occurs at 48 hours also results in an increase in denatured proteins that need to be 
degraded to avoid apoptosis {360). This suggests that between 48 hours and 7 days 
components of the protein degradation pathway ate upregulated to compensate for the 
increase m translation. mRNAs involved in biological adhesion are also upregulated at 7 
days. As discussed above, biological adhesion is related to the actin cytoskeletal network 
and the ECM. It is known that ECM deposition or fibrosis occurs during hypertrophy and 
this indicates that strucmre changes to the ECM occur on or before 7 days. 
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At both the pre- and hypertrophic stages of cardiac hypertrophy, angiogenesis and blood 
vessel formation factors are upregulated. During compensator) ' hj-pertrophy, the number 
of myocardial capillaries increases. However, after prolonged hypertrophy, the relative 
capillar)' density decreases as the cardiomyocytes increase in size, resulting in larger 
diffusion distances for oxygen and nutrients (361). 'I'his impairment in angiogenesis is one 
of the reasons the heart progresses from compensated to maladaptive hypertrophy {362). 
W e observed enrichment of angiogenesis factors at 7 days. Two of these angiogenesis 
factors, CTGF and heparm-bmdmg epidermal growth factor (HB-EGF) are known to be 
upregulated and secreted from cardiomyocytes in response to h)'pertrophy, suggesting that 
the enrichment of m R N A s associated with angiogenesis is not derived from other cell 
t)'pes (363, 364). The increase in these factors at 7 days is consistent with the notion that 
there is a larger densit)' of capillaries when the heart is compensating against the pressure 
overload. 
Genes that were downregulated at both 48 hours and 7 days had less significant 
enrichment, with the lowest FDR for genes that positively regulate transcription at 15.4%. 
These genes encode transcription factors or transcription co-activators including KLF15, 
Jun and Pparg l ca . I<J^F15 inhibits gene expression and the hypertrophic response {365, 
366). It does this by repressing the transcription factors Mef2 and GATA4, and the 
transcriptional co-activator myocardin that stimulate h)'pertrophic growth {36S). 
Downregulat ion of K1.F15 therefore removes this repression and results in the re-
expression of hypertrophic genes including A N F and a -SkA as obser\'cd in our data {366). 
Similarly, J un (or c-jun) is a transcription factor that regulates the cytoskeleton and 
counteracts the mcreased fibrosis that occurs after pressure overload {367). The 
enrichment of transcription does not refer to an overall decrease in the levels of 
transcription, but rather refers to downregulation of transcription factors that mediate gene 
expression involved in cardiac hypertrophy. 
5 . 3 . 3 . C C O M P A R I S O N TO OTHER STUDIES 
The differentiaUy regulated m R N A s were compared to other studies that have documented 
genome wide expression changes m hypertrophy. 24% of the mRNAs we detected as 
differentiaUy expressed have been reported in other studies to change m the same direction 
durmg hypertrophy. The smdies we made comparisons with have aU used microarrays as a 
measure of gene expression. It is possible that there were not probes on the microarrays 
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for all o f the genes we have detected. It is also plausible that these m R N A s changed within 
the data, but did not meet the statistical cut-offs used in other studies. Furthermore, these 
studies used different end points a n d / o r different models of cardiac hypertrophy. For 
instance, van den Bosch et al. described gene expression changes at multiple time points 
after T A G banding, the latest o f which was 8 weeks post-surgery {301). At this late stage in 
hypertrophy when it is progressing to decompensation, a different gene expression profile 
could be expected. Similarly, the study by Friddle et al. used Isoproterenol or Angiotensin-
II to induce hjrpertrophy and thus activated different signalling pathways compared to 
pressure overload induced hypertrophy {302). In fact, there are no m R N A s that are 
differentially regulated in all of the four studies used as a comparison, highlighting the 
differences between these studies (data not shown). Despite the difference in the smdy 
design, 17.5% of the m R N A s were also regulated in the opposite direction in a heart 
development time course {168). This provides further confirmation that the heart is 
remrning to a foetal Hke gene program. 
After redoing the GO-term enrichment only for the m R N A s unique to our data, it was 
evident that the main biological processes remained enriched. A large number of genes still 
contribute to translation, actin cytoskeleton organisation and fatt)' acid metabolism. These 
processes are critical for the progression of compensated to decompensated hypertrophy. 
So while the same pathways have remained enriched, we may have identified novel 
m R N A s that could ser\'e as therapeutic targets for heart disease. 
WhUe the expected biological pathways were identified, the genes that contribute to this 
enrichment represent a minor proportion of the m R N A s that were differentiaUy expressed. 
This leads to the question, what are the remaining m R N A s doing? Are they contributing to 
the same biological pathways but they are not currentiy annotated sufficiendy to be 
classified with a GO-term? The gene expression data presented in this chapter can be used 
as a resource for m R N A s that are altered during cardiac hypertrophy and derived primarily 
f rom cardiomyocytes. 
5 . 3 . 3 . D L I M I T A T I O N S O F G O - T E R M E N R I C H M E N T A N A L Y S I S 
There are also limitations to GO-term enrichment as an analysis of global gene expression 
changes. For instance, G O - t e r m enrichment doesn't take into account the expression levels 
or changes associated with each gene and each gene is treated equaUy. The information 
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about the degree of change could be used to assign weighting to each gene, which could 
provide more information about the pathways that are changing (36S). Furthermore, some 
biological processes have been smdied in more depth than others, and subsequendy have 
more annotated genes associated with that term. Therefore, these well-annotated pathways 
are more likely to be significandy enriched. Some annotations are also incomplete and not 
all genes ate functionally annotated. This could explain why pathways already known to 
change with cardiac hypertrophy are sigmficantly enriched but novel pathways are not. 
5.3.4 C H A N G I N G 3' UTRs 
The second mam aim of this chapter was to determine if mRNAs changed their 3' UTR 
usage in cardiac hypertrophy. We detected a slight reduction in the global 3' UTR length in 
the TAG samples and have documented 424 mRNAs with 3' UTR changes at 48 hours. 
This was based on pairwise comparisons with an FDR less than 70%. While this FDR was 
high, the changing 3' UTRs of seven out of eight mRNAs tested with FDRs ranging from 
35-64% could be confirmed with RT-qPCR (Figure 5.19). A similar study conducted in 
Zebrafish did not apply a statistical model but filtered their data for genes that changed 
more than 30% in pairwise comparisons (///)• Other publications have used more 
stringent criteria. For instance, a study looking at 3' UTR changes during mouse 
development calculated the use of the distal poly(A) site relative to the proximal site and 
then used a microarray analysis package to detect genes with an FDR less than 10% {161). 
As there is not consistency between the reporting or analysis of 3' sequencing data, we 
thought It was reasonable to use the mRNAs with an FDR less than 70%, then filter 
further for expression level and change in 3' UTR usage. 
5 . 3 . 4 . A I M P R O V I N G T H E 3 ' U T R S T A T I S T I C S 
There are a number of mRNAs with multiple 3' seq peaks with two or more peaks in close 
proximity. For example, GSIC3b has three peaks at the proximal end of the 3' UTR and 
one peak at the distal end of the 3' UTR (Figure 5.10.E). The pairwise comparisons to 
detect changes in 3' UTR ratios were made between individual 3' seq peaks. However, 
merging peaks that are withm close proximity to each other may identif)' changes in 3' 
UTR length that were not identified when considermg the peaks individuaUy. This would 
remain biologically meaningful if «V-regulator)' elements were present between the short 
and long 3' UTRs. 
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5 . 3 . 4 . B W H A T CONTROLS A P A ? 
The choice of poly(A) cleavage site and thus the 3' UTR length is dictated by the 
concentrat ion of 3' processing factors, the interaction of trans-acting factors and 
transcription. The distal poly(A) site is usually stronger than the upstream site and thus is 
preferentially used by the 3' processing machinery [160). Upregulation of core processing 
factors can result in higher usage of a weaker proximal poly(A) site {369, 370). The was first 
illustrated for CstF-64 and the IgM mRNA, where high levels of CstF-64 during B cell 
maturation result in use of a proximal poly(A) cleavage site within an intron {369). The 
merged differential expression data was examined for the core components of the 3' 
processing machinery. However, there was no change in expression for any of the 
components examined (data not shown). It is stiU possible that the protein levels increase 
due to translational control. Nevertheless, this indicates that at least on the mRNA level 
there is no correlation between the global 3' UTR length and 3' processing factors during 
cardiac hypertrophy. This is not surprising as there is only a mild reduction in the mean 3' 
UTR length and thus it could be expected that there is no bulk change in 3' processing 
factors. 
The choice of poly(A) cleavage site can also be influenced by trans-acting proteins. For 
instance, the poly(A)-binding protein nuclear 1 ( P A B N l ) generates longer 3' UTRs by 
associating with the proximal poly(A) cleavage sites and preventing their cleavage {292). 
Conversely, the Cytoplasmic polyadenylation element binding protein 1 (CPEBl ) increases 
the use of the weaker proximal poly(A) cleavage sites by binding and recruiting the 3' 
processing factors {371). The activity of such proteins and the control of alternative 
polyadenylation in the heart remains to be investigated. 
Polyadenylat ion is closely coupled to transcription, with 3' processing factors associating 
with RNA Pol 11 and transcription factors {372). It is posmlated that these interactions 
increase the efficiency of cleavage and polyadenylation and therefore increase the use of 
proximal poly(A) cleavage sites {373). Increases in transcriptional activity- leads to increased 
cleavage at the proximal poly(A) cleavage sites {374). As transcription is known to increase 
during cardiac hypertrophy {333), this could account for the sHghtly shorter global 3' UTR 
length in the T A C samples. Another hypothesis for the link between transcription and 3' 
end processing is kinetic coupling. A decrease in the elongaOon rate of RNA Pol II results 
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in an increased use of the proximal poly(A) cleavage site, presumably because it takes a 
longer period of time to reach the distal poly(A) cleavage site and thus allowing more time 
for the proximal site to be cleavage ( i / i ) . Both of these mechanisms would result in a net 
change in 3' UTR usage, with an increase in transcriptional activity resulting in a preference 
for the proximal 3' UTR. 
5.3.4.C CORRELATION W I T H G E N E E X P R E S S I O N 
W e could not observe a correlation between changes in 3' UTR length and overall 
transcript levels. Other studies have not observed a negative correlation between 3' UTR 
length and gene expression {171, 287, 376). This suggests that for most genes alternative 
polyadenylation does not greatiy impact on transcript stabtUt}'. As mentioned in section 
5.3.2.C, the length of the 3' UTR can impact on translational efficiency and change the 
binding sites available for miRNAs and other RBPs. In eukarj-otes, miRNAs can repress 
their targets by translational repression (65) . Therefore, while we would see a difference at 
the protein level for the m R N A 3' UTRs with different miRNA binding sites, we may not 
observe a difference at the RNA level. 
5.3.4.D CARDIAC H Y P E R T R O P H Y R E L A T E D G E N E S W I T H C H A N G I N G 3' 
UTRs 
A small proport ion (4.7%) of cardiac hypertrophy related genes had different proportions 
of 3' UTRs between the Sham and TAG samples at 48 hours. The function of these genes 
is diverse, suggesting that 3' UTR changes are not specific to a cellular pathway. In 
addition, the signalling pathways that are activated in response to cardiac hypertrophy are 
regulated at the post-translational level (See section 1.1.2 for more details on the signalling 
pathways). For example, the M A P K pathway is a series of phosphorj ' lation events which 
results in the phosphor>'lation and activation of transcription factors ( i i ) . It is no surprise 
then that components of this pathway are not regulated by alternative polyadenylation (data 
not shown). 
5.3.5 CONCLUSIONS 
In this chapter, we have described the 3' UTRs expressed in murine cardiomyocytes, and 
documented changes in 3' UTRs during tiie induction of cardiac hypertrophy. Each m R N A 
m the heart has on average 2.35 3' UTRs, which increases the area for regulatory sequences 
225 
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and interactions. This data provides an important resource for the 3' UTRs used in the 
heart, particularly when most novel 3' UTRs are tissue specific (289). It can be used for 
miRNA target predictions, as well as to identify novel cis- or trans- regulator)' elements. A 
number of mRNAs changed the proportion of their 3' UTRs in response to h)'pertrophy 
and this can be used to identify miRNA and RBP interactions with disease stage specific 3' 
UTRs. 
CHAPTER SIX 
ISOMIR FUNCTION 
6 . 1 INTRODUCTION 
IsomiR function 
The small RNA sequencing described in Chapter Four illustrated that the cardiac specific 
miR-133a exists as multiple start (5') and end (3') isomiRs derived from both the 5p and 3p 
arms (Figure 4.15.A). Furthermore, the major 5' isomiRs of the miR-133a-3p are associated 
with multiple 3' ends. In both human and mouse, miR-133a has two genomic locations and 
is transcribed as a bicistronic transcript with miR-1 (Figure 6.1.A). Both of the loci 
encoding the identical miR-133a-l and miR-133a-2 in the mouse are activated by MEF2-
and SRF-dependent enhancers {48, 112). The MEF2 transcription factor is activated by 
Calcmeurin-NFAT signaling during hypertrophy and orchestrates the expression of stress-
responsive genes, while SRF is a transcription factor that regulates pathological cardiac 
remodeling leading to heart failure {377) (See section 1.1.2.A for more details on MEF2). 
Several of the targets for miR-133a-3p have also been identified, including SRF that is 
repressed in a negative feedback loop (shown in Figure 6.1.B) {37g). The targets identified 
thus far implicate miR-133a-3p in numerous pathways critical to the heart, including 
proliferation, cardiac conduction, fibrosis and cardiac hypertrophy signaling {140, 378-381). 
Nevertheless, these studies have not taken into account the multiple processing variants 
that can be generated from the pre-miR-133a hairpin. 
The critical role of miR-133a in the heart has been highUghted by functional studies where 
the level of miR-133a has been altered. For instance, an antagomiR against miR-133a-3p 
that was continuously delivered into the murine heart resulted in an increase in 
hypertrophy markers such as waU thickness and the re-expression of the cardiac fetal genes 
{140). The same smdy also showed diat overexpression of the entire miR-133a hairpin 
using an adenovirus reduced the size of cardiomyocytes and decreased the expression of 
hypertrophic markers in a transgenic mouse overexpressing Akt {140). While studies such 
as this suggest that the miR-133a locus is antihypertrophic, the methods used to 
knockdown miR-133a-3p or overexpress the miRNA hairpin actuaUy manipulate the levels 
of both the strands of the miR-133a hairpm and their associated isomiRs. It is therefore 
critical to estabHsh if these isomiRs have different targeting properties and function. 
The aim of this chapter was to determine if the isomiRs of miR-133a-3p have different 
targeting specificities. This was addressed using luciferase vectors containing putative miR-
133a-3p binding sites within the 3'UTR. 
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Figure 6.1. miR-133a-3p is a central regulator of the heart. 
(A) miR-133a is encoded as two bicistronic elements with miR- l . In the mouse, miR-133a-l is 
encoded with miR-1-2 in an Intron of M ib l , while miR-133a-2 is encoded in an intergenic region 
with miR-1-1 {H9). The expression of miR- l and miR-133a are regulated by the transcription 
factors MEF2 and SRF (112, 16S). (B) Experimentally vaUdated targets of the mouse miR-133a-3p 
[140, 378-382). miR-133a-3p regulates heart homeostasis by repressing key mRNAs in processes 
critical to the heart. 
I s o m i R func t ion 
6 .2 RESULTS 
6 .2 .1 MIR-133A-3P 'I ARGETS 
The first step to understanding the function of the miR-133a-3p isomiRs identified (Figure 
6.2.A) was to examine the predicted targets for each. The respective seed sequences 
(nucleotides 2-8) of the major 5' isomiRs (designated can/23 nt and iso/22 nt, Figure 
6.2.A) were used to predict mRNA targets using TargetScan (Figure 6.2.B). This analysis 
yielded both common and unique targets, with both 5' isomiRs being predicted to target 
many genes involved in cardiovascular disease as determined by GO-term enrichment, 
although few of the latter were in common. This implies that both 5' isomiRs may regulate 
similar cardiomyocyte functions though frequentiy through different mRNA targets. 
To experimentally test whether these 5' isomiRs can indeed have different targeting 
specificities we next needed to select miR-133a-3p targets with the potential to specifically 
respond to either the can/23 nt or the iso/22 nt variant of miR-133a-.3p. Due to the 
uncertainty associated with targeting prediction algorithms, it was not practical to base our 
selections on computational predictions alone. For this reason, a mRNA dataset was 
sourced from a miR-133a knockout mouse smdy (279). Importantly, the whole pre-miRNA 
sequence, which contains the isomiRs for both the 5p and 3p strands, was deleted in this 
model. Comparison of viable double knockout mice and wild-type hearts had been 
performed using microarray analysis at postnatal day 1. To find potential targets of isomiRs 
generated from the 3p arm, the data was filtered for mRNAs that were upregulated more 
than 2-fold in the miR-133a' ' hearts compared to the wild-type. This Ust was then 
inspected for predicted targets of miR-133a-3p. Each target prediction algorithm uses a 
different set of criteria to detect targets. For example, the degree of sequence 
complementarity, the thermodynamics of the binding mteraction and/or the phylogenetic 
conser^.ation of the binding site are often used to fmd and rank the putative targets 
(reviewed m {383)). For this reason, the list of upregulated genes was cross-referenced with 
the outputs of several target prediction algorithms (searches were performed in 2011); this 
mcluded Targetscan for the canomcal miR-133a-3p (67), a custom Targetscan search using 
the isomiR seed sequence, the miRanda algorithm at microRNA.org {38^ and miRNA 
viewer rtittp://cbio.mskrr.orp/cw-bm/-^i--n.viewer/mirnaviewer.pl). which used an earHer 
version of the miRanda algorithm {384). Interestingly, the miRNA viewer used the iso/22 
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nt miR-133a-3p sequence for its target predictions, providing an excellent resource to 
identify targets that may be unique to one version of miR-133a-3p. This generated a list of 
predicted targets for the can/23 nt or the iso/22 nt miR-133a-3p that are upregulatcd after 
deletion of the miR-133a locus. This list was then visually inspected for target sites that 
may exhibit different binding preferences between the can/23 nt and iso/22 nt miR-133a. 
Two miRNA binding sites were chosen for downstream applications, derived from 
connective tissue growth factor (CTGF) mRNA for the canonical miR-133a-3p (can/23 nt) 
and phosphoglycerate mutase 1 (PGAMl) mRNA for the isomiR (iso/22 nt) (Figure 
6.2.C). In fact, CTGF has been previously reported as an experimentally validated target of 
miR-133a-3p that is critical in the production of the ECM during cardiac hypertrophy 
{38S). 
Next, these target sites were cloned as three concatemers behind RenUla luciferase in a 
reporter construct (Figure 6.2.C). Expression of this reporter can be a measure of miRNA 
activity, where an interaction between the miRNA and the target sites results in a decrease 
in the level of Renilla luciferase protein. Mutated binding sites containing an additional 
nucleotide in the seed-binding region were also generated. The construction of the 
luciferase vectors and subsequent transfcctions are detailed in the next section. 
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F i g u r e 6.2. miR-133a-3p i s o m i R s have d i f ferent p red i c t ed targets . 
(A) Count frequency of i-mR-133a-3p isomiRs; isomiRs chosen for targeting analysis are indicated 
by the arrow. (B) Predicted targets (TargetScan) for the canonical and 5' isomiR of miR-133a-3p. 
Enrichment of gene function terms using IPA software identified targets involved in cardiovascular 
disease. (C) miR-133a-3p isomiR-specific binding sites (connective dssue growth factor (CTGF) 
and phosphoglycerate mutase 1 (Pgaml) ) were cloned in three concatemers belund ReniUa 
luciferase in a reporter construct. Mutated binding sites containing an additional nucleotide in the 
seed sequence were also cloned. 
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6 . 2 . 2 C O N S T R U C T I N G L u c i F i i R A S E V E C T O R S 
T h e miR-133a-3p binding sites were ordered as four miRNA binding cassettes within a 
miniGene in the p I D T S M A R T - A M P plasmid (see Figure 2.1 for the sequence). Each 
cassette contained three o f each binding site (labeled as Pgaml 3 site, Pgaml M U T 3 site, 
Ctgf 3 site, Ctgf M U T 3 site), and a No/I restriction site that separated the cassettes. 
Additionally, each cassette contained a unique restriction site at the 3' end, as well as a Sah 
site between the first and second binding site. The structure o f the pIDTSNLVRT-AMP 
plasmid is shown in Figure 6.3.A. 
The cassettes were isolated from p I D T - S M A R T using a No/I digestion (Figure 6.3.B). The 
bands corresponding to 100 nt ( C T G F 3 sites) and 125 nt ( P G A M l 3 sites) were isolated 
(Figure 6.3.C). These bands were then ligated into a psiCHECK'""'^ vector using the No/1 
site behind the Renilla lucifetase gene (psiCHECK^M digested with No/I is shown in Figure 
6.3.B-C). After ligation, ten clones o f each were used for subsequent analysis and cloning. 
The ligated p s i C H E C K - 2 products were then checked for the correct insertion size using 
another No/I digestion (Figure 6.4). The correct size was detected for the 125 nt insert 
(Figure 6.4.A) and the 100 nt insert (Figure 6.4.B) in all clones. The t>'pe o f cassette and the 
orientation o f the cassette were then determined by performing a restriction enzyme 
digestion with EcoRl, which occurs outside o f the No/I insert, and the cassette specific 
restriction enzyme. An example for the C T G F cassettes (psiCHECK-2 with 100 nt insert) 
is shown in Figure 6.5. T h e correct cassette and orientation would result in a band ~ 715 nt 
in length, while an incorrect orientation or incorrect cassette would give bands 800 nt and 
830 nt respectively. T h e gels for the ps iCHECK-2 vectors containing the 100 nt inserts are 
shown in Figure 6.6. Three clones were identified that contained the C T G F 3 sites in the 
correct orientation, and two clones with the C T G F mutated 3 sites in the correct 
orientation. T h e same approach was applied for the 125 nt inserts, with three P G A M l 3 
sites in the correct orientation identified and two P G A M l mutated 3 sites (data not 
shown). T h e inserts were then confirmed using conventional sequencing (Appendix 8.14). 
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Figure 6.3. pIDTSMART-AMP minigene construct. 
(A) Schematic showing the four miR-133a target cassettes (CTGF, CTGF mut, PGAMl and 
PGAMl mut) within the pIDTSMART-AMP minigene. A No/l site separated the cassettes. Each 
cassette contained three miR-133a or isomiR binding sites, with the first and second site separated 
by a Sail site, and a cassette specific restriction site after the third site. (B) Both pIDTSMART and 
psiCHECK-2 were digested with Notl. (C) The 125 nt (corresponding to PGAMl cassettes) and 
100 nt (corresponding to 125 nt cassettes) were excised and inserted into the AVI site of 
psiCHECK-2. 
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Figure 6.4. p s i C H E C K - 2 contains inserts that cor respond to the expected cassette size. 
(A) T h e ten c lones of p s i C H E C K - 2 Hgated wi th the 125 nt cassettes conta in inserts approximate ly 
125 nt in length . (B) T h e ten c lones of p s i C H E C K - 2 l igated wi th the 100 nt cassettes conta in 
inserts approx imate l y 100 nt in length. HypV; hyper ladder V, psi-2; p s iCHECK-2 . 
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Figure 6.5. Strategy for determining correct construct and orientation. 
The ps iCHECK-2 plasmids thought to contain the CTGF cassettes were digested with EcoRl and 
the cassette specific enzyme {Bsim or Spel) to determine if the cassette was correct. (A) If the 
cassette was correct and in the correct orientation, bands of 715 nt and 125 nt would be visible. (B) 
If the cassette was correct but in the incorrect orientation then a band ~ 800 nt would be seen. (C) 
If the cassette does not correspond to the chosen cassette specific enzyme, then a band ~ 830 nt 
would be visible. 
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Figure 6.6. Detection of the correct cassettes witliin psiCHECK-2. 
(A) ps iCHECK-2 vectors with 100 nt insert were digested with BJ/IH and EioRl. Clones 4,6 and 7 
contain the correct insert (CTGF sites) and are indicated by the red boxes, they have bands 
corresponding to 715 nt and 125 nt. (B) psiCHECK-2 vectors with 100 nt insert were digested with 
Spel and EcoRL Clones 1 and 5 contain the correct insert (CTGF mutated sites) and are indicated 
by the red boxes, they have bands corresponding to 715 nt and 125 nt. Psi-2, psiCHECK-2. 
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Once the constructs were determined to be correct, further restriction digestions were 
performed to reduce the number of binding sites in each cassette to two or one (Figure 
6.7.A). The SalV site was positioned between the first and second binding site in each 
cassette. This was used in conjuction with either the XAoI site (upstream of the insert site in 
psiCHECK-2), or the cassette specific restriction enzyme, to reduce the number of sites in 
the cassettes. Figure 6.7.A shows the excision and ligation to generate a cassette containing 
only one site. The removal of the site was confirmed by performing another digestion with 
No/\, and the number of sites determined by the size of the bands after gel electrophoresis. 
Cassettes containing three sites wiU appear as a larger band on an agarose gel. As shown in 
Figure 6.7.B, digesting with SalV and the cassette specific enzyme reduced the size of the 
insert from —150 nt to less than 100 nt. The same approach was used for generating 
cassettes with two sites (Figure 6.7.A, data not shown). The cassettes were also confirmed 
by conventional sequencing (Appendix 8.14). 
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Figure 6.7. Reducing the number of binding sites in ps iCHECK-2 
(A) Strategy to reduce binding sites to two or one. Digestion with Xhol and Sail removes Site 1, 
leaving two sites in ps iCHECK-2. Digestion with Sail and the cassette specific restriction enzyme 
removes Site 2 and 3, leaving one site in ps iCIIECK-2. (B-C) Reducing p s i C n E C K - 2 to one site. 
(B) ps iCHECK-2 were digested with SuH and the cassette specific restriction enzyme, the bands 
were excised, blunt ended and ligated. (C) Digestion with Nofl conf irmed correct number of sites. 
The casettes with three sites gave rise to a product - 1 5 0 nt, while cassettes containing only one site 
were less than 100 nt. 
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6 . 2 . 3 F U N C T I O N O F M I R - 1 3 3 A - 3 P I S O M I R S 
The function of the 5' isomiRs for miR-133a-3p (can/23 nt and iso/22 nt), were tested 
using the constructs generated in 6.2.2. Custom Synthetic MISSION miRNA mmucs were 
designed to correspond to the can/23 nt and iso/22 nt variants (Shown in Figure 6.2.A). 
These mimics are double-stranded RNA molecules that do not undergo processing. This is 
critical when examining the function of isomiRs as the start and end site positions need to 
be exact. Furthermore, the opposing strand of the miRNA mimic is chemically modif ied so 
it cannot be incorporated into the RISC complex, minimizing any unintended effects by 
the passenger strand. A non-specif ic mimic was also generated as a control. 
The mimics were transientiy transfected into HeLa cells, which express low levels of miR-
133a-3p, with one of the ps iCHECK-2 vectors containing either CTGF 3 sites, CTGF 3 
mutated sites, P G A M l 3 sites or P G A M l 3 mutated sites. To first determine die 
appropriate concentration for comparisons between the miRNA mimics, a serial dilution 
experiment was performed using the CTGF 3 sites with the can/23 nt mimic, and the 
P G A M l 3 sites with the iso/22 nt mimic (Figure 6.8.A-B). W e used a concentration of 
lOnM in subsequent experiments as it resulted in sufficient repression for both 
combinat ions (Figure 6.8.A-B) and had minimal cell death (data not shown). The CTGF 
site was strongly repressed by the can/23 nt mimic, with a 20-fold repression obser\'ed at 
the higher concentrat ions of can/23 nt (Figure 6.8.A). In comparison, the maximal 
repression of the P G A M l site with the iso/22 nt mimic was approximately 8-fold (Figure 
6.8.B). This suggested that the CTGF site was more efficiently repressed by the can/23 nt 
miR-133a than the P G A M l site was by the iso/22 nt. 
Comparisons were then made between the can/23 nt and iso/22 nt miR-133a mimics and 
their effects on the 3 site luciferase constructs. This revealed marked preferential targeting 
by each variant (Figure 6.8.C). There was significantly greater repression of the CTGF 3 
site construct by the canomcal miR-133a-3p (can/23 nt) compared to the isomiR (iso/22 
nt), and vice versa for the P G A M l 3 site construct. Minimal repression was obser^-ed for the 
mutated sites (CTGF M U T 3 sites and P G A M l M U T 3 sites) and no repression was 
detected m die presence of the control mimic. This provides proof-of-prmciple evidence 
for preferential alternative m R N A targeting by 5' isomiRs of miR-133a-3p. 
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Figure 6.8. miR-133a isomiRs have different targeting properties. 
(A) The fold repression of the CTGF sites ps iCHECK-2 vector is shown for O.lnM to lOOnM of 
can/23 nt mirmc. (B) The fold repression of the PGAMI sites psiCIIECK-2 vector is shown for 
O.lnM to lOOnM of can/23 nt mimic. The binding site and miRNA mimic is shown above each 
graph. lOnM of each miRNA mimic was used for downstream applications (C) miR-133a-3p 5' 
isomiRs exhibit binding site-dependent differenual repression activit}-, not observed with mutated 
bmding sites (**** p < 0.0001, one way-ANOVA with Bonferroni's post-hoc analysis). Data is 
presented as mean with SEM (n=4-5). 
IsomiR function 
The endogenous mRNAs of CTGF and PGAMl contain only one target site within their 
3' UTR. Therefore to better match the endogenous mRNA, luciferase constructs with 
fewer sites were used for transfections. The cassette containing CTGF 2 sites was still 
robusdy repressed by the can/23 nt miR-133a, with Htde to no repression by the iso/22 nt 
mimic or the control (Figure 6.9.A). However, the PGAMl 2 site cassette was repressed 
only slighdy by the iso/22 nt mrmic and this did not reach significance (Figure 6.9.B). 
When considering the cassettes that contain only 1 binding site, can/23 miR-133a still 
repressed the CTGF site to a significandy greater extent than the iso/22 nt mimic (Figure 
6.10.A). However, when looking only at one site it is evident that the mutated CTGF site is 
also significandy repressed by both the can/23 nt and the iso/22 nt. Conversely, can/23 nt 
and iso/22 nt showed no differential repression of the PGAMl 1 site (Figure 6.10.B). 
While this repression was significant compared to the control miRNA, the mutated 
PGAMl site is regulated to the same extent. In summari,-, the CTGF sites show selective 
repression by the can/23 nt miR-133a even when only one site is present in the 3'UTR. 
The two mimics initially chosen varied in length (22 versus 23 nt). Therefore, we wanted to 
ensure that the 3' end or the length of the miRNA did not impact on targeting specificit)'. 
Two more mimics were generated that represented the other length for each miR-133a 
variant (can/22 nt and iso/23 nt). These mimics were then transfected with the 
psiCHECK-2 vectors containing 3 binding sites (CTGF 3 sites, PGAMl 3 sites. Figure 
6.11). The targeting abilit}- of the canonical miR-133a was not altered by the miRNA 
length, with the fold repression remaining the same for the can/22 nt mimic (Figure 
6.11.A). The introduction of the iso/23 nt with the PGAMl 3 sites did result in a slightly 
lower repression compared to the iso/22 nt mimic, but tiiis difference was not significant 
(Figure 6.11.A). In conclusion, for these two examples, the 3' end of the miRNA does not 
impact on the specificity of the miRNA. 
The final question we asked was whether the miR-133a-3p isomiRs were acting 
cooperatively, or competing for the same binding sites within the 3' UTR. This was 
addressed by transfecting different proportions of two miR-133a-3p mimics as a mix while 
keeping the total level of transfected mimics constant, together with either the CTGF 3 site 
or P G A M l 3 site plasmids (Figure 6.11.B-C). Increasing the proportion of can/23 nt 
relative to the iso/22 nt correlated with the increased repression of the CTGF 3 site 
(Figure 6.11.B). By contrast, altering the proportions in a mix of can/23 nt and can/22 nt 
did not have an impact on die repression of the CTGF 3 site. Similarly, increasing the 
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Figure 6.9. C T G F 2 sites is selectively repressed by the canonical miR-133a-3p. 
(A) miR-133a-3p 5' i somiRs exhibit differential repression against two copies of the CTGF site; the 
can/23 nt miR-133a-3p represses this cassette while the iso/22 nt and the control mimic do not. 
No repression is seen for two copies of the CTGF mutated site. (B) The iso/22 nt mimic represses 
two copies of the P G A M I site slightly more than the can/23 nt but tliis is not significant. (** p < 
0.01, one w a y - A N O V A with Bonferroni 's post-hoc analysis). Data is presented as mean with SEM 
(n=3). 
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Figure 6.10. C T G F 1 site but not P G A M I 1 site is selectively repressed by the canonical 
niiR-133a-3p. 
(A) miR-133a-3p 5' isomiRs exhibit differential repression against one copy of the CTGF site; the 
can/23 nt n i iR '133a-3p represses this cassette 2-fold while the iso/22 nt mimic represses only 1.5-
fold, and the control mimic does not. A small amount of repression is seen for one copy of the 
C T G F mutated site. (B) The iso/22 nt mimic and the can/23 nt mimics repress one copy of the 
P G A M I site and one copy of the P G A M I mut site to the same extent. (** p < 0.01, one way-
A N O V A with Bonferroni 's post-hoc analysis). Data is presented as mean with SEM (n=4-5). 
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Figure 6.11. miR-133a-3p 3' isomiRs do not impact on targeting specificity. 
(A) miR-133a-3p 3' i somiRs do not exhibit binding-site dependent repression at either the CTGF 
or P G A M I 3 sites. (B-C). miR-133a isomiRs do not competively bind to the target site. (B) 
Repression of the C T G F 3 sites with changing proportions of the iso/22 nt and can/23 nt or 
can/22 nt and can/23 nt. (C) Repression of the P G A M I 3 sites with the can/23 nt and iso/22 nt or 
iso/23 nt and iso/22 nt. 
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proport ion of iso/22 nt relative to the can/23 nt correlated with the increased repression 
of the P G A M l site (Figure 6.1 l .C) . Again, changing the proportion of 3' isomiRs had 
minimal impact on the repression of the P G A M l sites. Collectively, these results suggest 
that for the binding sites examined, the miR-133a-3p isomiRs do not compete for the same 
binding site. 
6 . 3 D I S C U S S I O N 
The miR-133a-3p 5' isomiRs are predicted to have overlapping and unique targets, with 
both being predicted to target m R N A s involved in cardiovascular disease. Using luciferase 
constructs containing a known and a predicted miR-133a binding site we have shown that 
miR-133a-3p 5' isomiRs can have different targeting specificity and efficiency. The largest 
difference m targeting was observed when using constructs that contained 3 binding sites. 
The experiment was designed to get maximal repression of the binding sites so that any 
differences in miRNA targeting could be observed. However, three consecutive miRNA 
binding sites for the same miRNA are not often observed within an endogenous 3' UTR. 
It is important to note that due to technical limitations and the inability' to discriminate 
between the isomiR sequences, the relative expression level and A G O incoportation of 
each isomiR was not measured following transfection. Differing concentrations and 
incorporation of the isomiR mimics would affect their activity and subsequent repression 
levels. However , one isomiR strongly repressed only one of the luciferase constructs, 
suggesting the concentrations were comparable. 
The can/23 nt mimic had a stronger effect on the CTGF 3 sites, compared to the effect of 
iso/22 nt on the P G A M l 3 sites. The P G A M l binding site contains a G:U pair (or G:U 
wobble) within the seed region (Figure 6.2.C). This G:U wobble is tolerated in a 
m iRNA:mRNA interaction if there is sufficient binding at 3' end to compensate (SS). It has 
been demonstrated that a G:U wobble within the seed region can still result in protein 
repression but is less effective {386, 38/), which could explain the stronger repression 
exhibited by the CTGF 3 sites. This difference becomes more evident when the number of 
binding sites is reduced to 2 or 1. The CTGF site stiU remams selectively repressed by the 
can/23 nt mimic when only one site remains. However, when there is only one P G A M l 
site both the can/23 nt and iso/22 nt variants of miR-133a repress the 3' UTR to the same 
weak extent. This might be attributable to the extended complementarity' along the full 
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length of the miRNA, which is known to compensate for mismatches in the 5' end of the 
miRNA {388){ Figure 6.2.C). This would also explain why the P G A M l mutated site (Figure 
6.10.B) is repressed to the same weak extent as the P G A M l site. Despite the P G A M l sites 
showing no differential repression when only 1 site is present, these expermients still 
provide evidence that miRNA isomiRs can have different targeting specificit}-, in particular, 
that miRNA variants can have both common and unique mRNA targets. 
Another recent study reported that 54% of miR-133a-3p in the rat left ventricle is 
equivalent to the iso/22 nt variant {389). They also demonstrated using the DIANA-
microT targeting prediction algorithm that the canonical miR-133a and the iso/22 nt 
variant have overlapping and umque targets, which is consistent with the analysis presented 
in this Chapter {390). The 3' UTR for one of these targets, GelsoHn, was cloncd behind a 
reporter gene and it was shown that the canonical miR-133a-3p was more efficient at 
suppressing this target compared to the iso/22 nt variant. This study provides further 
evidence that the 5' isomiRs of miR-133a-3p can have different targeting specificity'. 
6 . 3 . 1 OUTLOOK: 
To extend the conclusions obtained from our experiments and to appreciate the full 
function of miR-133a-3p isomiRs, similar studies should be conducted in a cell t\'pe 
relevant to its expression, such as the HL-1 cardiomyocyte cell line. This would allow for 
the identification of endogenous targets in the relevant cellular system. However, miR-
133a-3p is already highly expressed in cardiomyocytes so its targets are likely aheady 
repressed. Furthermore, the high levels of endogenous miR-133a-3p would mteract with 
the targets being interrogated making it difficult to untangle the effects of a synthetic 
miRNA mimic. Ideally, a system where the endogenous levels of miR-133a-3p were 
reduced and specific variants reintroduced would be used to identify' their targets. One 
study has overexpressed miR-133a in the mouse heart and sequenced the RNA present in 
the RISC complex to identify' mRNA targets {76). An experiment such as this using the 
c m / l i nt and iso/22 nt would provide the information necessary to uncover the mRNA 
target network of miR-133a-3p 5' isomiRs. 
There are several hypotheses for the biological function of 5' isomiRs. It may be that the 
isomiRs have completely different mRNA targets that increase the complexity of the 
miRNAs, or that the co-expression of isomiRs leads to reinforced repression of core 
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targets, and reduces off-target effects {8S). Either way, the existence of such isomiRs needs 
to be taken into account when analysing the funcUon of miRNA or considering a miRNA 
for therapeutic intervention against a disease. 
CHAPTER SEVEN 
GENERAL DISCUSSION & 
FUTURE DIRECTIONS 
Discussion 
7 . 1 D I S C U S S I O N 
In this thesis I have presented detailed miRNA and mRNA profiles of cardiomyocytes 
purified from normal, prc-h^-pertrophic and compensated hypertrophic murine hearts. A 
model of LV hypertrophy was successfully established and confirmed by haemodynamic, 
physiological and biochcmical measurements. RNA extracted from purified 
cardiomyocytes was then used for NGS of both small RNAs and mRNA 3' ends. 
Differential expression of both rrdRNAs and mRNAs was detected, as well as processing 
variation in miRNA sequence and mRNA 3' UTRs. Firstly, a static picture of all the 
variants present in cardiomyocytes was generated, and then the data was analysed for 
differences in processing between control and h\-pcrtrophic samples. The functional role of 
5' isomiRs for a cardiac specific miRNA was then determined using in vitro luciferase 
assays. In this chapter, I discuss the outcomes of these studies, integrating both the 
miRNA and 3' end datasets and the importance of this dataset for cardiac biology. 
Cardiac hypertrophy is a dynamic process that involves several signalling pathways and 
multiple levels of gene regulation. Furthermore, we now appreciate that gene expression is 
highly regulated at the post-transcripdonal level. The precise balance of rrdRNAs and 
mRNA 3' L'TRs expressed within a cell control the amount of protein produced from a 
particular mRNA transcript. Our study makes a key advance in understanding this 
phenomena by considering alternative processing of miRNAs and mRNA 3' UTRs in these 
processes. Previous smdies have often focussed on one aspect of gene regulation in cardiac 
hypertrophy. This is the first study to simultaneously document miRNA processing 
variants and mRNA 3' UTRs. Furthermore, this is the first smdy to use enriched 
cardiomvocytes for miRNA and mRNA differential expression. Other smdies looking at 
rrdRNA expression in mouse models of cardiac hypertrophy have taken the whole LV and 
most have been based on microarray analysis [120, 121, 127, 128), resulting in incomplete 
datasets defined by the probesets represented on the arrays and confounded by the 
presence of non-cardiomyocytes in the sample. Two studies have used NGS to profile 
miRNAs after TAG, but again this was in the whole LV and they did not interrogate the 
data for miRNA processing variants {130, 131). Of the miRNA smdies, only one other has 
looked at an earHer time point and they reported that 24 hours after TAC-bandmg only one 
miRNA, miRNA-1, changed in expression (/27). In addition, these smdies have not looked 
for the presence of miRNA processing variants or assessed for changes in cardiac 
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hypertrophy. The expression levels of mRNAs in response to TAG have been described at 
multiple tune points, including 48 hours and 7 days {168, 187, 301, 302). Alike to the 
miRNA analysis, these studies have used the whole heart or whole LV and microarray 
analysis. One study has performed NGS for both miRNAs and mRNAs at 7 days post-
TAC, as well as NGS of mRNA transcripts present within RISC to establish miRNA: 
m R N A interactions {131). However, this study did not take into account the presence of 
multiple 3' UTRs per mRNA transcript. Lasdy, the 3' UTRs of some mRNA transcripts 
have been documented in whole LV samples using microarray analysis {168). This study 
also documented shortening of some 3' UTRs in TAG banded mice after 7 days, but the 
publication did not provide an extensive dataset of the 3' UTRs expressed as it relied on 
microarray probes. To summarise, this is the fust study to document expression changes in 
miRNAs and mRNAs in cardiomyocytes purified from pre- and hypertrophic hearts. 
Furthermore, this is the first study extensively documenting the miRNA processing 
variants and 3' UTRs expressed in primary murine cardiomyocytes, and thus to identify 
miRNA variants and 3' UTRs that change in response to pressure overload-induced 
hypertrophy. 
7 . 1 . 1 T R A N S C R I P T I O N A L RESPONSE TO PRESSURE OVERLOAD 
In addition to documenting processing variants, differential expression analysis was 
conducted for both miRNAs and mRNAs. There arc some interesting obser\'ations when 
comparing the results of both analyses. Firstly, as indicated by the Spearman correlation, 
there was less variation between cardiomyocytes in the miRNA population compared to 
the mRNA transcriptome. The miRNA population was dominated by relatively few, highly 
expressed cardiomyocyte-enriched miRNAs that did not alter in expression levels, thus 
resulting in high Spearman correlations. This was also reflected in the differential 
expression analysis, with only a small number of miRNAs being statistically significant in 
comparison to the mRNA differential expression. 
The second major difference m the expression profiles for miRNAs and mRNAs was the 
kinetics for the response to pressure overload. Two miRNAs had significant changes in 
expression at 48 hours, while 16 significandy changed expression at 7 days. In contrast, 469 
mRNAs had sigmficant differential expression at 48 hours and 307 were sigmficandy 
altered at 7 days. Therefore regulation at the level of mRNA abundance occurred faster 
than alteration in miRNA levels. This could be due to a number of reasons. Firstly, 
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miRNAs have an average half-life of ~ 5 days and are up to 10 rimes more stable than 
mRNA transcripts {219). Thus a reducrion in the level of a miRNA may take longer than 
that of an mRNA transcript. Secondly, many miRNAs are processed from the introns of 
protem-coding genes and thus the levels of these host genes could be expected to change 
first, followed by a subsequent change in the rrdRNA level. For example, miR-208b is 
encoded within |3-MHC, which is increased sKghtly at 48 hours and sigmficandy 
overexpressed at 7 days {24S). The same trend is observed for miR-208b-5p, with a larger 
increase at 7 days but the fold change values are small and it does not reach significance. 
The processing time of a miRNA could also account for the delayed rrdRNA response. In 
support of this, the levels of the pri-miR and pre-miR are often upregulatcd weU before the 
mature rruRNA can be detected (2/5, 391). Therefore, the stability and processing of a 
miRNA could be why the mRNA levels change prior to the miRNAs. In support of this 
finding, another study looking at a time-course of miRNA and mRNA regulation in 
melanoma cells reported the same phenomenon {392). After stimulation with interferon 
gamma (IFN-y), the mRNA expression levels change first and then the rrdRNA levels were 
altered by a second wave of transcription. It was hypothesised that the increase in the levels 
of transcription factors in the initial response was required for the activation of rrdRNAs. It 
is therefore possible that the mRNA levels increase soon after TAG banding to diitiate a 
compensatory response, which is then subsequendy followed by an increase in miRNAs to 
fine-mne or adjust the hypertrophic response {392). 
7 . 1 . 2 M I R N A S A N D M R N A S E X I S I AS PROCESSING V A R I A N T S 
One of the major goals of this thesis was to determine the extent of sequence variation in 
miRNAs as weU as mRNA 3' UTR usage in murine cardiomyocytes. I have presented 
evidence to suggest that both miRNAs and mRNA 3' UTRs have substanrial variarion in 
their processing. Nearly all of the miRNAs expressed in the heart showed some degree of 
sequence variarion including arm bias, 5' and 3' isomiRs as well as non-templated addirions. 
Sdnilarly, the mRNAs do not always express the annotated 3' UTR and an mRNA has on 
average 2.35 3' UTRs. This compHcates our view of the miRNA:mRNA interacrion 
network, with several different mteracrions possible from the same miRNA and/or mRNA 
genomic loci depending on which variant is produced. 
The static maps of mRNA 3' UTRs and miRNA processing variants have important 
implications for cardiac biology. It is critical when looking at the impact of a miRNA m a 
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cellular system to have the details about the miRNAs and mRNA 3' UTRs that are 
expressed. This is particularly important when predicting miRNA targets. The target 
prediction algorithms are mostly based on the 3' UTRs from cDNA sequence repositories 
such as Refseq {393, 394). Release 6 of Targetscan now includes all 3' UTRs from Refseq 
rather than using only the longest 3' UTR from each gene {67). However, this only includes 
annotated 3' UTRs and the target prediction algorithms don't take into account cell-
specific 3' UTRs. Furthermore, the canonical miRNA defined in miRBase is used for target 
predictions. Thus, the accuracy of target predictions would be improved if the cell or 
tissue-specific 3' UTR and miRNA variants as described here were used as the input. 
7 . 1 . 3 P R O C E S S I N G CHANGES WITH CARDIAC H Y P E R I R O P H Y 
The N G S data was also analysed for changes in miRNA processing and 3' UTR usage 
between the Sham and TAG cardiomyocytes. While 1 found that the majorit}' of miRNAs 
exist as processing variants, in general these variants did not change in a directional manner 
during the induction of hypertrophy. This is in contrast to the 3' end sequencing data, 
where 3' UTRs variants for over 400 mRNAs were found to change in proportion in the 
pre-hypcrtrophic cardiomyocytes. This suggests that miRNA processing remains fairly 
consistent while the 3' UTRs are changing. This could be attributable to the processing 
steps required to generate these two RNA tjpes. The 3' UTR of an mRNA contains more 
cis-regulatory elements and thus has more scope for alterations in processing. 
7 . 1 . 4 I N T E G R A T I O N OF M I R N A AND 3 ' U T R DATA 
The long-term goal of this work, beyond the scope of this PhD thesis, is to integrate the 
miRNA and 3' UTR data to generate a systems level interaction map of miRNAs and their 
targets during hypertrophy. We hypothesised that there would be examples where 
alterations in the 3' UTR would disrupt the interaction with a miRNA (Figure 7.1.C) or 
miRNA processing variants would be produced with a different targeting spectrum (Figure 
7.1.D). I have already demonstrated how the isomiRs of miR-133a-3p can have different 
targeting properues but the function of 3' UTR variants remains unexplored. I started 
mining the data for examples of miRNA: 3' UTR interactions and found an example where 
integrating both datasets revealed potential for atered miRNA regulation that was 
previously hidden. 
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Figure 7.1. Potential role of non-conventional miRNA and m R N A processing in cardiac 
hypertrophy. 
(A) Cleavage of an APA site results in m R N A s with different 3' UTR length and miRNA binding 
sites (purple box). (B) Non-canonical m iRNA processing can result in the other strand or isomiRs 
(with different 5' start posit ions and targedng properties) being incorporated into RISC. (C) 
Hypertrophic-specif ic APA usage can result in disrupted miRNA-mediated repression. (D) 
Hypertrophic-specif ic m iRNA processing can produce a novel miRNA species able to repress 
disease-relevant mRNAs . 
Discussio. — 
Cyclin D2 (Ccnd2) regulates the Gl-progression of the cell cycle and is necessary for the 
development of hypertrophy (JOS). CCnd2 levels increase during hypertrophy and CCnd2 
phosphorylates retinoblastoma (Rb)( i i ' i ) . Hypertrophic growth requires new protein 
synthesis and transcription of tRNA genes by RNA pol III. When phosphorylated Rb 
becomes inactive, its association with subunits of RNA pol Ill-specific transcription factor 
B is disrupted, allowing them to activate RNA pol III JPff). Ccnd2 is expressed as 
three major 3' UTRs in the 3' seq data; one proximal and two distal 3' UTRs approximately 
4.5 kb downstream (Figure 7.2.B.i). Both miR-133a-3p and miR-145-5p repress the 
expression of the Ccnd2 3' UTR in luciferase assays, indicating they direcdy target Ccnd2 
{279, 397). The expression levels of miR-145-5p and miR-I33a-3p do not significandy 
change in the pre-hypertrophic or hypertrophic cardiomyocytes (Figure 7.2.A). However, 
the proportion of the short 3' UTR increases at both time points, with a larger increase at 
48 hours, compared to the two longer 3' UTRs (Figure 7.2.ii). The short 3' UTR is not 
under the regulation of miR-145-5p or miR-133a-3p, so while their We l s have not 
changed, altering the 3' UTR of Ccnd2 changes its post-transcriptional regulation. There is 
no obvious correlation between this 3' UTR change and the overall levels of the Ccnd2 
mRNA (Figure 7.2.B.ii). However, miRNAs can act via translational repression and thus 
the protein levels of Ccnd2 may increase. In agreement, it has been previously shown that 
the protein levels of Ccnd2 increase after TAG and after treatment with angiotensin II 
{230, 30S). This illustrates an example where miRNA shows no change while the 3' UTR 
does, which could still result in different protein levels. 
This example demonstrates how this data can be used to understand the intricacies of 
miRNA regulator)' networks in the heart. There may be instances where the miRNA 
changes but the predicted binding sites may not be present, or where the levels of the 
miRNA remain constant but the 3' UTR changes, releasing the repression of the miRNA. 
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Figure 7.2. The shortening of Ccnd2 3' UTR removes miRNA binding sites. 
(A) Levels of miR-145-5p and miR-133a-3p according to NGS. The data is presented as normalised 
CPM. (B) (i) Schematic of the Ccnd2 3' UTR. The dark blue box indicates the annotated 3' UTR, 
with the location of the 3' seq peaks indicated above by the red lines. Each 3' UTR represented by 
the 3' seq peak drawn below. The coloured bars represent the canonical or non-canonical PAS. The 
black triangles indicate known miR-133a-3p binding sites and the grey triangles indicate known 
miR-145a-5p binding sites, (ii) Change in proportion of the 3' seq peaks for Ccnd2; data shown as 
percentage contribution to Ccnd2. (m) Levels of the Ccnd2 transcript according to NGS. The data 
is presented as normalised CPM. 
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7 . 1 . 5 C A R D I A C M I R N A S AS T i i E R A P i a r n c s FOR CARDIOVASCULAR 
DISKASE 
The data from this thesis is important to the development of appropriate miRNA-based 
therapeutics for heart disease (398). Although the processing of miRNAs was not altered 
during cardiac hypertrophy, an understanding of the miRNA variants expressed in the 
heart is crucial when designing therapeutics that remove or introduce a specific miRNA. 
The current treatments for CVD primarily slow down disease progression and as a result 
the prevalence, mortality, and costs associated with CVD continue to increase {3P9). The 
ability to manipulate miRNA expression in animal models has triggered enthusiasm for 
miRNAs as potential therapeutic targets. 
There are two mam approaches for miRNA therapeutics; miRNA antagonists to reduce 
endogenous miRNA levels that exhibit a gain-of-function in disease or miRNA mimics to 
restore loss-of-function (reviewed in {400)). miRNA antagonists are chemically modified 
miRNA strands complementary' to the target miRNA that bind with high affinity and 
inhibit its activit)'. miRNA mimics or "miRNA replacement therapy" reintroduces a 
miRNA that is expressed in a healthy cell but lost in the disease state (40t). 
The most clinically advanced example of miRNA therapeutics is against hepatitis C virus 
(HCV) infection. An antagonist against miR-122 blocks the replication of HCV and is 
currentiy being evaluated in Phase 2 clinical trials {402, 403). Thus far, no miRNA-based 
therapies against cardiovascular disease have entered human cUnical trials but several 
candidates are in preclinical development. MGN-9103, an antagonist against miR-208 and 
miR-499, is in development with Santaris Pharma as a therapy against chronic heart failure. 
Deletion of the miR-208 hairpin in mice results in resistance to fibrosis, cardiac 
hypertrophy and heart failure after cardiac stress, suggesting that decreasing the levels of 
miR-208 could prevent or reduce the damage induced from heart disease {114). However, 
55% of the miR-208a hairpin is derived from the 5p arm in our NGS data, meaning that 
both strands of miR-208a are available for target interactions. It is important to estabHsh if 
the proportions of miR-208 strands are expressed in equivalent proportions in the human 
heart. The function of miR-208 has been ascertained by knocking out the miR-208 hairpin 
and thus decreasing expression of both strands. Therefore, to achieve the protective effects 
achieved in the knockout mouse model, it may be necessary to design antagomiRs agamst 
both strands of miR-208 for therapeutic use. 
Discusshii 
There are also challenges associated with the deliver)' of miRNA mimics or inhibitors. 
Currcndy, there is not an effective cardiac-specific delivery method for RNA therapeutics 
and as such, treatment would rely on systemic injection {404). As one miRNA can have 
hundreds of targets, there is the risk of side effects in other organs or cell types. However, 
a dssue-specific miRNA would have reduced risk of non-target effects on other organs. 
For example, inhibition of miR-208a, which is heart specific, by subcutaneous delivery of 
an antagonist was sufficient to prevent cardiac remodelling and improve cardiac function in 
hypertensive rats {114, 40S). The successful use of miRNy^s as therapeutics for 
cardiovascular disease will also rely on improvements in the delivery or targeting of the 
molecule to be tissue and/or cell specific. 
The future of disease-associated miRNA research wiU need to address the complexity of 
mRNA and miRNA isoforms to better understand disease pathology and develop precision 
miRNA-based therapeutics. Therefore, this study may help to identify' miRNA-based 
points of therapeutic interv'ention by understanding which miRNA isoforms support the 
development of hypertrophy and which mRNA isoforms they regulate to achieve this 
outcome. 
7.2 FUTURE DIRECTIONS 
Our NGS has provided a wealth of information about miRNA and mRNA 3' UTR 
isoforms in cardiomyocytes. Several questions arise as a result of the data presented in this 
thesis, some of which have been raised akeady in this discussion. 
The next stage of analysis would be to integrate the miRNA changes with mRNA 3' UTR 
usage on the global scale. As mentioned above, the long-term goal of this work is to 
provide a systems level understanding of the miRNA interactions that occur in 
hj-pertrophy. The hypertrophy-related changes to miRNA sequences and mRNA 3' UTR 
usage could be biomformaticaUy cross-referenced to known and predicted miRNA:mRNA 
interactions. This analysis will answer key questions, such as; are cardiac miRNAs targeting 
mRNAs that are modulating their 3' UTR and thus binding sites in hypertrophy? Are the 
miRNA variants such as isomiRs targeting the same mRNAs? Are hypertrophy-related 
mRNAs changmg their 3' UTR length to prevent or gam post-transcriptional gene 
regulation during the hj'pertrophic response? This would also generate a Ust of potential 
DiscusHu >. 
interactions that could be validated with other methods or used for experiments 
investigating the functional implications of such variants. 
The miRNA:mRNA target interaction network could then be further improved using 
methods that identify targets by their physical interaction with the miRNA. As mentioned 
previously, such an experiment has been conducted in the mouse heart by overexpressing 
miR-133a and sequencing the RNA present m the RISC complex (7(5). Overexpression of 
different miRNA isomiRs would identify' their unique and common targets. Furthermore, if 
the exact binding site was determined then the interaction with 3' UTR variants could also 
be determined. 
Questions still remain about the biological function and mode of action of miRNA variants 
and 3' UTR length. Apart from different targeting properties of miRNA variants, it would 
be interesting to see if isomiRs act through different mechanisms, for example 
deadenylation, exonucleolytic decay or translational repression. This could be discerned 
using polysome profiling, which measures the translational properties of specific mRNA 
molecules {406). This method could also be used to determine the consequences of 3' UTR 
site choice on gene expression. It is assumed that a shorter 3' UTR, due to use of a 
proximal poly(A) site, will increase translational efficiency and mRNA stabilit)' due to loss 
of aV-regulating elements, including miRNA binding sites. The translational efficiency of 
cardiac mRNAs identified from the sequencing data could therefore be examined, and 
mampulation of miRNA levels could further determine if 3' UTR variants have different 
susceptibility to miRNA action. 
Within the existing 3' sequencing dataset, there is a considerable amount of data that 
remains unexplored. For instance, the Orphan peaks that were identified may correspond 
to novel protein coding transcripts or non-coding RNAs such as lincRNAs. This data 
could be investigated for aspects of gene transcription such as promoter elements or cross-
referenced with existing RNA seq data to determine if we have detected novel transcripts. 
We also detected polyadenylation of UncRNAs and miRNAs. The polyadenylated miRNAs 
correspond to primary miRNA transcripts and could be correlated with the mature miRNA 
levels to gam msight mto the regulation of miRNA processing. Lasdy, the peaks that were 
upstream of the stop codon or within mtronic regions were not analysed in this thesis. 
These peaks could correspond to the 3' UTRs of spUce variants, which would also contain 
miRNA bmding sites. The data could be remterrogated taking mto account all of the 
259 
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transcript variants of a genomic loci encompass ing the exon and intron peaks. In summar}', 
both the miRNA dataset and the m R N A 3' end data offer a variety of possibilities for 
future cardiac biology research. 
7 .3 CONCLUDING REMARKS 
The overall a im of this thesis was to profi le miRNAs and m R N A 3' ends in an established 
model of LV hypertrophy and then to interrogate this data for evidence of miRNA 
processing variants and m R N A alternative polyadenylation. These aims have been achieved 
and this is the first study to document both the miRNA isoform population and m R N A 3' 
UTRs in purif ied cardiomyocytes simultaneously. 
CHAPTER EIGHT 
APPENDIX 
— Refcix'ir , 
Due to the large size, the appendix files have been included digitally. Please refer to the 
attached CD. 
8 .1 . SCRIPTS FOR M I R N A MAPPING 
The following files used for the mapping and counting o f miRNA sequencing are included; 
• Adaptortrim.pl 
• miRNA.bowtie.SGE.pl 
• countGff 
• miRNAcountsBAM.pl 
• miRNAcounts.mysql.pl 
• mmu. features 
8 .2 . R SCRIPT FOR M I R N A DIFFERENTIAL EXPRESSION ANALYSIS 
The details for miRNA normalisation and differential expression are contained in the file in 
the R script file 8.1. 
8 .3 . SCRIPTS FOR 3 ' END SEQUENCINC; MAPPING 
The following files used for the mapping and counting of 3' end sequencing are included: 
Csqvfilter.pl 
Cspolyaextender.pl 
HnkCoveragePeaks.pl 
getTranscripts.pl 
processTable.pl 
8 .4 . R SCRIPT FOR MERGING 3 ' SEQ PEAKS AND Dll 'FERENTIAL EXPRESSION 
The details for merging 3' seq peaks associated with the same gene ID, mRNA 
normaHsation and differenual expression are contained in the file m the R script file 8.4. 
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8 .5 . G O - T E R M ENRICHMENT 1 « R DIL'FERENTIALLY EXPRESSED M R N A 
TR,\NSCRIPTS 
The perl script 8.5.pl was used to perform GO-term enrichment of the differentially 
expressed mRNAs . 
8 .6 . M I R N A DIFFERENTIAL EXPRESSION ANALYSIS 
The excel fde 8.6 contains the details for miRNA differential expression analysis, including 
taw counts, normalisation factors, normalised counts per million, log2-FC, spearman 
correlations and the miRNAs with a FDR < 30% for each pairwise comparison. 
8 .7 . M I R N A DTFFERI-NTIAL EXPRI'SSION ANALYSIS USING UPPER QUARTILE 
NORMALISATION 
The excel file 8.7 contains the details for miRNA differential expression analysis after 
upper quartile normalisation, including raw counts, normalisation factors, normalised 
counts per million^ log2-FC, spearman correlations and the miRNAs with a FDR < 30% 
for each pairwise comparison. 
8 .8 . PROCESSING VARIATION OF M I R N A S 
The excel file 8.8 contains the proportion of arm bias, 5' isomiRs, 3' isomiRs, non-
templated editions and internal editing for all miRNAs that have a CPM greater than 10. 
8 .9 . WEIGHTED LINEAR MODEL FOR MIRN.V PROCESSING CHANGES 
The excel file 8.9 contains the details of the statistical model applied for all miRNA 
processing variants (arm bias, 5' and 3' isomiRs, non-templated additions and internal 
editing). The number of miRNAs with varying FDR cut-offs are Hsted, and if a miRNA 
was identif ied as changing proportion then further details are provided m the tabs labeUed 
"Ust". 
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8 . 1 0 . CONVENTIONAL SEQUENCING OF 3 ' U ' r R s AFTER 3 ' RACE 
The conventional sequencing of m R N A 3' ends validated using 3' race are listed. The 
cloning site, primer sequences and the region that matches the expected genomic sequence 
are highlighted. 
8 . 1 1 . M R N A DIFFERE'NTIAL EXPRESSION 
The excel file 8.11 contains the details for m R N A differential expression analysis, including 
raw counts, normalisation factors, normalised counts per miUion, log2-FC, spearman 
correlations and the m R N A s with a FDR < 30% for each pairwise comparison. 
8 . 1 2 . C ; 0 - T E R M ENRICHMENT FOR DIFFERI-NTIALI.Y EXPRESSED M R N A S 
The enriched biological processes, molecular functions, cellular compartments and KEGG 
pathways with FDRs <30% are listed for all differentially expressed mRNAs as well as the 
m R N A s that are novel to this study. 
8 . 1 3 . VX/EIGHTED LINEAR MODEL FOR CHANGES IN 3 ' U T R USAGE 
The excel file 8.13 contains the details of the statistical model applied for changes in die 
proport ion of 3' seq peaks within an mRNA. The 3 'UTRs that increase or decrease in 
length at 48 hours and 7 days are provided. 
8 . 1 4 . CONVENTIONAL SEQUENCING OF M I R - 1 3 3 A LUCIFER.\SE CONSTRUCTS 
The conventional sequencing for psiCHECKTM-2 plasmids contaming CTGF, CTGF mut, 
P G A M l and P G A M l mut sites in one, two and three copies are Ksted. The miRNA 
binding sites and restriction enzyme sites arc highlighted. 
8 . 1 5 . I^XPRESSION OF SNORN.VS IN CARDIOMYOCYTH SAMPLLIS 
The miRNA expression measured using RT-qPCR was normaHsed to the average 
expression of five smaU nucleolar RNAs (snoRNAs); s n o R N A 4 3 5 , snoRNA-202, 
Referencc-
snoRNA-55, snoRNA-412 and snoRNA-234. The expression of each snoRNA across the 
20 cardiomyocyte samples is shown in Figure 8.1. 
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Figure 8.1. Expression of snoRNAs in cardiomyocytes. 
Relative expression values of five snoRNAs (snoRNA-135, snoRNA-234, snoRNA-55, snoRNA-
412 and snoRNA-202) measured using RT-qPCR on the 20 cardiomyocyte samples. Data shown as 
reladve expression for each individual replicate. 
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